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Preface
Jose´ R. Maldonano, MD, FAPM, FACFE
Guest Editor
Crit Care Clin 24 (2008) xiii–xivCritical care units are among the most stressful and psychologically chal-
lengingplaces to be in a generalmedical hospital, whether youare a health care
professional or a patient. The purpose of this volume is to help intensivists, an-
esthesiologists, internists, and surgeons understand the complex and diverse
psychologic problems their patients face during their stay in the ICU.
Drs. Arciniegas (of the University of Colorado) and McAllister (of Dart-
mouth Medical School) discuss the neurology of traumatic brain injury with
a special focus on the neurobehavioral sequelae of head trauma, including
the evaluation and treatment of behavioral problems following trauma.
The United States population is increasingly older. Dr. Lee and his col-
leagues from Johns Hopkins provide an excellent review of the presentation
and management of dementia and cognitive impairments in the critical care
units.
Delirium is the most common neurobehavioral disorder experienced by
critically ill patients. It aﬀects patient’s morbidity and mortality, and it also
interferes with the safe delivery of care and aﬀects the outcome of treatment.
In two separate articles, Dr. Maldonado (of Stanford University School of
Medicine) conducts a comprehensive review of the epidemiology, etiologic
factors, characteristics, and methods of diagnosis and summarizes the evi-
denced-based data on methods of treating and preventing delirium in critical
care units. Next, Dr. Maldonado distills years of available research and of-
fers a comprehensive theory for understanding the pathophysiology and
neurobiology of delirium. Taken together, these models may help guide fu-
ture research into eﬀective techniques for preventing and treating delirium.0749-0704/08/$ - see front matter  2008 Elsevier Inc. All rights reserved.
doi:10.1016/j.ccc.2008.06.003 criticalcare.theclinics.com
xiv PREFACEDrs. Ferrando (of the Weill Medical College of Cornell University) and
Freyberg (of Columbia University College of Physicians and Surgeons) re-
view the infectious agents that directly infect the central nervous system
and may complicate the assessment and clinical management of ICU pa-
tients. They suggest treatments for each disorder covered. Substance abuse
and potential withdrawal syndromes are common causes for admission to
critical care units and often complicate the management of these patients.
In their article, Drs. Tetrault and O’Connor (of the Yale School of Medi-
cine) review the epidemiology of substance abuse and provide clinical rec-
ommendations regarding the treatment of common withdrawal syndromes.
Mood disorders and suicide attempts and their sequelae are unfortunate
common causes for admission to the ICU. Drs. Steven Dubovsky (of the
University of NewYork at Buﬀalo) andAmelia Dubovsky (HarvardMedical
School) oﬀer an insight into the aftermath of attempted suicide and the acute
management of these patients until stabilization and transfer to the appropri-
ate psychiatric facility ismade. Similarly, the incidents leading to an admission
to an acute care unit and the procedures and process of a critical care unit may
render patients and family members liable to suﬀer a number of anxiety symp-
toms. Drs. Kross, Gries, and Curtis (of the University ofWashington) discuss
the presentation andmanagement of posttraumatic stress disorder as a sequela
to the critical care environment. Dr. Shapiro and colleagues (of Columbia
University) summarize the speciﬁc psychiatric challenges that are experienced
by patients in acute, intensive, and critical care who have heart and lung
disease. They focus on the most common psychiatric presentations of these
patients and discuss eﬀective treatment strategies to help optimize care.
Patients undergoing organ transplantation invariably are managed in the
critical care setting both before and after transplantation. This population,
too, is likely to experience a number of psychiatric complications. In their
article Drs. DiMartini and Dew (of the University of Pittsburg), Crone
(of George Washington University), and Fireman (Oregon Health and Sci-
ence University) discuss the pretransplantation psychosocial evaluation and
review the psychologic complications commonly seen in patients undergoing
transplantation. Finally, during the average critical care unit stay, critically
ill patients are exposed to a signiﬁcant number of medications. Many of
these agents are used speciﬁcally to aﬀect the patient’s cognition and behav-
ior or have psychoactive side eﬀects. Drs. Smith, Wittmann, and Stern (of
Massachusetts General Hospital) review the most common medical compli-
cations associated with the use of psychoactive agents.
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Psychiatric medications are frequently an essential component of care for
critically ill patients. Their use may lead to medical complications, however,
as a result of (1) direct toxicity from psychotropic medications, (2) drug-drug
interactions, or (3) intoxication or withdrawal states. These complications
may be a nuisance (eg, dry mouth and nausea) or serious and life-threatening
(eg, neuroleptic malignant syndrome [NMS] and cardiac arrhythmias).
This article addresses the most important medical complications (organized
by organ systems) of psychiatric treatment.
Crit Care Clin 24 (2008) 635–656Central nervous system
Neuroleptic malignant syndrome
NMS is a serious and rare idiopathic clinical syndrome that is most often
manifest by high fever, muscle rigidity, autonomic instability, and altered
mental status. It is caused by a decrease in central nervous system dopamine
function and is fatal in approximately 10% of cases [1]. Antipsychotics
(eg, haloperidol) that are potent dopamine-blockers are generally impli-
cated, although atypical antipsychotics with less dopamine receptor aﬃnity
(eg, olanzapine, quetiapine, and risperidone) have also been linked with* Corresponding author. Department of Psychiatry, Massachusetts General Hospital,
Warren 605, 55 Fruit Street, Boston, MA 02114.
E-mail address: fsmith2@partners.org (F.A. Smith).
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636 SMITH et alNMS [2]. Other dopamine-blocking agents frequently used in the medically
ill (including metoclopromide, droperidol, and promethazine) may also
cause NMS, as can abrupt withdrawal of dopamine agonists (eg, levodopa
or amantadine). The incidence of NMS varies (especially in the setting of
disparate diagnostic criteria), but it is approximately 0.2% in those treated
with neuroleptics [3]. The fact that NMS is rare should not obscure the
importance of early recognition and diagnosis of this syndrome given its
potentially fatal course.
Several risk factors predispose one to NMS: dehydration, a history of
underlying brain abnormalities, low serum iron levels, and concomitant
use of lithium [4]. The syndrome typically develops over several days and
lasts approximately 5 to 10 days [5] even after the oﬀending agent has
been discontinued (it is longer with depot neuroleptics). Major clinical man-
ifestations include high fever (often O40C), so-called ‘‘lead-pipe’’ rigidity,
confusion or altered level of consciousness, and autonomic instability.
Downstream complications (including renal failure caused by elevated crea-
tine phosphokinase or rhabdomyolosis from muscle breakdown in the
setting of rigidity and hyperthermia) may be severe. Respiratory failure, pul-
monary embolus, and disseminated intravascular coagulation are also seen.
The potential manifestations and complications of NMS are as follows:
Major features
Severe muscle rigidity
Fever
Associated features
Depressed level of consciousness (stupor or coma)
Autonomic disturbance
Dysphagia
Mutism
Tremor
Incontinence
Laboratory results
Leukocytosis
Elevated creatine phosphokinase
Low serum iron
Of particular note is that the symptoms of NMS overlap considerably
with those of other medical illnesses (eg, central nervous system infection,
malignant hyperthermia, and anticholinergic delirium) making it diﬃcult
to provide a deﬁnitive diagnosis, especially in an ICU setting. When the di-
agnosis is unclear, the symptoms of NMS should be treated and oﬀending
agents discontinued. Care should be provided, at least initially, in an ICU
setting, because the complications of the syndrome may be serious. After
removing all dopamine-blocking agents, treatment is largely supportive
and guided by the particular constellation of symptoms that arise. These
include use of antipyretics and cooling blankets for high fevers, rehydration,
637MEDICAL COMPLICATIONS OF PSYCHIATRIC TREATMENTand use of standard treatments for autonomic instability. Pharmacotherapy
(eg, with dantrolene for muscle rigidity or bromocriptine and amantadine to
reinforce the dopamine system) is often used, but it has not been shown to
be consistently superior to application of supportive measures [1]. Finally,
neuroleptics may be cautiously reintroduced to patients who have recovered
from NMS after 2 weeks of abstinence.Serotonin syndromeSerotonin syndrome results from serotonergic excess; it is most often
described by a triad of mental status changes, abnormal neuromuscular
ﬁndings, and autonomic hyperactivity [6]. Although there are numerous
potentially causative agents (Box 1), antidepressants are most commonly
implicated. Signs and symptoms of serotonin syndrome are varied, ranging
from mild (with diarrhea and nausea) to life-threatening (eg, with delirium,
autonomic instability, and hyperthermia). Box 2 provides a more complete
list of the clinical features of serotonin syndrome. The onset is generally
quite rapid and risk factors include overdose of a serotonergic agent and
polypharmacy (ie, with multiple drugs working on the serotonin system or
inhibiting the metabolism of serotonergic drugs). The combinations of med-
ications most strongly associated with severe cases of serotonin syndrome
include monoamine oxidase inhibitors (MAOIs) (eg, phenelzine, tranylcy-
promine, and isocarboxazid) in conjunction with meperidine, dextromethor-
phan, and selective serotonin reuptake inhibitors (SSRIs) (eg, ﬂuoxetine,
paroxetine, ﬂuvoxamine, sertraline, citalopram, and escitalopram) [6]. Con-
comitant use of illicit drugs (eg, ecstasy and cocaine) is also quite dangerous
and should not be overlooked. Because of its protean manifestations, sero-
tonin syndrome is diﬃcult to diﬀerentiate from other medical conditions
and from NMS (especially when patients are taking both dopamine antag-
onists and serotonergic drugs). Typically, serotonin syndrome involves
hyperarousal or agitation, whereas stupor is most often seen with NMS.
Serotonin syndrome is generally self-limited and quick to resolve;
however, it can be fatal. The mainstay of treatment is removal of the precip-
itating serotonergic agents. Like NMS, supportive care that is tailored to
individual manifestations of the syndrome is essential. In particularly severe
cases, 5-HT2a antagonists (eg, cyproheptadine) may be used, although their
eﬃcacy has not been convincingly established [7]. Benzodiazepines are also
often used to help manage agitation. Unfortunately, there are little data to
guide rechallenge with serotonergic agents after the onset of serotonin
syndrome; at the very least, avoidance of multidrug regimens with signiﬁ-
cant potential drug-drug interactions seems prudent.DeliriumDelirium is deﬁned as a disturbance of consciousness that cannot be
accounted for by dementia; it involves the reduced ability to focus, to
Box 1. Selected serotonergic medications
Selective serotonin reuptake inhibitors
Citalopram
Escitalopram
Fluoxetine
Fluvoxamine
Paroxetine
Sertraline
Atypical antidepressants
Buspirone
Duloxetine
Mirtazapine
Nefazodone
Trazodone
Venlafaxine
Tricyclic antidepressants
Amitriptyline
Clomipramine
Desipramine
Imipramine
Nortriptyline
Monamine oxidase inhibitors
Isocarboxazid
Moclobemide
Phenelzine
Selegiline
Tranylcypromine
Stimulants
Amphetamines
Cocaine
MDMA (ecstasy)
Analgesics
Fentanyl
Meperidine
Tramadol
Antimigraine agents
Sumatriptan
Antibiotics
Linezolid
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Cold remedies
Dextromethorphan
Data from Boyer EW, Shannon M. The serotonin syndrome. N Engl J Med
2005;352:1112–20; Fricchione GL, Huffman JC, Stern TA, et al. Catatonia, neuro-
leptic malignant syndrome, and serotonin syndrome. In: Stern TA, Fricchione
GL, Cassem NH, et al, editors. Massachusetts General Hospital handbook of
general hospital psychiatry, 5th edition. Philadelphia: Mosby; 2004. p. 513–30.
639MEDICAL COMPLICATIONS OF PSYCHIATRIC TREATMENTsustain, or to shift attention and it tends to ﬂuctuate during the course of the
day [8]. Delirium is common in the critical care setting given the complicated
nature of illnesses treated there, and although a comprehensive discussion of
this condition is beyond the scope of this article, a brief outline of delirium
as a result of psychiatric treatment is warranted. In this context, an altered
mental status most often results from use of, or withdrawal from, particular
medications. Typically, these include benzodiazepines (both their use and
withdrawal) and anticholinergic agents (often used to facilitate sleep or to
ameliorate side eﬀects of other psychotropics, such as antipsychotics).
In rare instances both serotonergic agents and antipsychotics may also
lead to delirium in the cases of serotonin syndrome and NMS, respectively.
Delirium from benzodiazepine (or barbiturate) use is seen more frequently
(likely caused by the prevalence of their use in the general hospital setting).
Patients become confused and may alternate between being somnolent and
agitated. Nystagmus and slurred speech may serve as clinical clues.Box 2. Clinical features of serotonin syndrome
Neuromuscular excitation
Clonus
Hyperreflexia
Akathisia
Muscular rigidity (variable)
Hyperthermia (variable)
Agitation
Diaphoresis
Mydriasis
Autonomic instability
Hypertension
Tachycardia
Increased bowel sounds or diarrhea
Data from Boyer EW, Shannon M. The serotonin syndrome. N Engl J Med
2005;352:1112–20.
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of a safe environment until the delirium clears. This is the opposite of the
treatment of delirium from benzodiazepine withdrawal, which occurs in
the setting of abrupt cessation (or signiﬁcant reduction of dose) of this class
of medication. In addition to delirium, clinical manifestations of benzodiaz-
epine withdrawal (including fever, tachycardia, hypertension, hyperarousal,
diaphoresis, tremor, hyperreﬂexia, hallucinations, and seizures in severe
cases) are similar to those of alcohol withdrawal. Treatment includes reinsti-
tution of a benzodiazepine (most are cross-reactive at the g-aminobutyric
acid receptor); titrating the dose to the resolution of symptoms; and then
tapering slowly.
Anticholinergic delirium, however, results when high doses or combina-
tions of anticholinergic agents are used. Rudolph and coworkers [9] have
developed a risk scale to rate the potential for delirium from anticholinergics
typically used in psychiatric and medical settings. The clinical presentation
most often seen with this type of toxicity includes agitation; hypervigilance;
dry mouth; hot and erythematous skin; constipation; urinary retention; and
autonomic instability (involving tachycardia, tachypnea, and hypertension).
Treatment involves removal of the precipitating agents and administration
of supportive care. Although intravenous physostigmine may be used eﬀec-
tively, conservative management is generally preferred because of poten-
tially serious side eﬀects (eg, seizures) from physostigmine administration.
NMS, serotonin syndrome, and delirium from benzodiazepine withdrawal
or anticholinergic toxicity are all potentially serious complications of psychi-
atric treatment encountered in the critical care setting with similar symp-
toms. Table 1 outlines their characteristic features to help distinguish
among them.SeizuresSome antipsychotics and (to a lesser extent) antidepressants have been
implicated in lowering the seizure threshold and causing seizures. The SSRIs
seem to have the safest proﬁle in this regard, whereas clomipramine,Table 1
Distinguishing features of NMS, serotonin syndrome, and anticholinergic delirium
Clinical signs
Neuroleptic malignant
syndrome
Serotonin
syndrome
Anticholinergic
delirium
Hyperthermia þþ þ/- þ/-
Rigidity þþ þ -
Reﬂexes Decreased Increased Normal
Mental status Stupor/coma Agitation/coma Agitation
Skin Pallor/diaphoresis Diaphoresis Hot and dry
Mucosa Sialorrhea Sialorrhea Dry
Bowel sounds Wnl or hypoactive Hyperactive Hypoactive
Data fromBoyer EW, ShannonM.The serotonin syndrome.NEngl JMed 2005;352:1112–20.
641MEDICAL COMPLICATIONS OF PSYCHIATRIC TREATMENTchlorpromazine, bupropion, and clozapine seem to be more problematic
[10]. General risk factors include a history of seizures; rapid dose escalation;
higher doses of medication (including overdose); and a history of head
trauma or cerebrovascular accident. In the case of bupropion in particular,
seizure risk is associated with higher doses (especially with doses greater
than 450 mg/day and with its use in individuals with an eating disorder or
a seizure disorder) of the immediate-release preparation. There is less risk
at lower doses and with the sustained-release formulation [11]. With regard
to antipsychotics, clozapine, olanzapine, and quetiapine are thought to play
a more signiﬁcant role in evoking seizures than are haloperidol and risper-
idone [12,13]. Withdrawal from benzodiazepines and from barbiturates may
also lead to seizures.Cerebrovascular accidentsRecent data suggest that use of atypical antipsychotics in the elderly with
dementia increases the risk of stroke. Speciﬁcally, a 2006 meta-analysis of
placebo-controlled trials of atypical antipsychotics (olanzapine, risperidone,
quetiapine, and aripiprazole) used in patients with dementia [14] indicated
a signiﬁcantly increased risk of cerebrovascular accident in this population
and a small increase in mortality [15]. Other studies have looked at similar
risks in the elderly who were treated with conventional antipsychotics versus
atypicals; mixed results were noted [16–18]. Although more data are needed
to clarify this situation, management of agitation and behavioral distur-
bances in the medically ill elderly with dementia is currently best served
by weighing the risks of treatment with the risks of ongoing behavioral dis-
turbance (taking into account alternative treatment strategies and the under-
lying risk factors for cerebrovascular accident) [19]. Finally, several case
reports have suggested an association between serotonergic antidepressants
and the so-called ‘‘Call-Fleming syndrome’’ (diﬀuse cerebral vasoconstriction)
leading to stroke [20,21]. Although this comprises merely an association,
any patient who presents with the hallmark symptoms of Call-Fleming
(ie, severe headache and focal deﬁcits with evidence of cerebral ischemia
or vasoconstriction) merits a thorough review of medications that enhance
serotonergic transmission.Extrapyramidal symptomsEach of the four main extrapyramidal syndromes (eg, dystonia, akathisia,
parkinsonism, and tardive dyskinesia) associated with use of psychotropic
medications is seen in the medical setting. Acute dystonia and akathisia
(the inability to sit still) are thought of as acute manifestations of extrapyra-
midal syndromes, whereas parkinsonism and tardive dyskinesia are subacute
or chronic forms. Acute dystonia involves contraction of voluntary muscle
that leads to a postural distortion. The neck is a common site of dystonia,
whereas oculogyric crisis tends to be better known although considerably
642 SMITH et alless common [19]. Acute dystonia usually appears early in the course of anti-
psychotic treatment (or of another dopamine blocker) and is more common
with higher doses and a younger age [22]. Treatment consists of stopping
the oﬀending agent and administering an anticholinergic agent. Akathisia
(with restlessness, pacing, or ﬁdgetiness) often is seen when a patient receives
an antipsychotic. Patients often describe a subjective sensation of inner rest-
lessness or ‘‘crawling out of one’s skin.’’ b-Blockers may help reduce this
sensation. Higher-potency typical antipsychotics are associated with more
extrapyramidal syndromes than are lower-potency agents, whereas the newer
atypical antipsychotics seem to confer even less risk [5,23].
The more chronic forms of extrapyramidal syndromes (including parkin-
sonism and tardive dyskinesia) are also caused by antipsychotics and by
other dopamine-blockers (eg, phenothiazine antiemetics or metoclopra-
mide). Parkinsonism is generally subacute (ie, arising weeks to months after
a dopamine blocker is started), and includes a triad of bradykinesia, rigidity,
and tremor that mimics the disease by the same name. Of the antipsychotics,
the atypical agents, quetiapine and clozapine, least commonly cause parkin-
sonian side eﬀects. If the oﬀending agent cannot be stopped, an anticholin-
ergic agent can be added to ameliorate these symptoms. Finally, tardive
dyskinesia is generally the most chronic form of extrapyramidal syndromes,
starting months or years after treatment with an antipsychotic. It generally
starts with involuntary movements of the muscles of the tongue, lips, mouth,
and face [19], although any part of the body may be aﬀected. Dyskinesias
generally worsen with continued antipsychotic use, and the elderly are at
greater risk of developing tardive dyskinesia. For patients who require
ongoing antipsychotic treatment, a switch to clozapine or quetiapine often
leads to improvement in symptoms [24].SedationSedation is a side eﬀect of many psychotropics (eg, most antipsychotics,
anticonvulsants, mood-stabilizers, benzodiazepines, and certain antidepres-
sants). Unfortunately, oversedation predisposes patients to medical compli-
cations (eg, aspiration, deep venous thrombosis [from an inability to
mobilize], malnutrition, and general deconditioning). This is especially true
when these medications are added to already complex regimens that may
include other sedating agents (eg, narcotics), or when the underlying illness
predisposes the patient to somnolence (eg, a central nervous system infection
or a respiratory infection). Although psychotropics are often important
adjuncts or essential components of treatment, the motto, ‘‘start low, go
slow’’ provides a framework for dose titration in critical care settings.ThermoregulationAntipsychotics can also interfere with temperature regulation, making
those who take them poikilothermic and susceptible to both hyperthermia
643MEDICAL COMPLICATIONS OF PSYCHIATRIC TREATMENTand hypothermia [25]. This is especially true when antipsychotics are-
combined with anticholinergic agents. Medically ill patients may be even
more susceptible to these eﬀects given comorbid conditions that also aﬀect
temperature regulation.Cardiovascular
Psychotropics contribute to a variety of cardiovascular eﬀects, including
arrhythmias and conduction disturbances; changes in blood pressure (hypo-
tension and hypertension); and in rare cases, myocardial infarction and
myocarditis.ArrhythmiasTricyclic antidepressants (TCAs) have quinidine-like eﬀects on cardiac
conduction, leading to delays in cardiac conduction, increases in heart
rate, and prolongation of the QT and PR intervals. Although these eﬀects
are often insigniﬁcant in patients without underlying cardiac conditions,
they may become meaningful in those who are predisposed to arrhythmias.
When administered to patients with hypomagnesemia, hypokalemia, or con-
current QTc prolongation, TCAs may cause a life-threatening depression of
cardiac conduction, heart block, or ventricular dysrhythmias. This is espe-
cially true when TCAs are coadministered with other class I antiarrhythmics
(eg, quinidine and procainamide). Furthermore, when given to patients with
atrial ﬁbrillation, quinidine-like drugs (eg, TCAs) may lead to ventricular
dysrhythmias; extreme caution is advised [5].
Although all antipsychotics can aﬀect electrocardiographic intervals,
those agents with the greatest propensity to prolong the QTc are thiorida-
zine, pimozide, droperidol, sertindole, mesoridazine, and ziprasidone. The
atypical antipsychotics and haloperidol are generally thought to be safest
in this regard, although it is important to note that there are no head-to-
head studies to conﬁrm this. Risk factors for QTc prolongation with anti-
psychotics are the same as those for TCAs. In addition, concomitant use
of other medications that either increase levels of antipsychotics or TCAs
by cytochrome P-450 interactions (eg, ﬂuoxetine and paroxetine), or
prolong the QTc themselves (eg, ﬂuoroquinolones and methadone) increase
the risk of this complication by their additive eﬀects. Checking an EKG and
maintaining potassium and magnesium in the high normal ranges is recom-
mended for patients taking antipsychotics and TCAs (because they are at
risk for QTc prolongation).Orthostatic hypotensionOrthostatic hypotension is a common and potentially serious side eﬀect of
antipsychotics, TCAs, MAOIs, and the atypical antidepressant, trazodone.
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ical antipsychotics seem to be the worst oﬀenders, whereas higher-potency
agents (eg, haloperidol) confer less risk. Patients with underlying congestive
heart failure or dehydration are particularly susceptible as are those who are
receiving vasodilators or a1-adrenergic blockers. Orthostatic hypotension
may lead to signiﬁcant morbidity, including falls (especially in the elderly)
and impaired tissue perfusion.HypertensionHypertension is also a potential side eﬀect of psychotropics, including
venlafaxine, bupropion, and stimulants (eg, methylphenidate and amphet-
amine). Although this is usually relatively mild, blood pressure should be
checked in patients receiving these medications at the time of their initiation
and with dose increases. A more serious complication is that of hypertensive
crisis with MAOIs, where patients experience an abrupt rise in blood pres-
sure, and headache, nausea, vomiting, and diaphoresis. If not treated
quickly with an a-blocker (eg, phentolamine or nifedipine), the dread com-
plications of intracranial hemorrhage or myocardial infarction may ensue.
Hypertensive crisis in this case is a consequence of the interaction of the
MAOI with vasopressor amines, anorexiants, stimulants, pain killers
(ie, meperidine), and many over-the-counter cold preparations [26] or inges-
tion of tyramine-containing food products. Drug-drug interactions should
be checked carefully for any patient receiving a MAOI and patients should
be placed on a tyramine-free diet.Myocarditis and cardiomyopathyMyocarditis and cardiomyopathy have each been linked with use of sev-
eral psychotropics, although most consistently with clozapine [27]. A recent
retrospective review puts the incidence of myocarditis between 0.7% and
1.2% of treated patients [28] with the condition generally developing during
the ﬁrst few weeks of treatment. Cardiomyopathy, however, is thought to
result from more chronic use. The pathophysiology may involve a type I
IgE hypersensitivity reaction as evidenced in part by peripheral eosinophilia
(which is often present) [29]. Clinical features and treatment are similar to
those of myocarditis of other etiologies. Stopping clozapine is the ﬁrst
step in treatment of clozapine-associated cardiomyopathy.Gastrointestinal
Gastrointestinal complications of psychiatric illnesses range from minor
discomfort to severe complications (including pancreatitis and acute liver
failure). This section addresses the minor complications and then focuses
on the more severe complications.
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medications. It is most frequently related to treatment with anticholinergics
(eg, diphenhydramine and benztropine) and TCAs (eg, amitriptyline,
nortriptyline, imipramine, and desipramine). It is also associated with
many other commonly used medications, including the SSRIs and some
antipsychotics with signiﬁcant anticholinergic properties (eg, chlorproma-
zine, thioridazine, olanzapine, and quetiapine). Xerostomia has been associ-
ated with dental caries, but with short-term use it is primarily a source of
patient discomfort.SialorrheaExcessive salivation has also been associated with use of psychotropics,
most notably with the antipsychotic clozapine; roughly 31% of clozapine
users are aﬀected [30]. It has also been associated with use of risperidone;
1% to 6% of adults and up to 22% of children receiving risperidone has
experienced this side eﬀect [31]. Among clozapine users, sialorrhea may
result from muscarinic stimulation or from a2 antagonism [32]. Although
a nuisance during the day, it has been linked to aspiration pneumonia dur-
ing sleep. Several interventions have been used, but the use of ipratropium
nasal inhalers has been most eﬃcacious.Gastrointestinal distressGastrointestinal distress (nausea, vomiting, and diarrhea) has been
widely reported with psychotropics, but it seems to be most common with
use of SSRIs (including ﬂuoxetine, duloxetine, venlafaxine, and paroxetine);
nausea occurs in 20% to 25%, and vomiting occurs in 2% to 3% of individ-
uals. This adverse eﬀect is most prevalent at the outset of therapy, although
it may also be seen in overdose. Although these symptoms are primarily
a source of irritation for patients, one must monitor for signs of toxicity.
In patients taking lithium, for example, the constellation of nausea, vomit-
ing, and tremor often heralds lithium toxicity. In these cases, a thorough
history, physical examination, and laboratory evaluation (eg, checking a lith-
ium level, assessing renal function, and checking serum electrolytes) helps to
diﬀerentiate between a relatively benign medication side eﬀect and a major
complication.PancreatitisPancreatitis is a rare but serious complication from psychiatric medica-
tions that is most commonly associated with use of clozapine, risperidone,
olanzapine, and valproate. Valproic acid therapy has been associated with
pancreatitis without a clear relation to dose or serum level. Cases have
646 SMITH et aloccurred both early and late in the course of treatment with valproic acid.
Atypical antipsychotics have also been associated with pancreatitis. In cases
reported to the Food and Drug Administration, 40% were caused by cloza-
pine, 33% by olanzapine, and 16% by risperidone [33]. Twelve percent of
the cases were associated with haloperidol, but in 50% of these cases an
atypical antipsychotic was also prescribed [33].Hepatic dysfunctionHepatic eﬀects of psychotropics are commonly reported and range from
elevations in liver function tests and hyperammonemia to hepatitis and
acute liver failure. This section focuses on the most severe and most com-
mon complications. The agent most often linked with hepatotoxicity is val-
proic acid. Valproic acid is associated with elevation in liver function tests
with both acute and chronic use and monitoring is recommended. Acute
liver failure most commonly occurs within the ﬁrst 6 months of treatment;
the risk of fatality is 1 of 37,000 for adults on valproate monotherapy
[34]. Hyperammonemic encephalopathy has also been reported with
valproic acid during both early and chronic treatment and it can occur with-
out a change in liver function tests. Episodes of confusion in patients taking
valproic acid should prompt the clinician to check an ammonia level.
If elevated, stopping the medication generally reverses the problem.
In mild cases of hyperammonemia (while taking valproic acid), L-carnitine
at doses of 50 to 100 mg/kg/d may be used to improve symptoms and to
reduce ammonia levels [35].
Hepatic complications (including hepatitis and liver failure) have also
occurred with other anticonvulsants (speciﬁcally lamotrigine and carbama-
zepine) that are commonly used for psychiatric indications. Many
antidepressants have also been associated with liver abnormalities, but ne-
fazodone more commonly has been associated with fatal liver failure
(occurring at a rate of 1 per 250,000–300,000 patient-years) [36]. Finally,
hepatic complications have been associated with use of several antipsy-
chotics. Chlorpromazine has been connected to cholestatic jaundice and to
hepatocellular jaundice, with an overall rate of 0.1% in all patients [37]. No-
tably, patients older than 70 years were 12 times as likely to have a hepatic
complication caused by chlorpromazine as those under the age of 50, with
a risk of 0.3% in those older than 70 years [37].Immunologic
There are relatively few immunologic complications from psychiatric
treatments; however, many medications are associated with drug-induced
systemic lupus erythematosus. This section focuses primarily on the medica-
tions that have been most frequently associated with this complication and
other immunologic issues are brieﬂy discussed.
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erythematosus and drug-induced systemic lupus erythematosus. Drug-
induced systemic lupus erythematosus is often associated with polyarthral-
gias, arthritis, rash, or fever. Renal and central nervous system involvement
are rarely seen in drug-induced systemic lupus erythematosus. Anemia,
leukopenia, and lymphadenopathy are also less common in drug-induced
systemic lupus erythematosus when compared with systemic lupus erythe-
matosus. Carbamazepine has been reported in several case reports as a cause
of drug-induced systemic lupus erythematosus [38]. Although drug-induced
systemic lupus erythematosus usually occurs early in treatment, it may arise
at any point in the course of treatment. Chlorpromazine and other pheno-
thiazines have been associated with positive antinuclear antibodies. This
association seems related to the length of therapy and to the dose, with
increased rates of antibodies associated with more than 3 years of therapy
[39] and with doses greater than 400 mg/day [40]. Most patients remain
asymptomatic, but some go on to develop drug-induced systemic lupus
erythematosus. Clozapine and lithium have also been reported as a cause
of drug-induced systemic lupus erythematosus, although there have only
been a few published case reports.LymphadenopathyLymphadenopathy has also been associated with some psychotropics
(including carbamazepine, duloxetine, and in one report with lamotrigine)
[41]. Duloxetine has been reported to cause lymphadenopathy, at rates rang-
ing from 0.1% to 1% [42].Renal
Potential renal complications from psychiatric medications range from
an increase in urinary frequency to the development of nephrotic syndrome.
Among psychotropics, lithium is one of the most well-known agents with
signiﬁcant renal side eﬀects.NephrotoxicityLithium can cause nephrotoxicity after either short- or long-term treat-
ment. Studies have found tubular atrophy, reduction in tubular function,
and a decrease in the total number of sclerotic glomeruli in patients chron-
ically treated with lithium. Studies have suggested that 15% to 20% of
patients on long-term therapy develop a slow decline in glomerular ﬁltration
rate [43]. Progression to end-stage renal disease as a result of lithium is
uncommon; however, in patients who progressed to end-stage renal disease
there was an average of 20 years between the onset of therapy and end-stage
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for renal impairment. Nephrogenic diabetes insipidus resulting in polyuria
or polydipsia occurs in up to 20% of patients chronically taking lithium
[43]. Lithium has also been associated with nephrotic syndrome
(infrequently); more frequently it results in minimal change disease, whereas
occasionally it is caused by focal-segmental glomerulosclerosis. Finally, the
course of renal recovery following discontinuation of lithium is variable;
some patients recover some renal function.
Drug-drug interactions are important to consider when examining renal
complications of lithium therapy. Many drugs aﬀect the serum levels of lith-
ium. Nonsteroidal anti-inﬂammatory drugs, angiotensin-converting enzyme
inhibitors, angiotensin II receptor antagonists, thiazide diuretics, tetracy-
cline, spectinomycin, metronidazole, and the cyclooxygenase-2 inhibitors
all increase serum lithium levels. Aminophylline, theophylline, acetazola-
minde, mannitol, and sodium bicarbonate can all decrease lithium levels.
Given the many potential drug-drug interactions with lithium, it is essential
to review concomitant medications, and to adjust lithium dosages accord-
ingly as new interacting medications are added.HyponatremiaHyponatremia is another side eﬀect of psychotropics. Carbamazepine
and oxcarbazepine are two of the agents frequently associated with hypona-
tremia. One study found prevalence rates of 29.9% and 13.5% for oxcarba-
zepine and carbamazepine, respectively [46]. Unfortunately, a clear
mechanism has yet to be identiﬁed as a cause of drug-induced hyponatre-
mia. Carbamazepine has also been reported in several cases as a cause of
renal failure; no clear mechanism for this complication has been identiﬁed.
SSRIs are also frequently associated with hyponatremia, a ﬁnding that is
often attributed to the syndrome of inappropriate anti–diuretic hormone
secretion. Several risk factors have been associated with hyponatremia
and SSRI use; these include older age, female gender, concomitant use of
a diuretic, lower body weight, and low baseline sodium level. Prevalence
rates for hyponatremia have varied widely (from 0.5%–32%) and most
cases have occurred in patients over the age of 60 years [47]. In patients
who have developed SSRI-associated hyponatremia, discontinuation of
the drug has been a major part of treatment. Patients have been rechallenged
after resolution of their symptoms, and some have had symptoms recur,
whereas others have tolerated the medication without subsequent hypona-
tremia. There is no reliable way to predict what happens when medication
is reintroduced.Urinary dysfunctionMany psychiatric medications (including clozapine, mirtazapine, benz-
tropine, SSRIs, and TCAs) have been associated with urinary retention,
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mediated by anticholinergic eﬀects. None of these medications, however,
have been reported to cause these eﬀects at rates above 1%.Endocrinologic and metabolic
Weight gain
Weight gain with psychotropics is common and had generally been
considered more of a nuisance until recent ﬁndings that link many of the
atypical antipsychotics to signiﬁcant weight gains, dyslipidemia, and diabe-
tes [48–50]. Although the association between atypical antipsychotics and
the so-called ‘‘metabolic syndrome’’ is not completely understood, studies
have linked signiﬁcant weight gain [48–50], dyslipidemia [50], and new-onset
diabetes mellitus [51,52] to the use of clozapine and olanzapine and to que-
tiapine and risperidone (to a lesser extent). Several reports note diabetic
ketoacidosis in patients who are taking clozapine or olanzapine but are
without a history of diabetes [52]. The side eﬀects of weight gain, hyperlip-
idemia, and diabetes are especially important in the critical care setting
because they put patients at increased risk of cardiac, respiratory, and infec-
tious comorbidities.Thyroid dysfunctionThyroid dysfunction (eg, hypothyroidism) is most commonly linked with
the use of lithium. Lithium is thought to interfere with the production of
thyroid hormones through a variety of mechanisms that are beyond the
scope of this article. Women over the age of 50 years seem to be at increased
risk of developing this side eﬀect [53], although it may develop in either gen-
der and in patients of any age. Treatment consists of either stopping lithium
or administering thyroid hormone. Hyperthyroidism has also been associ-
ated with lithium use, although this side eﬀect is far less common.Hematologic
Blood dyscrasias
Many psychotropics have been associated with hematologic adverse
events (including agranulocytosis, aplastic anemia, neutropenia, eosinophilia,
and thrombocytopenia) [54]. The most important ones are highlighted in
the following section.
Agranulocytosis is a rare (except with clozapine), but potentially quite
serious, side eﬀect of antipsychotics. The low-potency agents confer a higher
risk than do the higher-potency agents [54]. Clozapine causes agranulocyto-
sis most often; approximately 0.8% [55] of patients who take this medication
are aﬀected. It is most often seen in the ﬁrst 6 months after starting the
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registration in a national registry and weekly blood determinations.
TCAs, MAOIs, and certain mood stabilizers (ie, carbamazepine and lamo-
trigine) have also been associated with agranulocytosis.
Carbamazepine is associated with potentially deadly agranulocytosis
and aplastic anemia that is thought to be caused by direct bone marrow
toxicity [56]. Valproic acid, however, can cause neutropenia, thrombocyto-
penia, and macrocytic anemia. Although there is no consensus on its
frequency, a complete blood count should be checked periodically when
these medications are used. Finally, lithium induces leukocyte prolifera-
tion and demargination and may be used to treat leukopenia from other
causes.Increased bleeding riskSSRIs and serotonin-norepinephrine reuptake inhibitors (SNRIs) (like
venlafaxine and duloxetine) are associated with bruising and with bleeding
caused by inhibition of platelet function [57]. These eﬀects have been asso-
ciated with an increased risk of gastrointestinal bleeding, especially when
taken in conjunction with aspirin or nonsteroidal anti-inﬂammatory drugs
[58,59]. Reports of increased bleeding when SSRIs are taken in conjunction
with warfarin [60] exist, although this link has not been ﬁrmly established.Respiratory
Respiratory depression
Respiratory depression is the most common side eﬀect of psychotropics
on the respiratory system. This is seen primarily with benzodiazepines,
because they alter the central nervous system’s response to hypoxia.
Longer-acting benzodiazepines are potentially more dangerous in this
regard. Clinicians should also watch for the additive eﬀects of other central
nervous system depressants, including antipsychotics, sedating TCAs, and
alcohol, among other agents. Those at particular risk include patients
with an underlying obstructive sleep apnea; respiratory dysfunction; or
acute illnesses (eg, pneumonia). In the medically ill, use of shorter-acting
agents (eg, lorazepam) is advised.Pulmonary embolismPulmonary embolism is a rare but serious complication linked with use of
clozapine, olanzapine, risperidone, and quetiapine [61–66]. Deep venous
thrombosis has also been associated with clozapine use, and the ziprasidone
package insert lists pulmonary embolism as a possible side eﬀect. A causal
relationship, however, between these drugs and this complication has not
been ﬁrmly established.
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Dermatologic side eﬀects of psychotropics range from more common
and relatively benign events (eg, sweating [from SSRIs and SNRIs];
acne [from lithium]; and alopecia [from lithium]) to serious adverse reac-
tions (eg, drug-induced cutaneous reactions). This section focuses on the
latter.Rash and Stevens-Johnson syndromeToxic epidermal necrolysis and Stevens-Johnson syndrome are rare,
potentially fatal, drug-induced cutaneous reactions that may be caused by
mood-stabilizing medications (including carbamazepine and lamotrigine)
[67,68]. The clinical manifestations include erosions of the mucous mem-
branes, detachment of the epidermis, and severe constitutional symptoms
[67] that may lead to death. Although benign rashes are seen in 5% to
20% of patients taking carbamazepine, lamotrigine, and valproate [5], the
more serious syndromes are less common. The risk of developing Stevens-
Johnson syndrome is highest during the ﬁrst 2 months of treatment and
at times of dose escalation. Patients who develop a rash on of these medica-
tions should stop their medication until a physician sees them.Reproductive
A complete review of the eﬀects of psychotropics used during pregnancy
and the postpartum period is beyond the scope of this article; however,
a brief review of the potential teratogenic risks for agents used in the critical
care setting is warranted. Priapism, another potentially dangerous side eﬀect
of psychiatric medications, is then discussed.TeratogenesisMedications used to treat bipolar disorder, including anticonvulsants
and lithium, have the greatest potential for teratogenic eﬀects. The risk
of fetal malformations depends on the time of fetal exposure and on
the particular properties of the drug used. For example, exposure in
the ﬁrst 32 days of pregnancy may have an impact on neural tube devel-
opment, whereas heart formation is aﬀected during days 21 to 56, and
development of the lip and palate is inﬂuenced by exposure during
days 42 to 63 [69]. Lithium use during the ﬁrst-trimester of pregnancy
is most associated with Ebstein’s anomaly (downward displacement of
the tricuspid valve into the right ventricle with associated right ventricle
hypoplasia) [69]. During later pregnancy, the concern with regard to ma-
ternal (and possibly fetal) toxicity is raised at the time of delivery because
of a rapid decline in vascular volume. This can be avoided by decreasing
(or stopping) lithium in the last several weeks of pregnancy [70]. Fetal
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ated with a twofold risk of neural tube defects (eg, spina biﬁda and an-
encephaly); craniofacial anomalies; microcephaly; growth retardation; and
heart defects [69,71]. Lamotrigine, however, is generally preferred for
treatment of bipolar disorder during pregnancy because of its lower asso-
ciation with fetal malformations [69,72].
Haloperidol is the preferred antipsychotic for use during pregnancy
because it has been used for approximately 40 years and has a fairly exten-
sive safety database for use in pregnancy [73]. As far as the use of newer
atypical antipsychotics in pregnancy, there are little data available. One
study, however, showed a higher proportion of low birth weight babies
[74] when mothers were taking these medications during pregnancy.
When contemplating use of antipsychotics, anticonvulsants, or lithium
for women of child-bearing age in the critical care setting, it is essential
to test for pregnancy and then make an informed decision while weighing
the risks versus the beneﬁts of treatment and choosing medications with
lower risk proﬁles.PriapismPriapism (a sustained painful erection) is another serious side eﬀect of
psychotropics. Although trazodone is perhaps the best-known psychiatric
medication associated with priapism, most of the antipsychotic medications
can also be a cause [75]. Because priapism is underreported, rates of occur-
rence are not well understood. The major complication of priapism is ﬁbro-
sis of the corpora cavernosa, which may result in impotence or abnormal
erectile function if untreated within 4 hours of its onset [76]. Patients with
sickle cell anemia, leukemia, hypercoaguable states, and autonomic dysfunc-
tion and cocaine-users, are at higher risk of developing priapism (because of
low-ﬂow states). Particular care should be taken when prescribing trazodone
or antipsychotics in these populations. Priapism should be treated as a uro-
logic emergency because of the potential morbidity, and patients taking
these medications should be reminded to watch for development of this
condition.Summary
The use of psychiatric medications in hospitalized patients is an impor-
tant component of comprehensive care. It is important, however, to be on
the lookout for medical complications of psychiatric treatment that may
result from direct medication toxicity, drug-drug interactions, or intoxica-
tion-withdrawal states. In this regard, it is essential to consider the potential
complications of psychotropics while balancing the important role they
serve in treatment of the medically ill.
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Delirium in the Acute Care Setting:
Characteristics, Diagnosis and Treatment
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Delirium is an acute or subacute organic mental syndrome characterized
by disturbance of consciousness, global cognitive impairment, disorienta-
tion, the development of perceptual disturbance, attention deﬁcits,
decreased or increased psychomotor activity (depending on the type of de-
lirium), disordered sleep-wake cycle, and ﬂuctuation in presentation
(eg, waxing and waning). The term ‘‘delirium,’’ from the Latin roots de
(meaning ‘‘away from’’) and lira (meaning ‘‘furrow in a ﬁeld’’) and ium
(Latin for singular), literally means ‘‘a going oﬀ the ploughed track, a mad-
ness.’’ The term ‘‘delirium’’ is reported to have been coined by the lay
Roman writer Celsus (1AD) and described in his compendium De Medicina
[1,2]. Clear descriptions of the syndrome are contained in Hippocrates’s
writings, who called the syndrome by the term phrenitis [3]. In 1813, the
British physician Thomas Sutton introduced the term delirium tremens to
designate delirium caused by the withdrawal from central nervous system
(CNS) depressant agents, but which is almost exclusively applied in modern
times to delirium resulting from alcohol withdrawal [4].
In the acute care setting, many names are used to describe the acute men-
tal status changes associated with delirium. Commonly used terms include
‘‘intensive care unit (ICU) psychosis’’ or ‘‘sundowning.’’ The ﬁrst describes
the fact that mental status changes are often seen in the ICU, the second is
a descriptor of a pattern by which subjects tend to experience confusion
more frequently during periods of decreased or inappropriate stimulation,
such as at night or ‘‘sun down.’’ The psychiatric literature uses other terms
that usually describe common characteristics or features of the syndrome,
such as ‘‘acute confusional state’’ (ie, acute, confusion) and ‘‘acute brain
failure’’ to describe the gravity of the situation. Yet, neurologists and inter-
nists prefer the term ‘‘encephalopathy,’’ which literally means ‘‘disease of
Crit Care Clin 24 (2008) 657–722E-mail address: jrm@stanford.edu
0749-0704/08/$ - see front matter  2008 Elsevier Inc. All rights reserved.
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658 MALDONADOthe brain.’’ The term encephalopathy is meant to convey a brain mal-
function in the face of systemic metabolic derangements (eg, metabolic
encephalopathy), cardiopulmonary or vascular problems (eg, hypoxic or hy-
pertensive encephalopathy), renal disease (eg, uremic encephalopathy), liver
disease (eg, hepatic encephalopathy), or endocrine disease (eg, Hashimoto’s
encephalopathy); or to be a consequence of toxic factors (eg, toxic ence-
phalopathy or Wernicke’s encephalopathy) or problems with oxygenation
(eg, hypoxic encephalopathy). Unfortunately, the use of these various terms,
even if accurate, may add to the confusion and diﬃculties of identifying and
treating the syndrome of delirium.Epidemiology of delirium
Delirium is the most common psychiatric syndrome found in the general
hospital setting. Its prevalence surpasses most commonly known and iden-
tiﬁed psychiatric syndromes and varies depending on the medical setting.
Table 1 compares the incidence of delirium in diﬀerent medical settings
and various psychiatric disorders [5]. The incidence of delirium among med-
ically ill patients ranges from 10% in the general medicine ward to 85% in
advanced cancer [6–11]. This wide range is associated with the organ system
and disease process under consideration. For example, in the adult general
medicine population the incidence of delirium ranges from 10% to 24%: as
reported by Speed and colleagues 10.9% [12], Maldonado and colleagues
14% [13], Ritchie and colleagues 14.6% [14], and Gonzalez and colleagues
24% [15]. As expected, the incidence goes up with increased severity of ill-
ness, rising to 13% to 48% in after-stroke victims [16], 20% to 40% among
HIV/AIDS patients [17,18], 60% in frail-elderly patients [19], 60% to 80%
among patients in the medical ICU [20], and as high as 80% to 90% in ter-
minally ill cancer patients [21]. One study found that 89% of survivors of
stupor or coma progressed to delirium [22].
A European multinational study (n ¼ 3,608) by Valde´s and colleagues
[23] found a delirium prevalence rate of 9.1% in the general hospital popu-
lation. A Spanish study by Gonzalez and colleagues [15] conﬁrmed ﬁndings
in the United States and similarly suggested that the average hospital stay is
prolonged from 12 days to 17.5 days when delirium is present. Similarly,
a study conducted in Western Australia found a 10.9% prevalence rate of
delirium among patients admitted to two general medicine wards
(n ¼ 1,209) [12].
Similarly, in the general surgical population the incidence of delirium is
about 37% to 46% [24], and postoperative delirium has been described to
occur in 10% to 60% of patients [25]. Again, the range in incidence of post-
operative delirium depends on the type of surgery and the population stud-
ied: 25% to 32% among patients undergoing coronary artery bypass
grafting (CABG); 50% to 67% among patients undergoing cardiotomy
(eg, cardiac valve replacement) [26–29]; about 20% of elderly patients after
Table 1
A comparison of the incidence of psychiatric disorder in the general population and delirium
among medically ill patients
Incidence of
psychiatric
disorders
% of general adult
us population [5]
Incidence of delirium
in selected
medical populations %
Major depression 6.7 General medicine wards 10–18
Dysthymic disorder 1.5 HIV/AIDS 30–40
Bipolar disorder 2.6 Medical-ICU 60–80
All mood disorders 9.5 General surgical
wards (range)
37–46 (10–60)
After stroke 13–48
Panic disorder 2.7 After CABG 25–32
OCD 1 After cardiotomy 50–67
PTSD 3.5 Elderly
GAD 3.1 Out-patient minor
(cataract) surgery
4.4
Social phobia 6.8 At time of hospitalization 10–15
Agoraphobia 8.7 In nursing homes 15–60
All anxiety disorders 18.1 After hip replacement 21–63
In cancer patients
Schizophrenia 1.1 General prevalence 25–40
Anorexia nervosa 0.5–3.7 Hospitalized cancer patients 25–50
Bulimia 2–5 Bone marrow transplant 73
Alzheimer’s Disease 65–80 years old ¼ 10%
O80 years old ¼ 50%
Advanced cancer Up to 85
Abbreviations: CABG, coronary artery bypass graft surgery; GAD, generalized anxiety
disorder; OCD, obsessive-compulsive disorder; PTSD, posttraumatic stress disorder.
Data from National Institute of Mental Health: Statistics on Mental Disorders in America.
http://www.nimh.nih.gov/health/publications/the-numbers-count-mental-disorders-in-america.
shtml. Accessed March 21 2008.
659DELIRIUM IN THE ACUTE CARE SETTINGsurgery for gynecologic malignancies [30]; 33% of patients undergoing
abdominal aneurysm repair [31]; 12.5% in patients undergoing spine surgery
[32]; 41% after bilateral knee replacement [33]; and 25% of elderly patients
undergoing elective hip or knee replacement, compared with 65% after fem-
oral neck fracture repair [34–36]. Acute mental status changes, neuropsychi-
atric dysfunction, and neurocognitive deﬁcits are common after cardiac
surgery [37]. Delirium and other forms of acute organic mental syndrome
occurred in 32% to 80% of patients undergoing cardiac surgery [29,38,39].
The incidence of delirium is well documented in the acutely medically ill
patient. A study by Ely and colleagues [20] involving patients admitted to
the medical intensive care unit (MICU), 50% of which were receiving
mechanical ventilation, found that 81.3% of MICU patients developed
delirium during the course of their ICU stay. The mean onset of delirium
was 2.6 days (standard deviation or SD  1.7), and the mean duration
was 3.4 days (SD  1.9). The duration of delirium was associated with
length of stay in the ICU (r ¼ 0.65, P ¼ .0001) and total length of hospital
660 MALDONADOstay (LOS) (r ¼ 0.68, P ¼ .0001). Multivariate analysis demonstrated that
delirium was the strongest predictor of LOS in the hospital (P ¼ .006),
even after adjusting for severity of illness, age, gender, race, and days of ben-
zodiazepine and narcotic drug administration.
Maldonado and colleagues [13] found an 18% incidence of delirium in an
acute ICU (eg, combined medical and surgical patients) based on Diagnostic
and Statistical Manual of Mental Disorders, Fourth Edition (DSM-IV)
criteria. As in previous studies, the average delirious patient age was over
65 years old and mostly male (60%). The presence of delirium signiﬁcantly
extended the overall length of stay (ie, 15 days in delirious patients, com-
pared with 11 days in nondelirious counterparts).
Finally, delirium has been found to be the most common clinical neuro-
psychiatric condition in specialized palliative care units. It has been reported
to occur in 26% to 44% of cancer patients admitted to hospital or hospice.
As the disease progresses, over 80% of all advanced cancer patients eventu-
ally experience delirium in their ﬁnal days [21,40].Etiology of delirium
The syndrome of delirium is better thought of as having a multifactorial
etiology, as is often the case in most medically ill patients. Patients in the
ICU are usually critically ill, which makes them more susceptible to devel-
oping delirium. There are many risk factors known to contribute to the
development of delirium.Delirium clinical risk factors
Age (greater than 75 years old)
Baseline cognitive functioning:25% delirious are demented
40% demented in hospital develop delirium
Male gender
Sensory impairment
Use of intravenous lines, bladder catheters, and physical restraints
Severe illness
Infections (particularly urinary tract infections and pneumonias, in
older persons)
Hip fracture
Hyperthermia
Hypothermia
Hypotension and hypoperfusion
Hypoxia or anoxia
Malnutrition and nutritional deﬁciencies (eg, thiamine deﬁciency lead-
ing to Wernicke’s encephalopathy)
661DELIRIUM IN THE ACUTE CARE SETTINGMetabolic disorders
Acute metabolic encephalopathies (eg, cardiac, hepatic and renal
failure)
Acute vascular problems (eg, myocardial infarction, pulmonary
embolism)
Endocrinopathies (eg, hyper- and hypothyroidism)
Water and electrolyte abnormalities
Hypo- or hyperglycemia
Hypo- or hypernatremia
Hypo- or hyperkalemia
DehydrationElevation in serum cortisol levels
CNS pathology (ie, stroke, intracranial hemorrhages, normal pressure
hydrocephalus)
Trauma (eg, severe physical trauma or surgery)
Exogenous substances
Medication side eﬀects:
Polypharmacy (more than three medications)
Psychoactive medications
Serotonergic agents
Anticholinergic agents
Over-the-counter substancesSubstance abuse and withdrawal
Alcoholism
CNS-depressant substances (both prescribed and illegal)
CNS-depressant withdrawal (eg, delirium tremens)
CNS-stimulant substances (both prescribed and illegal)
Hallucinogens
Over-the-counter substancesHeavy metal poisoning
Toxins (ie, toxic psychosis)
Sleep deprivation
Over-sedation
Pain, poorly controlled
Two of the known risk factors for delirium include the patient’s age and
the presence of a baseline cognitive disorder (eg, dementia, stroke). Studies
have suggested that increasing age was an independent predictor of transi-
tioning to delirium. A study of mehanically ventilated adults (n ¼ 275) sug-
gests that there is an incremental risk for transitioning into delirium for
patients older than 65 years (odds ratio or OR of transitioning to delirium
for age was 1.02 [1.00–1.03; P ¼ .04]). In fact, the results suggest that for
each additional year after age 65, the probability of transitioning to delirium
increased by 2% (multivariable P values ! 0.05) (Fig. 1) [41]. Similarly,
a study of elderly patients undergoing hip surgery, found that mini-mental
Fig. 1. Age and the probability of transitioning to delirium.Themost notable ﬁnding related to age
was that probability of transitioning to delirium increased dramatically for each year of life after 65
years. Adjusted OR 1.01 (1.00, 1.02) (P¼ .03). Y-axis¼ Probability; X-axis¼ Age in years. (From
Pandharipande P, Shintani A, Peterson J, et al. Lorazepam is an independent risk factor for transi-
tioning to delirium in intensive care unit patients. Anesthesiology 2006;104(1):23; with permission.)
662 MALDONADOstate examination (MMSE) scores were identiﬁed as an independent predic-
tor of postoperative delirium [42].
Milstein and colleagues [43] reported on the development of delirium
among the elderly patient undergoing relatively simple outpatient surgery.
They studied elderly patients (n ¼ 296) undergoing cataract surgery and
found a 4.4% incidence of postoperative delirium. As others have suggested,
those developing delirium were older (82.1 versus 73.06 years; P! .001) and
received higher benzodiazepine doses as pre-medication for surgery (69%
versus 39.9%; P ! .002).
In a prospective study evaluating neuropsychologic performance in older
patients (ie, O70 years), subjects (n ¼ 100) who were free of dementia and
admitted for elective orthopedic surgery underwent a series of neuropsychi-
atric testing pre- and postoperatively [44]. Findings suggest that subtle
preoperative attention deﬁcits were closely associated with postoperative
delirium. Patients who developed postsurgical delirium had signiﬁcantly
slower mean reaction times (P % .011) and greater variability of reaction
time (P ¼ .017) preoperatively. A four- to ﬁvefold increased risk of delirium
was observed for people one standard deviation above the sample means on
these variables.
A study by Wahlund and Bjorlin [45] found that approximately 70% of
elderly patients admitted to a specialized delirium ward had a pre-existing
cognitive disorder, either dementia or mild cognitive impairment. Bergmann
and Eastham [46] studied elderly patients (n ¼ 100) admitted to an acute
medical unit in a general hospital for the presence of psychiatric morbidity.
They found that 7% suﬀer from dementia, while 16% suﬀered from acute
663DELIRIUM IN THE ACUTE CARE SETTINGdelirious states. Demented patients or patients suﬀering from other condi-
tions associated with deﬁcient brain function (ie, traumatic brain injury,
drug and alcohol abuse and withdrawal) have a lower threshold for devel-
oping delirium and do so with greater frequency. Similarly, a study of elderly
subjects undergoing hip or knee replacement (n ¼ 572) demonstrated that
the presence of dementia increased the occurrence of delirium [36]. Twenty
four percent of subjects had preoperative dementia. Postoperatively, all
(100%) of demented subjects developed delirium, compared with 31.8%
in the nondemented population.
Poor oxygenation (ie, hypoperfusion and hypoxemia) has long been asso-
ciated with the development of delirium, both because of medical problems
as well as postoperatively. Severe illness processes, combined with both de-
creased oxygen supply and increased oxygen demand may lead to the same
common end problem, namely decreased oxygen availability to brain tissue
[47–50]. Inadequate oxidative metabolism may be one of the underlying
causes of the basic metabolic problems initiating the cascade that leads to
the development of delirium, namely: inability to maintain ionic gradients
causing cortical spreading depression (ie, spreading of a self-propagating
wave of cellular depolarization in the cerebral cortex) [51–56]; abnormal
neurotransmitter synthesis, metabolism and release [57–65]; and a failure
to eﬀectively eliminate neurotoxic by-products [58,59,63].
A study of postthoracotomy patients demonstrated that 21% of the
patients developed clinically signiﬁcant postoperative delirium [66]. In this
sample, delirium occurred in all patients who had inadequate oxygenation.
The treatment of choice was supplementary oxygen, with a near perfect
treatment success. Others have similarly linked delirium to the presence of
poor oxygenation associated with untreated obstructive sleep apnea [67]
and to the presence of occult hypoxia after total hip arthroplasty [68].
Of note, animal studies have suggested that subjects with baseline organic
cerebral disorders, such as cerebrovascular disease, may be particularly sen-
sitive to hypoxic injury. Miyamoto and colleagues [69] submitted laboratory
animals to hypocapnia during surgical anesthesia, causing tissue damage in
the caudoputamen. This model may suggest that a similar mechanism may
be responsible for long-lasting postoperative delirium in patients with stroke
or dementia.
Sleep is another factor that seems to play a signiﬁcant role in developing
delirium in the ICU. Sleep deprivation has long been linked to the develop-
ment of delirium [70] and psychosis [71]. Studies have found that the average
amount of sleep in ICU patients is limited to 1 hour and 51 minutes per
24-hour period [72]. Many factors may aﬀect sleep in the ICU, including fre-
quent therapeutic interventions, the nature of diagnostic procedures, pain,
fear, and the noisy environment. Similarly, oversedation has been found
to be an independent predictor of prolonged mechanical ventilation. In
a prospective, controlled study (n ¼ 128) of adults undergoing mechanical
ventilation, subjects were randomized to either continuous sedation or daily
664 MALDONADOawakenings [73]. They found that the median duration of mechanical venti-
lation was 4.9 days in the intervention group (ie, daily awakening), as
compared with 7.3 days in the control group (P ¼ .004), and the median
LOS in the intensive care unit was 6.4 days as compared with 9.9 days,
respectively (P ¼ .02).
A great number of medications have been associated with an increased
risk of delirium (Box 1). The highest incidence medication-induced delirium
has been observed in patients taking more than three medications [74],
medications with high psychoactive activity [75], and when drugs have
high anticholinergic potential [76].
Medications with signiﬁcant psychoactive eﬀects have long been identiﬁed
as a frequent cause of delirium. Several studies have linked the use of psycho-
active agents to the etiology of 15% to 75% of delirium cases [19,21,77–81].
More speciﬁcally, opioids, corticosteroids, and benzodiazepines have been
identiﬁed as major contributors to delirium in several studies (Fig. 2) [75].
Other medications, such as nonsteroidal anti-inﬂammatory agents, and
chemotherapeutic agents, were also identiﬁed as causes of delirium.
There is signiﬁcant evidence to suggest that there is a direct association
between a medication’s anticholinergic potential and their incidence of caus-
ing delirium [74,76,82–86]. Some drugs (eg, diphenhydramine, atropine) are
easier to identify as having a high anticholinergic load. On the other hand,
others are not so obvious. Several studies have demonstrated a direct rela-
tionship between a drug’s anticholinergic potential (as measured by serum
anticholinergic activity) and the development of delirium [76,85,87–90].
Tune has conducted several studies looking at the cumulative eﬀect of drugs
with subtle anticholinergic potential and their serum anticholinergic activity
(Box 2, Table 2) [76,83,84,86,90,91].
Blazer and colleagues [92] conducted a study of the potential for anticho-
linergic toxicity among long-term care residents. Their study included resi-
dents aged 65 years and older (n ¼ 5,902) who continuously resided in
a nursing home for 1 year and determined drug administration and drug
quantity. The survey revealed that 60% of residents received drugs with
signiﬁcant anticholinergic properties and nearly 10% of the residents
received three or more medications with high anticholinergic load. Finally,
Han and colleagues [93] followed medical inpatients (n ¼ 278) and measured
their exposure to anticholinergic medications. They found that exposure to
anticholinergic agents was an independent risk factor for the development of
delirium, and speciﬁcally associated with a subsequent increase in delirium
symptom severity.
As suggested by many others, many gamma amino-butyric acid (GABA)-
ergic medications have been implicated in the development of delirium
[20,94–97]. It is now beginning to be understood that agents commonly
used for achieving postoperative sedation may in fact contribute to delirium
by (a) interfering with physiologic sleep patterns and (b) causing a centrally
mediated acetylcholine deﬁcient state (ie, interruption of central cholinergic
Box 1. Drugs believed to induce delirium
5-FU
Acetophenazine
Acyclovir
Aldesleukin
Alprazolam
Amandatine
Amidoarone
Amitriptyline
Amphetamine (in overdose)
Amphotericine B
Ampicillin
Anticonvulsants
Antihistamines
Antiparkinsonian Rx
Asparginase
Aspirin
Atropine
Azathioprine
Azithromycin
Barbiturates
Benzodiazepines (and ‘‘paradoxical disinhibition’’)
Benzquinamide
Beta-blockers
Betamethasone (and psychosis)
Bupropion
Cabergoline
Captopril
Cefalothin
Cefoxitin
Celecoxib
Cephalosporins
Chloramphenicol
Chlordiazepoxide
Chlorpromazine (and psychosis)
Chlorthalidone
Choline salicylate
Cimetidine
Ciprofloxacin
Clindamycin
Clioquinol
Clomipramine
Clozapine
(continued on next page)
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Cocaine
Codeine
Corticosteroids
Cortisone (and psychosis)
Cotrimozazole
Cyclobenzaprine
Cycloserine
Cyclosporine
Desipramine
Dexamethasone (and psychosis)
Diazepam
Digoxin (and psychosis)
Diltoiazem
Dimenhydrinate
Diphenhydramine
Dipyridamole
Disulfiram (and mania and psychosis)
Dopamine
Doxepin
Droperidol
Ergotamine
Ethanol
Famotidine
Fentanyl
Fludarabine
Flurazepam
Furosemide
Gentamicin
Glutethimide
Halothane
Hydralazine
Hydrocortisone (and psychosis)
Hydrochlorothiazide
Hydroxyzine
Interleukin-2
Imipramine
Interferon
Isoflurane (and psychosis)
Isosorbide monotitrate
Itraconazole
Ketamine (and psychosis)
Ketoprofen
Box 1 (continued)
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Levodopa/carbidopa (and psychosis)
Lidocaine
Lithium (and organic brain syndrome)
Lorazepam (and ‘‘paradoxical disinhibition’’)
Magnesium salicylate (and psychosis, headache, dizziness,
drowsiness, confusion)
Monoamine oxidase inhibitors
Medazepam (and withdrawal syndromes)
Mefloquine
Memantine
Methohexital
Methyldopa
Methylprednisolone (and psychosis)
Methotrexate
Metrizamide
Midazolam
Mirtazapine
Nicotine (and withdrawal syndromes)
Nifedipine
Nitrazepam (and withdrawal syndromes)
Nitroprusside (and psychosis)
Nortriptyline
Opiates (and withdrawal syndromes)
Oxazepam
Oxycodone
Pancuronium
Paraldehyde
Paramethasone (and psychosis)
Paroxetine
Perazine
Perphenazine
Perphenazine/amitriptyline
Phenelzine
Phenobarbital (and withdrawal syndromes)
Phenytoin (and psychosis)
Piperacillin
Prednisolone (and psychosis)
Prednisone (and psychosis)
Promazine (and psychosis)
Propofol (and central a-chol synd)
Protriptyline (and central a-chol synd)
Quinidine
Rantidine
(continued on next page)
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Rasagiline
Risperidone (and anxiety, depression, apathy)
Rofecoxib (and psychosis)
Scopolamine
Sodium salicylate
Sodium Thiosalicylate
Sympathomimetics
Tacrine
Tamoxifen
Tricylic antidepressants
Teceleukin (and psychosis, paranoia. fatigue, apathy,
drowsiness, sleep disturbances)
Thophylline
Thiothixene
Tiaprofenic acid
Tobramycin
Trazodone
Triamcinolone (and psychosis)
Triamterene
Trimethobenzamide (central a-chol synd)
Triprolidine (and restlessness, insomnia, euphoria, nervousness,
irritability, palpitations, nightmares, or seizures)
Vancomycin
Vincristine
Warfarin
Zolpidem
Zotepine (and anxiety, agitation)
Data from Electronic Physicians Desk Reference, 2007.
Box 1 (continued)
668 MALDONADOmuscarinic transmission at the level of the basal forebrain and hippocam-
pus) [95–97]. A study of blood and urine melatonin levels revealed an
abolition of the circadian rhythm of melatonin release in deeply sedated
ICU patients [98]. This suggests that sedative agents may contribute to
the development of delirium by more than one mechanism (ie, disruption
of sleep patterns; central acetylcholine inhibition; disruption of melatonin
circadian rhythm). Therefore, it appears that commonly used sedative (eg,
propofol, midazolam) may promote the development of delirium.
The irony is that these are the same medications physicians often use to
manage agitated or delirious patients. This practice, even if immediately
eﬀective in tranquilizing a patient may, in the long run, aggravate and per-
petuate the syndrome of delirium. One of the ﬁrst studies to demonstrate the
Fig. 2. Delirium cases potentially caused by opioids, corticosteroids and benzodiazepines in six
case-series. aBreitbart and colleagues [78], bMorita and colleagues [80], cTuma and DeAngelis [79],
dLawlor and colleagues [21], eOlofsson and colleagues [81], fFrancis and colleagues [19]. (FromGau-
dreau JD,Gagnon P, RoyMA, et al. Association between psychotogenic medications and delirium
in hospitalized patients: a critical review. Psychosomatics 2005;46(4):304; with permission.)
669DELIRIUM IN THE ACUTE CARE SETTINGrelationship between benzodiazepine use and delirium was conducted by
Marcantonio and colleagues [94]. They found that development of delirium
was signiﬁcantly associated with postoperative exposure to benzodiazepines
(OR, 3.0; 95% conﬁdence interval or CI, 1.3–6.8). These ﬁndings have been
conﬁrmed by Pandharipande and colleagues [41], who studied adult venti-
lated patients (n ¼ 275) in the ICU for the development of delirium. They
found that lorazepam was an independent risk factor for daily transition
to delirium (OR, 1.2; 95% CI, 1.1–1.4; P ¼ .003) (Fig. 3). These ﬁndings
conﬁrm many others who have previously suggested benzodiazepines to
be culprits in the development of delirium and other cognitive impairment
in medically ill patients [20,94,99,100]. Being aware of what types of medi-
cations a patient is taking and eliminating unnecessary medications can
help reduce the potential for anticholinergic side eﬀects.
As in the case with sleep, both pain and medications used for the treat-
ment of pain have been associated with the development of delirium. Vaurio
and colleagues [25] demonstrated that presence of postoperative pain is an
independent predictor of delirium after surgery. Furthermore, they found
a direct relationship between levels of preoperative pain and the risk for
the development of postoperative delirium. On the other hand, the use of
opioid agents has been implicated in the development of delirium [101–
103]. Opioids are blamed for nearly 60% of the cases of delirium in patients
with advanced cancer [40]. A study of cancer patients (n¼ 114) showed a sig-
niﬁcant associations between opioids and delirium, after controlling for
other medications used [104]. Several studies have reported that patients
Box 2. Commonly used medicines that have anticholinergic
effects
Antihistamines
Diphenhydramine
Hydroxyzine
Cardiovascular
Captopril
Chlorthalidone
Digoxin
Diltiazem
Dipyridamole
Furosemide
Hydrochlorothiazide
Hydralazine
Isosorbide mononitrate
Methyldopa
Nifedipine
Triamterene
Warfarin
Central nervous system
Alprazolam
Amitriptyline
Chlordiazepoxide
Codeine
Desipramine
Diazepam
Doxepin
Flurazepam
Imipramine
Oxazepam
Oxycodone
Phenelzine
Phenobarbital
Corticosteroids
Corticosterone
Dexamethasone
Hydrocortisone
Prednisolone
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Gastroinitestinal
Atropine
Cimetidine
Ranitidine
Immunosuppression
Azathioprine
Cyclosporine
Infection
Ampicillin
Cefalothin
Cefamandole
Cefoxitin
Clindamycin
Cycloserine
Gentamicin
Piperacillin
Tobramycin
Vancomycin
Muscle relaxants
Pancuronium
Respiratory system
Theophylline
Data from Tune LE. Anticholinergic effects of medication in elderly patients.
J Clin Psychiatry 2001;62 Suppl 21:13.
671DELIRIUM IN THE ACUTE CARE SETTINGwho used oral opioid analgesics as their sole means of postoperative pain
control were at decreased risk of developing delirium in comparison with
those who used opioid analgesics via intravenous (IV) patient-controlled
analgesia technique (OR, 0.4; 95% CI, 0.2–0.7) [25,103].
There is some data that suggests that some opioid agents may have
greater deliriogenic potential than others. For example, several reports sug-
gest that meperidine has a greater deliriogenic potential than other opioids
[94,101,105]. Other studies have suggested that an opioid rotation from
morphine to fentanyl has been associated with improved pain management
and lower delirium rating scores [106]. Similarly, at least one case report
suggests that the use of acetylcholinesterase inhibitors successfully reversed
opioid-induced hypoactive delirium [107]. This may implicate an anticholin-
ergic mechanism of opioid induced delirium.
Besides their potential anticholinergic eﬀect or their disruption of sleep
patterns, medications may cause delirium by disrupting thalamic gating
Table 2
Anticholinergic drug levels in 25 medications ranked by the frequency of their prescription for
elderly patients
Medicationa
Anticholinergic drug level (ng/mL
of atropine equivalents)b
1. Furosemide 0.22
2. Digoxin 0.25
3. Dyazide 0.08
4. Lanoxin 0.25
5. Hydrochlorothiazide 0.00
6. Propranolol 0.00
7. Salicylic acid 0.00
8. Dipyridamole 0.11
9. Theophylline anhydrous 0.44
10. Nitroglycerin 0.00
11. Insulin 0.00
12. Warfarin 0.12
13. Prednisolone 0.55
14. Alpha-methyldopa 0.00
15. Nifedipine 0.22
16. Isosorbide dinitrate 0.15
17. Ibuprofen 0.00
18. Codeine 0.11
19. Cimetidine 0.86
20. Diltiazem hydrochloride 0.00
21. Captopril 0.02
22. Atenolol 0.00
23. Metoprolol 0.00
24. Timolol 0.00
25. Ranitidine 0.22
a At a 10–8 M concentration.
b ¼ Threshold for delirium ¼ 0.80ng/mL.
Data from TuneL, Carr S,HoagE, et al. Anticholinergic eﬀects of drugs commonly prescribed
for the elderly: potentialmeans for assessing riskof delirium.AmJPsychiatry 1992;149(10):1393–4.
672 MALDONADOfunction (ie, the thalamus ability to act as a ﬁlter, allowing only relevant in-
formation to travel to the cortex). The cholinergic and the dopaminergic sys-
tems interact not only with each other but with glutamatergic and GABA
pathways. Besides the cerebral cortex, critical anatomic substrates of psy-
chotic pathophysiology would comprise the striatum, the substantia nigra/
ventral tegmental area, and the thalamus. The thalamus can be understood
as acting as a ﬁlter, usually allowing only relevant information to travel to
the cortex. On the other hand, drugs of abuse (eg, phencyclidine, Ecstasy),
as well as psychoactive medications frequently prescribed to hospitalized
patients (eg, benzodiazepines, opioids, sympathomimetics, steroids) could
compromise the thalamic gating function, leading to sensory overload and
hyperarousal. Gaudreau and Gagnon [108] have propose that drug-induced
delirium would result from such transient thalamic dysfunction caused by
exposure to medications that interfere with central glutamatergic, GABAer-
gic, dopaminergic, and cholinergic pathways at critical sites of action.
Fig. 3. Lorazepam and the probability of transitioning to delirium. The probability of transi-
tioning to delirium increased with the dose of lorazepam administered in the previous 24 hours.
This incremental risk was large at low doses and plateaued at around 20 mg per day. Y-axis ¼
Delirium risk; X-axis¼ Lorazepam dose (in mg). (From Pandharipande P, Shintani A, Peterson J,
et al. Lorazepam is an independent risk factor for transitioning to delirium in intensive care unit
patients. Anesthesiology 2006;104(1):21–6; with permission.)
673DELIRIUM IN THE ACUTE CARE SETTINGThere are several surgical procedures known to increase the risk of devel-
oping delirium, presumably because of the complexity of the surgical proce-
dure, the extensive use and type of intraoperative anesthetic agents, and
potential postoperative complications [109]. For example, in cases of cardiac
surgery the following factors have been associated with the increased risk for
delirium: the use of cardio-pulmonary by-pass (CPB) (eg, hypoperfusion,
embolic load), management strategies (eg, pH stat versus alpha stat, on-
pump versus oﬀ-pump) or to the type of procedure (eg, intracardiac
versus extracardiac) [39,110–112]. In the case of orthopedic procedures,
fat embolism, blood loss, older age, and the type of anesthetic agent used
have all been associated with a greater risk of delirium [105,113,114].
Certain psychiatric diagnoses, including a history of alcohol and other sub-
stance abuse (6.9%), as well as schizophrenia and bipolar disorder (up to
14.6%) have also been associated with a higher incidence of delirium [14,115].
Finally, the severity of the patient’s underlying medical problems has
a signiﬁcant role in the development and progression of delirium. Pandhar-
ipande and colleagues [41] found that increased severity of illness, as mea-
sured by the modiﬁed Acute Physiology and Chronic Health Evaluation
(APACHE) II (ie, removing the Glasgow Coma Scale) is associated with
a greater probability of transitioning to delirium. Furthermore, it indicated
that the incremental risk becomes larger until reaching a plateau APACHE
score of 18 (Fig. 4). The adjusted odds ratio of transitioning to delirium for
APACHE II score was 1.06 (1.02–1.11; P ¼ .004). This odd ratio suggests
that for each additional APACHE II score, the probability of transitioning
to delirium increased by 6%. Similarly, in a study of elderly patients
Fig. 4. Severity of illness and the probability of transitioning to delirium. The probability of
transitioning to delirium increased dramatically for each additional point in APACHE II sever-
ity of illness score until reaching a plateau APACHE score of 18. (From Pandharipande P, Shin-
tani A, Peterson J, et al. Lorazepam is an independent risk factor for transitioning to delirium in
intensive care unit patients. Anesthesiology 2006;104(1):21–6; with permission.)
674 MALDONADOundergoing hip surgery, APACHE II scores were identiﬁed as an indepen-
dent predictor of delirium [42].Mortality and morbidity of delirium
According to the latest statistics (2006) from the Society of Critical Care
Medicine, there are 5,980 ICUs in the United States, caring for approxi-
mately 55,000 patients per day [116]. The incidence of delirium in the
ICU has been reported to be as high as 81.3% [20]. Several studies have
found that patients who developed delirium fare much worse than their non-
delirious counterparts when controlling for all other factors. One study [19]
found that the mortality rate was higher among delirious patients, as high as
8% (compared with 1% in nondelirious patients). In another study, ICU-
patients who developed delirium had higher 6-month mortality rates (34%
versus 15%, P ¼ .03) (Fig. 5) [117]. Similarly, another study found that
the 90-day mortality was as high as 11% among delirious patients,
compared with only 3% among nondelirious elderly patients [118].
Not only is delirium associated with an increased mortality, but the rate of
morbidity is also increased.Multiple studies have demonstrated that delirious
patients have prolonged hospital stays (ie, average 5–10 days longer), com-
pared with patients suﬀering from the same medical problem who do not
develop delirium as a complication [13,19,20,117]. Similarly, a study of
psychiatric inpatients demonstrated that the hospital stays of patients with
delirium were 62.1% longer than those of patients without delirium [14].
Fig. 5. Analysis of delirium in the ICU and 6-month survival. (From Ely EW, Shintani A,
Truman B, et al. Delirium as a predictor of mortality in mechanically ventilated patients in
the intensive care unit. JAMA 2004;291(14):1758; with permission.)
675DELIRIUM IN THE ACUTE CARE SETTINGThere are concerns regarding the long-term eﬀects of delirium. It has
been estimated that about 40% of delirium cases develop some form of
chronic brain syndrome [118]. Some have suggested that the functional
decline observed during the acute delirious state may persist 6 months or
longer after discharge from the hospital [119]. In fact, Maldonado and col-
leagues [13] found that only about 14% of those patients who developed
delirium returned to their baseline level of cognitive functioning by the
time of discharge from the hospital. Levkoﬀ and colleagues [120] found
an even lower rate of recovery. In their sample, only 4% of delirious patients
experienced full resolution of all symptoms of delirium before discharge
from the hospital. After following this sample longitudinally, they found
that an additional 20.8% achieved resolution of symptoms by the third
month after hospital discharge; and an additional 17.7% by the sixth month
after discharge from the hospital. Furthermore, a study by Newman and
colleagues [121] reported that cognitive deﬁcits at discharge were signiﬁ-
cantly associated with poor long-term cognitive functioning for up to 5 years
after cardiac surgery. This may explain why patients who develop delirium
while in the hospital have a greater need for placement in nursing homes or
rehabilitation facilities instead of returning home (16% versus 3%) [19,122].
Others have also suggested that elderly patients who develop delirium ‘‘are
never the same’’ even after they recover from the acute event [118,120,123].
Fann and colleagues [124] looked at the impact of delirium on cognition
in myeloablative hematopoietic stem-cell transplantation (HSCT) patients
(n ¼ 90). All patients completed a comprehensive battery of neuropsychiat-
ric testing before receiving their HSCT and were subsequently followed for
30 and 80 days after transplantation. After adjusting for confounding fac-
tors, patients who experienced delirium after HSCT had signiﬁcantly worse
executive functioning (beta ¼ 1.1; P ! .02), and worse attention and
676 MALDONADOprocessing speed postoperatively (beta ¼ 4.7 and 5.4, respectively)
compared with those who did not experience delirium.
In addition to a patient’s increased morbidity and mortality, increased
risk of delivery of care to medical and nursing staﬀ, and causing distress
to the patient, the family, and medical caregivers, the development of post-
operative delirium has been associated with greater care costs, poor func-
tional and cognitive recovery, and prolonged hospital stays [117,125,126].
An increasingly recognized phenomena is the development of posttraumatic
stress disorder (PTSD) secondary to the dramatic and bizarre delusional and
hallucinatory experiences that occur during a delirious state. The theory
behind this phenomenon is that the strong emotional tone of the frightening
delusions may have contributed to the development of PTSD, particularly in
individuals with no factual recall of their ICU stay [78,127–130].
The economic impact of delirium is substantial, rivaling the health care
costs of falls and diabetes mellitus. Maldonado and colleagues [13]
conducted a retrospective chart review of all patients who experienced delir-
ium on a step-down critical care unit. The sample of medical and surgical
patients (n ¼ 254) included all subjects admitted to the unit over a predeter-
mined, 60-day period. Delirious patients were initially identiﬁed from a nurs-
ing log of patients who manifested symptoms of delirium. Medical records
were extensively reviewed to validate whether delirium occurred, and regis-
tered the duration of symptoms and the treatment regimen applied in each
case. Supporting data included two or more of the following: administration
of antipsychotic agents or a benzodiazepine for the management of agitation
or psychosis, use of a sitter or physical restraints for the management of
confusion or agitation, and results of cognitive function assessment methods
(eg, MMSE, Delirium Rating Scale or DRS). Overall, 14% of patients
developed delirium during their ICU stay. Collectively, all patients had
a total of 1,471 inpatient days. Delirious patients were reported to be symp-
tomatic for a total of 318 days. Thus, even though they were only 14% of
the entire critical care unit population, they used 22% of the total inpatient
days. Men were over-represented among all admissions to the unit (61%);
however, the proportion of men manifesting delirium was statistically iden-
tical to that of the nondelirious patient group (chi square ¼ 0.757, P ¼ .38).
The average number of days from symptomatic onset to resolution was
10.8 days for untreated patients and 6.3 days for treated patients. As
a group, delirious patients were older (71.3 versus 63.6 years), remained hos-
pitalized longer (16.4 versus 6.6 days), and represented greater total costs
per case ($63,900 versus $30,800).
Similarly, Leslie and colleagues [131] studied hospitalized elderly patients
and looked at the diﬀerence in health care costs for those developing
delirium. Regression models were used to determine costs associated with
delirium after adjusting for patient sociodemographic and clinical character-
istics. In their sample (n ¼ 841), 13% of patients developed delirium during
the index hospitalization. Patients with delirium had signiﬁcantly higher
677DELIRIUM IN THE ACUTE CARE SETTINGunadjusted health care costs and survived fewer days. After adjusting for
pertinent demographic and clinical characteristics, average costs per day
survived among patients with delirium were more than 2.5 times the costs
among patients without delirium. Total cost estimates attributable to delir-
ium ranged from $16,303 to $64,421 per patient. Another study demon-
strated that in patients who developed delirium in the ICU, the health
care costs were 31% higher than for patients with similar medical problems
but without delirium ($41,836 versus $27,106) [126]. The national burden of
delirium on the health care system has been estimated to range from $38 bil-
lion to $152 billion each year [131].Diagnosing delirium
Despite its high prevalence, delirium remains unrecognized by most ICU
clinicians in as many as 66% to 84% of patients experiencing this complica-
tion [19,132]. Several studies have demonstrated that hospital staﬀ in general
and physicians in particular are not good at identifying delirium. Often,
mental status changes associated with delirium are misattributed to demen-
tia, depression, or just an expected occurrence in the critically ill patient.
A study by Farrell and Ganzini [133] found that about 41.8% of subjects
referred to the psychiatry consultation service for depression were in fact
delirious, highlighting how easy it is to misdiagnose this condition. Simi-
larly, Kishi and colleagues [134] looked at the rate of missed diagnosis of
delirium by general medicine and surgical services. Again, they found these
services missed the diagnosis of delirium in 46% of requested psychiatric
consultations (ie, they called psychiatric consultations for reasons other
than delirium, but delirium was the cause for the behavior for which the
consult was requested). The factors associated with their failure to identify
delirium accurately were ﬁrst, the presence of a past psychiatric diagnosis,
which the primary team used to explain delirium symptoms; and second,
the presence of pain.
Eissa and colleagues [111] followed patients (n ¼ 48) after cardiac surgery
for signs of postoperative confusion. Subjects were assessed by a nonstruc-
tured physician interview, and by the short portable mental status question-
naire (SPMSQ). The ‘‘ward interviews’’ involved informal dialogue between
the patients and medical staﬀ during routine ward visits. There was no struc-
tured format to the questions asked by the physician, although standard
clinical management includes assessment of the subject’s orientation to
time, place, person, and dialogue. Ultimately, the presence or absence of
confusion was based solely on the medical staﬀ’s subjective decisions. The
nonstructured physician interview detected confusion in only 2% of the sub-
jects, whereas the SPMSQ diagnosed confusion in 31% of them. The
nonstructured ward interviews failed to detect confusion in 14 of the 15 sub-
jects (93%) detected by the SPMSQ and also provided no standardized
means by which to classify the degree of confusion. This study highlights
678 MALDONADOthe need to actively assess for the presence of delirium in medically ill pa-
tients. These ﬁndings are similar to those of Rolfson and colleagues [135],
who followed 71 patients after cardiac surgery to detect the incidence of de-
lirium using the Confusion Assessment Method (CAM) [136], the MMSE
[137], the clock drawing technique [138,139], and DSM-III-R (revised) crite-
ria [140]. They found that delirium was present in 32.4% of subjects.
The lack of recognition may be worsened by medical personnel’s
unawareness of the patient’s pre-existing cognitive deﬁcits. In a study of
elderly patients (ie, older than 65) (n ¼ 165) admitted to the ICU,
researchers assessed patients and interviewed their families for evidence of
pre-existing cognitive deﬁcits. They found that the prevalence of pre-existing
cognitive impairment was 38%. Yet ICU attending physicians were unaware
of the existence of these in 53% of the cases. The number was similar (59%)
for resident physicians [141]. As previously discussed, the presence of cogni-
tive deﬁcits predicts a greater occurrence of delirium; thus, it is important
for physicians to know the substrate they are working with and institute
techniques that would minimize delirium in populations at risk.
Overall, the most important aspects of accurate diagnosis are vigilance
and a high level of suspicion, particularly in patients at higher risk. The di-
agnostic gold standard for delirium is the Diagnostic and Statistical Manual
for Mental Disorders, Fourth edition, text revised (TR) (Box 3) [142].
There are a number of clinically available instruments (Box 4) developed
to assist nonpsychiatric personnel in screening for the presence of delirium.
These instruments were designed to help nonpsychiatrists (eg, nurses,Box 3. DSM-IV-TR diagnostic criteria for delirium
A. Disturbance of consciousness (ie, reduced clarity of awareness
of the environment) with reduced ability to focus, sustain, or
shift attention.
B. A change in cognition (eg, memory deficit, disorientation,
language disturbance) or
C. Development of a perceptual disturbance that is not better
accounted for by a pre-existing, established, or evolving
dementia.
D. Disturbance develops over a short period of time (usually
hours to days) and tends to fluctuate during the course of the
day.
E. There is evidence from the history, physical examination, or
laboratory findings that the disturbance is caused by the direct
physiological consequences of a general medical condition.
Data from APA, Diagnostic and Statistical Manual of Mental Disorders. 4th edi-
tion. Washington, DC: American Psychiatric Association; 1994. p. 129.
Box 4. Objectives measures for the diagnosis of delirium
DSM-IV-TR (Gold Standard; APA 1994) [142]
Cognitive Test for Delirium (CTD) (Hart, et al 1996) [271]
Confusion Assessment Method (CAM) (Inouye, et al) [136]
Confusion Assessment Method for the Intensive Care unit
(CAM-ICU) (Ely, et al) [145]
Confusional State Evaluation (CSE) (Robertsson, et al 1997) [272]
Delirium Assessment Scale (DAS) (O’Keeffe 1994) [273]
Delirium Detection Score (DDS) (Otter, et al 2005) [274]
Delirium Index (DI) (McCusker, et al 1998) [275]
Delirium Rating Scale (DRS) (Trzepacz, et al 1988) [144]
Delirium Rating Scale-revised-98 (DRS) (Trzepacz, et al 2001)
[146]
Delirium Severity Scale (DSS) (Bettin, et al 1997) [276]
Delirium Symptom Interview (DSI) (Albert, et al 1992) [277]
Memorial Delirium Assessment Scale (MDAS) (Breitbart, et al) [211]
Short portable mental status questionnaire (SPMSQ)
(Pfeiffer 1975) [278]
Brief tests of cognitive functioning
Mini-Mental State Examination (MMSE) (Folstein, et al) [137]
Modified Mini-Mental State Examination (3MS) (Bland, et al 2001)
[279]
Trail-Making, A and B (O’Donnell 1983) [280]
679DELIRIUM IN THE ACUTE CARE SETTINGinternists and research assistants) diagnose delirium [143,144]. All these
scales (eg, CAM [136], CAM-ICU [145], DRS [144], and DRS-98 [146])
have been derived from, and validated against expert psychiatric opinions
and the DSM diagnostic criteria. Unfortunately, these tools have a high
false-positive rate (as high as 10%), thus the team that developed the instru-
ment recommends that all patients identiﬁed as delirious by screening instru-
ments ‘‘have a complete clinical evaluation to conﬁrm the diagnosis’’
[136,147]. The most critical part of the assessment, given the characteristic
waxing and waning of this syndrome, is to add the interview of the family
members, nursing and medical staﬀ, and a thorough review of the chart
for behaviors exhibited during the preceding 24 hours to the clinical exam-
ination. The DRS was administered by the study’s research assistant and
used only as a conﬁrmatory measure.
Another potential clue of the presence of delirium may come from a thor-
ough neuropsychiatric examination. In the author’s experience, patients with
delirium tend to exhibit a re-emergence of primitive signs (Box 5). This
appears to be more consistent in cases of hypoactive delirium. The
Box 5. Primitive reflexes
These are clinical features that indicate brain dysfunction but that
cannot be precisely localized or lateralized. When present,
these signs suggest cortical disease, especially frontal cortex,
resulting in disinhibition of usually extinguished or suppressed
primitive reflexes. Their clinical significance is uncertain and is
difficult to correlate with psychiatric illnesses and other
behavior disorders, including delirium.
Glabellar reflex: with the examiner’s fingers outside of patient’s
visual field, tap the glabellar region at a rate of one tap per
second. A pathologic response is either absence of blink, no
habituation, or a shower of blinks. Normal response equals
blinking to the first few taps with rapid habituation.
Rooting reflex: tested by stroking the corner of the patient’s lips
and drawing away. Pursing of the lips and movement of the
lips or head toward the stroking is a positive response.
Snout reflex: elicited by tapping the patient’s upper lip with finger
or percussion hammer causing the lips to purse and the mouth
to pout.
Suck reflex: tested by placing your knuckles between the
patient’s lips. A positive response would be puckering of the
lips.
Grasp reflex: elicited by stroking the patient’s palm toward
fingers or crosswise while the patient is distracted, causing the
patient’s hand to grasps the examiner’s fingers.
Palmomental reflex: test by scratching the base of the patient’s
thumb (noxious stimulus of thenar eminence). A positive
response occurs when the ipsilateral lower lip and jaw move
slightly downward, and does not extinguish with repeated
stimulation.
Babinski sign: downward (flexor response) movement of the
great toe in response to plantar stimulation.
Adventitious motor overflow: seen as the examiner tests one
hand for sequential finger movements, and the fingers of the
other hand wiggle or tap. Also, if there are choreiform
movements.
Double simultaneous stimulation discrimination: tested with the
patient’s eyes closed. The examiner simultaneously brushes
a finger against one of the patient’s cheeks and another finger
against one of the patient’s hands, asking the patient where he
has been touched.
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681DELIRIUM IN THE ACUTE CARE SETTINGrelationship between poor cognitive status and primitive reﬂexes has been de-
scribed in patients suﬀering fromHIV-related cognitive disorders [148] and in
cases of dementia [149]. There is at least one study describing the presence of
primitive reﬂexes in postcardiotomy patients suﬀering from postoperative
neuropsychiatric complications [150]. Further studies are needed to deter-
mine whether an assessment for the presence of primitive reﬂexes may add
to the diagnostic accuracy for delirium, or at least assist in the characteriza-
tion of delirium type, or whether it has any prognostic value.
Some have advocated the use of the electroencephalogram (EEG) as
a way to identify and diagnose delirium. Engel and colleagues [151] were
the ﬁrst to describe the relationship between delirium and the diﬀuse slowing
and progressive disorganization of rhythm seen in the EEG. The most com-
mon EEG ﬁndings in delirium include slowing of peak and average frequen-
cies, and decreased alpha activity but increased theta and delta waves.
Studies suggest that EEG changes correlate with the degree of cognitive def-
icit, but there does not appear to be a relationship between EEG patterns
and delirium motoric type [152–160]. The clinical usefulness of EEG in
the diagnosis of delirium may be limited by its limited speciﬁcity (given there
are a number of conditions and medications that may aﬀect the EEG) and
the practicality of conducting the test (particularly in the case of agitated
and combative patients). Still, the EEG may provide useful in diﬀerentiating
delirium from other psychiatric and neurologic conditions, such as catatonic
states, seizure activity, somatoform disorders, and malingering.
The most critical part of the assessment, given the characteristic waxing
and waning of this syndrome, is to obtain as much information and from as
many sources as possible (eg, interview of family members, nursing and
other medical staﬀ), coupled with a thorough review of the chart for behav-
iors exhibited during the preceding 24 hours to the clinical examination.Delirium subtypes
Liptzin and Levkoﬀ [147] were the ﬁrst to characterize the diﬀerent types
of delirium based on behavioral characteristics (Table 3). Others have con-
ﬁrmed the presence of these motoric subtypes. According to these studies,
there are at least three types of delirium based on their clinical manifesta-
tions: hyperactive, hypoactive, and mixed (Fig. 6) [161,162]. The most com-
mon type is the mixed form (46%), followed by the hyperactive (30%) and
the hypoactive (24%). To most physicians, the most clear and recognizable
form is the hyperactive type. Most clinicians agree that a confused, disori-
ented patient who does not have a pre-existing psychiatric diagnosis, who
suddenly becomes agitated, combative, or assaultive, is probably suﬀering
from the hyperactive or ‘‘agitated type’’ of delirium. The term ‘‘mixed
type’’ is used to describe the classic ‘‘waxing and waning’’ pattern, com-
monly seen in medically ill patients who appear agitated and combative at
times, with alternating episodes of somnolence and hypoactivity.
Table 3
Delirium subtypes
Hyperactive (three or more) Hypoactive (four or more)
Hypervigilance Unawareness
Restlessness Lethargy
Fast/loud speech Decreased alertness
Anger/irritability Staring
Combativeness Sparse/slow speech
Impatience Apathy
Uncooperative Decreased motor activity
Laughing
Swearing/singing
Euphoria
Wandering
Easy startling
Distractibility
Nightmares
Persistent thoughts
Data from Liptzin B, Levkoﬀ SE. An empirical study of delirium subtypes. Br J Psychiatry
1992;161:843–5.
682 MALDONADOThe most diﬃcult type of delirium to identify is the hypoactive type. Clas-
sically, these patients present with symptoms that are commonly associated
with depression [147]. These include unawareness of the environment,
lethargy, apathy, decreased level of alertness, psychomotor retardation,
decreased speech production, and episodes of unresponsiveness or staring.
Patients with hypoactive delirium often endorse depressive symptoms,
such as low mood (60%), worthlessness (68%), and frequent thoughts of
death (52%) [133]. Studies have demonstrated that a large percentage of
these patients are inappropriately diagnosed and treated as depressed
[133]. The author’s own experience at Stanford University Hospital parallels
that of others [133,134]. Maldonado and colleagues [13] found that 42% of24%
30%
46%
Hypoactive Hyperactive Mixed
Fig. 6. Motoric subtype of delirium. (Data fromMeagher DJ, O’Hanlon D, O’Mahony E, et al.
Relationship between symptoms and motoric subtype of delirium. J Neuropsychiatry Clin
Neurosci 2000;12(1):51–6.)
683DELIRIUM IN THE ACUTE CARE SETTINGthe time when the psychiatry consultation service was called to treat a patient
for ‘‘depression,’’ the patient’s correct diagnosis was hypoactive delirium.
The same study found that nearly 80% of these patients had been inappro-
priately prescribed antidepressant medications.Management of delirium
Clinicians have three potential approaches when it comes to the manage-
ment of delirium: (1) managing delirium (ie, symptomatically managing
behavioral dyscontrol, such as agitation and psychosis); (2) treatment of
delirium (ie, directly addressing either the underlying causes and the neuro-
chemical cascade triggered by the underlying cause itself); or (3) prevention
of delirium (ie, use of techniques or methods, either pharmacologic or
behavioral, with the purpose of avoiding the development of delirium).
This section covers the ﬁrst; the following section addresses the third. The
second section is covered in the article by Dr. Maldonado, elsewhere in
this issue.
The adequate treatment of delirium includes the following steps: (1) accu-
rate diagnosis of the condition (eg, hypoactive delirium versus depression),
(2) management of the behavioral and psychiatric manifestations and symp-
toms to prevent the patient from self-harm or harming of others, (3) identi-
ﬁcation of the etiologic causes of delirium, and (4) treatment of underlying
medical problems. Adequate medical management begins with timely diag-
nosis and early intervention, as shown in the following algorythm for the
prevention and management of delirium.Algorithm for the prevention and management of delirium
I. Be vigilant for the possibility of delirium.
A. Obtain baseline level of cognitive functioning information from ac-
cessory sources.
B. Screen for the development of delirium in high risk groups, either by
the use of psychiatric consultants or objective scales (eg, DRS-98;
CAM).
C. Use psychiatric consultants to help with assessment and design of the
treatment plan, if available.
II. Identify and treat underlying medical causes.
III. Non-Pharmacological Treatment Strategies:
A. Correct malnutrition, dehydration and electrolyte abnormalities
should be corrected as quickly and safely as possible.
B. Remove immobilizing lines and devices (ie, IV lines, chest tubes,
bladder catheters and physical restraints) as early as possible.
C. Correct sensory deﬁcits (ie, eyeglasses, hearing aids).
D. Promote as normal a circadian light rhythm as possible. Better if this
can be achieved by environmental manipulations, such as light
684 MALDONADOcontrol (ie, lights on & curtains drawn during the day; oﬀ at night)
and noise control (ie, provide ear plugs, turn oﬀ TVs, minimize night
staﬀ chatter), rather than by the use of medications.
E. Provide adequate intellectual and environmental stimulation as early
as possible.
F. Minimize environmental isolation.
IV. Pharmacological Treatment Strategies:
A. Conduct an inventory of all pharmacological agents been adminis-
tered to the patient. Any medication or agent known to cause delir-
ium (see Table C) or to have high anticholinergic potential (see Table
G) should be discontinued, if possible, or a suitable alternative
instituted.
B. Avoid using GABAergic agents to control agitation, if possible. Ex-
ceptions: cases of CNS-depressant withdrawal (ie, alcohol, benzodi-
azepines, barbiturates) or when more appropriate agents have
failed and sedations is needed to prevent patient’s harm.
C. Adequately assess and treat pain.
D. Avoid the use of opioids for behavioral control of agitation.
E. For the pharmacological management of delirium (all types) consider
using:
i. Acetylcholinesterase inhibitor (eg, rivastigmine, donepezil, physo-
stigmine, rivastigmine) for correction of central anticholinergic
syndrome.
ii. Serotonin antagonist (eg, ondansetron) to control toxic elevations
of 5-HT usually associated with hypoactive delirium, although
some studies have suggested its use may be indicated in all types
of delirium.
iii. Rotate opioids from morphine and meperidine to fentanyl or
hydromorphone.
iv. Melatonin or melatonin agonists (eg, ramelteon) to promote
a more natural sleep.
v. Dopamine agonists to manage the theorized abnormally elevated
levels of dopamine, and provide restoration of putative hippo-
campal functions (eg, short-term memory) and reversal of other
regional brain disturbances (eg, agitation, psychosis, primitive re-
ﬂexes), as well as to protect neurons against hypoxic stress and
injury. The dose of dopamine antagonist use may depend on
the type of delirium been treated.
vi. Alpha-2 agonists (eg, dexmedetomidine, clonidine), for protec-
tion against the acute NE released secondary to hypoxia or ische-
mia, leads to further neuronal injury and the development of
worsening of delirium.
vii. NMDA-receptor blocking agents, to minimize glutamine induced
neuronal injury (eg, amantadine, memantine).
685DELIRIUM IN THE ACUTE CARE SETTINGF. In case of hyperactive delirium:
i. Use low to moderate dose haloperidol (eg, ! 20mg/24hr), if the
patient’s cardiac condition allows it and there are no signiﬁcant
electrolyte abnormalities.a. Before using haloperidol: obtain 12-lead ECG; measure
QTc & electrolytes. Correct Kþ & Mgþ, if needed.
b. If possible avoid other medications known to increase QTc
and/or inhibitors of CPY3A4.
c. Discontinue its use if QTc increases toO25% of baseline or
O500msec.ii. When the use of haloperidol is contraindicated or not desirable,
atypical antipsychotics should be considered:a. Better evidence for: risperidone, quetiapine.
b. Limited data for: olanzepine, aripripazole, perospirone.
c. Avoid: clozapine, ziprasidone.G. In case of hypoactive delirium:
i. Evidence suggests that DA antagonists may still have a place
given the excess DA theory.a. If haloperidol is use, recommended doses are in the very low
range (ie, 0.25 to 1mg / 24hr).
b. If an atypical is preferred, consider an agent with low seda-
tion (ie, risperidone); unless a sedative agent is needed to re-
store sleep-wake cycle not responding to E-iv (see above).ii. In cases of extreme psychomotor retardation or catatonic fea-
tures, in the absence of agitation or psychosis, consider the use
of psychostimulant agents (eg, methylphenidate, dextroamphet-
amine, modaﬁnil) or conventional dopamine agonists (eg, bromo-
criptine, amantadine, memantine).Nonpharmacologic treatment strategiesGiven the ﬁndings reported by Inouye and colleagues [74,163], a multi-
component approach is recommended; targeting identiﬁed, treatable con-
tributing factors must be undertaken early. As mentioned above, given
the high rate of under and missed diagnosed cases, vigilance and a high level
of suspicion is essential, particularly in high-risk patients. The routine use of
assessment scales or diagnostic interviews by properly trained personnel is
key both in prevention and timely treatment. Early involvement of the
Psychosomatic Medicine team (Psychiatry) or a Geropsychiatric service
has been shown to be extremely valuable, both in prevention and early
intervention. An active search for possible etiologies of delirium must ﬁrst
attempt to rule out the common causes of the syndrome (see list titled
‘‘Delirium clinical risk factors’’ above). This must include a review of all
medications and identiﬁcation and possible discontinuation of agents with
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assays should be ordered and reviewed in a timely fashion, and all abnormal
ﬁndings addressed accordingly.
Immobilizing lines and devices (eg, chest tubes, IV lines, bladder catethers)
should be removed as early as possible. Similarly, physical restraints should be
avoided and eliminated as soon as it is safe to do so. Early correction of sen-
sory deﬁcits should be undertaken. That is, eyeglasses and hearing aids should
be replaced or ﬁtted (if not using them before the hospitalization) as soon as
possible. This will allow patients to familiarize themselves with the environ-
ment and reorient themselves early on. It will also minimize the occurrence
of misperceptions or misinterpretation of environmental cues and stimuli.
Environmental isolation should be minimized if possible. Family members
and loved ones should be encouraged to visit and provide a familiar and
friendly environment, as well as provide appropriate orientation and stimula-
tion to patients, especially those with baseline cognitive deﬁcits.
Dehydration and electrolyte abnormalities should be corrected as quickly
and safely as possible. Malnutrition should be corrected, unless there are
good reasons not to (eg, terminal dementia).
Early correction of sleep disturbance, preferably by nonpharmacologic
means, should occur, although the use of nonbenzodiazepine agents, such as
melatonin or melatonin agonists (ie, ramelteon) or sedating antidepressant
agents (eg, trazodone or mirtazapine) should be considered. On the other
hand, cliniciansmust consider factors, such as drug–drug interaction andmed-
ication half-lives when prescribing. For example, mirtazapine and trazodone
may indeed promote night sleep, but their eﬀects may last well into the next
day, interfering with cognition, attention, and concentration. Sedative agents
with high anticholinergic load, such as antihistaminic agents (eg, diphenhydra-
mine, hydroxizine) or tricyclic antidepressants (eg, amitriptyline) should be
avoided, as theywill aggravatedeliriumeven if immediately eﬀective inpromot-
ing sleep. Similarly, benzodiazepines should also be avoided if at all possible.
Finally, conduct an inventory of all pharmacologic agents being admin-
istered to the patient. Any medication or agent known to cause delirium
(see Box 1) or to have high anticholinergic potential (see Box 2) should be
discontinued, if possible, or a suitable alternative instituted.Pharmacologic treatment strategiesIt cannot be overstated that the deﬁnitive treatment of delirium is the
accurate identiﬁcation and treatment of its underlying causes. Nevertheless,
pharmacologic intervention with various psychoactive agents is often
needed to help manage agitated patients. Following the Hippocratic princi-
ple of ‘‘ﬁrst, do no harm,’’ clinicians should ﬁrst avoid the use of GABAer-
gic agents, if at all possible. As described above, all such agents
(ie, benzodiazepines, propofol) may cause or aggravate delirium and its
behavioral manifestations [20,41,94]. The use of benzodiazepines in the
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delirium related to the withdrawal from a CNS-depressant agent (ie, alco-
hol, barbiturates, benzodiazepines); or (b) when other more appropriate
agents (see below) have failed and the level of agitation and need for behav-
ioral control outweighs the potential detrimental eﬀects of benzodiazepines.
Similarly, clinicians should do everything possible to avoid the use of opioid
agents to tranquilize agitated patients, as opioids have been implicated in
the development of delirium in many patient populations [25,40,101–106].
On the other hand, opioids should be administered when there is evidence
that pain may be a contributor to the patient’s agitation.
The literature has long recognized that intravenous neuroleptic agents are
the recommended emergency treatment for agitated and mixed type delirium
[164–169]. The intravenous administration of haloperidol has always been
thought of as superior to oral administration because the IV route has
more reliable absorption, even in cases of systemic organ failure. Intrave-
nous haloperidol use has the added advantage of requiring no patient’s
cooperation, thus facilitating its use even in uncooperative and agitated
patients. Studies suggest that the IV use of high-potency neuroleptic agents
is associated with minimal eﬀects on blood pressure, respiration, and heart
rate [167,170–175].
Further research suggests a decreased incidence of extrapyramidal symp-
toms (EPS) when the intravenous route versus the oral route is used [176].
This study consisted of a retrospective chart review of all patients admitted
to a large university hospital receiving haloperidol in any form over a 90-day
period. A total of 238 subjects receiving haloperidol were identiﬁed during
the index period, using data obtained through the digital pharmacy distribu-
tion system (Pyxis). Only patients with a known pre-existing movement
disorder (eg, Parkinson disease) were excluded. In this sample, 51% of the
subjects were women and the mean age was 62 years for women and 55 years
for men. The most common reasons for which haloperidol was prescribed
included delirium (69%), psychosis (11%), nausea or vomiting (9%), aﬀec-
tive disorder (6%), and dementia (5%). Haloperidol doses ranged from
0.5 mg to 90 mg per day for subjects receiving intravenous administration,
and from 0.5 mg to 20 mg per day for those receiving oral administration.
Results show that patients receiving IV-haloperidol experienced much lower
EPS than patients receiving the oral form (7.2% versus 22.6%; P ! .01).
In this sample, the most common forms of EPS observed included medica-
tion-induced Parkinsonism (50%), akathisia (32%), and acute dystonic
reactions (14%). The investigators found no cases of signiﬁcant respiratory
depression or Torsade de Pointes (TdP) deemed to have been caused by hal-
operidol use. These ﬁndings are similar to those previously reported, also
suggesting a lower incidence of EPS when haloperidol is administered intra-
venously [168].
Maldonado and Dhami [177] conducted a prospective study, involving all
patients (n ¼ 225) admitted to the critical care unit during a 6-month period.
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tiveness of a protocol-based management of delirium among critical care
patients. Subjects were followed daily by the study research assistant, using
objective methods to assess delirium (ie, the MMSE [137] and the DRS
[144]). There were slightly more surgical cases (n ¼ 129), than medical cases
(n ¼ 96). A total of 18% of the subjects were identiﬁed as being delirious by
DRS-criteria during the index period. Consultations to the Psychosomatic
Medicine Service (PMS) were called in only 42% of the cases. On average,
the surgical team consulted psychiatry 2.8 days after the onset of manifesta-
tion of delirium, whereas medicine services called after 4.2 days. Pharmaco-
logic management varied signiﬁcantly between the two groups (ie, standard
of care versus study protocol). Medical and surgical services managed their
delirious patients with varying combinations of medications, including opi-
oids, benzodiazepines (ie, primarily midazolam or lorazepam), propofol,
and various neuroleptic agents, usually on an as-needed basis. On the other
hand, the treatment used by the PMS consisted of the routine use of IV hal-
operidol given throughout the day, on a regular schedule every 0400-, 1000-,
1600-, and 2200-hours. Lorazepam was used in cases of agitated delirium
not responding to haloperidol alone, in cases of primary CNS-depressant
agent withdrawal (ie, alcohol, benzodiazepines), or at night only to help
promote sleep. The treatment regime doses were adjusted every 24 hours
and titrated to eﬀect. The dosing diﬀerence maintained a haloperidol-
to-lorazepam ratio of at least two-to-one (the H2A protocol) to avoid the
possibility of disinhibition by the benzodiazepines. That is, when used, the
lorazepam dose was always less than half the haloperidol dose in milligrams.
Nevertheless, because of the possibility that benzodiazepines themselves
may contribute to delirium, the lowest eﬀective dose was always used.
Whenever possible, no benzodiazepines were used.
The results demonstrated that the PMS-management approach (ie, sched-
uled IV haloperidol use) was superior to the ‘‘standard approach’’ (ie, as-
needed use of sedatives and antipsychotics) at treating delirium [177]. The
length of stay (15 versus 11 days) (Fig. 7A), total duration of delirium
(13 versus 6 days) (Fig. 7B), and percentage time being delirious (86% ver-
sus 58%) (Fig. 7C) were all shorter on patients treated by the PMS protocol.
In addition, a signiﬁcant improvement in cognitive functioning was
observed in patients treated with the PMS-protocol. Finally, complete reso-
lution of delirium (as measured by a MMSE greater than 26 and a DRS less
than 10) at the time of discharge home was greater for patients treated with
the PMS-protocol than (90% in the psychiatry group versus 14% in the
medical/surgical group) (Fig. 7D). As many previous studies have indicated,
these results suggest that a rational and controlled approach to the early
identiﬁcation and treatment of delirium in critical care patients results in
a more accurate and prompt diagnosis, shorter hospital stays, a reduction
in the use of restraints, faster recovery, and a substantially greater resolution
of symptoms of delirium at the time of hospital discharge. Even though the
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Fig. 7. Eﬀects of the early identiﬁcation and treatment of delirium according to protocol. (A)
total length of stay; (B) average total delirious days; (C) percentage of delirious days. Final bar
graph represents complete resolution; (D) percentage of complete resolution of delirium on
discharge home by treatment groups. Red ¼ treatment as usual by medical/surgical teams;
Blue ¼ psychological protocol treatment. (From Maldonado JR, Dhami N. ‘‘Recognition
and Management of Delirium in the Medical and Surgical Intensive Care Wards.’’ Poster pre-
sentation. 17th World Congress on Psychosomatic Medicine, Waikoloa, Hawaii. August 27,
2003; with permission; Data from Maldonado JR, Dhami N. Recognition and management
of delirium in the medical and surgical intensive care wards. Journal of Psychosomatic
Research 2003;55(2):150.)
689DELIRIUM IN THE ACUTE CARE SETTINGnumber of patients treated by ‘‘standard or conventional’’ approach achiev-
ing a complete resolution of their symptoms of delirium appears dismal,
these ﬁndings may represent more of the rule than the exception.
Levkoﬀ and colleagues [120] followed all older patients (n ¼ 325) admit-
ted to the medical and surgical services of a teaching hospital. During the
index period, 10.5% of all patients fulﬁlled DSM-III [178] criteria for delir-
ium on admission and an additional 31.1% developed delirium during the
index hospitalization. Similar to previous studies, development of delirium
was associated with prolonged hospital stay and an increased risk of institu-
tional placement among community-dwelling older persons. In their sample,
only 4% of delirious patients in their study experienced full resolution of
delirium symptoms before discharge from the hospital. On longitudinal fol-
low-up, an additional 20.8% had resolution of all symptoms by 3 months,
and an additional 17.7% had resolution of all symptoms by 6 months after
discharge from the hospital.
Despite the widespread use of IV haloperidol and multiple reports in
the literature describing its safety [166,167,169–172,174,175,179], even
when used at fairly high doses, some reports suggesting a range of
690 MALDONADO500 mg–1,000 mg per day [172], fears about its use remain. The main con-
cern when used in the acute care setting is related to it potential eﬀect in pro-
longing QTc. There have been reports regarding the occurrence of QTc
prolongation and even the development of TdP associated with haloperidol
use. Nevertheless, the literature suggests that the risk is relatively low
(0.27%) [180]. One of the problems in determining the exact contribution
of IV haloperidol on TdP is that most patients for whom IV haloperidol
is prescribed are very medically ill, usually in a critical care environment,
and receiving multiple medications, many of which themselves could cause
QTc prolongation and lead to TdP (Table 4) [181]. Justo and colleagues
[182] conducted a review of published cases (n ¼ 70) of TdP induced by psy-
chotropic agents (PAs). They concluded that the most commonly identiﬁed
risk factor for this patient population included female gender (50 of 70,
71.4%); advanced heart disease (24 of 70, 34.2%); hypokalemia; high doses
of the oﬀending agent (19 of 70, 27.1%); concomitant use of more than one
PA, or another agent that might prolong the QT interval (21 of 70, 30%),
and a history of long-QT syndrome (13 of 70, 18.5%) (Fig. 8). ForTable 4
Twenty drugs most commonly associated with Torsades de Pointes (TdP) according to adverse
drug reactions (ADR) reported to world health organization, 1983–1999
Drug TdP Na Fatal Nb Total Nc TdP/total %
Sotalol 130 1 2,758 4.71
Cisapride 97 6 6,489 1.49
Amiodarone 47 1 13,725 0.34
Erythromycin 44 2 24,776 0.18
Ibutilide 43 1 173 24.86
Terfenadine 41 1 10,047 0.41
Quinidine 33 2 7,353 0.45
Clarithromycin 33 0 17,448 0.19
Haloperidol 21 6 15,431 0.14
Fluoxetine 20 1 70,929 0.03
Digoxin 19 0 18,925 0.10
Procainainide 19 0 5,867 0.32
Terodiltne 19 0 2,248 0.85
Fluconazole 17 0 5,613 0.30
Disopyramide 16 1 3,378 0.47
Bepridil 15 0 384 3.91
Furosemide 15 0 15,119 0.10
Thioridazine 12 0 6,565 0.18
Flecainide 11 2 3,747 0.29
Loratadine 11 1 5,452 0.20
a Total number of ADR reports that named TdP for this drug.
b Number of ADR reports that named TdP with fatal outcome.
c Total number of ADR reports for this drug.
Data from Vieweg WV. New Generation Antipsychotic Drugs and QTc Interval Prolonga-
tion. Primary care companion to the Journal of clinical psychiatry 2003;5(5):213.
Fig. 8. Prevalence of risk factors for Torsade de Pointes among patients with TdP induced
by psychotropic drugs. (From Justo D, Prohorov V, Heller K, et al. Torsade de Pointes in-
duced by psychotropic drugs and the prevalence of its risk factors. Acta Psychiatr Scand
2005;111(3):171–6; with permission.)
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TdP, see Yap and Camm (Table 5) [183].
A MEDLINE and manual search of the literature published between
1966 and 1996 was conducted looking for cases of conduction disturbances
associated with the use of butyrophenone antipsychotics [184]. They found
only 18 patients described and concluded that, ‘‘it seems reasonable to sug-
gest that the incidence of adverse cardiovascular eﬀects due to droperidol
and haloperidol is small.’’ The investigators made several recommendations
regarding the use of haloperidol in the critically ill patient. Before initiating
therapy with haloperidol, a baseline QTc interval and serum magnesium and
potassium concentrations should be measured. Electrolytes should be cor-
rected, if necessary, before initiation of treatment. If the baseline QTc inter-
val is greater than or equal to 440 msec, and patients are receiving other
drugs that may prolong the QTc interval or in the presence of signiﬁcant
electrolyte disturbances, a butyrophenone antipsychotic should be used
with caution. Once treatment has been initiated, all critically ill patients
receiving haloperidol should undergo regular electrocardiograph monitor-
ing and QTc interval measurement. Special attention should be given to
those receiving doses greater than 50 mg every 24 hours. Based on the cur-
rently available literature, any critically ill patient receiving droperidol or
Table 5
Drugs that can prolong QT interval and Torsades de Pointes (this list is not comprehensive)
Antiarrhythmic drugs Type 1A (TdP reported in all)
Quinidine (TdP reported)
Procainamide (TdP reported)
Disopyramide (TdP reported)
Ajmaline (TdP reported)
Type 1C (increase QT by prolonging QRS interval)
Encainide
Flecainide
Type 3 (TdP reported in all)
Amiodarone
Sotalol
d-Sotalol
Bretylium
Ibutilide
Dofetilide
Amakalant
Semantilide
Calcium channel blockers Prenylamine (TdP reported, withdrawn)
Bepridil (TdP reported, withdrawn)
Terodiline (TdP reported, withdrawn)
Psychiatric drugs Thioridazine (TdP reported)
Chlorpromazine (TdP reported)
Haloperidol (TdP reported)
Droperidol (TdP reported)
Amitriptyline
Nortriptyline
Imipramine (TdP reported)
Desipramine (TdP reported)
Clomipramine
Maprotiline (TdP reported)
Doxepin (TdP reported)
Lithium (TdP reported)
Chloral hydrate
Sertindole (TdP reported, withdrawn in the UK)
Pimozide (TdP reported)
Ziprasidone
Antihistamines Terfenadine (TdP reported, withdrawn in the
United States)
Astemizole (TdP reported)
Diphenhydramine (TdP reported)
Hydroxyzine
Ebastine
Loratadine
Mizolastine
Antimicrobial and antimalarial drugs Erythromycin (TdP reported)
Clarithromycin (TdP reported)
Ketoconazole
Pentamidine (TdP reported)
Quinine
Chloroquine (TdP reported)
Halofantrine (TdP reported)
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Sparﬂoxacin
Grepaﬂoxacin (TdP reported, withdrawn in the UK
and United States)
Pentavalent antimonial meglumine
Ketanserin (TdP reported)
Serotonin agents Amantadine (TdP reported)
Promotility agents Cisapride (TdP reported, withdrawn in the UK
and United States)
Immunosuppressant Tacrolimus (TdP reported)
Antidiuretic hormone Vasopressin (TdP reported)
Other agents Adenosine
Organophosphates
Probucol (TdP reported)
Papaverine (TdP reported)
Cocaine
Data from Yap YG, Camm AJ. Drug induced QT prolongation and Torsades de Pointes.
Heart 2003;89(11):1367.
693DELIRIUM IN THE ACUTE CARE SETTINGhaloperidol therapy, whose QTc interval lengthens by greater than or equal
to 25% over baseline, should undergo dose reduction or should be switched
to a diﬀerent agent.
Despite these concerns, in 1995 a task force of more than 40 experts in
disciplines related to the use of analgesic and sedative agents in the ICU
was convened from the membership of the American College of Critical
Care Medicine and the Society of Critical Care Medicine (SCCM) [185].
This consensus of experts provided six recommendations with supporting
data for intravenous analgesia and sedation in the ICU setting:
Morphine sulfate is the preferred analgesic agent for critically ill patients.
Fentanyl is the preferred analgesic agent for critically ill patients with
hemodynamic instability, for patients manifesting symptoms of hista-
mine release with morphine, or morphine allergy.
Hydromorphone can serve as an acceptable alternative to morphine.
Midazolam or propofol are the preferred agents only for the short-term
(! 24 hours) treatment of anxiety in the critically ill adult.
Lorazepam is the preferred agent for the prolonged treatment of anxiety
in the critically ill adult.
Haloperidol is the preferred agent for the treatment of delirium in the
critically ill adult.
Similarly, the use of IV haloperidol as the agent of choice for critically ill
patients was reinforced by the SCCM’s most recent guidelines, published in
2002 [186]. Since then, a ‘‘best evidence topic in cardiac surgery’’ was written
according to a structured protocol, addressing the issue of haloperidol safety
for critically ill patients. Their search included 294 articles and concluded
that haloperidol should be considered the ﬁrst-line drug for agitated patients
after cardiac surgery [187].
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issued a ‘‘black-box’’ warning for the ‘‘oﬀ-label’’ clinical practice of using IV
haloperidol [188]. It is important to remember that haloperidol has never
been approved by the FDA for IV use.Alternatives to haloperidolBecause of the stigma and potential side eﬀects associated with typical
antipsychotics, atypical agents (also known as second-generation antipsy-
chotics, or SGA) have been used at increasing rates over the last few years
for management of psychiatric symptoms (eg, agitation, psychosis, delirium)
in medically ill patients. Large studies, particularly head-to-head compari-
son between SGA and more conventional agents (ie, haloperidol) are lack-
ing. At least one study suggested that SGA may have a greater incidence of
adverse eﬀects than typical agents, excluding EPS [189]. Leucht and col-
leagues [190] conducted a meta-analysis of all randomized, controlled trials
in which new generation antipsychotics (ie, SGA) had been compared with
conventional drugs. The study included studies that met quality criteria A or
B in the Cochrane Collaboration Handbook, and assessed quality with the
Jadad scale. The investigators included in their analysis 31 studies with
a total of 2,320 participants. The ﬁndings concluded that of the new gener-
ation drugs, only clozapine was associated with signiﬁcantly fewer EPS (risk
diﬀerence or RD ¼ 0.15, 95% CI, 0.26 to 0.4, P ¼ .008) and higher
eﬃcacy than low-potency conventional drugs. The reduced frequency of
EPS seen with olanzapine was of borderline signiﬁcance (RD ¼ 0.15,
CI, 0.31 to 0.01, P ¼ .07). Similarly, they identiﬁed only one inconclusive
trial of quetiapine and risperidone, and no investigations of ziprasidone and
sertindole. They concluded that as a group, new generation drugs were mod-
erately more eﬃcacious than low-potency antipsychotics, largely irrespective
of the comparator doses used; and that optimum doses of low-potency con-
ventional antipsychotics might not induce more EPS than new generation
drugs.
Other problems to consider when choosing an alternative agent include the
fact that SGA may be associated with weight gain, dyslipidemia, high blood
pressure, and ultimately with cardiovascular disease, diabetes, and metabolic
syndrome [191]. As when considering the use of typical agents (ie, haloperi-
dol), clinicians must consider these factors and weigh potential risks and ben-
eﬁts before prescribing these agents to a critically ill patient. Finally, there is
also evidence that some atypical agents may aggravate or cause delirium
(eg, clozapine, olanzepine), probably because of their anticholinergic poten-
tial [189]. Data on most atypical agents are limited to small case reports.
Horikawa and colleagues [192] conducted a prospective open trial on ris-
peridone for the treatment of delirium among medically ill patients (n ¼ 10).
They reported an overall eﬀectiveness of 80%, using doses of risperidone
between 0.5 mg to 2 mg per day. Side eﬀects included sedation in 30%
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results (n ¼ 10) with risperidone, using a mean daily dose of 0.75 mg. The
largest, open-label risperidone study was reported by Parellada and col-
leagues [194], who followed subjects hospitalized for a medical condition
(n ¼ 64). Once the diagnosis of delirium was established (based on the
DRS) treatment with risperidone was initiated. The investigators reported
improvements on all studied measures (ie, Clinical Global Impressions or
CGI scale, DRS, and MMSE) after 7 days of treatment. There was a very
low incidence of overall adverse eﬀects (3.1%) and no EPS reported. On
the other hand, there are at least four publications reporting risperidone-
induced delirium [195–198].
There are six publications reporting on the use of quetiapine for the treat-
ment of delirium. Torres and colleagues [199] reported improvements on
MMSEandDRS-R-98 in two subjects. Similarly, Al-Samarrai and colleagues
[200] reported on another two delirious subjects responding to quetiapine.
Sasaki and colleagues [201] reported on a prospective, open-label study
(n ¼ 12) of delirious subjects treated with a mean daily dose of quetiapine of
45mg plus or minus 31mg per day. They found amean duration of symptoms
of 4.8 plus or minus 3.5 days and improvements on MMSE, and reported no
signiﬁcant side eﬀects. Similarly, Kim and colleagues [202] reported on
another 12 subjects treated with a mean daily dose of quetiapine of 94 mg
plus or minus 23 mg per day. The mean duration of symptoms was 5.9 plus
or minus 2.2 days, as well as improvements on the clock drawing test and
MMSE. Pae and colleagues [203] treated 22 subjects with a mean daily dose
of quetiapine of 127.1 mg plus or minus 72.2 mg per day. In this group, the
meandurationof symptomswas 8.5 plus orminus 4.5 days, aswell as improve-
ments onDRS-R-98 andCGI.Again, no signiﬁcant side eﬀects were reported.
Maneeton and colleagues [204] studied the eﬀectiveness of quetiapine in the
management of delirium (n ¼ 22) in an open-label study. The means (SDs)
dose and duration (SD) of quetiapine treatment were 45.7 (28.7) mg per day
and 6.5 (2.0) days, respectively. Results show that the DRS and CGI-S scores
of days two to sevenwere signiﬁcantly lower than those of day 0 (P! .001) for
all comparisons. The incidence of side eﬀects was minimal. Finally, Balit and
colleagues [205] and Sim and colleagues [206] reported on a case each in which
quetiapine was the suspected cause of delirium.
There are several publications reporting the use of olanzapine for the
treatment of delirium. Kim and colleagues [207] reported on an open trial
(n ¼ 20) on the use of olanzapine for the treatment of delirium caused by
multiple medico-surgical conditions. The average olanzapine dose was
5.9 mg plus or minus 1.5 mg per day and the average duration of treatment
was 6.6 plus or minus 1.7 days. Their data showed improvement in the DRS
at relatively low doses (5.9 mg  1.5 mg per day) and no evidence of signif-
icant side eﬀects. Passik and Cooper [208] and Halil and colleagues [209]
reported a single case report each in which olanzepine was successfully
used in the treatment of delirium associated to a medical problem. Breitbart
696 MALDONADOand colleagues [210] conducted an open, prospective trial of olanzapine for
the treatment of delirium in hospitalized cancer patients (n ¼ 79). In this
sample, olanzepine was eﬀective in treating 76% of delirium patients as evi-
denced by the Memorial Delirium Assessment Scale (MDAS) [211], but
recorded problems with excessive sedation in 30% of patients. They also
described several factors signiﬁcantly associated with poorer response to
olanzapine treatment for delirium, including age greater than 70 years, his-
tory of dementia, central nervous system spread of cancer and hypoxia as
delirium etiologies, hypoactive delirium, and delirium of ‘‘severe’’ intensity
(as measured by an MDAS greater than 23). Robinson and colleagues
[212], Steil [213], Morita and colleagues [214], Samuels and Fang [215],
Prommer [216], Arora and Praharaj [217], and Lim and colleagues [218]
all reported on cases associated with olanzapine-induced delirium at thera-
peutic doses. Delirium has been reported as a side eﬀect in 54% of the cases
when large doses of olanzepine have been ingested in an overdose. Patients
with olanzapine-induced delirium had an increased length of hospital stay
and ICU admission rate (50%), and 70% of them required physical or
chemical restraint [219].
Aripiprazole has been described as an eﬀective treatment of delirium in two
case reports [220]. Straker and colleagues [221] reported on an open-label
series of subjects (n ¼ 14) treated with aripiprazole for management of delir-
ium used in a ﬂexible dosing range, from 5 mg per day to 15 mg per day,
titrated over a 7-day period, with dose increases on day 3 and day 7, as clin-
ically indicated. DRS-R-98 scores declined from 25.1 (5.2) on initial evalu-
ation to 9.4 (4.9) at treatment end-point. Fifty percent of the subjects (7 out of
14) had improved signiﬁcantly (ie,R 50% reduction in DRS-R-98 scores) by
day 5, while 12 of the 14 subjects had a reduction in their DRS-R-98 scores
greater than or equal to 50% by treatment end-point.
To date, there are two single case reports on the use of ziprasidone for the
management of delirium [222,223]. There is at least one open-label study
(n¼ 38) on the use of perospirone, a recently developed atypical antipsychotic
with potent serotonin 5-HT2 and dopamine D2 antagonist activity. Perospir-
one was eﬀective in 86.8% of patients (based onDRS-98 assessments) and the
eﬀect appearedwithin several days (5.1 4.9 days). The initial dosewas 6.5mg
plus or minus 3.7 mg per day and maximum dose of perospirone was 10.0 mg
plus or minus 5.3 mg per day. Reported side eﬀects included fatigue (15.2%),
sleepiness (6.1%), akathisia (3.0%), and hypotension (3.0%) [224].
There is little published data regarding controlled studies of atypical
antipsychotics for the treatment of delirium. Sipahimalani and Masand
[225] conducted a single-blind study using olanzepine versus haloperidol.
Eleven subjects with delirium were treated, using a mean daily dose of
olanzepine of 8.2 mg plus or minus 3.4 mg versus haloperidol 5.1 mg plus
or minus 3.5 mg per day. Peak response (ie, the number of days the patient
received the neuroleptic before achieving maximum improvement) was
similar in both groups (mean  SD: 6.8  3.5 days for olanzapine and
697DELIRIUM IN THE ACUTE CARE SETTING7.2  4.9 days for haloperidol, P ¼ .8279). Mean plus or minus SD pretreat-
ment DRS scores were comparable in the olanzepine (17.9  4.4) and the
haloperidol (20.1  5.2) groups (P ¼ .2968). Mean plus or minus SD af-
ter-treatment DRS scores were 10.3 plus or minus 4.8 for the olanzapine
group and 11.1 plus or minus 7.1 for the haloperidol group (P ¼ .7601).
The mean improvement was 7.6 for the olanzapine group and 10 for the hal-
operidol group. Five of the olanzapine subjects and six of the haloperidol
subjects showed a greater than 50% reduction in their DRS scores.
Schwartz and Masand [226] performed a single-blind study of quetiapine
versus haloperidol in delirious subjects (n¼ 11). The quetiapine average daily
dosewas 200mg per day. The investigators reported an eﬀectiveness of greater
than or equal to 50% in reducing DRS scores. When compared with haloper-
idol, there was no diﬀerence in onset of symptom resolution, duration of
treatment, and overall clinical improvement. Skrobik and colleagues [227]
conducted an open-label, prospective randomized trial, comparing the use of
enteral olanzepine (dosed at 5 mg per day) or haloperidol (dosed at 2.5 mg–5
mgevery 8hours) in the treatment of delirium in a critical care setting.Delirium
Index decreased over time in both groups, as did the administered dose of ben-
zodiazepines. Clinical improvement was similar in both treatment arms. The
dose of rescue haloperidol, opiates, sedatives other than benzodiazepines,
Ramsay scores, vital signs, and liver function tests were no diﬀerent between
groups. Thus, no signiﬁcant clinically eﬀective diﬀerence was appreciated
between groups. Liu and colleagues [228] conducted a single-blind risperidone
versus haloperidol study. They treated 41 subjects with a mean daily dose of
risperidone of 1.2 mg plus or minus 0.75 mg per day. The investigators found
no signiﬁcant diﬀerence in the eﬃcacy or frequency of response rate between
haloperidol and risperidone on any of the measures (ie, DRS, MDAS).
The only published double-blind, randomized study looked at 28 subjects
with delirium who were randomly assigned to receive a ﬂexible-dose regimen
of haloperidol or risperidone over a 7-day treatment period [229]. The sever-
ity of delirium was assessed by using the MDAS and the DRS. The study
investigators found no signiﬁcant diﬀerence in the eﬃcacy, frequency, or
rate of response between haloperidol and risperidone on any of the mea-
sures. Similarly, there were no clinically signiﬁcant side eﬀect diﬀerences
among study groups.
A Cochrane Database review study looking at the use antipsychotics for
the treatment of delirium was conducted and included haloperidol and all
atypical antipsychotics for which data has been published [230]. Only three
studies met the design criteria. These compared haloperidol with risperi-
done, olanzapine, and placebo in the management of delirium and the inci-
dence of adverse drug reactions. The authors concluded that the decreases in
delirium scores were not signiﬁcantly diﬀerent comparing the eﬀect of low
dose haloperidol (! 3.0 mg per day) with the atypical antipsychotics olan-
zapine and risperidone (OR 0.63; 95% CI, 10.29–1.38; P ¼ .25), and that
low-dose haloperidol did not have a higher incidence of adverse eﬀects
698 MALDONADOthan the atypical antipsychotics. Finally, low-dose haloperidol may be eﬀec-
tive in decreasing the degree and duration of delirium in postoperative
patients, compared with placebo.
Ozbolt and colleagues [231] conducted a search of the published literature
on atypical antipsychotic agents for the treatment of delirium using MED-
LINE and PubMed for articles (including review articles, randomized con-
trolled trials, clinical trials, or meta-analyses) written in English. They found
that risperidone was the most thoroughly studied atypical antipsychotic for
the management of delirium. In most studies, risperidone was found to be
approximately 80% to 85% eﬀective in treating the behavioral disturbances
of delirium at doses of 0.5 mg to 4 mg per day. The search indicates that
olanzapine was approximately 70% to 76% eﬀective in treating the behav-
ioral manifestations of delirium at doses of 2.5 mg to 11.6 mg per day. There
were very few studies conducted using quetiapine, although available data
suggests that it also appears to be a safe and eﬀective alternative to high-
potency antipsychotics. In the limited number of trials comparing atypical
antipsychotics to haloperidol, haloperidol consistently produced a higher
rate (an additional 10% to 13%) of extrapyramidal side eﬀects.
Antipsychotics are widely used to manage behavioral disorders, including
delirium, in patients with dementia. Recently, serious concerns have been
raised about the stroke and mortality risk of atypical antipsychotics when
administered to patients with dementia. Schneider and colleagues [232]
reviewed 15 clinical trials, including 16 contrasts of atypical antipsychotic
drugs with placebo (aripiprazole [n ¼ 3], olanzapine [n ¼ 5], quetiapine
[n ¼ 3], risperidone [n ¼ 5]) and a total of 3,353 subjects randomized to
study drug versus 1,757 randomized to placebo. The investigators found
that death occurred more often among patients randomized to drugs (118
or 3.5% versus 40 or 2.3%; the OR by meta-analysis was 1.54; 95% CI,
1.06–2.23; P ¼ .02; RD 0.01; 95% CI, 0.004–0.02; P ¼ .01). The results sug-
gested that atypical antipsychotic drugs may be associated with a small
increased risk for death compared with placebo.
Yet, an even more recent study by Raivio and colleagues [233] examined
the use of antipsychotic agents to manage behavioral disorders in patients
(n ¼ 254) with dementia. In this sample, nearly half (48.4%) of the patients
were administered antipsychotic medication. A total of 37.4% received con-
ventional neuroleptics (n ¼ 95), while only 11.0% received atypical antipsy-
chotics (n ¼ 28). The mean number of hospital admissions was higher
among the non-users than among the users of conventional or atypical
antipsychotics. Among the users of atypical antipsychotics (eg, risperidone,
olanzapine), 32.1% died within 2 years, compared with 45.3% in the con-
ventional neuroleptics group, and 49.6% in the non-neuroleptic user group.
In the Cox proportional hazard model, a high number of medications and
the use of physical restraint predicted higher mortality at 2 years. On the
other hand, the use of atypical antipsychotics showed lower risk of mortal-
ity, if any. The investigators concluded that neither the use of atypical
699DELIRIUM IN THE ACUTE CARE SETTINGantipsychotics, nor the use of conventional neuroleptics increased mortality
or hospital admissions.
One study pooled QTc interval data from acutely agitated patients across
four double-blind trials and showed that when all of the intramuscular olan-
zapine data were considered, QTc interval changes were small, variable, and
generally symmetric at around 0, suggesting that these values were reﬂective
of normal and random intra-individual variability [234]. A series of case
reports by Balit and colleagues [205] implicated that quetiapine poisoning
was associated with an increase in the mean QTc interval. The FDA has
published data on the eﬀect of atypical antipsychotics on QTc interval
(Table 6). Yet, no new generation antipsychotic drug has been associated
with Torsade de Pointes. All of them have been associated with QTc interval
prolongation. In order of degree, QTc interval prolongation is greatest with
ziprasidone and least with olanzepine [235].
Finally, one must consider the fact that newer antipsychotic agents
(SGA) have a wider range of pharmacologic aﬃnity (ie, aﬀects a greater
number of neurotransmitters and receptors) than older agents. Although
SGA may have lower EPS side eﬀects, they have other undesirable side ef-
fects, such as high sedation and anticholinergic activity (Fig. 9). The sedative
eﬀect may be considered desirable in the case of agitated agents, although
given the agents relatively long half-lives this may later aﬀect attention
and cognition and be detrimental in cases of hypoactive delirium. On the
other hand, anticholinergic side eﬀects are never desirable when it comes
to delirium and this may be a consideration when making treatment choices.Nonantipsychotic agentsAddressing the theory that proposes delirium is caused by a central cho-
linergic deﬁciency state, some researchers and clinicians have experimented
with the use acetylcholinesterase inhibitor agents. Most of the published
data consists of small series of case reports associated with the use of riva-
stigmine in the treatment of delirium in older persons [236,237]. There have
been at least 19 articles, mostly case reports, suggesting thatTable 6
Eﬀects of orally-administered antipsychotics on the QT interval
Drug Mean increase in QTc (ms) % of subjects with O 60 ms increase in QTc
Thioridazine 35.8 29
Ziprasidone 20.6 21
Quetiapine 14.5 11
Risperidone 10.0 4
Olanzapine 6.4 4
Haloperidol 4.7 4
Data from Huﬀman JC, Stern TA. QTc Prolongation and the use of antipsychotics: A case
discussion. Primary Care Companion to the Journal of Clinical Psychiatry 2003;5(6):278–81.
Fig. 9. Binding of atypical antipsychotics at dopamine 2 (D2) and muscarinic receptors (MR).a
700 MALDONADOacetylcholinesterase inhibitor agents (eg, donepezil, galantamine, physostig-
mine, rivastigmine) may be eﬀective in the treatment of delirium (Box 6).
Some have theorized that an impaired serotonin metabolism may play
a role in the development of delirium. At least one report suggests that
the antiemetic agent ondansetron (ie, a selective serotonin 5-HT3-type recep-
tor antagonist) may be eﬀective in the treatment of delirium. Bayindir and
colleagues [238] conducted a prospective study of patients (n ¼ 35) who
developed delirium in the intensive care unit after coronary artery bypass
graft surgery. The investigators developed a behavioral scoring scale, withBox 6. Case reports suggesting a positive effect
of acetylcholinesterase inhibitors in the treatment of delirium
Burt 2000 [281]
Bruera, et al 2003 [282]
Dautzenberg, et al 2004 [236]
Fisher, et al 2001 [283]
Gleason 2003 [284]
Hasse and Rundshagen 2007 [285]
Hori, et al 2003 [286]
Kaufer, et al 1998 [287]
Kobayashi, et al 2004 [82]
Logan and Stewart 2007 [288]
Moretti, et al 2007 [266]
Palmer 2004 [289]
Rabinowitz 2002 [290]
Weizberg, et al 2006 [291]
Wengel, et al 1998 [292]
Wengel, et al 1999 [293]
701DELIRIUM IN THE ACUTE CARE SETTINGnormal scored as 0, and severe verbal and physical agitation was scored as 4.
After a subject was determined to be delirious, patients received a single IV
dose of ondansetron (ie, 8 mg), and were re-evaluated 10 minutes later. Be-
fore the treatment, 7 subjects had a score of 2 (20%); 10 subjects had a score
of 3 (28.6%); and 18 subjects had a score of 4 (51.4%). After the treatment,
28 subjects (80%) dropped their score to 0; 6 subjects (17.1%) dropped to
a score of 1, and 1 subject (2.9%) remained at a score of 4. The mean score
dropped from 3.20 plus or minus 1.01 to 0.29 plus or minus 0.75 after treat-
ment. No adverse side eﬀects were reported.What about the treatment of hypoactive delirium?This is a diﬃcult aspect to discuss, as there is no available literature to
guide us. As discussed above, most of these cases are unrecognized or mis-
diagnosed as depression. In either case, lack of recognition and treatment
leads to the same poor outcomes previously described. Therefore, vigilance
and screening, particularly in high-risk populations is imperative. Early
intervention by specialized clinicians (eg, Psychosomatic Medicine Service
or Geropsychiatric Service) has been shown to improve outcomes. Overall,
several clinical principles apply: (1) prevention is key (see next section);
(2) all other factors described above under nonpharmacologic approaches
apply; (3) if pharmacologic agents are to be used, consider the least sedating
available agents, such as haloperidol (for typical) or risperidone (for atypi-
cal). Furthermore, take into consideration the anticholinergic potential of
the antipsychotic agent use (see Fig. 9). There may be reasons to consider
use of nonantipsychotic agents (as described in the section above) to accel-
erate the rate of recovery and prevent further deterioration of cognitive sta-
tus, but good controlled studies are lacking. Similarly, given the mechanism
of delirium development, there may be a rationale for the use of very low
doses of nonsedating antipsychotic agents (see the article by Maldonado ti-
tled, A Comprehensive Multifoactorial Understanding of the Neurobiology
of Delirium and an Evidence-based Approach to Prevention & Treatment,
elsewhere in this issue). Similarly, the use of activating agents (eg, modaﬁnil
and psychostimulants) may help mobilize hypoactive patients, particularly
to address extreme psychomotor retardation and extreme somnolence
once all potential contributing pharmacologic agents (eg, sedatives, opioids)
have been removed.Prevention of delirium
As described above, there are many risks factors for the development of
delirium. Controlling for some of these may better assist on delirium preven-
tion. The majority of patients in the ICU, particularly those who are
mechanically ventilated, receive some form of sedation to reduce anxiety,
encourage sleep, and to increase tolerance to the critical care environment,
702 MALDONADOincluding multiple lines, pain management, endotracheal tubes, and ventila-
tors. Sedative and analgesic drugs are among the most commonly prescribed
medications in the ICU [239]. As discussed above (see etiology section), sed-
ative agents (mostly GABAergic) and opioids may contribute to the devel-
opment of delirium by one of ﬁve mechanisms: (1) interfering with
physiologic sleep patterns; (2) interfering with central cholinergic function;
(3) increasing compensatory up-regulation of N-methyl D-aspartate and
kainite receptors and Ca2þ channels; (4) disrupting the circadian rhythm
of melatonin release; and (5) disrupting thalamic gating function. To try
to prevent delirium altogether, Maldonado and colleagues [240] were the
ﬁrst to report on the use of novel agents as alternative sedation in order min-
imize delirium by avoid the use of benzodiazepines and related agents
(eg, midazolam, propofol) during the postoperative state. Postcardiotomy
patients were selected, given the high incidence of delirium in postcardiot-
omy patients (around 57%) nationwide [26].
In the ﬁnal analysis, Maldonado and colleagues [241] studied patients
(n ¼ 118) undergoing cardiac surgery (ie, repair or replacement) with CPB.
Intraoperative anesthesia for the surgical procedures was standardized for
all subjects.All procedureswere performedviamedian sternotomy in conjunc-
tionwithCPBand inductionofmoderate hypothermia.After successfulwean-
ing from CPB, subjects were started on one of three randomly assigned,
postoperative sedation regimens: dexmedetomidine, propofol, or midazolam.
Upon arrival at the ICU, a standardized protocol for postoperative care was
implemented for all subjects. Study results show there were no signiﬁcant
preoperative or intraoperative diﬀerences between treatment groups (eg,
age, sex, American Society of Anesthesiologists classes, bypass time, clamp
time, or lowest temperature achieved). The only real diﬀerence inmanagement
between groups was the type of postoperative sedation. Final results demon-
strated an incidence of delirium of 3% (1 out of 30) for subjects on dexmede-
tomidine, 50% (15 out of 30) for propofol, and 50% (15 out of 30) for
midazolam (P! .01) (Fig. 10). The absolute risk reduction in the incidence
of delirium associated with using dexmedetomidine was 47% (95% CI,
28%–66%) corresponding to anNTT (number needed to treat) of 2.1 subjects
(95% CI, 1.5–3.6). As in other studies, subjects who developed postoperative
delirium experienced signiﬁcantly longer intensive care stays (4.1 versus
1.9 days, P ! .001) and longer total hospitalization (10.0 versus 7.1 days,
P! .001) compared with subjects without delirium. The average age of sub-
jects who developed delirium was signiﬁcantly older than those who did not
(64.9  15.9 versus 52.9  16.1 years, P! .001) (Table 7).
Even though previous reports have suggested that the cognitive decline
observed after cardiac surgery could be attributed to the use of the CPB
pump [110,242,243], Van Dijk and colleagues [244] found no diﬀerence in
cognitive outcomes in cardiac patients operated with the aid of CPB
and without (oﬀ-pump), suggesting that factors other than CPB may be
responsible for cognitive decline after cardiac surgery. Maldonado and
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Fig. 10. Dexmedetomidine prophylaxis in postsurgical valve disease patients versus dexmedeto-
midine. P !.01, adjusted for comparing multiple group means. (From Maldonado J, Wysong
A, van der Starre PJA, et al. Dexmedetomidine and the reduction of postoperative delirium
after cardiac surgery. Accepted for publication. Psychosomatics. 2008; with permission.
Copyright  2008, American Psychiatric Association.)
703DELIRIUM IN THE ACUTE CARE SETTINGcolleagues [241] study results support this theory, and suggest that postop-
erative sedation, not the CPB, is an independent negative factor for mental
status changes (ie, delirium) in cardiac surgery patients.
The investigators proposed at least two sets of theories used to explain
the fact that patients in the dexmedetomidine group experienced a lower
incidence of postoperative delirium [241]. The ﬁrst theory suggests that dex-
medetomidine has intrinsic ‘‘delirium-sparing eﬀects.’’ Several speciﬁc char-
acteristics of the drug may account for this eﬀect. First, studies have
suggested that the likelihood of delirium is increased with the number of
neurotransmitter pathays disrupted [245–247]. Dexmedetomidine asserts
its sedative eﬀects by blocking a single neurotransmitter, norepinephrine,
via aB2B-adrenoceptor binding. The second characteristic is its eﬀect in pre-
synaptic noradrenergic transmission. Changes in the noradrenergic system
have been described as potential causative factors in delirium, with increased
levels of plasma free-MHPG (3-methoxy-4-hydrophenylglycol) concentra-
tion observed in some delirious states [246,248]. Third, dexmedetomidine
produces sedation without respiratory depression [249]. Studies have dem-
onstrated that hypoxia and anoxia in the central nervous system are critical
events leading to the biomolecular derangements in delirium [245,250], while
others [66] have reported lower postoperative oxygen saturation in postthor-
acotomy patients who developed delirium, compared with patients who did
not develop delirium with the resolution of mental status changes after
oxygen supplementation. Fourth, dexmedetomidine lacks clinically signiﬁ-
cant anticholinergic eﬀects and, in fact, has some mild cholinergic activation
[251]. A strong association has been documented between medications with
anticholinergic potential and the development of delirium [86,88,90]. Fifth,
several studies have suggested that postoperative sedation with dexmedeto-
midine has been associated with lower opioid requirements, an average of
Table 7
Selected postoperative outcome variables for cardiac patients with cardiopulmonary bypass by intervention group
Dexmedetomidine
(n ¼ 30)
Propofol
(n ¼ 30)
Midazolam
(n ¼ 30)
overall
p-value
Dex
versus propofol
Dex
versus
midazolam
Delirium
Incidence of delirium
(per protocol)
1/30 (3%) 15/30 (50%) 15/30 (50%) !0.001 !0.001 !0.001
Incidence of delirium (ITT) 4/40 (10%) 16/36 (44%) 17/40 (44%) !0.001 0.001 0.002
Number of days delirious 2/216 (1%) 45/276 (16%) 75/259 (29%) !0.001 !0.001 !0.001
Average length of delirium
Pa(days)
2.0  0 3.0  3.1 5.4  6.6 0.82 0.93 0.63
Time variables
ICU length of stay (days) 1.9  .9 3.0  2.0 3.0  3.0 0.11 0.14 0.14
Hospital length of stay (days) 7.1  1.9 8.2  3.8 8.9  4.7 0.39 0.42 0.12
Intubation time (hours) 11.9  4.5 11.1  4.6 12.7  8.5 0.64 0.91 0.34
As needed medications
Fentanyl (mcg) 320  355 364  320 1,088  832 !0.001 0.93 !0.001
Total morphine equivalents (mg)Pb 50.3  38 51.6  36 122.5  84 !0.001 0.99 !0.001
Antiemetic usec 15/30 (50%) 17/30 (57%) 19/30 (63%) 0.58
As needed medications for the management of deliriumd
Lorazepam 1/30 (3%) 7/30 (23%) 6/30 (20%) 0.07 0.06 0.11
Haloperidol 0/30 3/30 (10%) 2/30 (7%) 0.23 0.07 0.15
a Of patients who developed delirium.
b Sum of average morphine equivalents (fentanyl, oxycodone, and hydrocodone) received in postoperative days 1 to 3.
c Number of patients who received dolasetron mesylate or promethazine HCl in postoperative day 1.
d Average amount over 3 days. None of these medications were given until a diagnosis of delirium was established.
Data from Maldonado J, Wysong A, van der Starre PJA, et al. Dexmedetomidine and the reduction of postoperative delirium after cardiac surgery.
Accepted for publication, Psychosomatics 2008, in press; with permission.
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705DELIRIUM IN THE ACUTE CARE SETTING40% lower [252,253]. This is signiﬁcant, as studies have demonstrated
a direct relationship between opiate use and development of delirium
[254,255]. Sixth, dexmedetomidine is believed to promote a more physio-
logic sleep-wake cycle in the ICU setting [249,256]. This is important, as
sleep deprivation and disruption have been implicated in the onset and per-
petuation of delirium [166]. Finally, dexmedetomidine has been shown to
have neuroprotective eﬀects [257] in animal models of ischemia [258] and
in human beings undergoing cardiac surgery [259].
The second theory suggests that the reason subjects had signiﬁcantly less
delirium in the dexmedetomidine group was not because of its use per se, but
because those subjects were not exposed to other sedative agents with much
greater delirium potential. As suggested by many others, GABAergic agents
(ie, propofol, midazolam) have been implicated in the development of delir-
ium. In fact, GABAergic medications and narcotics are among the factors
associated with the onset and worsening of delirium [20,41,95,96], by inter-
fering with physiologic sleep patterns and causing a centrally mediated
acetylcholine deﬁcient state, via interruption of central cholinergic musca-
rinic transmission at the level of the basal forebrain and hippocampus
[95,97,245]. These may be mechanisms by which midazolam or propofol
may contribute to higher rates of delirium [41,96]. Midazolam and propofol
were speciﬁcally chosen as comparators, given these agents are customarily
used in routine medical practice throughout critical and intensive care
settings, and are both commonly used for postoperative sedation after car-
diac surgery.Antipsychotic agents for prevention of deliriumAntipsychotic agents have longbeenused for the treatment of thebehavioral
symptomsofdelirium.Somesuspect that they couldbeused topreventdelirium
aswell. At least one randomized, controlled trial addressed the issue of prophy-
lactic haloperidol. In at-risk patients aged greater than 70 years, oral haloper-
idol 0.5 mg twice a day was administered from up to 72 hours preoperatively
until the third postoperative day. The study found that prophylactic haloperi-
dol use did not alter the incidence of postoperative delirium (15.1%) compared
with placebo (16.5%; relative risk or RR 0.91; 95% CI, 0.59–1.44) [260].
On the other hand, in another study, elderly patients (n ¼ 430) undergo-
ing hip surgery were given 1.5-mg haloperidol per day or placebo, started
preoperatively and continued for up to 3 days postoperatively [261]. Neuro-
psychiatric evaluations demonstrated that the overall incidence of postoper-
ative delirium was 15.8%, but that subjects in the haloperidol group had
a slightly lower incidence compared with placebo (15.1% versus 16.5%)
(RR 0.91, 95% CI, 0.6–1.3); the mean highest DRS-R-98 score plus or mi-
nus SD was 14.4 plus or minus 3.4 and 18.4 plus or minus 4.3, respectively
(mean diﬀerence 4.0, 95% CI, 2.0–5.8; P ! .001); delirium duration was
5.4 versus 11.8 days, respectively (mean diﬀerence 6.4 days, 95% CI,
706 MALDONADO4.0–8.0; P ! .001); and the mean number of days in the hospital was
17.1 plus or minus 11.1 and 22.6 plus or minus 16.7, respectively (mean dif-
ference 5.5 days, 95% CI, 1.4–2.3; P ! .001). No haloperidol-related side
eﬀects were noted. Thus, the study suggests that although prophylactic
treatment with low-dose haloperidol had no eﬃcacy in reducing the inci-
dence of postoperative delirium, it did have a positive eﬀect on the severity
and duration of delirium and shortened the length of hospital stay.
Prakanrattana and Prapaitrakool [262] conducted a randomized, double-
blinded, placebo controlled trial (n ¼ 126) of patients undergoing cardiac
surgery with CPB. Subjects were randomly assigned to receive either 1-mg
risperidone or placebo sublingually when they regained consciousness
(ie, immediately after surgery). They found that the incidence of postopera-
tive delirium in the risperidone group was lower than the placebo group
(11.1% versus 31.7% respectively, P ¼ .009, RR 0.35, 95% CI, 0.16–
0.77). A recently presented abstract reported a signiﬁcant decreased in the
incidence of postoperative delirium following orthopedic joint replacement
surgery (n ¼ 400). The study compared olanzepine (5-mg Zydis formulation,
administered just preoperatively, and 5 mg administered immediately after
surgery upon awakening) to placebo. Researchers found the incidence of
delirium in the intervention group was 15%, compared with 41% in the
placebo-controlled group (P ! .0001) [263].Acetylcholinesterase inhibitors in delirium preventionDespite the logical premise behind the prophylactic use of acetylcholines-
terase inhibitor agents, two studies have failed to demonstrate eﬃcacy in the
prevention of postoperative delirium. The ﬁrst study was a randomized,
double-blind, placebo-controlled trial involving elderly patients undergoing
elective total joint replacement surgery (n ¼ 80) [264]. Each participant was
evaluated before surgery and then received donepezil or placebo for 14 days
before surgery and 14 days afterward. Delirium, diagnosed by DSM-IV cri-
teria, was found in 18.8% of subjects, but there were no signiﬁcant diﬀer-
ences between the donepezil and placebo groups. Subsyndromal delirium
was found in 68.8% of subjects, but again, there was no diﬀerence between
groups.
A second study also failed to demonstrate eﬃcacy of donepezil in pre-
venting postoperative delirium after elective total hip replacement surgery
in older people without pre-existing dementia (n ¼ 33) [265]. The investiga-
tors randomized (double-blind, placebo controlled) subjects to receive either
placebo or donepezil (5 mg) immediately postoperatively and every 24 hours
thereafter for the ﬁrst 3 postoperative days, with no serious adverse events
reported. The overall incidence of postoperative delirium was 21.2% in all
subjects, but there was no signiﬁcant diﬀerence between the groups. The
unadjusted risk ratio (donepezil versus placebo) for delirium was 0.29
(95% CI, 0.06, 1.30). The mean length of hospital stay was 9.9 days for
707DELIRIUM IN THE ACUTE CARE SETTINGthe donepezil group versus 12.1 days in the placebo group; diﬀerence in
means equals 2.2 days (95% CI, 0.39, 4.78).
There have been some positive trials involving other agents. A study of
dementia patients (n ¼ 366) demonstrated that the chronic rivastigmine
(a slowly reversible inhibitor of acetylcholinesterase and butyrylcholinester-
ase) group had a much lower incidence of delirium (45.5%), compared with
the control group (88.9%) (P ! .05) [236]. Another study has also demon-
strated a decrease in the occurrence and duration of delirium in elderly
patients (n ¼ 246) suﬀering from vascular dementia [266]. Subjects were
divided into two homogenous groups (matched for age and education
levels): Group A received 3-mg to 6-mg rivastigmine per day, while Group B
received 100-mg cardioaspirin per day. Both groups presented episodes of
delirium, which occurred during a concomitant medical illness. During the
follow-up period, the incidence of delirium was 40% in Group A versus
62% in group B (P ! .001). Moreover, the mean duration of the delirium
was shorter in Group A (mean duration 4  1.71 days) compared with
Group B (7.86  2.73 days; P ! .01).Other pharmacologic agents as prevention strategiesA randomized, double-blind study involving children (n ¼ 85) undergo-
ing dental repair studied the eﬀectiveness of ketamine (versus placebo) for
the prevention of delirium in sevoﬂurane-induced anesthesia using the Pedi-
atric Anesthesia Emergence Delirium scale. The study demonstrated a sub-
stantially lower incidence of emergence agitation in the ketamine group
(16.6%) compared with the placebo group (34.2%). There was no diﬀerence
in time to meet recovery room discharge criteria between the two groups
[267].Nonpharmacologic prevention strategiesStill, not all proposed prophylactic methods are pharmacologic. Inouye
and colleagues [166] conducted a landmark study of hospitalized patients
(n ¼ 852) and assessed for manifestations of delirium in response to the cor-
rection of environmental factors commonly associated with increased risk
for delirium. The intervention consisted of simple techniques applied by
the hospital staﬀ, including reorientation, appropriate cognitive stimulation
three times a day, the implementation of a nonpharmacologic sleep protocol
to help normalize a patient’s sleep-wake cycle, early mobilization after
surgery or extubation, timely removal of catheters and restraints, correction
of sensory deﬁciencies (ie, eyeglasses and hearing aids), and early cor-
rection of dehydration and electrolyte abnormalities. As a result to these en-
vironmental manipulations, they observed an astonishing 40% reduction in
odds for delirium (Fig. 11).
Another study looked at the eﬀectiveness of proactive geriatric consulta-
tion compared with usual care (ie, control group) in reducing delirium in
Fig. 11. A multicomponent intervention to prevent delirium in hospitalized older patients.
(From Inouye SK, Bogardus ST, Charpentier PA, et al. A multicomponent intervention to
prevent delirium in hospitalized older patients. N Engl J Med. 1999;340(9):674; with permission.
Copyright  1999, Massachusetts Medical Society.)
708 MALDONADOa group of patients 65 and older (n ¼ 126) admitted emergently for surgical
repair of hip fracture [114]. There were no statistical diﬀerences between
intervention and control groups regarding baseline measures and character-
istics. The results suggest a reduction in the occurrence of delirium in the
intervention group (32%) compared with usual care (50%) (P ¼ .04), repre-
senting a relative risk of 0.64 (95% CI, 0.37–0.98) for the consultation
group. One case of delirium was prevented for every 5.6 subjects in the
geriatrics consultation group. There was an even greater reduction in cases
of ‘‘severe delirium,’’ occurring in 12% of intervention subjects and 29% of
usual-care subjects, with a relative risk of 0.40 (95% CI, 0.18–0.89). Despite
this reduction in delirium, length of stay did not signiﬁcantly diﬀer between
intervention and usual-care groups (median  interquartile range ¼ 5 
2 days in both groups), likely because protocols and pathways predeter-
mined length of stay.
Lundstro¨m and colleagues [268] randomly assigned elderly patients
(n ¼ 190) after femoral neck fracture repair to postoperative care in a spe-
cialized geriatric ward (ie, intervention group) or a conventional orthopedic
ward. The intervention consisted of staﬀ education focusing on the assess-
ment, prevention, and treatment of delirium and associated complications.
As a result of the intervention, the number of days of postoperative delirium
was fewer (5.0  7.1 days versus 10.2  13.3 days, P ¼ .009) compared with
controls. A lower proportion of intervention subjects were delirious postop-
eratively than controls (54.9% versus 75.3%, P ¼ .003). Similarly, subjects
in the intervention group suﬀered from fewer complications (eg, decubitus
ulcers, urinary tract infections, nutritional complications, sleeping problems,
and falls). Overall, the total postoperative hospitalization was shorter in the
intervention ward (28.0  17.9 days versus 38.0  40.6 days, P ¼ .028),
suggesting that prevention methods can have a signiﬁcant impact on
709DELIRIUM IN THE ACUTE CARE SETTINGpostoperative delirium, resulting in fewer days of delirium, lower incidence
of medical complications, and shorter length of hospitalization.
Others have studied the use of light therapy as a method of maintaining
or restoring the natural circadian rhythm [269]. The investigators followed
patients (n ¼ 11) after esophageal cancer and after removal of the endotra-
cheal tube. Subjects were either exposed to therapeutic lighting (ie, 5,000 lx
at a distance from the light source of 100 cm; study group), or placed in
a natural lighting environment (control group) after extubation. The study
found that the incidence of delirium was 16% in the study group compared
with 40% in the control, group suggesting that alterations in circadian
rhythm may serve as a possible contributor to the development of delirium.
It also suggests that light therapy may serve as potential prophylaxis or
treatment option.
Finally, a Cochrane database review study was conducted (searching the
Specialized Register of the Cochrane Dementia and Cognitive Improvement
Group and searches in MEDLINE, EMBASE, CINAHL and PsycINFO
for delirium prevention trials; searched on October 28, 2005) to assess the
eﬀectiveness of interventions for preventing delirium in hospitalized patients
[270]. The ﬁnal analysis included only six randomized, controlled trials. The
researchers found there was heterogeneity in methods, participants, and out-
comes examined. The investigators concluded that at the time of their search
there was little evidence from delirium prevention studies to guide clinical
practice. In summary, there was no trial evidence available on the eﬀectiveness
of pharmacologic strategies. Based on a single study, the investigators suggest
that prophylactic low-dose haloperidol may reduce severity and duration of
delirium episodes and shorten length of hospital admission in hip surgery,
but that further studies of delirium prevention are needed. A study on the
proactive use of geropsychiatric consultations showed favorable results in
reducing the severity and duration of postoperative hip surgery.Summary
Delirium is a neurobehavioral syndrome caused by the transient disrup-
tion of normal neuronal activity secondary to systemic disturbances. It is
also the most common psychiatric syndrome found in the general hospital
setting, its prevalence surpassing most commonly known psychiatric syn-
dromes. In addition to causing distress to patients, families, and medical
caregivers, the development of delirium in general, and postoperative delir-
ium in particular, has been associated with increased morbidity and mortal-
ity, increased cost of care, increased hospital-acquired complications, poor
functional and cognitive recovery, decreased quality of life, prolonged hos-
pital stays, and increased placement in specialized intermediate and long
term care facilities. Given increasing evidence that delirium is not always
reversible and the many sequelae associated with its development, physi-
cians must do everything possible to prevents its occurrence or shorten its
710 MALDONADOduration by recognizing its symptoms early, correcting underlying contrib-
uting causes, and using treatment strategies proven to help recover func-
tional status.References
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The elderly (65þ) population, comprised of 36.3 million people, is the
fastest growing sector of the United States population [1]. Most of the 5 mil-
lion elders suﬀering from dementia in the United States belong to this age
group, and the number of dementia cases in the United States is expected
to triple unless a cure or a preventive strategy is developed [2]. This rapid
increase in the elderly population and the associated incidence of dementia
cases is of critical importance to ICUs around the country because patients
in this age group currently account for 42% to 52% of ICU admissions [3,4]
and for more than half of all ICU days [5].
With or without pre-existing cognitive impairments, such as mild cogni-
tive impairment (MCI) or dementia, the application of critical care provides
life-saving beneﬁt to older persons. Pre-existing cognitive impairment does
put a patient at heightened risk for complications from intensive care inter-
ventions because of their increased vulnerability. For example, patients with
dementia have been known to be at the highest risk for developing delirium
and subsequent poor ICU outcomes [6]. Although the detection and man-
agement of delirium has garnered much interest from critical care specialists,
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724 LEE et alsparse data are available to guide intensivists in detection and care of
patients with dementia in the ICU. This article reviews broadly the available
literature on the impact of pre-existing cognitive impairment in care of ICU
patients and provides an overview on detection and care of dementia
patients for clinicians in the ICU setting.Deﬁnitions of delirium and pre-existing cognitive impairment
Delirium is a disorder of sensorium or level of consciousness. Conscious-
ness, deﬁned as a function of the nervous system, is concerned with the per-
ceptual experience of information from the environment and from one’s
own body. The American Psychiatric Association’s Diagnostic and Statisti-
cal Manual of Mental Disorders, 4th edition (DSM-IV) deﬁnes delirium as
a syndrome of disturbed consciousness, which results in a change in cogni-
tion (memory, disorientation, or language disturbance) or in perception
from baseline, and is not caused by dementia [7].
Dementia is deﬁned as ‘‘global decline of cognitive capacity in clear con-
sciousness’’ [8]. There are three elements to the deﬁnition of dementia. First,
the term ‘‘global’’ means that multiple areas of cognition are impaired.
Unlike aphasia or amnestic syndrome, dementia means that more than
one area of cognition is impaired. In addition to impairment in memory,
other cognitive domains, such as language, abstraction, calculation, percep-
tion, and judgment, are impaired. Second, ‘‘decline’’ means deterioration
from previous level of cognitive capacity. This element distinguishes demen-
tia from other cognitive disorders, such as mental retardation and learning
disorders, which are present from birth. Additionally, the level of decline
should be severe enough to impair one’s daily activities. This level of
decline distinguishes dementia from MCI. Finally, ‘‘in clear consciousness’’
means that the level of consciousness is not impaired. This element distin-
guishes dementia from delirium. Box 1 lists the DSM-IV criteria for the
diagnosis of dementia of the Alzheimer’s type, the most common form
of dementia [7].
Most patients with dementia experience measurable cognitive decline
before actually meeting the criteria for dementia [9]. The clinical entity of
MCI represents the boundary of normal aging and early dementia. It refers
generally to complaints of memory functioning in elderly people, which are
judged to have a high probability of progressing toward Alzheimer’s demen-
tia. The cognitive deﬁcits in a MCI patient are detectable, yet unlike in
a patient with dementia, they are not severe enough to impair daily activities
(Box 2) [9]. It has been estimated that 17% of the elderly population meet
criteria for MCI [10,11], and of those, 10% to 15% progress to dementia
every year compared with healthy control subjects [12,13]. ‘‘Pre-existing cog-
nitive impairment’’ (PCI) is a broader term that refers to either dementia or
MCI that is present in chronic form before hospital admission [14]. This
Box 1. DSM-IV criteria for the diagnosis of dementia
of the Alzheimer’s type
A. The development of multiple cognitive deficits manifested
by both
1. Memory impairment (impaired ability to learn new
information or to recall previously learned information)
2. One or more of the following cognitive disturbances
(a) Aphasia (language disturbance)
(b) Apraxia (impaired ability to carry out motor activities
despite intact motor function)
(c) Agnosia (failure to recognize or identify objects despite
intact sensory function)
(d) Disturbance in executive functioning (ie, planning,
organizing, sequencing, abstracting)
B. The cognitive deficits in criteria A1 and A2 each cause
significant impairment in social or occupational functioning
and represent a significant decline from a previous level of
functioning
C. The course is characterized by gradual onset and continuing
cognitive decline
D. The cognitive deficits in criteria A1 and A2 are not caused by
any of the following
(1) Other central nervous system conditions that cause
progressive deficits in memory and cognition (eg,
cerebrovascular disease, Parkinson’s disease,
Huntington’s disease, subdural hematoma, normal-
pressure hydrocephalus, brain tumor)
(2) Systemic conditions that are known to cause dementia
(eg, hypothyroidism, vitamin B or folic acid deficiency,
niacin deficiency, hypercalcemia, neurosyphilis, HIV
infection)
(3) Substance-induced conditions
E. The deficits do not occur exclusively during the course
of a delirium
725PRE-EXISTING COGNITIVE IMPAIRMENTdistinguishes pre-existing cognitive impairment from delirium or cognitive
impairments that may result directly from the illness or hospitalization.
Pre-existing cognitive impairment and incidence of delirium in the ICU
Based on a sample of medical ICU patients above age 65, Pisani and col-
leagues reported prevalence estimates of pre-existing cognitive impairment
to be approximately 31% to 37% [14,15]. These ﬁgures double the
Box 2. Criteria for amnestic MCI
Memory complaint, preferably corroborated by an informant
Impaired memory function for age and education
Preserved general cognitive function
Intact activities of daily living
Absence of dementia
Data from Petersen RC, Stevens JC, Ganguli M, et al. Practice parameter: early
detection of dementia: mild cognitive impairment (an evidence-based review).
Report of the Quality Standards Subcommittee of the American Academy of
Neurology. Neurology 2001;56:1133–42.
726 LEE et alprevalence rates of cognitive impairment reported for community dwelling
(10%–18%) and hospitalized non-ICU (20%) patients with pre-existing
cognitive impairment [14]. The same study found that patients who have
pre-existing cognitive impairments are signiﬁcantly older, more likely to
be women, less likely to be currently married, more likely to have been
admitted to the ICU from a nursing home, and more likely to have higher
APACHE II scores on ICU admission [14]. Between patients with and with-
out pre-existing cognitive impairments, however, no diﬀerence was found
between the two groups in terms of characteristics, such as education, num-
ber of comorbidities on admission, code status on admission, and admission
from respiratory or cardiac causes [14].
Delirium is very common in the ICU with a reported prevalence of nearly
70% to 87% among patients [16–18]. Delirium causes increased morbidity,
mortality, nursing home placement, longer ICU and hospital stays, and
costlier hospitalizations [19–21]. In patients who receive mechanical ventila-
tor assistance, delirium is a predictor of 6-month mortality [22]. Patients
with one episode of delirium had a 40% increase in length of stay in the
ICU and total hospital costs, after controlling for confounding variables,
compared with patients with no delirium [20].
Several previous studies have demonstrated that dementia is an impor-
tant risk factor for delirium [23–26]. A recent cohort study of 304 medical
ICU patients 60 years of age or older reported that dementia was the stron-
gest risk factor for delirium (odds ratio [OR], 6.3; 95% conﬁdence interval
[CI], 2.9–13.8) [18]. Other risk factors included the administration of benzo-
diazepines before ICU admission (OR, 3.4; 95% CI, 1.6–7); an elevated cre-
atinine level (OR, 2.1; 95% CI, 1.1–4); and low arterial pH (OR, 2.1; 95%
CI, 1.1–3.9). Delirium is listed as one of the six leading causes of preventable
injury in those older than 65 years [27]. For patients with pre-existing cog-
nitive impairments, an ICU clinician should be even more vigilant about
detection and treatment of delirium to reduce the associated high morbidity
and mortality [22].
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Cognitive impairment in medical units is often unrecognized and
untreated by hospital physicians [28,29]. In a study of 163 medical inpatients
in which the prevalence of cognitive impairment was 31%, attending physi-
cians recognized the cognitive impairment in only 13% of cases and junior
medical staﬀ recognized it in only 9% of cases [28]. Most patients admitted
to an acute care hospital do not have prior documentation of their cognitive
function [30,31]. Because ICU physicians primarily rely on past medical
records from referring physicians to obtain information about a patient’s
baseline cognitive status, pre-existing cognitive impairment may not be
appropriately evaluated or managed. In a cohort of 163 acute medical
ward patients aged 65 and older, attending physicians were unaware of
the existence of previous cognitive impairment in 53% of cases, and intern
physicians were unaware in 59% of cases [32].
The biggest barrier to detection of pre-existing cognitive impairment is
the fact that direct, in-depth assessment of cognitive functioning is imprac-
tical in the ICU setting because of multiple factors, such as mechanical ven-
tilation, related communication diﬃculties, sedation, wounds, and patient
fatigue. Delirium can be diagnosed reliably and rapidly with the Intensive
Care Delirium Screening Checklist [33] or the Confusion Assessment
Method for the Intensive Care Unit [16]. Additionally, the Mini-Mental
State Examination [34] is a popular, brief cognitive screening tool that
can detect severity of global cognitive impairment. None of the aforemen-
tioned instruments, however, provides any information about a patient’s
cognitive state before the acute illness. Without information on the previous
level of function or cognition, a low score on Mini-Mental State Examina-
tion could be a reﬂection of dementia, delirium, or delirium superimposed
on dementia. The Mini-Mental State Examination by itself does not help
diﬀerentiate among these three syndromes.
The use of proxy interview-based assessment of pre-existing cognitive
impairment has been examined to aid physicians in the ICU. The Modiﬁed
Blessed Dementia Rating Scale (MBDRS) [35] and the Informant Ques-
tionnaire on Cognitive Decline in the Elderly (IQCODE) [36] were specif-
ically developed for proxy administration and have been widely used for
identiﬁcation of pre-existing cognitive impairment in both outpatient and
hospital settings. Administration of either instrument takes less than 5 min-
utes. The MBDRS is an 11-item instrument that has been shown to corre-
late with pathologic assessment of dementia, to discriminate between
demented and nondemented subjects, and to correlate well with objective
patient measures of dementia. The IQCODE is a 16-item questionnaire
designed to measure cognitive decline over time, providing a longitudinal
perspective of cognitive functioning. The IQCODE has also been shown
to correlate with direct patient assessment using cognitive screening tests
and has been used to evaluate the presence of dementia in non–critically
728 LEE et alill medical inpatients and to predict the development of dementia after hos-
pital discharge.
A recent study found that both IQCODE and MBDRS could be reliably
used to detect pre-existing cognitive impairment in the ICU [37]. The choice
of instrument to assess pre-existing cognitive impairment depends on the
goals of the study. The IQCODE does require a proxy respondent who
has observed the patient over a 5-year period. If such proxy is available,
IQCODE is more sensitive to detect mild existing cognitive impairment
than the MBDRS. In cases in which detection of moderate to severe cogni-
tive impairment is suﬃcient and in which proxies with knowledge of the
5-year history of the patients may not be consistently available, the MBDRS
is recommended.Management of behavioral and psychologic symptoms of dementia
in the ICU
Although the most common cause of agitation, psychosis, and mood
symptoms in the intensive care setting is delirium, ICU clinicians should
be aware of the common behavioral and psychologic symptoms of dementia
(BPSD). BPSD have become increasingly recognized as part and parcel of
the progression of MCI and dementia. Such symptoms include aﬀective dis-
orders (eg, depression, anxiety, euphoria); personality change; psychotic
symptoms (eg, hallucinations, delusions); and behavioral disturbances (eg,
agitation, aggression, aberrant motor behavior or wandering, apathy, irrita-
bility, sleep and eating disturbance, disinhibition).
ICU clinicians are likely to encounter BPSD among patients with pre-
exiting cognitive impairment. In the Cardiovascular Healthy Study, among
the dementia participants, 75% (N ¼ 270) had exhibited a neuropsychiatric
symptom in the past month (62% were clinically signiﬁcant); 55% (N ¼ 199)
reported two or more; and 44% (N ¼ 159) three or more disturbances in the
past month [38]. When combined with another study, the 18-month preva-
lence rate of neuropsychiatric symptoms was estimated to be 88.6% [39].
Symptoms seem to be quite persistent because 81% of those who initially
had symptoms continued to have symptoms 18 months later [40].
Prevalence of noncognitive behavioral symptoms in MCI seems to be also
much higher than in the general population, but lower than in dementia
[38,41]. Based on the Memory andMedical Care Study, Chan and colleagues
[41] reported that compared with dementia subjects, those classiﬁed as MCI
had a lower prevalence (47.1% versus 66.1%) of any symptoms (psychosis,
depression, or agitation) and of agitation (24.8% versus 45.1%). In the Car-
diovascular Health Study, of the 682 individuals with dementia orMCI, 43%
ofMCI participants exhibited neuropsychiatric symptoms (29% rated as clin-
ically signiﬁcant) with depression (20%), apathy (15%), and irritability
(15%) being most common, whereas 75% of dementia participants exhibited
neuropsychiatric symptoms in the previous month [38].
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BPSD. Sometimes, depression can closely mimic mild delirium and MCI,
and should be in diﬀerential diagnosis of all cognitive evaluations. Table 1
compares the features of delirium, dementia, and depression. Behavioral
symptoms of delirium are generally associated with acute impairment in
the level of consciousness, along with ﬂuctuating level of symptom severity.
BPSD tends to be more stable in severity and does not involve impairment
in attention. Often, behavioral symptoms of delirium can be superimposed
on pre-existing cognitive impairment. In this case, treatment of underlying
cause of delirium should triumph over addressing the behavioral symptoms.
The following sections discuss management strategies for speciﬁc neuropsy-
chiatric symptoms in the absence of delirium.DepressionEstimates for the prevalence of major depression in patients with demen-
tia are 20% to 25% [42]. Depressive disorders in dementia are often some-
what diﬀerent from those occurring in the absence of dementia. Overly
relying on DSM-IV diagnostic criteria may result in an underdiagnosis
and undertreatment of depression among dementia patients in ICU. For
example, patients with depression and dementia may not endorse hopeless-
ness, suicidal thoughts, or worthlessness. Instead, dementia patients express
such symptoms as anxiety, anhedonia, irritability, lack of motivation, and
agitation [43]. Anxiety is often the most noticeable symptom, and delusions,
typically of a paranoid nature, also accompany depression among dementia
patients.Table 1
Comparative features of delirium, dementia, and depression
Delirium Dementia Depression
Deﬁnition Impaired sensorium
(reduced level of
consciousness)
Global decline in
cognitive capacity in
clear consciousness
Disturbance in mood,
with associated low
vital sense and low
self-attitude
Core symptoms Inattention,
distractibility,
drowsiness,
befuddlement
Amnesia, aphasia,
agnosia, apraxia,
disturbed executive
function
Sadness, anhedonia,
crying
Common associated
symptoms
Cognitive impairment,
hallucinations,
mood lability
Depression, delusions,
hallucinations,
irritability
Fatigue, insomnia,
anorexia, guilt,
self-blame,
hopelessness,
helplessness
Temporal features Acute or subacute
onset
Chronic onset,
usually gradual
Episodic, subacute
onset
Diurnal features Usually worse in the
evening and night
No clear pattern Usually worse in the
morning
730 LEE et alNonpharmacologic or behavioral interventions for the treatment of
depression are not practical in the ICU setting. Also, given the presence of
cognitive impairment, psychotherapy is generally not beneﬁcial. Serotonin-
speciﬁc reuptake inhibitors have been shown to be eﬃcacious in treatment
of depression in Alzheimer’s disease [42]. It is important to begin at a low
dose of serotonin-speciﬁc reuptake inhibitor (eg, about one fourth of the
full adult antidepressant dose, such as sertraline 25 mg once a day) and
increase slowly as tolerated, closely monitoring for the development of side
eﬀects and improvement in mood. It is also important not to undertreat, rec-
ognizing that most patients with Alzheimer’s disease have optimal responses
in the moderate to high dose range (eg, 100 mg of sertraline) of serotonin-
speciﬁc reuptake inhibitors. Other non–serotonin-speciﬁc reuptake inhibitor
options for the treatment of depressive symptoms include starting mirtaza-
pine at 7.5 mg before bedtime; bupropion at 100 mg once a day of the
extended-release preparation; or serotonin-norepinephrine reuptake inhibi-
tors (eg, venlafaxine starting at 37.5 mg once a day of the extended-release
preparation). Table 2 lists common antidepressants and their recommended
dosage for treatment of depressive symptoms in patients with MCI or
dementia.Delusions and hallucinationsAlthough delirium is the most common cause of psychotic symptoms in
the ICU, delusions and hallucinations often occur in dementia in the
absence of delirium. In the absence of clouded sensorium, attentional distur-
bance, and sleep-wake cycle disruption, psychosis caused by dementia
should be considered and treated accordingly. Delusions associated with
dementia tend to occur more commonly than hallucinations. In popula-
tion-based studies, the prevalence of delusions in dementia is approximately
25%, whereas for hallucinations it is 10% to 15% [44]. Rather than system-
ized delusions, dementia patients tend to have isolated paranoid beliefs. For
example, when they lose a wallet because of their memory impairment, they
might become convinced that it was stolen and persist in this belief despite
evidence to the contrary. Among dementia patients, visual hallucinations
are also more common than auditory hallucinations, particularly in demen-
tia of Lewy bodies [45]. Hallucinations associated with dementia often
involve seeing familiar people, including those who are deceased, which
may not be distressing to the patients.
Similar to the treatment of depression associated with dementia, behav-
ioral interventions for psychotic symptoms are available, but not practical
in the ICU setting. Distraction techniques and avoiding arguments are often
helpful, but pharmacologic interventions might become necessary. Neurolep-
tics are eﬀective in reducing hallucinations and delusions in dementia
patients, but because of safety concerns associated with increased stroke
and transient ischemic episode risk in dementia patients, the US Food and
Table 2
Common antidepressant medications in mild cognitive impairment and dementia
Medication
Initial
daily dose
Target
daily dose
Notable
adverse events Comments
Fluoxetine 10 mg 20–40 mg Restlessness Long half-life
Gastrointestinal distress
Hyponatremia (SIADH)
Sertraline 25 mg 100–150 mg (same as above)
Citalopram 10 mg 20–40 mg (same as above) Minimal drug-drug
interactions
Paroxetine 10 mg 20–40 mg (same as above)
Sedation
Anticholinergic eﬀects
Bupropion 75 mg 150–300 mg Seizure (rare) Tends to be stimulating
Mirtazapine 7.5 mg 7.5–30 mg Sedation Sometimes used as
a hypnotic
Trazodone 25 mg 50 mg Orthostatic hypotension Usually used
as a hypnoticPriapism
Sedation
Venlafaxine 37.5 mg 75–150 mg Restlessness Tends to be stimulating
Gastrointestinal distress
Hyponatremia (SIADH)
Hypertension at high
dose
Duloxetine 20 mg 30–60 mg Restlessness Also indicated for
diabetic neuropathy
Gastrointestinal distress Likely useful in a variety
of comorbid pain
syndromes
Hyponatremia (SIADH)
Abbreviation: SIADH, syndrome of inappropriate antidiuretic hormone.
731PRE-EXISTING COGNITIVE IMPAIRMENTDrug Administration added a ‘‘black box’’ warning for their use in patients
with dementia [46]. Other side eﬀects to consider include sedation; medica-
tion-induced parkinsonism; metabolic syndrome; and orthostatic hypo-
tension, to which frail elderly patients with dementia are particularly
vulnerable. At low doses (eg, 0.25–1mg of risperidone daily; 2.5–5mg of olan-
zapine daily; 12.5–50 mg of quetiapine daily), however, these medications are
tolerable and eﬀective in treatment of psychotic symptoms in dementia. The
decision to initiate neuroleptic treatment involves careful consideration and
an open discussionwith the patient and family regarding the potential beneﬁts
of treatment of hallucinations or delusions versus the potential risk for side
eﬀects [47]. Close monitoring for response and medication side eﬀects is indi-
cated. Table 3 lists common antipsychotics and their recommended dosage
for treatment of psychosis in patients with MCI or dementia.Agitation and aggressionAgitated behaviors, such as irritability, yelling, restlessness, and physical
aggression, are common in dementia with an estimated prevalence of 20%
Table 3
Common antipsychotic medications for patients with mild cognitive impairment or dementia
Medication
Initial
daily dose
Target
daily dose Adverse events Comments
Risperidone 0.25 mg 0.25–1 mg EPS, elevated
prolactin level
Available as orally
disintegrating tablet
At doses R 6 mg,
EPS similar to
conventional
antipsychotics
Quetiapine 25 mg 25–100 mg Sedation Low incidence of EPS
Olanzapine 2.5 mg 2.5–10 mg Sedation Available in an
intramuscular injection
and as orally
disintegrating tablet
Weight gain
Diabetes mellitus
Haloperidol 0.25 mg 0.25–2 mg EPS Conventional
antipsychotic
Dystonic
reactions
Available as liquid
and intramuscular
formulations
Fluphenazine 0.25 mg 0.25–2 mg EPS Conventional
antipsychotic
Dystonic
reactions
Available as liquid
and intramuscular
formulations
Abbreviations: EPS, extrapyramidal symptoms; SIADH, syndrome of inappropriate antidiu-
retic hormone.
732 LEE et alto 25% [44]. Clinicians should keep in mind that agitation is a nonspeciﬁc
phenomenon with a broad diﬀerential diagnosis. The most common etiolo-
gies for such behaviors include medical illnesses (eg, urinary tract infection,
pneumonia); delirium; environmental stressors; psychiatric disorders (eg,
depression psychosis); and the underlying dementia itself. The treatment
of agitation and aggression depends on the underlying cause of the behavior
(eg, depression, delirium, pain). If no underlying etiology beside dementia is
apparent and the agitation or aggression is severe, empiric use of neurolep-
tics can be considered (eg, 0.25–1 mg of risperidone daily; 2.5–5 mg of olan-
zapine daily; 12.5–50 mg of quetiapine daily).
An alternative to atypical antipsychotic agents may be the acetylcholines-
terase inhibitors andmemantine. Several studies have shown these agentsmay
help stabilize cognitive and behavioral problems in demented patients [45].
The reported eﬃcacy among these agents varied, with the greatest positive ef-
fects seen with donepezil, which also has the greatest number of studies [48].
Other agents, such as the mood stabilizers valproic acid and carbamazepine,
have been helpful. Anticonvulsants are useful second-line treatments with
possible eﬃcacy noted for valproic acid [49,50] and carbamazepine [51].
Benzodiazepines can be very eﬀective in maintaining patient and staﬀ
safety in a behavioral emergency, but can exacerbate cognitive impairment.
733PRE-EXISTING COGNITIVE IMPAIRMENTTheir use in the ICU setting should be kept to a minimum. Lorazepam is
a benzodiazepine with the particular advantage of being available for
both intravenous and intramuscular use, and a dose of 0.25 to 0.5 mg is
often eﬀective in such emergencies. Midazolam is an ultra-short-acting
benzodiazepine whose use is usually restricted to critical care settings, which
can be similarly useful if intravenous access is available.
Clinicians should keep in mind that one of the most overlooked and un-
dertreated causes of agitation associated with dementia is pain [52]. It would
be most unfortunate if a dementia patient with agitation from unrecognized
pain is given neuroleptic medication that not only fails to address the under-
lying problem, but can place the patient at risk for side-eﬀects associated
with this type of medication.Catastrophic reactionsA catastrophic reaction is a sudden, out-of-proportion expression of neg-
ative emotion (eg, sadness, frustration, anxiety, anger) that is precipitated by
an environmental event or an interaction with someone (eg, family, medical
staﬀ) [8]. Such reactions often have little warning in a patient who otherwise
has appeared calm and content, and they are typically time-limited. Cata-
strophic reactions can sometimes be associated with physical aggression.
These episodes can be frightening for the patient, and for caregivers and staﬀ.
Given that catastrophic reactions are usually time-limited events, reassur-
ance and a calm demeanor by the clinician and staﬀ is generally suﬃcient. In
cases of severe episodes, a low dose of an as-needed medication may be help-
ful during the acute crises. Potential pharmacotherapy interventions include
lorazepam (0.25–0.5 mg); risperidone (0.25–0.5 mg); quetiapine (12.5–
50 mg); and trazodone (25–50 mg). Precipitants for the catastrophic reaction
should be identiﬁed to avoid future recurrence.Other behavioral symptomsCognitive impairment is the most common and apparent psychologic
symptom of dementia. Four cholinesterase inhibitors (ie, tacrine, donepezil,
rivastigmine, and galantamine) are approved for treatment of mild-to-
moderate dementia caused by Alzheimer’s disease. Given that the beneﬁt
of cholinesterase inhibitors or memantine (an N-methyl-D-aspartate recep-
tor antagonist agent approved for the treatment of Alzheimer’s disease) to
the long-term progression of dementia has not been shown conclusively,
however, ICU clinicians should not feel compelled to start them during
the acute medical management. All cholinesterase inhibitors carry risk of
increased gastric acid secretion, nausea, vomiting, and diarrhea. Cholines-
terase inhibitors, less commonly, can cause muscle cramps, bradycardia,
or exacerbations of asthma. It is reasonable to stop cholinesterase inhibitors
when dementia patients are admitted to the ICU.
734 LEE et alApathy is often mistaken for depression in patients with dementia.
Apathetic patients often show diminished volition, low self-motivation,
low vitality, diminished emotions, and decreased goal-directed behavior.
Unlike depressed patients, apathetic patients usually are not distressed,
but appear contented. Psychostimulants (eg, methylphenidate), activating
antidepressant agents (eg, bupropion), and amantadine have been shown
to be beneﬁcial, but in the ICU speciﬁc treatment is unlikely to be necessary.Summary
With an aging population and longer life expectancy, the incidence of
MCI and dementia is expected to increase in society. This vulnerable, elderly
population with cognitive impairments is likely to be aﬄicted with medical
problems requiring acute hospitalization, often in ICUs. A substantial
proportion of patients with pre-existing cognitive impairments, such as
dementia and MCI, are vulnerable to delirium and frequently suﬀer from
noncognitive, behavioral symptoms. ICU physicians should become vigilant
in recognizing pre-existing cognitive impairments to prevent delirium and to
aid in the management of neuropsychiatric symptoms associated with
dementia. Successful detection and management of noncognitive, behavioral
symptoms associated with dementia in ICU leads to improved delivery of
life-saving critical care to elderly patients.References
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Critical care professionals are increasingly involved in the early post-
injury management of individuals hospitalized after a traumatic brain injury
(TBI). Approximately 230,000 persons in the United States experience
a TBI-associated hospitalization annually [1,2], the majority of which are
acquired through injuries involving transportation, falls, assaults, or ﬁre-
arms. Adolescents, young adults, and older persons are overrepresented
among persons hospitalized who have TBI, as are persons who have mod-
erate or severe injuries [1,2]. Although the overall rate of TBI-associated
hospitalization declined 51% between the early 1980s and late 1990s [1,2],
that decline largely is attributable to reductions in hospital-based care of
mild and moderate TBI (61% and 19%, respectively). An absolute
increase of 90% in hospitalization rates after severe TBI (from 10 to 19
per 100,000 persons per year) occurred during this same time. Concurrently,
in-hospital TBI mortality rates declined 17%. Improvements in trauma care,
pre- and in-hospital, are cited as among the most important factors contrib-
uting to the increased numbers of persons with severe TBI presenting to
hospitals despite absolute reductions in TBI-associated hospitalizations,
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738 ARCINIEGAS & MCALLISTERand also to improvements in post-TBI survival [1,2]. This trend also indi-
cates that many individuals now present to hospital with and survive TBI
despite severities of injury that in years past often would have been fatal.
Among those hospitalized after a moderate or severe TBI, approximately
35% (or approximately 80,500 persons annually) are expected to develop
permanent disability as a result of that TBI [2,3]. Posttraumatic physical,
cognitive, and behavioral impairments, denoted collectively by the term,
neurobehavioral, are particularly common among persons who have severe
TBI [4–8]. The neurobehavioral sequelae of TBI contribute substantially
to postinjury disability [9–11] and present substantial challenges for patients
and their families during and after the early postinjury period [10,12–14].
The care provided to persons who have TBI in critical care settings, to the
authors’ knowledge, rarely is framed as neurobehavioral. Given the poten-
tial for loss of life and severe medical or neurologic compromise in the acute
postinjury period, the focus on such matters in the critical care setting is
understandable and necessary. There is no doubt, however, that the initial
treatment of posttraumatic neurobehavioral disturbances also begins in
the emergency department (ED) and critical care unit (CCU). Identifying
and treating neurobehavioral disturbances and avoiding interventions with
the potential for acute or long-term neurobehavioral complications are
essential if improvements in long-term neurobehavioral outcomes from
TBI are to be achieved. Accordingly, developing critical care professionals’
expertise in the neurobehavioral management of TBI is an important objec-
tive. In the service of this objective, this article begins by deﬁning TBI, in-
cluding its several subtypes and severities, and reviewing the commonly
used methods of identifying and characterizing TBI in the critical care
setting. The neurobiology of TBI, including neuroanatomy, neurochemistry,
and brain-behavior relationships, relevant to the management of acute post-
injury neurobehavioral problems is described. Finally, recommendations
regarding the management of posttraumatic neurobehavioral problems in
the critical care setting are oﬀered.Deﬁning and characterizing traumatic brain injury
General clinical case deﬁnition
Consistent with the Guidelines for Surveillance of Central Nervous System
Injury developed by the United States Centers for Disease Control and Pre-
vention [15], TBI is deﬁned as a functionally signiﬁcant disruption of brain
function manifested as immediately apparent cognitive or physical impair-
ments that result from blunt or penetrating trauma or rapid acceleration
or deceleration forces. This deﬁnition excludes lacerations or contusions
of the face, eye, or scalp, and fractures of facial bones alone as evidence
of TBI. Additionally, injury to the brain resulting from birth trauma, hyp-
oxic-ischemic (anoxic), inﬂammatory, toxic, or metabolic encephalopathies,
739NEUROBEHAVIORAL MANAGEMENT OF TBIprimary ischemic or hemorrhagic strokes, seizure disorders, intracranial sur-
gery, and cerebral neoplasms also are outside the deﬁnition of TBI.
Although the standard clinical case deﬁnition used in federally funded
central nervous system injury surveillance programs permits skull fracture
alone as evidence suﬃcient to merit a diagnosis of TBI, this article uses a def-
inition that requires evidence of brain dysfunction even if skull fracture is
present; although skull fracture is associated with an increased likelihood
of intracranial (cerebral) injury [16–18], it is not a suﬃciently reliable predic-
tor of such injury to serve as the sole clinical ﬁnding with which to diagnose
TBI [19]. Thus, use of head injury as a synonym for TBI is discouraged and
is not used herein.
Under this deﬁnition of TBI, no single symptom or sign (eg, loss of con-
sciousness, altered mental status, or subdural hematoma) is pathognomonic
of TBI. The deﬁnition of TBI also does not specify the duration of disrupted
brain function produced. The Guidelines deﬁne clearly the data elements
necessary to describe the occurrence and severity of TBI (Table 1) [15],
but interpreting those data with respect to rendering a diagnosis of TBI is
left to the judgment of clinicians.Characterizing severity of traumatic brain injury
in the critical care settingTBI severity is divided into three categories: mild, moderate, and severe.
The Glasgow Coma Scale (GCS) [20] is the measure used most commonly
in the ED and CCU to determine TBI severity, with mild, moderate, and
severe TBI deﬁned by GCS scores 13–15, 9–12, and 3–8, respectively. On
admission and throughout the initial hospitalization, interpretation of
GCS scores requires contextualization: intoxication with illicit or prescribed
agents, severe facial trauma, language barriers, and other premorbid condi-
tions (eg, severe developmental disabilities or advanced dementia) at the
time of GCS assessment may lower performance on this measure and provide
potentially misleading information regarding TBI severity. Additionally,
although it is commonpractice in critical care settings to qualify theGCS score
among intubated patients by placing a ‘T’ next to their score (eg, GCS 3T), the
clinical and predictive validity of such qualiﬁed GCS scores is not established
clearly. Such caveats [21] regarding the interpretation and limitations of GCS
scores notwithstanding, GCS assessment on ED presentation and serially (at
least once every 24 hours) throughout the critical care period provides imme-
diately relevant information about patient clinical status and prognosis
[6,22,23]. Exceptions to this rule are patients who have GCS scores in the
13–15 range and abnormal CT or MRI; outcomes in these patients resemble
those of persons who have moderate TBI and, hence, are designated as com-
plicated mild TBI [24,25]. In these cases, the neurologic and neurobehavioral
treatment needs and prognostic implications require considerable attention
despite GCS scores that are, at face value, in the mild range.
Table 1
Conditions and the evidence that may be used to substantiate the occurrence of TBI
Conditions suggesting traumatic
brain injury Evidence suggestive of the condition
Decreased level of consciousness
(observed or self-reported)
Alteration or complete loss of consciousness,
including states described as obtundation, stupor,
or coma
Amnesia Loss of memory for events immediately preceding
an injury (retrograde amnesia), for the injury
or the events that follow it (anterograde amnesia),
or both
Objective neurologic abnormality Motor (including speech), sensory, or reﬂex
abnormalities evident on neurologic examination
and/or the occurrence of seizures
Objective neuropsychologic
abnormality
On mental status (including standardized
neuropsychological) examinations, there is
evidence of impairment in cognition
(eg, disorientation or confusion), disturbances
of behavior (eg, agitation), or other abnormalities
in neuropsychiatric status (eg, personality change)
Diagnosed intracranial lesion By CT, MRI, or other neurodiagnostic test, there
is evidence of diﬀuse axonal injury; epidural,
subdural, subarachnoid, or intracerebral
hematoma; cerebral contusion or laceration;
or penetration of brain by a foreign body
(eg, gunshot wound)
Data from Marr AL, Coronado VG. Central nervous system injury surveillance data sub-
mission standardsd2002. Atlanta (GA): Department of Health and Human Services, Centers
for Disease Control and Prevention National Center for Injury Prevention and Control; 2002.
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tion of posttraumatic amnesia (PTA) also is suggested. PTA describes the
period of dense impairment in the ability to learn new information (with
or without some degree of retrograde amnesia) and is best assessed using
one of the several currently available PTA scales [26–30]. Among these,
the authors recommend the Orientation Log (O-Log) for use in the CCU
[31]. In keeping with the deﬁnition of mild TBI oﬀered by the American
Congress of Rehabilitation Medicine (ACRM) [32], PTA duration of less
than 24 hours is consistent with mild TBI. Russell and Smith (1961) [33],
progenitors of the concept and assessment of PTA, suggested additional cat-
egories of severity beyond 24 hours deﬁned by PTA durations of 1 to 7 days
and more than 7 days. In view of the ACRM deﬁnition, these durations of
PTA would now serve most usefully as cutoﬀs for moderate and severe TBI,
respectively. Regardless of the cutoﬀs used to deﬁne categories of TBI sever-
ity, PTA duration (as a continuous variable) is a robust predictor of func-
tional independence [30,31,34] and disability [34] at the end of acute
inpatient rehabilitation, Glasgow Outcome Scale [35] scores at 6- and 12-
months post injury [36,37], long-term cognitive recovery [38–40],
741NEUROBEHAVIORAL MANAGEMENT OF TBIproductivity [41], employment [42], and community reintegration [43]. As
with the GCS, noninjury factors (sedating medications, severe communica-
tion impairments, and so forth) may confound assessment of PTA duration.
Nonetheless, including serial examination using the O-Log or another mea-
sure of PTAdat the earliest point after TBI at which a patient is capable of
participating in such examinationsdis recommended strongly as a means by
which to characterize not only injury severity but also to develop prognostic
formulations and guide treatment planning.Neurobiology of traumatic brain injury
Developing a rational approach to the neurobehavioral management of
persons who have TBI in the critical care setting requires familiarity with
the neuroanatomy and neurochemistry of this condition. As described later
in this section, the neurobiology of TBI not only predicts the neurobehavio-
ral problems that arise commonly in the early postinjury period but also
informs treatment selection (agents to use and those that are best avoided).
The neurobiological bases of TBI are grouped broadly into several cate-
gories: biomechanical injury, cytotoxic injury, and secondary or systemic
complications with eﬀects on the brain. Blast-related injury is another
possible category of TBI and is discussed brieﬂy.Biomechanical injuryThe biomechanical eﬀects of nonpenetrating injuries may be divided
broadly into two types, both of which usually are operative in severe TBI:
contact and inertial. Contact injuries result when the brain, moving inside
the skull, strikes the inner surface of skull or is struck by material (eg, pro-
jectiles or bone fragments) entering the intracranial space. In the former
circumstance, movement of brain against the various ridges and bony pro-
tuberances of the anterior (frontal) and middle (temporal) fossas is particu-
larly injurious to the temporal and frontal poles and the ventral anterior,
medial, and lateral temporal and frontal cortices [44–48]. In the latter
form of contact injury, tissue displacement or destruction by a projectile;
fragmentation and deposition of bone or a projectile within brain tissue;
contamination of the intracranial space by potential infectious material on
a projectile or the tissues through which it passes; subarachnoid, subdural,
or epidural hematomas; and other process contribute to the brain injury.
Linear translation and rotational forces, which in combination produce
angular acceleration or deceleration, can result in straining, shearing, and
compression of brain tissue [49–55]. Strain and shear forces are tolerated
poorly by brain tissue; when these forces exceed the tolerances of brain tis-
sue, TBI is produced. These forces tend to be maximal in brain areas that
experience the highest angular acceleration or deceleration forces
(superﬁcialO deep and anteriorO posterior), at the planes between tissues
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matter), and at the rotational center of mass in the intracranial space (ros-
tral brainstem). The eﬀects of high-speed, long-duration acceleration or
deceleration injuries are maximal on axonal projections and small blood ves-
sels within and from the brainstem, the parasagittal white matter of the
cerebrum, the corpus callosum, the gray-white junctions of the cerebral cor-
tex [56], and especially at gray-white junctions in the ventral and anterior
frontal and temporal lobes [44]. Although injury to axons produced by
inertial injury usually is described as diﬀuse axonal injury, this term, despite
its well-accepted use in the TBI literature, is a misnomer: regional diﬀerences
in susceptibility to the eﬀects of inertial forces results in pattern that is
described more appropriately as multifocal rather than diﬀuse [56].Nonpenetrating and penetrating traumatic brain injuryNonpenetrating injuries comprise the vast majority of TBI; are most
commonly sustained through motor vehicle accidents, falls, and assaults;
and disproportionately involve adolescents, young adults, and older persons
[2]. Across nonpenetrating TBI at all levels of severity, inertial forces are the
principal drivers of the pathophysiology of TBI and diﬀuse axonal injury is
the primary consequence [56–58]. In more severe TBI, contact injuries also
occur and produce focal injuries in the patterns described in the preceding
section of this article.
Penetrating TBI refers to contact injury to the brain produced by objects
entering the intracranial space. In the United States, penetrating injuries
represent the minority (approximately 10%) of TBI, generally are caused
by ﬁrearms (also approximately 10% of all TBI), frequently are fatal
(90%), and often are self-inﬂicted (67%) [2]. The damage sustained in pen-
etrating injuries is predominantly focal, involving the path through which an
object travels within the brain. Although the eﬀects of inertial forces
imparted by a missile on the skull or brain may play a role in the pathophys-
iology of penetrating TBI [59], this type of injury tends to be stroke-like with
regard to its focal eﬀects on the brain and the posttraumatic neurobehavio-
ral deﬁcits and outcome with which it is associated. Although penetrating
injuries are not excluded from consideration in the remainder of this article,
the material presented herein is more immediately relevant to nonpenetrat-
ing TBI.Cytotoxic injuryInjurious cytotoxic processes are initiated by biomechanical injury, and
these add to and complicate TBI (see Povlishock and Katz [57] and Bigler
[60] for review). Injury-induced calcium and magnesium dysregulation,
free radical formation, and excitatory amino acid and neurotransmitter dis-
turbances (reviewed by Arciniegas and Silver [61]) are major elements of the
743NEUROBEHAVIORAL MANAGEMENT OF TBIpostinjury cytotoxic cascade that contribute to neuronal injury and cell
death.
Excesses of excitatory amino acids (ie, glutamate) result in an inﬂux of
calcium into neurons that produces neuronal depolarization, initiates oxida-
tive processes, activates proteolytic enzymes, and ultimately injures or de-
stroys the neuron or its axonal terminus [56,60]. Additionally, glutamate
excesses drive glucose use, oxidative metabolism, and the production of
potentially toxic accumulations of lactate [62,63]. Cholinergic excesses
also seem to be excitotoxic, may amplify the destructive eﬀects of excitatory
amino acid excesses, and may be particularly injurious to brain areas where
acetylcholine and excitatory amino acids are densely co-located (ie, hippo-
campus and frontal cortices) [64].
The eﬀects of cerebral monoaminergic excesses in the cytotoxic cascade
are not understood fully, although in experimental injury models traumati-
cally induced elevations of cerebral serotonin seem to decrease cerebral
glucose use (possibly counterposing the eﬀects of glutamate) [65,66]. Consis-
tent with this observation, serotonin-augmenting agents administered in the
acute period after severe TBI do not improve posttraumatic neurobehavio-
ral status or TBI outcome [67,68]. Administration of catecholamine antag-
onists impedes recovery from brain injury [69–71] and delay emergence
from PTA in humans [72], suggesting that blocking catecholamine excesses
is not an eﬀective means by which to mitigate the cytotoxic cascade after
TBI.
Neurotransmitter excesses seem to wane over the ﬁrst several weeks after
TBI [73,74], although the time course of their resolution is not characterized
fully. TBI in humans produces chronic cerebral cholinergic deﬁcit via injury
to ventral forebrain cholinergic nuclei [75,76] and their cortical projections
[76–78]. It is possible that TBI also results in primary or secondary distur-
bances in monoaminergic systems [79], the eﬀects of which may be ampliﬁed
by individual genetically mediated variations in catecholamine metabolism
[80]. There is a substantial body of evidence suggesting roles for cholinergic
or catecholaminergic augmentation in the remediation of posttraumatic
impairments in attention and memory [61,79,81,82]. These interventions
generally have been studied in the subacute or late postinjury period, how-
ever, with few exceptions [83,84], leaving their role in the management of
posttraumatic neurobehavioral disturbances in the critical care setting
uncertain.Secondary and systemic complicationsBiomechanical and cytotoxic injury processes may occur without medical
or neurological complication; however, such complications may occur fre-
quently particularly in the setting of severe TBI. Among the more common
of these secondary processes are traumatic hematomas (eg, subdural, epidu-
ral, subarachnoid, and intraparenchymal hematomas). Other common
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edema, elevated intracranial pressure (ICP), obstructive hydrocephalus,
hypoxic-ischemic injury, and infection (particularly with the introduction
of foreign material into the intracranial space). Less commonly, or when
these processes are unable to be well controlled, subfalcine or transtentorial
herniation may occur. Even when not fatal, such herniations may compro-
mise vascular supply, resulting in stroke superimposed on TBI. Because TBI
frequently occurs in the context of other injuries (polytrauma), other sys-
temic medical complications, such as volume depletion or blood loss, hypo-
perfusion, hypo- or hyperthermia, hypoxia, infection, and related problems,
commonly are comorbid with TBI. Their occurrence may further compro-
mise a patient’s neurologic status and increase posttraumatic mortality
and morbidity; aggressive treatment directed at these problems, therefore,
is essential [85].Blast-related traumatic brain injuryIn addition to the biomechanical and cytotoxic injury processes and sec-
ondary and systemic complications contributing to penetrating and nonpe-
netrating TBI, increasing attention has been given recently to the possibility
of a third basic category of TBI: blast injury [86–93]. The combination of
eﬀective overpressure and positive pulse duration may eﬀect injury through
primary (blast wave), secondary (objects displaced by the blast striking or
penetrating the body or brain), tertiary (body or brain displaced by blast
striking objects or ground), and quaternary or miscellaneous means
[91,94–96]. Quaternary or miscellaneous injury refers to burns, exposure
to toxic gases and dust, hypoxia resulting from airway compromise or toxic
exposure, structural collapse, body rupture, and psychologic trauma associ-
ated with the blast event. Experimental injury studies [97–102] suggest that
blast forces may injure the brain and brainstem via aﬀerent hyperexcitabil-
ity, increased neurotransmitter and vasoconstrictor or vasodilator autacoid
release, or kinetic energy transfer of blast overpressure to the brain. Others
[103–105] note that blast exposure induces the vagally mediated pulmonary
defensive reﬂex, resulting in blast-related shock even in the absence of overt
external injury; it is possible, therefore, that the clinical phenomena attrib-
uted to TBI (eg, being ‘‘stunned’’ by a blast and alterations or loss of con-
sciousness) in some cases may reﬂect the occurrence of this vagally mediated
reﬂex rather than direct disruption of brain physiology by primary blast
forces. In light of the uncertain eﬀects of primary blast on the central ner-
vous system, particularly in the setting of blast exposures that fail to injure
hollow organs (which are at greatest risk for injury due to primary blast), it
may be most accurate to refer to TBI in the setting of blast exposure as
blast-related TBI. This term encompasses broadly and fairly the spectrum
of primary, secondary, tertiary, and miscellaneous (especially hypoxic and
psychologic) mechanisms that operate concurrently in blast exposures and
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may be produced.Neurobehavioral sequelae of traumatic brain injury
in the critical care setting
The biomechanical and cytotoxic processes induced by severe TBI dis-
proportionately aﬀect the anterior and ventral aspects of the frontal and
temporal lobes, medial frontal and temporal areas, ventral forebrain, the
diencephalon (thalamus and hypothalamus), the rostral and ventral areas
of the upper brainstem, and the white matter within and between these
areas [44,56,57,60,75,106–108]. These are neurobehaviorally salient areas,
and their injury results in predictable types of posttraumatic neurobehavio-
ral disturbances (Table 2). Patients sometimes present with a single focal
neurobehavioral deﬁcit after TBI, although this is seen more often after
penetrating rather than nonpenetrating TBI. Among persons who have
moderate or severe nonpenetrating TBI, neurobehavioral disturbances
arise in reasonably consistent (although not invariate) combinations and
usually evolve in a predictable manner during the postinjury period. The
term, posttraumatic encephalopathy (PTE), captures this broad spectrum
of TBI-induced neurobehavioral disturbances seen in the critical care
setting.
The authors, in clinical work and research in the early postinjury period,
ﬁnd it useful to divide PTE into ﬁve stages: posttraumatic coma, posttrau-
matic delirium, PTA, posttraumatic dysexecutive syndrome, and recovery.
These stages are named according to the most salient (although not the
only) neurobehavioral feature of the clinical presentation: coma, a complete
impairment of arousal; delirium, an alteration in arousal, profound inatten-
tion, with or without agitation or aggression; amnesia, a dense impairment
in new learning; dysexecutive function, a constellation of impairments in
higher-level attention, memory, and other cognitive functions; and recov-
ered neurobehavioral health. These stages parallel those described by the
Rancho Los Amigos Levels of Cognitive Functioning Scale (RLAS)
(Table 3), one of the more commonly used methods of characterizing and
staging TBI recovery in rehabilitation settings [109,110].
The impairments that comprise each stage occur on a continuum, which
makes drawing clear distinctions between the PTE and RLAS stages diﬃcult
when working with speciﬁc patients. Nonetheless, identifying the stage of
PTE that best describes a patient is useful: it facilitates the development
of a treatment plan that is appropriate to a patient’s current clinical status
and that anticipates the course of spontaneous and treatment-facilitated
recovery. As a corollary to this thesis, identifying the stage of PTE also helps
identify deviations from the expected course of recovery and, hence, the
need to evaluate patients for neurologic, neuropsychiatric, and medical
problems responsible for such deviations.
Table 2
Brain-behavior relationships relevant to understanding the neurobehavioral sequelae of traumatic brain injury commonly encountered in the critical
care setting
Structure Neurobehavioral function Consequence of injury
Rostral and ventral brainstem
Reticulothalamic system (predominantly
ACh, Glu, GABA)
Arousal Partial or complete impairment
Reticulocortical system (DA, NE, 5-HT, ACh) Arousal, attention, facilitation of cortical
readiness for information processing
Diminished arousal, attention, inability to engage
eﬀectively in information processing
Thalamus
Reticulothalamic system As above As above
Thalamo-cortico-thalamic circuits
(predominantly Glu, GABA)
Subnuclei cross-link cortical and subcortical
areas
Impaired information processing within the
sensory, motor, or neurobehavioral domain
served by the aﬀected thalamic area
Hypothalamus Multiple subnuclei involved in autonomic,
neuroendocrine, circadian, and some
primitive social functions
Autonomic dysfunction, impaired
thermoregulation, impaired feeding behaviors,
endocrine abnormalities (including
panhypopituitary presentations), altered
sleep-wake cycles, pathologic laughter or anger
Ventral forebrain Cholinergic supply to medial temporal
and neocortical areas
Impaired information processing in multiple
cognitive domains, in particular attention,
memory, and executive functions
Medial temporal areas
Entrorhinal-hippocampal complex Preattentive information ﬁltering
(sensory gating), declarative memory;
also contributes to other attention
and working memory processes
Impairments in attention, working memory
and declarative memory (who, what, when,
and where)
Amygdala Generation of contextually relevant emotional
and social behavior
Aﬀective placidity, Klu¨ver-Bucy–like syndromes
Ventral frontal cortices (straight gyrus, lateral
orbitofrontal)
Social behavior, in particular restraint of
primitive (limbic) behaviors
Impulsivity, social (including sexual)
disinhibition, irritability, agitation, aggression
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Medial frontal (anterior cingulate) cortex Motivation Decreased goal-directed cognition, emotion,
and behavior (apathy)
Inferior (inferolateral) prefrontal cortex Working memory Impaired working memory
Dorsolateral prefrontal cortex Executive function Impairments in executive function (higher-level
cognition) and executive control of attention,
working memory, memory (retrieval),
language, motor planning, and other basic
cognitive functions
White matter Connections between cortical areas, rapi
information processing (myelinated ﬁb
Interruption of neural networks serving
cognition, emotion, and behavior, resulting in
slowed and ineﬃcient information processing
Abbreviations: 5-HT, serotonin; ACh, acetylcholine; DA, dopamine; GABA, g-aminobutyri ; Glu, glutamate; NE, norepinephrine.
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An rview of the stages of recovery from severe traumatic brain injury using the framework of posttraumatic encephalopathy and the Rancho Los Amigos
Le of Cognitive Functioning Scale
RL
sta Dominant features Description Posttraumatic encephalopathy stage
I No response A complete impairment of arousal with no
response to sensory input and no spontaneous
(purposeful or nonpurposeful) behavior;
posttraumatic coma.
Posttraumatic coma
II Generalized response A partial impairment of arousal in which patients
may appear alert but profoundly inattentive and
nonpurposeful (severe hypoaroused posttraumatic
delirium).
Posttraumatic delirium
III Localized response A partial but less severe impairment of arousal in
which patients are awake, intermittently attentive
to simple stimuli (people, objects, and stimulation),
and may be able to follow some simple commands
(moderately severe hypoaroused posttraumatic
delirium).
Posttraumatic delirium
IV Confused and agitated Patients are alert but cognitively impaired and agitated.
Severe impairments of attention, processing speed,
working memory, declarative memory, functional
communication, and executive function are present
and denoted collectively as confusion. Restlessness or
agitation is present, and aggression verbal or physical)
may occur with little or no provocation (agitated
posttraumatic delirium).
Posttraumatic delirium
7
4
8
A
R
C
IN
IE
G
A
S
&
M
C
A
L
L
IS
T
E
Rble
ove
vels
AS
ge
V Confused, inappropriate
behavior but not agitated
Similar to stage IV but without prominent or frequent
agitation or aggression and with improving ability to
be engaged in examination or treatment. Memory
impairment (PTA) is a salient feature of this stage
however, other cognitive impairments are present,
impair patients’ ability to organize behavior, and
contribute to the continued appearance of confus mild
posttraumatic delirium).
Resolving posttraumatic
delirium or early PTA
VI Confused but appropriate
behavior
Similar to stage V but with improved ability to perf basic
activities of daily living and to engage in examina or
treatment. Substantial cueing/supervision/assistan th
such tasks generally is needed (incompletely resolv
posttraumatic delirium or early PTA).
PTA
VII Automatic and appropriate
behavior
Patients generally are able to perform basic self-care vities,
and confusion no longer is present. Impairments i clarative
memory, however, often are the most salient and lematic
features of this stage of recovery (PTA), but func lly
signiﬁcant impairments in higher-level attention, w ing
memory, and executive function (including insight o are
present.
Resolving PTA or early posttraumatic
dysexecutive syndrome
VIII Purposeful and appropriate
behavior
Patients have emerged from PTA (the period of den pairments
in new learning) and are independent for basic se e abilities
and some higher-level activities of daily living. Hi level
impairments, however, in attention, working mem
declarative memory (retrieval), and executive func often
persist (posttraumatic dysexecutive syndrome), an
assistance or supervision for their performance ge lly
is required.
Posttraumatic dysexecutive syndrome
Data from Hagen C, Malkmus D, Durham P. Rancho Los Amigos Scale. Communication D ers Service, editor. Rancho Los Amigos Hospital; 1972.
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750 ARCINIEGAS & MCALLISTEREvaluating posttraumatic neurobehavioral disturbances
General considerations
A comprehensive assessment of the patient, including identiﬁcation of
relevant pre-injury medical, neurologic, psychiatric, and substance histories
and thorough neurologic and neurobehavioral examinations are prerequi-
sites to the evaluation and treatment of posttraumatic neurobehavioral dis-
turbances. Comprehensive and ongoing neurologic and medical evaluation
is standard care in the CCU, the guidelines for which are described else-
where [85] and form the foundation on which subsequent assessment of
posttraumatic neurobehavioral disturbances is predicated.
Among these neurologic and medical evaluations, several issues merit
special mention. Bedside electroencephalographic monitoring in the early
postinjury period is encouraged [111,112] for identiﬁcation of posttraumatic
(including nonconvulsive) seizures and as a method by which to distinguish
between ictal or postictal and injury-induced alterations in consciousness or
behavior. Vigilance for temporal relationships between alterations in mental
status or behavior and minor medical problems (eg, urinary tract infection,
metabolic disturbances, hypotension, hypoglycemia, and mild hypoxia) is
needed: in a manner similar to that of many geriatric patients, the earliest
manifestations of such problems in many persons who have moderate or
severe TBI often are neurobehavioral. When new neurobehavioral problems
develop or previously resolved ones recur, medical re-evaluation should be
initiated before prescribing agents (where possible) to manage that neurobe-
havioral change or decline.
Other common sequelae of TBI and polytrauma (in particular headache,
neck, back, or other sources of pain; dizziness; sleep disturbance; fatigue;
and psychologic responses) may produce or exacerbate TBI-related neuro-
behavioral disturbances. Similarly, the high frequency of alcohol and sub-
stance use disorders among persons who have TBI [113] suggests the need
to consider substance intoxication at the time of admission and substance
(especially alcohol) withdrawal during the early hospitalization period in
the diﬀerential diagnosis of posttraumatic neurobehavioral disturbances.
When any of these problems are identiﬁed, treatment directed at them is
necessary and may change the need for or selection of agents directed at
PTE speciﬁcally.Posttraumatic seizures and anticonvulsant agentsThe management of posttraumatic seizures and the medications used to
prevent their occurrence require special consideration in the diﬀerential
diagnosis and treatment of posttraumatic neurobehavioral disturbances.
As reviewed by Frey [114], persons who have moderate or severe TBI are
at risk for posttraumatic seizures by virtue of the anatomy (frontal and tem-
poral) and neurochemistry (especially excitotoxicity) of this condition.
751NEUROBEHAVIORAL MANAGEMENT OF TBIPosttraumatic seizures generally are divided into early (within 1 week of
injury) and late (after the ﬁrst week postinjury) types. Administration of
anticonvulsant medications (seizure prophylaxis) during the ﬁrst week
post TBI is associated with a decreased incidence of early posttraumatic
seizures [115] and their use for this purpose is consistent with the evi-
dence-based guidelines for traumatic brain injuries [85]. Reduction of early
seizures does not reduce mortality, long-term neurologic disability, or the
risk for late posttraumatic seizures [115]. Additionally, use of anticonvul-
sants after the ﬁrst week post injury does not prevent the development of
late posttraumatic seizures. Many of these agents, in particular phenytoin
[116,117] and carbamazepine [117], are associated with treatment-related
impairments in cognitive and motor function. Levetiracetam is gaining pop-
ularity as an agent for seizure prophylaxis in the critical care setting
[118,119], but there are no randomized, controlled studies supporting its
use for prophylaxis of early or late posttraumatic seizures. This agent also
may increase the risk for agitation and other neurobehavioral disturbances
[120,121], in particular among persons who have a history of psychiatric
problems. Valproate seems to be benign with respect to its eﬀects on cogni-
tion [122] and other neurobehavioral functions and for this reason is sug-
gested as preferable, from a neurobehavioral perspective, to phenytoin,
carbamazepine, and levetiracetam when prophylaxis against early posttrau-
matic seizures is undertaken. Continued use of any of these or other anticon-
vulsants, however, as prophylaxis against new-onset seizures after the ﬁrst
week post injury (ie, late posttraumatic seizures) is not recommended [85].
When early or late posttraumatic seizures (including nonconvulsive
types) occur, identifying ictal and postictal alterations of consciousness or
behavior directs treatment toward seizure control rather than the neurobe-
havioral disturbances per se. As discussed previously, valproate is preferred
from a neurobehavioral perspective to phenytoin, carbamazepine, or levetir-
acetam for the treatment of early and late posttraumatic seizures.Other medications that complicate neurobehavioral assessment
and recovery from traumatic brain injuryThere are a variety of potentially life-saving pharmacologic interventions
provided to persons who have moderate or severe TBI in the ED and CCU
that may complicate neurobehavioral assessment and possibly recovery
from TBI. Some historically common practices are recognized as unneces-
sary or potentially harmful, for example the administration of corticoste-
roids for improving outcome or reducing posttraumatic ICP or routine
administration of barbiturates for ICP management [85]. Other practices,
such as analgesic or hypnotic-based sedation during mechanical ventilation,
are common and necessary [123], but their eﬀects on neurologic and neuro-
behavioral recovery after TBI remain uncertain or concerning. Critical care
physicians and staﬀ face diﬃcult choices when selecting agents to assist with
752 ARCINIEGAS & MCALLISTERmechanical ventilation, to provide adequate analgesia, or to control agita-
tion among persons who have TBI. Accordingly, a proscriptive approach
to pharmacotherapy in the critical care setting is not reasonable. It is pru-
dent, however, to remain mindful of the potential to complicate neurobeha-
vioral status or delay neurologic and neurobehavioral recovery after TBI by
use of these types of medications and, therefore, to consider alternatives
to them.
For example, antagonists of type-2 dopamine (D2) receptors or benzodi-
azepines commonly are used in for the treatment of agitation and delirium
and as an adjunctive agent to improve compliance with mechanical ventila-
tion [124]. Agents with noradrenergic-attenuating eﬀects (eg, clonidine)
sometimes also are used for these and other purposes. Animal models sug-
gest, however, that dopamine and norepinephrine antagonists delay neuro-
nal recovery and impair neuronal plasticity [69,70,125,126]. Among persons
with TBI, typical antipsychotics exacerbate cognitive impairments [127] and
may prolong the period of PTA [72]. Benzodiazepines are known to impair
memory and other aspects of cognition [128] in healthy adults and seem to
do so also among persons with TBI [129]. The cholinergic deﬁcits resulting
from TBI leave patients vulnerable to the adverse cognitive and behavioral
eﬀects of agents with anticholinergic properties [61,81]. Opiate analgesia
produces impairments in memory among persons without TBI of severity
comparable to those encountered among persons in PTA [130], suggesting
a nontrivial risk for exacerbating or prolonging posttraumatic coma, post-
traumatic delirium, or PTA as a result of their administration. Avoiding,
eliminating, or using the minimum-necessary dose of any of these agents
for as brief a time as is feasible clinically is encouraged. Discontinuing these
medications also is necessary before drawing conclusions about the severity,
prognosis, and the need for treatment of PTE and attendance neurobehavio-
ral disturbances. Alternate medications for the management of posttrau-
matic neurobehavioral disturbances are discussed later.Assessment of posttraumatic encephalopathyThe assessment of PTE is most usefully and accurately undertaken using
standardized assessments appropriate to the phase of PTE in which patients
present to the critical care setting. These types of assessments facilitate
accurate diagnosis of the type and severity of posttraumatic neurobehavio-
ral problems and guide prognostic and therapeutic formulations. The use of
standardized assessments also improves the reliability of examinations per-
formed by diﬀerent CCU staﬀ members, and data derived from these mea-
sures can be used to track not only spontaneous recovery but also changes
(improvement or decline) in response to treatment.
During the period of posttraumatic coma, the Coma/Near-Coma Scale
[131] may be used to gauge coma severity and to monitor recovery. As
patients emerge from posttraumatic coma, the assessment of posttraumatic
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concurrently, serial assessment of PTA using the O-Log [29] should be ini-
tiated. After patients emerge from posttraumatic delirium, continued assess-
ment using the O-Log continues until patients meets criteria for emergence
from PTA (scores R25 on 2 consecutive days). During this period, other
neuropsychiatric disturbances, such as depression, mania, pathologic laugh-
ing and crying, anxiety disorders, psychosis, and nondelirium-related
impulse control problems and aggression may develop or be identiﬁed
more easily as problems not better accounted for by posttraumatic delirium.
When there is concern about the development of these problems, neuropsy-
chiatric consultation should be obtained before instituting deﬁnitive treat-
ments directed at them. During or shortly after the period of PTA,
further evaluation of cognition using the Mini–Mental State Examination
[133] and Frontal Assessment Battery [134] may be used to characterize
the severity of posttraumatic dysexecutive syndrome [135] and to guide
rehabilitative treatment planning.
The neurobehavioral evaluation is complemented usefully by structural
neuroimaging. Obtaining neuroimaging using at least CT of the brain is rec-
ommended for all patients who have suspected TBI [85]. The authors also rec-
ommendedMRI when formulating a neurobehavioral treatment plan, on the
basis that understanding the anatomy of injury informs on neurobehavioral
diagnosis and guides treatment selection usefully. For example, destructive or
ablative injury to the lateral orbitofrontal cortices and underlying white mat-
ter is a common consequence of severe TBI and is associated with impulsive,
disinhibited, or aggressive behavior. Neuroimaging demonstrating severe
damage to these areas suggests that pharmacologic agents (eg, selective sero-
tonin reuptake inhibitors [SSRIs], anticonvulsants, or atypical antipsy-
chotics) may be required to suppress brain (limbic) areas driving these
behaviors. By contrast, neuroimaging demonstrating injury restricted to
cerebral white matter with axonal sparing or revealing no imaging abnormal-
ities suggests a higher likelihood of improving neurobehavioral function
through pharmacologic interventions designed to augment the function of
the lateral orbitofrontal-subcortical circuit (eg, treatment with psychostimu-
lants or cholinesterase inhibitors). These represent very diﬀerent approaches
to the treatment of posttraumatic impulsive, disinhibited, or aggressive
behaviors, and ones that may be informed usefully by neuroimaging rather
than empiric treatment trials alone. When MRI is performed, requesting
T1, ﬂuid-attenuated inversion recovery, T2* gradient-echo, susceptibility-
weighted, and diﬀusion-weighted sequences is recommended.Treatment of posttraumatic neurobehavioral disturbances
The selection of treatments for posttraumatic neurobehavioral
disturbances is best guided by the published literature speciﬁc to TBI. As
discussed previously, some agents (eg, haloperidol and benzodiazepines)
754 ARCINIEGAS & MCALLISTERused routinely in the management of other critically ill patients may not be
well suited for use in this population. Unfortunately, the majority of the
treatment literature regarding posttraumatic neurobehavioral disturbances
consists of open-label case series, single case reports, and only a few
small-scale randomized, double-blind, placebo-controlled studies, leaving
unanswered many questions about the safety, tolerability, eﬃcacy, and
eﬀectiveness of most agents used in this population. Additionally, no med-
ication has received approval from the United States Food and Drug
Administration for the treatment of any neuropsychiatric consequence of
TBI. The suggestions oﬀered in this article represent, therefore, a combina-
tion of the published literature and the authors’ clinical experience and all of
them must be regarded as oﬀ-label uses. Clinicians are encouraged to con-
sider the application of these agents to the treatment of individual patients
a matter of empiric trial.Posttraumatic comaIf other agents that impair consciousness have been eliminated and post-
traumatic coma (including vegetative and minimally conscious states) is the
dominant feature of PTE, a combination of environmental, nonpharmaco-
logic, and pharmacologic interventions should be considered. Environmental
intervention is recommended for the purpose of facilitating adaptive engage-
ment with staﬀ and relevant portions of the environment while minimizing
the potential for overstimulation. For example, providing cues to entrain
sleep-wake cycles (lights oﬀ and in-room alarms silenced at night, lights on
during day) and appetitive or feeding rhythms (bolus rather than continuous
feeding) may be useful. Avoiding unnecessary procedures, particularly at odd
hours, is suggested and optimizing pain management (analgesia without
sedation, where possible) is required. Although the evidence supporting the
use of sensory stimulation (‘‘coma stimulation’’) treatment protocols is
limited [136], the low-cost and minimal risk of these interventions merits con-
sideration of their use for patients in posttraumatic coma in a CCU.
Although opportunities to treat posttraumatic coma directly in the ICU
setting occur infrequently, when they do occur, medications that directly
or indirectly augment catecholaminergic function are used most often for
the treatment of posttraumatic coma and hypoarousal. These agents include
amantadine (target dose 50–200 mg twice daily), bromocriptine (1.25–2.5 mg
twice daily), carbidopa or levodopa (target dose 25/100 to 25/250 up to
4 times daily), and methylphenidate (target dose 0.3 mg/kg twice daily).
Although studies are available to support the use of all of these agents for
this purpose, the evidence favors amantadine as the ﬁrst-line agent for the
treatment of posttraumatic coma [137,138]. Treatment generally begins
with amantadine (50 mg twice daily), and may be increased weekly (by
100 mg/day) to achieve symptomatic improvement, medication intolerance,
or maximum dosage (200 mg twice daily). Monitoring for side eﬀects, in
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required. If amantadine is ineﬀective or not tolerated, discontinuing it and
initiating treatment with bromocriptine may be of beneﬁt; treatment begins
with 1.25 mg twice daily and may be advanced after 3 to 7 days to 2.5 mg
twice daily. If necessary, additional serial trials of other agents (eg, carbidopa
or levodopa and methylphenidate) may be attempted. By the time empiric
trials of other agents are undertaken, however, patients usually are in a set-
ting other than a CCU (ie, acute rehabilitation, long-term acute care, or
skilled nursing facilities).Posttraumatic deliriumAfter patients emerge from posttraumatic coma, a period of posttrau-
matic delirium generally is expected. The combination of severe alterations
or ﬂuctuations of consciousness and impaired selective attention (confu-
sion), restlessness or agitation, aggression, hallucinations, paranoid or other
odd ideation, and aﬀective lability presents substantial management
challenges for CCU staﬀ. These challenges are compounded when these be-
haviors lead patients to pull on or pull out intravenous (IV) lines, attempt
self-extubation, transfer unsafely, or become threatening or assaultive to
family or staﬀ. These behaviors frequently prompt the use of high-dose hal-
operidol or other D2 receptor antagonists, benzodiazepines, opiates, and
other sedating medications. As discussed previously, these treatments pose
some theoretic risk for interfering with neuronal recovery and plasticity
and their use may delay clinical recovery.
The pathophysiology of deliriumdregardless of the context in which it
developsdseems to involve an imbalance between cerebral dopaminergic
(excessive) and cholinergic (deﬁcient) function [139]. In light of the
neurochemical disturbances produced by TBI (discussed previously), the
pharmacologic treatment of posttraumatic delirium, therefore, may be
undertaken most productively through the use of agents that facilitate
cholinergic function or maintain normal dopaminergic function. Although
the cholinesterase inhibitors (eg, donepezil, rivastigmine, galantamine, and
physostigmine) are, in principle, useful for patients whose delirium-related
behavioral disturbances are predicated on cholinergic deﬁcit, the evidence
supporting their use for this purpose is limited [140]. Atypical antipsychotics
seem as eﬀective as haloperidol for the treatment of delirium in patients who
are critically ill (including those who are mechanically ventilated), tend not
to interfere strongly with cerebral dopaminergic function, and produce
fewer adverse motor eﬀects than haloperidol [141]. These agents also may
facilitate, or at least not adversely aﬀect, cognition when used for the treat-
ment of posttraumatic delirium, although there currently are limited data
with which to support this suggestion [142,143].
The authors generally use quetiapine as ﬁrst-line for the treatment of
posttraumatic delirium in the CCU among patients in whom enteral
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mg twice daily) and increases rapidly to treatment response or intolerance.
In general, most patients seem to respond to quetiapine (600 mg or less total
daily dose), although substantially higher doses sometimes are required to
achieve reduction of agitiated, aggressive, and other disinhibited behaviors.
When enteral administration is not possible, olanzapine may be adminis-
tered by intramuscular (IM) injection. Treatment usually begins with olanza-
pine (2.5 mg IM every 12 hours), and may be advanced to olanzapine (5 mg
every 6 hours) as tolerated. In general, the total daily dose of olanzapine
IM is kept below 20 mg. If these agents are not fully eﬀective in the
management of agitation or aggression resulting from posttraumatic
delirium, adjunctive or alternative treatment with valproate (starting at
250–500 mg 3 times daily orally or IV) may be helpful.
If all of these interventions fail, then treatment with haloperidol 0.5 to
1 mg twice daily (by mouth, IM, or IV) may be considered. When used, hal-
operidol doses should not exceed 10 mg daily. At this dose, more than 80%
of striatal D2 receptors are occupied and extrapyramidal eﬀects become
likely [144]. Further, the apparent eﬀectiveness of high-dose haloperidol
likely reﬂects its additional dose-dependent eﬀects on a-1 adrenergic and
serotonin type-2A receptors [145]. If these eﬀects are required to achieve
improvement in the symptoms of posttraumatic delirium, then using an
atypical antipsychotic as monotherapy, preferably, or as an adjunct to
low-dose haloperidol is likely to be as eﬀective as high-dose haloperidol
neurobehaviorally and less problematic with respect to extrapyramidal
symptoms.
The short-term use of benzodiazpines is appropriate for the treatment of
alcohol withdrawal or delirium tremens in patients who have TBI. Their use
in the acute period after TBI is otherwise discouraged strongly.
Concurrent to pharmacotherapy, environmental and behavioral interven-
tions of posttraumatic delirium are necessary [146]. Controlling the environ-
ment in a manner that decreases the likelihood of sensory overstimulation
and subsequent agitation is helpful, even if sometimes diﬃcult to achieve
in a CCU. Normalizing light cues to better simulate day-night periods
may help entrain sleep-wake cycles. Proactively reorienting patients to cur-
rent circumstances and surroundings may help avoid frustration and agita-
tion borne of a patient’s confusion on these points. Additionally, 1:1 staﬃng
(sitters) in lieu of physical restraints is encouraged, as the latter predictably
increase agitation in confused patients, prompting medication administra-
tion and sedation that prolong further the period of confusion and
agitation.Posttraumatic amnesiaAfter emerging from posttraumatic delirium, most patients who have
moderate or severe TBI continue to exhibit impairments in declarative
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The memory impairments generally are striking; hence, this period (PTA) is
named for them, and they are an appropriate focus of nonpharmacologic
and pharmacologic treatment. Among the currently available pharmaco-
therapies, the cholinesterase inhibitors seem the most useful for the treat-
ment of posttraumatic memory impairments (reviewed by Arciniegas and
Silver [61] and Warden and colleagues [82]). Among patients who respond
to these agents, attention and executive function often also improve concur-
rently. Such beneﬁts seem conferred by this entire class of medication,
leaving route of administration, dosing, and tolerability as the primary
determinants of treatment selection.
Among patients in whom enteral administration is possible, donepezil
5 mg daily generally is used as the ﬁrst-line treatment. After 2 weeks, the
dose may be advanced to donepezil 10 mg daily. When enteral administra-
tion is not possible, IV physostigmine (3–12 mg daily, usually in 3 to 4 di-
vided doses) or transdermal rivastigmine (4.6–9.5 mg/24-hour patch) may
be considered. The administration frequency and side-eﬀect proﬁle of phy-
sostigmine are not favorable, although there are data supporting its use for
the treatment of posttraumatic memory impairments in the acute and late
post-injury periods. There are no published studies of transdermal rivastig-
mine among persons who have TBI; it is likely that this agent aﬀords ben-
eﬁts similar to those of the other cholinesterase inhibitors. The safety,
tolerability, eﬃcacy, and eﬀectiveness of this agent for PTA, however, re-
main uncertain and its use, if undertaken at all, requires caution. When
used, the rivastigmine patch is initiated at 4.6 mg per 24 hours, and should
not be increased to 9.5 mg per 24 hours before the end of 4 weeks of treat-
ment at the starting dose.
Impairments in speed of processing, higher-level (sustained, divided, alter-
nating) attention, working memory, and executive function also generally are
present during the period of PTA, although theymay be less salient features of
the clinical presentation as a result of the striking character of a patient’s am-
nesia. When a cholinesterase inhibitor is used, some of these other cognitive
impairments also may improve (in particular attention and executive func-
tion). Among patients who have clinically signiﬁcant impairments in process-
ing speed or impairments in higher-level attention, administration of
methylphenidate (5 mg twice daily, titrated in 5-mg twice-daily increments
every 2 to 3 days to a target dose of 0.3 mg/kg twice daily) may be of beneﬁt.
This treatment may secondarily beneﬁt depressive and aﬀective disturbances
andmay improve agitation or impulsivity among persons who have intact lat-
eral orbitofrontal-subcortical circuitry (ie, lateral orbitofrontal cortex, subad-
jacent white matter, and relevant subcortical structures).
Among patients requiring treatment for intermittent agitation or
aggression or disinhibition resulting from destructive or ablative lateral
orbitofrontal-subcortical system injury, methylphenidate and other cate-
cholamine-augmenting agents should be used with caution if used at all.
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manner described for posttraumatic delirium may be useful. When
depression, anxiety, or pathologic laughing and crying develop during the
period of PTA, treatment with SSRIs may be useful. Among the SSRIs, ser-
traline, citalopram, and escitalopram are preferred in light of their short
half-lives, limited drug-drug interactions, and absence of antimuscarinic
eﬀects. When any of these or other neurobehavioral problems develop in
the acute postinjury period, consultation with a neuropsychiatrist or behav-
ioral neurologist experienced in their management is encouraged.
Nonpharmacologic interventions also are important during the period of
PTA and include errorless learning (the proactive provision of correct infor-
mation to facilitate learning and avoid intrusions and frustration), cueing
and direction for daily tasks, and patient/family/staﬀ training and support.
Although none of these interventions seems to hasten the recovery process,
their use may decrease frustration and reduce the emergence of unwanted
behaviors resulting frommemory failures (including confabulation, agitation,
and aﬀective lability). During this period of recovery, involving rehabilitation
staﬀ (ie, physical therapy, occupational therapy, and speech-language pathol-
ogy) in theCCU-basedmanagement of patients and initiating referral to acute
rehabilitation services are appropriate and recommended.Posttraumatic dysexecutive syndromeAfter emerging from PTA, many patients who have moderate or severe
TBI continue to demonstrate functionally signiﬁcant impairments in
higher-level attention, processing speed, working memory, memory retrieval
(more than new learning), functional communication, and executive func-
tion. These impairments frequently are accompanied by other disturbances
in emotion (eg, depression, pathologic laughing and crying, and anxiety)
and focal neurobehavioral syndromes (eg, disinhibition or aggression result-
ing from lateral orbitofrontal injury, apathy resulting from bilateral anterior
cingulate injury, and partial Klu¨ver-Bucy–like states resulting from bilateral
anteromedial temporal injury).
When the occasion for their treatment presents itself in the critical care
setting, following the recommendations for treatment of cognitive, emo-
tional, and behavioral sequelae of TBI (discussed previously) is suggested.
Consultation and in-CCU management of posttraumatic neurobehavioral
disturbances by a physiatrist, rehabilitation staﬀ, and a neuropsychiatrist
or behavioral neurologist pending transfer of a patient to an inpatient or
outpatient neurorehabilitation program is suggested.Summary
TBI is a signiﬁcant public health problem and individuals who have TBI
commonly are encountered in critical care settings. The biomechanics of
759NEUROBEHAVIORAL MANAGEMENT OF TBIa typical brain injury result in a predictable injury proﬁle that often involves
frontal and temporal cortex, cerebral white matter, diencephalic, and mesen-
cephalic-brainstem areas. Damage to these regions is associated with a con-
stellation of neurobehavioral sequelae, including altered arousal, impaired
cognition, agitation, and impairment of impulse control. The response to
and recovery from TBI are usefully framed as a PTE with several pre-
dictable stages. Patients usually present initially with a disorder of con-
sciousness (coma or hypoarousal). This is followed by a period of altered
consciousness, inattention, and behavioral disturbances consistent with
a posttraumatic delirium. Over time, the delirium lessens revealing more
clearly prominent deﬁcits in new learning and memory (PTA). As memory
improves, many patients continued to experience signiﬁcant impairments
in executive function, including impairment in judgment, planning, self-
monitoring, and social comportment. The duration of PTA and the degree
of recovery from the posttraumatic dysexecutive syndrome are important to
assess and monitor as they are highly predictive of eventual functional
outcome. Treatment approaches vary across these diﬀerent stages but there
are several broad principles that are important to consider. These include
careful attention to other medical conditions (eg, seizures, infections, and
pain), reduction or elimination (where possible) of psychotropic medications
(eg, benzodiazepines, typical antipsychotics, and anticonvulsants), and man-
agement of environmental factors that can cause or exacerbate challenging
behaviors or hinder recovery. These considerations may assist critical care
practitioners in their eﬀorts to improve not only mortality and medical
morbidity but also neurobehavioral outcome after TBI.References
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Approximately 30% of Americans currently use tobacco products, 51%
currently use alcohol, and 8% currently use illicit drugs [1]. Substance use
has been shown to cause signiﬁcant morbidity and mortality. The ﬁrst
and third leading causes of death in the United States are tobacco use
(18.1% of all deaths) and alcohol consumption (3.5% of all deaths) [2]. Sub-
stance use often underlies hospital admissions for accidents and injury and
presents a major ﬁnancial burden to the United States health care system
[3,4]. Globally, the burden of alcohol, tobacco, and illicit drug use has enor-
mous impact on international public health on both the epidemiologic and
economic scales [5].
Substance abuse is considered a maladaptive pattern of substance use
resulting in repeated adverse social consequences; substance dependence,
the most severe form of abuse, is characterized by physiologic and behav-
ioral symptoms related to substance use (Table 1). Approximately 9% of
the United States population (22.6 million persons), 12 years of age or older,
meet criteria established by the Diagnostic and Statistical Manual of Mental
Disorders, 4th edition for substance abuse or dependence [1]. Speciﬁcally,
7% of the population meets criteria for alcohol abuse or dependence,
whereas 3% meets criteria for illicit substance abuse or dependence. The
illicit substances most commonly used include marijuana, cocaine, and pre-
scription opioids [1].
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Table 1
Diagnostic and Statistical Manual-IV criteria for substance abuse and withdrawala
Abuse Dependence
Deﬁned as a maladaptive pattern
of substance use leading to
clinically signiﬁcant impairment
or distress as manifested by one
(or more) of the following, occurring
within a 12-month period:
Deﬁned as a maladaptive pattern of substance
use leading to clinically signiﬁcant
impairment or distress, as manifested by
three (or more) of the following, occurring
any time in the same 12-month period:
1. Recurrent use resulting in failure
to fulﬁll major role obligation
at work, home, or school
1. Tolerance, characterized by either:
(a) A need for markedly increased amounts
of the substance to achieve intoxication
or the desired eﬀect or
(b) Markedly diminished eﬀect with continued
use of the same amount of the substance
2. Withdrawal, characterized by either:
(a) The characteristic withdrawal syndrome
for the substance or
(b) The same (or closely related) substance
is taken to relieve or avoid withdrawal
symptoms
3. Substance taken in larger amount
and for longer period than intended
4. Persistent desire or repeated unsuccessful
attempt to quit
5. Much time or activity to obtain, use,
recover from eﬀects of substance
6. Important social, occupational, or
recreational activities given up or reduced
7. Use continues despite knowledge
of adverse consequences
2. Recurrent use in physically
hazardous situations
3. Recurrent substance-related
legal problems
4. Continued use despite persistent
or recurrent social or interpersonal
problems caused or exacerbated
by the eﬀects of the substance
a According to the Diagnostic and Statistical Manual of Mental Disorders. 4th edition, a
person can be abusing a substance or dependent on a substance but not both at the same time.
Data from American Psychiatric Association. Diagnostic and statistical manual of mental
disorders. 4th edition. Washington DC: American Psychiatric Association; 1994.
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Substance use is often associated with motor vehicle accidents, falls,
drownings, thermal injury, homicide, and suicide [3,6–8]. Many studies
have noted a signiﬁcant association between alcohol use and injury
[3,7–10]. One review of articles published between 1995 and 2005 found
that patients presenting to the emergency department were more likely to
have a positive blood alcohol concentration and report drinking before
the injury than patients presenting for reasons other than injury [7]. In the
United States, up to half of trauma beds are occupied by patients involved
in alcohol-related traﬃc accidents [3]. Additionally, cocaine and cannabis
use place patients at higher risk for all types of injuries [11].
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admitted to the ICU and are associated with doubling of mortality [12].
Alcohol use can lead to multiple metabolic and systemic derangements
including thiamine deﬁciency and subsequent Wernicke’s encephalopathy,
hypomagnesemia, hypokalemia, hypophosphatemia, metabolic acidosis,
rhabdomyolysis, hepatic insuﬃciency, and pancreatitis [12]. Chronic alcohol
use has been independently associated with acute respiratory distress syn-
drome (odds ratio, 3.70; 95% conﬁdence interval, 1.83–7.71) and increases
the severity of multiorgan dysfunction in patients with underlying septic
shock [13,14].Common withdrawal-related issues
Withdrawal syndromes are physiologic responses to abrupt withdrawal
or reduced use of a drug and are common to many substances of abuse.
These syndromes may often complicate the care of critically ill patients
[6,15,16]. It may be especially challenging to treat patients with substance
withdrawal syndromes because of an unknown history of substance abuse,
altered mental status, or complex physiologic responses resulting from the
presenting illness, which can be confused with withdrawal [17]. Withdrawal
syndromes have been associated with the use of alcohol [18], opioids [19],
cocaine [20], benzodiazepines [21], marijuana [22], and nicotine [23]. It is
important to screen all high-risk critical care patients by performing urine
toxicology for drugs of abuse at the time of admission to the hospital or
to a critical care setting.
The management of patients with a substance withdrawal syndrome
presenting concomitantly with an underlying critical illness can be espe-
cially challenging [24]. The ﬁrst step in caring for any critically ill patient
is to ensure adequate airway management, intravenous access, and applica-
tion of general resuscitative measures [6]. General principles regarding the
management of substance withdrawal syndromes include use of a symp-
tom-triggered approach, substitution of a long-acting replacement for the
abused drug in gradual tapering doses, and establishing a plan for long-
term abstinence [25]. When assessing for superimposed substance with-
drawal, the critical care team must consider potential polysubstance abuse.
A thorough substance abuse history should be obtained from the patient
or family. It is important to determine which substances a patient may
be withdrawing from by taking a thorough substance abuse history and
performing urine toxicology on all patients. Common symptoms that un-
derlie many withdrawal syndromes include irritability, dysphoria, anxiety,
nausea, agitation, tachycardia, and hypertension [25]. Treatment protocols
may vary, however, and treatment of one syndrome may mask symptoms
of an additional syndrome, which, if untreated, may be life threatening
[25].
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Alcohol withdrawal
Clinical manifestations of alcohol withdrawal
The spectrum of alcohol withdrawal ranges from a mild physiologic re-
sponse to seizures and death. More severe responses are seen in patients
with prior episodes of withdrawal, a phenomenon known as ‘‘kindling’’
[26], or other underlying acute conditions. Chronic alcohol use has a depres-
sant eﬀect on g-aminobutyric acid transmission with compensatory in-
creased N-methyl-D-aspartate and adrenergic activity [25,27]. This sudden
increase in adrenergic activity, manifested by increased catecholamine
release, is what causes the most common symptoms including tachycardia,
hypertension, and tremor [6]. It is important to note that the symptoms of
alcohol withdrawal may occur not only with abrupt cessation of alcohol
use but also with a reduction in use.
Symptoms of alcohol withdrawal may begin as soon as 6 to 8 hours after
decreasing alcohol intake (Table 2). Early symptoms include tremulousness,
anxiety, palpitations, nausea, and anorexia [28]. These symptoms typically
subside after 24 to 48 hours. Alcohol withdrawal seizures are common in
patients with chronic alcohol use and usually occur between 6 and 48 hours
after decreasing alcohol use [29–31]. Early recognition and treatment of
alcohol-related seizures are important to prevent development of status
epilepticus. Approximately 12 to 48 hours after cessation of alcohol use,
alcoholic hallucinosis may occur. Alcoholic hallucinosis is characterized
by visual, auditory, or tactile hallucinations and is hallmarked by an intact
sensorium, in contrast to delirium tremens (DTs) [32,33].Table 2
Clinical manifestations of alcohol withdrawal
Phase Symptoms
Onset after
last drink Duration
Early withdrawal Tremulousness
Anxiety
Palpitations
Nausea
Anorexia
6–8 h 1–2 d
Withdrawal seizures Generalized tonic-clonic seizures 6–48 h 2–3 d
Alcoholic hallucinosis Hallucinations
Visual
Tactile
Auditory
12–48 h 1–2 d
Delirium tremens Tachycardia
Hypertension
Low-grade fever
Diaphoresis
Delirium
Agitation
48–96 h 1–5 d
771SUBSTANCE ABUSE AND CRITICAL CAREDTs typically occur 48 to 96 hours after withdrawal of alcohol and are
characterized by tachycardia, hypertension, low-grade fever, diaphoresis,
and delirium. Approximately 5% of patients experiencing alcohol with-
drawal develop DTs. Risk factors for the development of DTs include a pro-
longed drinking history, previous episodes of DTs, age greater than
30 years, comorbid illness, and a greater number of days since last drink
[34]. The syndrome is associated with a 5% to 15% mortality rate and death
is often caused by arrhythmias or associated critical illness (eg, pneumonia).
Older age, underlying lung disease, fever greater than 104F, and comorbid
liver disease are associated with an increase in mortality risk [34]. Patients
with DTs exhibit increased oxygen consumption, respiratory alkalosis
caused by hyperventilation, and subsequent decreased cerebral blood ﬂow
[35]. As a result of associated hyperthermia, diaphoresis, tachypnea, and
vomiting, DTs also often lead to dehydration. Hypokalemia is a common
manifestation resulting from both renal and extrarenal losses; hypomagne-
semia is also common and may predispose patients to the development of
seizures and arrythmias; hypophosphatemia may also be present and con-
tribute to further complications [15,36].
Common complications of chronic alcoholism and alcohol withdrawal
need to be considered when caring for a critically ill patient with a history
of alcohol abuse. The astute physician should be aware of the classic triad
of encephalopathy, oculomotor dysfunction, and gait ataxia associated
with Wernicke’s encephalopathy, caused by thiamine deﬁciency [37]. The
pathophysiology of this syndrome is poorly understood. Brain lesions are
associated with the syndrome and are characterized by vascular congestion,
microglial proliferation, and petechial hemorrhages in a symmetric distribu-
tion around the third and fourth ventricles. In the chronic state, demyelin-
ation may occur. Atrophy of the mamillary bodies is highly speciﬁc for this
process. The treatment of Wernicke’s encephalopathy consists of 100 mg of
thiamine intravenously or intramuscularly daily for 5 days, and prognosis
depends on prompt administration of thiamine. Care needs to be taken
when considering this syndrome because administration of glucose before
thiamine replacement may worsen the symptoms. Korsakoﬀ’s amnestic syn-
drome, a late manifestation of Wernicke’s encephalopathy, is characterized
by selective anterograde and retrograde amnesia [37]. The development of
Wernicke-Korsakoﬀ syndrome is best prevented by chronic oral administra-
tion of thiamine to outpatients at risk.
Other common complications of chronic alcoholism and alcohol with-
drawal include pneumonia, acute respiratory distress syndrome, sepsis,
upper gastrointestinal bleeding, necrotizing pancreatitis, and acute and
chronic liver disease [38].Management of alcohol withdrawal
Multiple studies have shown benzodiazepines, particularly ones with
longer duration of action, to be the preferred therapy for the treatment of
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alcohol withdrawal, published in 1968, treatment with chlordiazepoxide re-
sulted in a 2% combined risk of seizures and delirium compared with a 10%
to 16% risk in patients receiving chlorpromazine, thiamine, hydroxyzine, or
placebo [42]. A more recent meta-analysis of 11 studies comparing benzodi-
azepines with placebo or active control showed that early recognition and
treatment of alcohol withdrawal with benzodiazepines reduces duration
and severity of symptoms, the incidence of delirium, and seizures [39].
No one benzodiazepine has been proved to be superior for the treatment
of alcohol withdrawal [43]. Evidence points to longer-acting benzodiazepines
(chlordiazepoxide or valium) to be more eﬀective for the prevention of sei-
zures and DTs, whereas shorter-acting agents (alprazolam or oxazepam)
may be associated with the development of seizures during withdrawal.
The dose and duration of benzodiazepine treatment has been a subject of
much investigation. A landmark randomized clinical trial from 1994 [44]
that compared ﬁxed-dosing of chlordiazepoxide (four times daily) with
symptom-triggered dosing found that the ﬁxed-dosing approach required
a longer duration of treatment (68 versus 9 hours, P!.001) and more med-
ication (425 versus 100 mg of chlordiazepoxide, P!.001). No diﬀerences
were seen in severity of withdrawal or incidence of seizures [44]. Similar
results were noted in another study that compared symptom-triggered
approach with the treatment of alcohol withdrawal in the ICU with contin-
uous midazolam drip. In this study, use of the symptom-triggered approach
was associated with decreased time to symptom control and less benzodiaz-
epine used [45]. The most widely used and validated tool to assess severity of
symptoms of alcohol withdrawal is the Clinical Institute Withdrawal Assess-
ment for Alcohol Scale, Revised (CIWA-Ar) (Appendix 1) [46,47]. This tool
should be used only after the diagnosis of alcohol withdrawal is made and is
useful to guide treatment using the symptom-triggered approach.
Maldonado and colleagues [48] conducted a prospective, randomized
study comparing the eﬀects of lorazepam (short half-life) with those of
diazepam (long half-life) on physiologic (eg, vital signs) and psychophysio-
logic responses (eg, CIWA-Ar) of subjects undergoing alcohol withdrawal.
The study included 48 inpatients presenting with alcohol withdrawal symp-
toms at a university and a Veterans Aﬀairs hospitals. They found that there
was no signiﬁcant diﬀerence between the rates of change for either group on
either measure (PO.05). Similarly, there was no signiﬁcant diﬀerence in the
total equipotent benzodiazepine usage between groups (PO.05). Despite the
controversy regarding the beneﬁts of one benzodiazepine agent versus
another, this study found no evidence of a clinical advantage for choosing
benzodiazepines according to their half-lives. These ﬁndings suggest that
the choice of benzodiazepine in the management of alcohol withdrawal is
not as critical as had been anecdotally assumed.
A recently published study also shows that a signiﬁcant proportion of pa-
tients are inappropriately treated with symptom-triggered therapy for
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stringent evaluation for this treatment modality is needed [49].
Other medications have been evaluated for the treatment of alcohol with-
drawal. b-Blockers have been shown to be eﬀective for symptomatic treat-
ment through reductions in autonomic activity [50]. b-Blockers, however,
should not be used as monotherapy and caution should be taken with use
of these agents because they may mask signs and symptoms of a worsening
clinical scenario. a-Adrenergic agonists, also through reductions in auto-
nomic activity, have also been used in the treatment of alcohol withdrawal.
These agents also have no activity against delirium or seizures so should not
be used as monotherapy. Carbamazepine has been shown to be superior to
placebo for the treatment of alcohol withdrawal and to reduce ‘‘kindling’’
eﬀects [51]. Neuroleptic agents, such as haloperidol, are useful as adjunctive
treatment and reduce agitation and hallucinations [52]. Treatment of alco-
hol withdrawal with a tapering ethyl alcohol infusion oﬀers biologic plausi-
bility. A recent randomized clinical trial in ICU patients, however, found no
beneﬁt of treatment with alcohol over diazepam [40].
There is some evidence to suggest that the new a2-agonist, dexmedetomi-
dine, and other similar agents, may be eﬀective for the treatment of opioid
withdrawal. Riihioja and colleagues [53] compared the eﬀects of dexmedeto-
midine, a selective a2-adrenoceptor agonist, with those of diazepam and pro-
pranolol on alcohol withdrawal symptoms in rats. After the intoxication
period (4 days), rats were divided into four equal groups: (1) a dexmedetomi-
dine-treated group (30 mg/kg, subcutaneously); (2) a diazepam-treated group
(2 mg/kg, subcutaneously); (3) a propranolol-treated group (5 mg/kg, subcu-
taneously); and (4) a control group with nomedication.Medication was given
in thewithdrawal phase (2, 8, 14, and20hours after theonset of thewithdrawal
symptoms). The severity of the alcohol withdrawal symptoms (eg, rigidity,
tremor, irritability, and hypoactivity) was observed up to 33 hours after the
onset of the ethanol withdrawal symptoms. When measured as the sum score
of the three most speciﬁc withdrawal signs (eg, rigidity, tremor, and irritabil-
ity), dexmedetornidine and diazepam signiﬁcantly relieved the ethanol with-
drawal reaction, whereas propranolol attenuated tremor, but was ineﬃcient
against other withdrawal symptoms. In addition, dexmedetomidine was
found to relieve ethanol-induced neuronal loss in the locus ceruleus. Even
though there are nohuman studies, data from case reports suggest that dexme-
detomidine may be a valuable adjunct in the treatment of severe cases of
alcohol withdrawal by better controlling sympathetic overactivity while pro-
viding adequate sedation with minimal respiratory depression [54–56].Opioid withdrawal
Clinical manifestations of opioid withdrawal
Opioids include substances that are derived directly from the opium
poppy (eg, morphine and codeine); the semisynthetic opioids (eg, heroin);
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phase of opioid withdrawal, the patient typically experiences a range of
symptoms including diarrhea and vomiting, thermoregulation disturbances,
insomnia, muscle and joint pain, anxiety, and dysphoria (Table 3).
Although these symptoms generally include no life-threatening complica-
tions (unlike alcohol withdrawal syndrome), the acute opioid withdrawal
syndrome causes marked discomfort and frequently leads to a relapse to
drug use [57].
Opioid medications act as agonists at the m-opioid receptor and cause
reduced adrenergic activity at the locus ceruleus. Opioid withdrawal occurs
when opioids are abruptly discontinued or when opioid use has diminished.
The clinical phenomena associated with opioid withdrawal include neuro-
physiologic rebound and the central nervous system (CNS) suppression
that occurs with opioid use is replaced by CNS hyperactivity [58]. Abrupt
opioid withdrawal can be instituted with the administration of naloxone,
a complete opiate agonist, in a patient who has recently used opioids,
because naloxone binds to the opiate receptor with a greater aﬃnity
than do opiate agonists [6]. It is important to remember that opioid with-
drawal occurs as part of a physiologic response not only in patients depen-
dent on heroin or prescription opioid medications, but also in patientsTable 3
Clinical manifestations of opioid withdrawal
System Symptoms
Vitals Tachycardia
Fever
Hypertension
Central nervous system Restlessness
Irritability
Insomnia
Craving
Yawning
Tremor
Eyes Pupillary dilation
Lacrimation
Upper respiratory system Rhinorrhea
Sneezing
Skin Piloerection
Diaphoresis
Gastrointestinal Nausea
Vomiting
Diarrhea
Musculoskeletal Myalgias
Arthralgias
Bone pain
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pain.
The severity of opioid withdrawal varies with the dose and duration of
drug use. In addition, route of administration also seems to be important.
Data from one study suggest that injection drug use is associated with sig-
niﬁcantly higher withdrawal symptom scores than was inhaled opioid use
[59]. The time to onset of opioid withdrawal symptoms depends on the
half-life of the drug being used. For example, withdrawal may begin 4 to
6 hours after the last use of heroin, but up to 36 hours after the last use
of methadone [58]. Neuropharmacologic studies of opioid withdrawal
have supported the clinical picture of CNS noradrenergic hyperactivity
[58,60]. Evidence for the role of noradrenergic hyperactivity in opioid with-
drawal has been provided by studies showing elevated norepinephrine
metabolite levels [61].
Early ﬁndings of opioid withdrawal may include tachycardia and hyper-
tension. Bothersome CNS system symptoms also may occur and include
restlessness, irritability, and insomnia. Opioid craving in proportion to the
severity of physiologic withdrawal symptoms is typically present. Pupillary
dilation can be marked. A variety of cutaneous and mucocutaneous symp-
toms (including lacrimation; rhinorrhea; and piloerection, also known as
‘‘gooseﬂesh’’) can occur. Patients frequently report yawning and sneezing.
Gastrointestinal symptoms, which initially may be mild (anorexia), can
progress in moderate to severe withdrawal to include nausea, vomiting,
and diarrhea [25,57].
As with the onset of withdrawal, the duration also varies with the half-life
of the drug used and the duration of drug use. For example, the meperidine
abstinence syndrome, which generally begins 4 to 5 hours after the last dose
of meperidine, may peak within 8 to 12 hours and last only 4 to 5 days [58];
whereas heroin withdrawal symptoms, which begin 6 to 8 hours after the
last dose of heroin, often peak within 36 to 72 hours and may last for
7 to 14 days [62]. A protracted abstinence syndrome has been described,
in which a variety of symptoms may last beyond the typical acute with-
drawal period [63]. Findings in prolonged and protracted abstinence may
include mild abnormalities in vital signs and continued craving [64].Management of opioid withdrawal
The choice of pharmacotherapy used to treat opioid withdrawal may be
inﬂuenced by the presence and severity of patients’ underlying medical
comorbidities [65]. General supportive measures are necessary for managing
withdrawal, and reassuring patients and families that their symptoms are
taken seriously.
Substitution with a long-acting opioid in tapering doses is the treatment
of choice for managing opioid withdrawal [25]. For short-acting opioids, the
natural course of withdrawal generally is relatively brief, but more intense
and associated with a higher degree of discomfort than with equivalent
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considerable individual variation. One treatment strategy is to stabilize pa-
tients dependent on heroin with methadone, then gradually decrease the
methadone dose. Initially, methadone may be given in 5-mg increments as
the physical signs of abstinence begin to appear [66], up to a total of 10 to
20 mg over the ﬁrst 24 hours. Larger methadone doses are required to treat
patients who have larger opioid habits; for such patients, a routine starting
dose might be 30 rather than 5 mg. Once a stabilizing dose has been reached,
methadone is tapered by 20% a day for inpatients, leading to a 1- to 2-week
procedure. All patients treated with opioids require close monitoring for
treatment eﬀectiveness and toxicity.
a-Adrenergic agonists have also been shown to decrease symptoms of
opioid withdrawal. Gold and colleagues [67] reported amelioration of opi-
oid withdrawal symptoms by use of clonidine and postulated that both
morphine and clonidine blocked activation of the locus ceruleus, a major
noradrenergic nucleus that shows increased activity during opioid with-
drawal. Typical doses used to treat opioid withdrawal range between
0.1 and 0.2 mg every 6 hours with close monitoring of blood pressure.
Side eﬀects include sedation, dry mouth, orthostatic hypotension, and
constipation.
Buprenorphine is a high-aﬃnity, partial agonist at the m-opioid receptor.
Buprenorphine and buprenorphine-naloxone were approved by the US
Food and Drug Administration in October 2002 as a pharmacotherapy
for opioid dependence [68]. A recent Cochrane systematic review [69] of
18 studies (14 randomized clinical trials) of the use of buprenorphine for
opioid withdrawal found that buprenorphine treatment was superior to
clonidine and as eﬀective as methadone for ameliorating withdrawal symp-
toms, treatment retention, and treatment completion. It was also noted in
this review that the duration of withdrawal symptoms may be signiﬁcantly
less with buprenorphine compared with methadone [69]. These ﬁndings
were supported by a subsequent multicenter randomized clinical trial of
a 13-day detoxiﬁcation program using buprenorphine-naloxone versus
clonidine [70]. The usual dose of buprenorphine-naloxone required to treat
opioid withdrawal symptoms ranges between 8 and 24 mg daily. Therapy
with buprenorphine-naloxone should start with a dose of 8 mg and should
not begin until symptoms occur and 8 to 24 hours after the last dose of opi-
oid was taken (depending on the half-life of the opioid used). This is because
of buprenorphine-naloxone’s high receptor aﬃnity, which can precipitate
opioid withdrawal if administered while opioids are still bound to the opiate
receptor. Limitations to the use of buprenorphine in the treatment of opioid
dependence in the ICU are its sublingual administration and issues with
regard to pain control and sedation because opioids have little eﬀect in
patients receiving buprenorphine because of its high receptor aﬃnity.
In the course of managing opioid withdrawal, clinicians also need to be
able to address medical problems seen in this population [71,72]. Such issues
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may complicate withdrawal presentation and management. For instance,
one study suggests that injection drug use increases cytokine response in pa-
tients coinfected with HIV and hepatitis C virus [66].
A recent development in the treatment of opioid dependence is ultra-
rapid inpatient detoxiﬁcation from opiates, using sedatives and anesthetics
in combination with opiate antagonists. Ultrarapid opiate detoxiﬁcation
ﬁrst was described in a study of 12 opiate-dependent patients who were
given naloxone while under general anesthesia [73]. A more recent study
has suggested that ultrarapid opiate detoxiﬁcation may be no more eﬀec-
tive than simpler approaches to the treatment of opioid withdrawal
[74,75]. Additionally, safety concerns may limit the usefulness of ultra-
rapid opiate detoxiﬁcation [74,75]. Nevertheless, the risks remain consider-
able and research remains to be done to determine long-term outcomes
[73,74,76–78].Pain control in opioid-dependent patients
Opioid-dependent patients with both acute and chronic pain pose
a unique and challenging dilemma to treatment providers. Opioid medica-
tions are highly eﬀective for the treatment of both acute and chronic pain
and should not necessarily be withheld over concerns regarding current
and future abuse. Care needs to be taken, however, to minimize risk of
harm [79]. Controversy exists in the literature that the treatment of chronic
pain does not necessarily put an individual at risk of the development of opi-
oid addiction because pain is seen as a functional antagonist to the opioid
treatment [80]. Data are emerging, however, suggesting that the relationship
between opioid treatment of pain and the development of abuse is complex
and in need of further study [79,81].
A recent article by Alford and colleagues [82] outlines four common
misconceptions regarding treatment of acute pain concurrent with the treat-
ment of opioid dependence: the notions that (1) the medication used for opi-
oid dependence should cover the acute painful condition, (2) use of opioids
for analgesia may result in relapse, (3) addition of opioid treatment for acute
pain to opioid maintenance for dependence may result in CNS and respira-
tory depression, and (4) complaints of pain may constitute ‘‘drug-seeking’’
behavior. In general, patients should be maintained on medications to treat
opioid dependence (treatment programs should be contacted to verify dose
and to ensure easy transition from inpatient hospital stay back to the com-
munity) and supplemented with short-acting opioids titrated to pain relief
and use of nonopioid medications and techniques to treat pain. In ICU pa-
tients, physiologic responses, such as heart rate and blood pressure, may
have to be used to monitor pain relief in patients maintained on sedation
and mechanical ventilation. It should be recognized that patients with a his-
tory of opioid dependence likely exhibit tolerance to opioid medications and
may require higher than usual doses to treat pain [82].
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opioid dependence may be especially challenging. This is because buprenor-
phine has a higher aﬃnity for the m-opioid receptor than do opioids.
Options in this case include discontinuation of buprenorphine treatment
and transition to opioids only or opioids plus methadone; division of daily
dose of buprenorphine to three to four times daily to take advantage of pain
control properties of the medication; or continuation of buprenorphine and
titration of short-acting opioids [82].Cocaine-related complications
Clinical manifestations of cocaine intoxication
In 2006 in the United States, 1.7 million people reported cocaine abuse or
dependence [1]. Cocaine intoxication is characterized by increased adrener-
gic activity and may present as psychosis (Table 4). Cocaine intoxication
also often presents as acute vasospasm and may cause myocardial ischemia
or stroke. Additionally, cocaine lowers seizure threshold, and may cause
rhabdomyolysis, hyperthermia, and movement disorders.Management of cocaine intoxication
As with any acute intoxication, the ﬁrst step in management includes
establishment of adequate airway, breathing, and circulation. The toxicity
of cocaine ingestion is in large part caused by sympathetic nervous system
stimulation. Management consists of blood pressure control and alleviation
of any cardiovascular symptoms. A general principle in the management of
cocaine intoxication is avoidance of b-blocking agents [83]. Use of these
agents may cause an unopposed a-adrenergic eﬀect, which may in turn
worsen symptoms. The psychomotor agitation associated with cocaine
intoxication can usually be managed with benzodiazepines and other sup-
portive measures.Clinical manifestations of cocaine withdrawal
Cocaine withdrawal is characterized by depressed mood and any two of
the following: fatigue, vivid dreams, sleep disturbance, increased appetite,
psychomotor retardation, or agitation [84]. These symptoms are a result
of depleted dopamine stores.Management of cocaine withdrawal
Manifestations of cocaine intoxication, rather than cocaine withdrawal,
are more likely to get the attention of a critical care team [6]. For patients
presenting with suspected cocaine-induced vasospasm, avoidance of the
use of b-blockers, which may promote an unopposed a-eﬀect, is the general
rule. Cocaine withdrawal is typically mild and treated with supportive care
and treatment of complications.
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dependence. These include g-aminobutyric acid–acting agents including
gabapentin and tiagabine; dopaminergic agents including bromocriptine
and amantadine; immunotherapies; and propranolol, although its use might
aggravate vasospasm [84–86].Benzodiazepine-related complications
Clinical manifestations of benzodiazepine intoxication
The clinical manifestations of benzodiazepine overdose include slurred
speech, incoordination, confusion, unsteady gait, and impaired memory
and concentration (see Table 4). Severe intoxication can lead to stupor or
coma. It is important to recognize that symptoms of benzodiazepine intox-
ication are very nonspeciﬁc and can easily be confused with other substance
intoxication or medical problems.Management of benzodiazepine intoxication
Initial management of benzodiazepine intoxication includes general
supportive and resuscitative measures. Treatment with the benzodiazepine
antagonist, ﬂumazenil, should be considered in patients in whom benzo-
diazepine overdose is likely [87,88]. The starting dose of ﬂumazenil is
0.2 mg intravenously over 30 minutes. Flumazenil should not, however,
be routinely given to all patients presenting with nonspeciﬁc symptoms
that may represent benzodiazepine intoxication. This is because use of
ﬂumazenil may induce seizures in patients with benzodiazepine depen-
dence; because it may uncover other dangerous symptoms in patients
with mixed substance overdose; and because of the nonspeciﬁc nature
of benzodiazepine intoxication syndrome, it may be administered
inappropriately.Clinical manifestations of benzodiazepine withdrawal
Benzodiazepine withdrawal, similar to alcohol withdrawal, is character-
ized by autonomic hyperactivity and can result in seizures [25]. Clinical
manifestations often occur between 2 and 10 days after abrupt withdrawal
of the benzodiazepine. Increased anxiety and irritability may be a salient
feature of this syndrome [6]. The severity and duration of withdrawal symp-
toms depend in part on the half-life of the medication being used. The
benzodiazepine withdrawal syndrome can be precipitated by administration
of ﬂumazenil to patients taking benzodiazepines [89].Management of benzodiazepine withdrawal
Withdrawal from benzodiazepines follows the same treatment protocol
as for alcohol withdrawal. Treatment generally consists of use of a long-
acting benzodiazepine in tapering doses over time. The symptom-triggered
approach has been shown to be as eﬀective as the ﬁxed-dose approach for
Table 4
Manifestations and treatment of intoxication and withdrawal of certain substances of abuse
Substance
Signs or symptoms
of intoxication or withdrawal Treatment
Cocaine Intoxication
Myocardial ischemia
Stroke
Rhabdomyolosis
Hyperthermia
Seizures
Hypertension
Supportive management
Avoidance of b-blockers
Withdrawal
Depression mood
Fatigue
Vivid dreams
Sleep disturbance
Psychomotor retardation or agitation
Use of benzodiazepines
Supportive care
Benzodiazepines Intoxication
Slurred speech
Unsteady gait
Impaired memory or attention
Confusion
Stupor
Coma
Supportive management
Consider administration
of ﬂumazenil
Withdrawal
Autonomic hyperactivity
Seizures
Anxiety
Irritability
Substitution of a long-acting
benzodiazepine in tapering
doses with use of
a symptom-triggered
approach
Marijuana Withdrawal
Anger
Aggression
Anxiety
Irritability
Insomnia
Supportive care
Nicotine Withdrawal
Sweating
Frequent urination
Gastrointestinal disturbances
Drowsiness
Bradycardia
Supportive care
Hallucinogens Intoxication
Hallucinations or derealization
Pupillary dilation
Tachycardia
Sweating
Palpitations
Blurred vision
Tremors
Uncoordination
Supportive care
Withdrawal
Flashbacks
Anxiety
Depression
Urinary acidiﬁcation
Supportive care
Table 4
(continued )
Substance
Signs or symptoms
of intoxication or withdrawal Treatment
Methamphetamines Intoxication
Diaphoresis
Hypertension
Tachycardia
Agitation
Psychosis
Supportive care
Withdrawal
Fatigue
Irritability
Insomnia or sleep disturbance
Psychotic reactions
Anxiety
Supportive care
781SUBSTANCE ABUSE AND CRITICAL CAREthe treatment of benzodiazepine withdrawal [90]. Studies also suggest that
the use of carbamazepine is eﬀective in the treatment of benzodiazepine
withdrawal. The medication must be administered for at least 2 weeks
time, however, and then gradually tapered [25].Marijuana and nicotine withdrawalWithdrawal syndromes from marijuana and nicotine are generally con-
sidered mild (see Table 4). Marijuana withdrawal is characterized by anger,
aggression, anxiety, irritability, and insomnia [22]. Nicotine withdrawal is
associated with sweating, frequent urination, gastrointestinal disturbances,
drowsiness, and bradycardia [23]. Treatment for both consists of supportive
care. For nicotine withdrawal, however, transdermal nicotine can be admin-
istered, although a recent case control study suggests an association between
administration of nicotine replacement therapy in the ICU with increased
mortality [91].Relevant issues and complications regarding substance useIt is important to notice that patients with substance abuse often have
underlying psychiatric comorbidities, including mood disorders. Screening
for and treatment of psychiatric disorders is an essential part of treat-
ment of the underlying substance abuse [25]. Additionally, screening
for abuse of or dependence on other substances is necessary to treatment
planning.
Comprehensive substance abuse treatment planning is essential to the
care of patients with substance abuse issues. It is not adequate to care for
patients with substance use and withdrawal without facilitating referral
782 TETRAULT & O’CONNORfor long-term care after the initial critical care and inpatient hospitalization
phase [9,65]. It is up to the medical team caring for patients to have an
understanding of the resources available in the surrounding community.
Appropriate referral sources include detoxiﬁcation facilities, counseling ser-
vices, and area 12-step programs [92].Iatrogenic dependencePatients with critical illness often require prolonged stays in the ICU and
large cumulative doses of opioids and sedatives to facilitate pain control,
anxiety, and sedation. Acute withdrawal syndromes may present in patients
receiving opioids or benzodiazepines as a result of rapid weaning for transi-
tions to lower levels of care. Continuous infusions of opioids or benzodiaz-
epines may place patients at higher risk for the development of acute
withdrawal than would administration of these medications by bolus injec-
tion [6]. It is up to the critical care team to consider implementation of wean-
ing protocols, consisting of a 5% to 10% reduction per day, early on in the
course of a patient’s ICU stay [93].Summary
Substance use and withdrawal are common among patients presenting to
the ICU with critical illness and may complicate the treatment course. It is
important for the critical care team to consider underlying substance use dis-
orders and withdrawal syndromes in patients presenting for care. It may be
diﬃcult to obtain a history of these disorders as a result of altered mental
status and a patient’s family should also be asked. Additionally, it is impor-
tant to consider polysubstance use in any patient presenting with a substance
use issue.
General principles regarding the treatment of substance intoxication and
withdrawal include application of general resuscitative measures including
airway, breathing, and circulatory management. For speciﬁc withdrawal
syndromes, substitution of a long-acting agent (which acts on the same re-
ceptor pathway as the misused substance) in tapering doses is the general
rule. Additionally, use of a symptom-triggered approach to the treatment
of substance withdrawal decreases length of stay and cumulative medica-
tion administered. Of the utmost importance is long-term planning and
referral for patients with underlying substance use disorders to allow for
the best chances for successful treatment of these debilitating, chronic
conditions.
783SUBSTANCE ABUSE AND CRITICAL CAREAppendix 1
Clinical Institute Withdrawal Assessment for Alcohol Scale-Revised11 Note. Total score 67. Protocols should be tailored to consider a cut-off score to admin-
ister PRN medications only (eg, R8) and PRN medications added to scheduled medication
(eg, R15).
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doi:1‘‘We thus arrive at the proposition that a derangement in functional metab-
olism underlies all instances of delirium and that this is reﬂected at the clin-
ical level by the characteristic disturbance in cognitive functions.’’ (Engel
and Romano, 1959)Delirium is a neurobehavioral syndrome caused by the transient disruption
of normal neuronal activity secondary to systemic disturbances [1–3]. The
literature describes the sensorium of delirious patients as ‘‘waxing and
waning.’’ On the other hand, it is actually alertness (ie, a state of readiness
of an organism to integrate stimuli enabling possible responses to stimuli)
and vigilance (ie, paying attention to crucial external events) that are ﬂuctuat-
ing.Adelirious patient does indeed receive external information but integrates
it incorrectly, which produces behavioral responses that are inadequate to the
environment. So it is not really the attention, but the mental content that is
altered and ﬂuctuating.
The incidence of delirium is rather high in both medically and surgically
ill patients [4,5], and even higher among critically ill patients (up to 80%)
[6,7]. In addition to causing distress to patients, families, and medical care-
givers, the development of delirium has been associated with increasedarts of the article were presented at the annual meetings of the Academy of Psychosomatic
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790 MALDONADOmorbidity and mortality [8–12], increased cost of care [11,13], increased hos-
pital-acquired complications [12], poor functional and cognitive recovery
[4,10,14], decreased quality of life [12,14,15], prolonged hospital stays
[6,8,10–12,14–16], and increased placement in specialized intermediate-
and long-term care facilities [12,14,15]. Contrary to some deﬁnitions, delir-
ium is unfortunately not always reversible. A study conducted at a teaching
hospital suggested that once delirium occurs, only about 4% of patients ex-
perience full resolution of symptoms before discharge from the hospital [10].
In the same study, it was not until 6 months after hospital discharge that an
additional 40% experienced full resolution of symptoms.
To date, no single cause of delirium has been identiﬁed. Known risk fac-
tors for delirium include advanced age, preexisting cognitive impairment,
medications (especially those with high anticholinergic potential), sleep
deprivation, hypoxia and anoxia, metabolic abnormalities, and a history of
alcohol or drug abuse. Over time, a number of theories have been proposed
in an attempt to explain the processes leading to the development of delirium.
Most of these theories are complementary, rather than competing. The
‘‘oxygen deprivation hypothesis’’ proposes that decreased oxidative metabo-
lism in the brain causes cerebral dysfunction because of abnormalities of
various neurotransmitter systems. The ‘‘neurotransmitter hypothesis’’ sug-
gests that reduced cholinergic function; excess release of dopamine, norepi-
nephrine, and glutamate; and both decreased and increased serotonergic
and gamma-aminobutyric acid activity may underlie the diﬀerent symptoms
and clinical presentations of delirium. The ‘‘neuronal aging hypothesis’’ is
closely related to the changes in neurotransmitters observed in normal aging.
Accordingly, this theory suggests that elderly patients are more at risk for
developing delirium, likely because of age-related cerebral changes in stress-
regulating neurotransmitter and intracellular signal transduction systems.
The ‘‘inﬂammatory hypothesis’’ suggests that increased cerebral secretion
of cytokines as a result of a wide range of physical stresses may lead to the
development of delirium, probably by their eﬀect on the activity of various
neurotransmitter systems. The ‘‘physiologic stress hypothesis’’ suggests
that trauma, severe illness, and surgery may give rise to modiﬁcation of
blood-brain barrier permeability, to the sick euthyroid syndrome with abnor-
malities of thyroid hormone concentrations, and to an increased activity of
the hypothalamic-pituitary-adrenal axis. These circumstances may alter neu-
rotransmitter synthesis and cause the release of cytokines in the brain, thus
contributing to the occurrence of delirium. Finally, the ‘‘cellular-signaling
hypothesis’’ suggests that more fundamental processes like intraneuronal sig-
nal transduction (ie, second messenger systems that at the same time use neu-
rotransmitters as ﬁrst messengers) may be disturbed, aﬀecting therefore
neurotransmitter synthesis and release. It is likely that none of these theories
by themselves explain the phenomena of delirium, but rather it is more likely
that two or more of these, if not all, act together to lead to the biochemical
derangement we know as delirium (Table 1). At the end, it is unlikely that
Table 1
Theorized neurochemical mechanisms associated with conditions leading to delirium
Delirium source ACH DA GLU GABA 5HT NE Trp Phe His Cytok
HPA
axis
NMDA
activity
Chages
in RBF EEG Mel Inﬂam Cort
Anoxia/hypoxia Y [ [ Y Y Y [? [ [, Y [ Y [
Aging Y Y
CVA [ [
Hepatic Failure Y [ [ [ [ Y? [ [ [ Y
Sleep deprivation Y [
Trauma, Sx,
and post-op
Y [? Y [? Y [ [ [ [ Y Y [ [
Etoh and CNS-Dep
withdrawal
[? [? [ Y Y, [ [ Y 5 [ Y [
DA agonist [ Y [?
Infection/Sepsis Y? [? Y Y Y Y [ [ [
GABA use Y [ Y
Dehydration and
electrolyte imbalance
Y? [ [
Glucocorticoids [
Medical illness Y Y Y [ Y [
Hypoglyemia Y
Abbreviations: [, likely to be increased or activated; Y, likely to be decreased;5, no signiﬁcant changes; , likely a contributor, exact mechanism is unclear;
5HT, 5-hydroxytryptamine or serotonin; ACH, acetylcholine; CNS-Dep, central nervous system depressant agent; Cort, Cortisol; CVA, cerebro-vascular acci-
dent; Cytok, cytokines; DA, dopamine; EEG, electroencephalograph; Etoh, alcohol; GABA, gamma-aminobutyric acid; GLU, glutamate; His, histamine; HPA
axis, hypothalamic-pituitary-adrenocortical axis; Mel, melatonin; Inﬂam, inﬂammation; NE, norepinephrine; NMDA, N-methyl-D-aspartic acid; Phe, phenyl-
alanine; RBF, regional blood ﬂow; Sx, surgery; Trp, tryptophan.
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792 MALDONADOwe ﬁnd a stringently common pathway to the development of delirium, more
likely, the syndromes of delirium (ie, hyper, hypo, and mixed types) represent
the common end product of one or various independent neurochemical path-
ways (Table 2).
This article is an attempt to understand the pathophysiological contrib-
utors to delirium and their relationship regarding basic neurotransmitter
pathways and systems. The author will describe our interpretation of the
cascade of processes that lead to delirium based on a comprehensive re-
view of the literature (Fig. 1). Throughout the article we shall discuss
the diﬀerent neurochemical mechanisms and pathways that lead to the
common features of delirium. Finally, based on those theories and under-
standing, we can begin postulating potential prevention methods and treat-
ment techniques.The neurochemical pathways of delirium
Aging: acetylcholine, vascular supply, and delirium
Human studies have revealed that the cholinergic system is widely
involved in arousal, attention, memory, and rapid-eye-movement (REM)
sleep. A deﬁciency of cholinergic function relative to that of other neuro-
transmitters can be expected to alter the eﬃciency of these mental mecha-
nisms [17]. In fact, one leading hypothesis is that delirium results from an
impairment of central cholinergic transmission [18–20]. Low levels of acetyl-
choline (ACh) in plasma and cerebrospinal ﬂuid (CSF) have been described
in delirious patients [18,21–28].
Studies have suggested that age is an independent predictor of transi-
tioning to delirium. Some have demonstrated that older patients have
a higher incidence of developing postoperative delirium, even after rela-
tively simple outpatient surgery [29]. In fact, for each additional year after
age 65, the probability of transitioning to delirium increased by 2% (mul-
tivariable P values less than .05) [30]. Studies evaluating pre- andTable 2
Neurochemical mechanisms associated with delirium type
Delirium
type ACH DA GLU GABA 5HT NE O2
Sleep
deprivation Cytokines HPA Trp Phe EEG Mel
Hypo Y [ [ [ Y [ [ [ [ Y
Hyper Y [ Y Y [ [ [ [ [ Y
Mixed Y [ Y [ [ [ [ [Y
Abbreviations: [, likely to be increased; Y, likely to be decreased;5, uncertain action; 5HT,
5-hydroxytryptamine or serotonin; ACH, acetylcholine; DA, dopamine; EEG, electroencephalo-
graph; GABA, gamma-aminobutyric acid; GLU, glutamate; HPA, hypothalamic-pituitary-adre-
nocortical axis; Mel, melatonin; NE, norepinephrine; Phe, phenylalanine; Sx, surgery; Trp,
tryptophan.
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postoperative neuropsychological performance in older nondemented pa-
tients after elective orthopedic surgery found that the presence of preoper-
ative attentional deﬁcits was closely associated with postoperative delirium
[31].
The increased incidence of delirium in older patients may be associated
with a decrease in the volume of Ach-producing cells occurring during the
normal aging process [32]. Aging is also associated with decreased cerebral
oxidative metabolism [33]. Both of these factors lead to a normal decline in
ACh synthesis [32–35]. The decline in cognitive functioning associated with
the normal process of aging may be aggravated by the presence of even mild
hypoxia, which further inhibits ACh synthesis and its release [17,36,37].
Hypoxia leads to decreased oxygen supply to brain tissue, which leads to
a decreased redox state (nicotinamide adenine dinucleotide [NAD]-oxidized:
NADH-reduced), which may also result in decreased ACh production
[17,33,36–39].
Similarly, studies in both the acute medical ward and surgical units
suggest that the presence of baseline dementia increases the occurrence of
delirium [40–42]. Alzheimer’s disease, which is characterized by a loss of
cholinergic neurons, carries an increased risk of delirium, particularly asso-
ciated with the use of anticholinergic medication [33].
Higher levels for serum anticholinergic activity (SAA) [43] have been as-
sociated with an increased likelihood of delirium in both surgical [23,44,45]
and medical [18,46] inpatients. A dose-response relationship between symp-
toms of delirium and SAA has also been suggested [18]. Studies have shown
that SAA is signiﬁcantly higher in delirious, compared with nondelirious
patients, and that resolving delirium is correlated with decreasing SAA
[47]. In fact, some have observed that high SAA (ie, O20) has a predictive
value for delirium (deﬁned as confusion assessment method [CAM] positive)
of 100% [48].
Most clinicians had presumed this high association between SAA and de-
lirium to be the result of the use of exogenous anticholinergic substances.
Nevertheless, studies have demonstrated that detectable SAA levels in serum
have been found in delirious patients who were not exposed to pharmaco-
logic agents with known anticholinergic activity. These ﬁndings suggest
that endogenous anticholinergic substances may exist during acute illness
and may be implicated in the etiology of delirium [22,47,49].
Animal studies have demonstrated the negative inﬂuence of age on pre-
frontal ACh release and Fos (ie, Fos protein) response in the hypothalamic
paraventricular nucleus and the nucleus tractus solitarius (NTS) of rats fol-
lowing isoﬂurane anesthesia (known to decrease ACh release in most brain
regions). The old rat group showed signiﬁcantly greater Fos induction in the
paraventricular nucleus compared with the young adult rat group (P!. 05),
indicating that the old rats when subjected to anesthesia were more pro-
foundly aﬀected than young adult rats with regard to reductions in acetyl-
choline release and stress responses [35].
795NEUROBIOLOGY MODEL OF DELIRIUMIn another study, injecting atropine into rat brains, researchers were able
to mimic a model for delirium in humans (deﬁned by cortical electroenceph-
alogram [EEG] recordings, maze performance, and observation of behav-
iors) [50]. Using this model, researchers were able to demonstrate higher
EEG amplitudes and slower frequencies (hallmarks of drowsiness and sleep)
in the atropine condition. Atropine-treated rats exhibited signiﬁcant
elevation in their mean maze time (P ! .016, RM analysis of variance [re-
peated measures ANOVA]), and similarly to what is observed in delirious
human subjects, atropine-treated rats exhibited diﬃculty with attention
and memory, sleep-wake reversal, and changes in usual behavior.
Other animal studies have revealed impairment in cholinergic neurotrans-
mission in models of encephalopathy/delirium, hypoxia, nitrite poisoning,
thiamine deﬁciency, hepatic failure, carbon monoxide poisoning, and hypo-
glycemia [21,50,51]. Animal models have also demonstrated that immobili-
zation may cause widespread ACh reduction [52,53]. This model may mimic
the decreased mobility of critically ill patients.
Changes in ACh activity may be one of the mechanisms mediating the
diﬀuse slowing pattern often described in the electroencephalogram
(EEG) of patients suﬀering from delirium. The most common EEG ﬁnding
is that of slowing of peak and average frequencies, decreased alpha activity,
and increased theta and delta waves. Studies suggest that EEG changes cor-
relate with the degree of cognitive deﬁcit, but not with behavior assessed
solely on degree of spontaneous movements. In other words, low levels of
ACh do not slow the EEG to the point of sleep or absence of motor behav-
ior, but seem to slow cognition [2,50,54–60].
Also with aging comes a broad decline in cardiovascular and respiratory
reserves. Studies suggest that by age 85, vital capacity is reduced by nearly
40% and the arterio-alveolar gradient widens. Studies have demonstrated
signiﬁcant decreases in alveolar volume, nitric oxide and carbon monoxide
lung transfer measurements, membrane diﬀusion, and capillary lung volume
in relation to age (P ! .05) and continuous negative pressure induced
a signiﬁcant increase in all variables [61]. Oxygen delivery to the brain
may then be diminished at times of metabolic stress due to reduced capacity
for compensatory changes in the arterial vasculature because of vasculop-
athy and senile changes. The normal aging process is accompanied by
a complex series of changes in the autonomic control of the cardiovascular
system, favoring heightened cardiac sympathetic tone with parasympathetic
withdrawal and blunted cardiovagal baroreﬂex sensitivity. Together these
changes have the potential to further magnify the eﬀects of concomitant
cardiovascular disease [62].
Animal studies have suggested that in patients with baseline organic
cerebral disorders (eg, cerebrovascular disease) who are submitted to sur-
gery, hypocapnia during anesthesia may cause tissue damage in the caudo-
putamen, which may be responsible for long-lasting postoperative delirium
in patients with stroke and/or dementia [63].
796 MALDONADOChronic forms of hypoperfusion may lead to subcortical ischemic vascu-
lar dementia, a relatively common form of dementia. This is more likely due
to anatomic changes caused by aging in the arterial vascular system and pre-
disposes the elderly to the eﬀects of hypotension. Particular regions of the
brain are more susceptible to ischemic hypoperfusive injury, including the
periventricular white matter, basal ganglia, and hippocampus, leading to
cognitive and memory problems. This may explain why older patients
may be particularly sensitive to hypotension and hypoperfusion associated
with orthostatic hypotension, congestive heart failure, or the changes asso-
ciated with routine surgical procedures such as hip and knee replacement
and coronary artery bypass graft (CABG) [64].
Similarly, increasing evidence supports the notion that chronic oxidative
stress is the ﬁnal pathway implicated in two major brain disorders character-
ized by cognitive impairment: cerebral chronic small vessel disease (microan-
giopathic leukoencephalopathy) and Alzheimer’s disease (AD) [65]. Both
disease processes seem to involve chronic hypoperfusion. The process of
hypoperfusion appears to induce chronic oxidative damage in tissues and
cells, largely due to the generation of reactive oxygen species (ROS) and
reactive nitrogen species (RNS). These conditions outpace the capacity of
endogenous redox systems to neutralize these toxic intermediates and may
lead to a system imbalance or to a major compensatory adjustment to reba-
lance the system. This new redox state is generally referred to as ‘‘oxidative
stress’’ and is associated with other age-related degenerative disorders, such
as atherosclerosis, ischemia/reperfusion, and rheumatic disorders. Chronic
ischemic injury can also aﬀect diﬀerently selective areas of the brain [65]
due to a well-documented variation in vulnerability of cerebral areas, with
its imputability in spreading neuronal depression [66–68].Medications and deliriumFactors associated with medication-induced delirium include the number
of medications taken (generally more than 3) [69], the use of psychoactive
medications [70], and the agent’s anticholinergic potential [71]. There are
a number of pharmacologic agents identiﬁed with an increased risk of devel-
oping delirium (Box 1). The number of agents used may be associated with
pharmacokinetic or pharmacodynamic eﬀects of the combined agents (eg,
drug-drug interactions, metabolic inhibitions, additive negative eﬀects).
Similarly, studies have demonstrated a link between the use of pharmaco-
logic agents with psychoactive eﬀects and the occurrence of delirium in
15% to 75% of cases [15,72–77]. Certain agents with known psychoactive
activity (ie, opiates, corticosteroids, benzodiazepines, nonsteroidal anti-
inﬂammatory agents [NSAIDs], and chemotherapeutic agents) have been
identiﬁed as major contributors to delirium in several studies [70]. Data sug-
gest that a very high number of ventilated patients (more than 80%) develop
delirium [6,7]. Similarly, about 90% of ventilated patients receive
Box 1. Risk of delirium with certain commonly used drugs
High risk
Opioid analgesics
Antiparkinsonian agents (particularly anticholinergic agents)
Antidepressants (particularly anticholinergic agents)
Benzodiazepines
Centrally acting agents
Corticosteroids
Lithium
Medium risk
Alpha-blockers
Antiarrhythmics (lidocaine [lignocaine] has the highest risk)
Antipsychotics (particularly sedating agents)
b-Blockers
Digoxin
Nonsteroidal anti-inflammatory drugs
Postganglionic sympathetic blockers
Low risk
ACE inhibitors
Antiasthmatics (highest risk with aminophylline and lowest risk
with inhaled agents)
Antibacterials
Anticonvulsants
Calcium channel antagonists
Diuretics
H2-antagonists
Data from Bowen JD, Larson EB. Drug-induced cognitive impairment. Defining
the problem and finding the solutions. Drugs Aging 1993;3(4):349–57.
797NEUROBIOLOGY MODEL OF DELIRIUMbenzodiazepines, opioids, or both to facilitate their management and ease
the discomfort associated with intubation [78]. The question is, how are
these two factors related?
The fact is, opioid agents have been implicated in the development of
delirium [79–83] and are blamed for nearly 60% of the cases of delirium
in patients with advanced cancer [84]. Narcotic use has been associated
with the development of delirium [85–87]. Some have suggested that opioids
cause delirium via an increased activity of dopamine (DA) and glutamate
(GLU), while decreasing ACh activity [20]. The association of delirium
with the use of meperidine has been well documented [30,64,88–91]. Meper-
idine is itself metabolized to normeperidine, a potent neurotoxic metabolite
with marked anticholinergic potential [88]. Both its direct neurotoxic eﬀect,
798 MALDONADOas well as the strong anticholinergic activity, may contribute to the develop-
ment of delirium. Cases of opioid toxicity have been reported in relation to
fentanyl and methadone [92–94].
Increasing evidence from experimental studies and clinical observations
suggest that drugs with anticholinergic properties can cause physical and
mental impairment. It has long been thought that low ACh levels may be
associated with the disorientation, arousal, and cognitive problems observed
in delirious patients [12]. Several studies have demonstrated a relationship
between a drug’s anticholinergic potential, as measured by SAA and the
development of delirium [18,23,28,44,69,71,91,95–99]. Tune and colleagues
[28,44,71,91,99,100] conducted several studies looking at the cumulative
eﬀect of drugs with subtle anticholinergic potential and their SAA (Box 2;
Table 3).
A cross-sectional study [18] of 67 acutely ill older medical inpatients dem-
onstrated that elevated SAA was independently associated with delirium.
Furthermore, multivariate logistic regression revealed that the SAA quintile
remained signiﬁcantly associated with delirium, even after adjusted for ADL
impairment, admission diagnosis of infection, and elevated white blood cell
count. Among the subjects with delirium, a greater number of delirium
symptoms were associated with higher SAA. Each increase in SAA quintile
was associated with a 2.38-times increase in the likelihood of delirium
(Fig. 2). Similarly, a study of elderly (ie, older than 80 years) (n ¼ 364)
patients demonstrated that the use of anticholinergic drugs is associated
with impaired physical performance and functional status (Fig. 3) [101].
Studies have measured anticholinergic activity in blood and CSF from
patients admitted for urological surgery and compared peripheral (ie, blood)
and central (ie, CSF probes) anticholinergic levels [24]. Anticholinergic
activity was determined by competitive radioreceptor binding assay for
muscarinergic receptors and correlation analysis conducted for both sets
of samples. The mean anticholinergic levels were 2.4  1.7 in the patients’
blood and 5.9  2.1 pmol/mL of atropine equivalents in CSF, demonstrat-
ing that the anticholinergic activity in CSF was about 2.5-fold higher than in
patients’ blood. Still, there was a signiﬁcant linear correlation between blood
and CSF levels (Fig. 4). These studies have found that exposure to anticho-
linergic agents was an independent risk factor for the development of delir-
ium, and speciﬁcally associated with a subsequent increase in delirium
symptom severity.
Decreased cholinergic activity has been demonstrated in delirium and it is
suggested that ACh repletion may serve as treatment of delirium [102]. In
fact, physostigmine has been reported as reversing delirium when it was
induced by anticholinergic agents in healthy volunteers [103], as well as
delirium secondary to anticholinergic syndrome [104–108]. Conversely,
studies in animals and healthy elderly adults have shown that cholinergic
antagonist agents produced deﬁcits in information processing, arousal,
and attention and a reduced ability to focus [109,110].
799NEUROBIOLOGY MODEL OF DELIRIUMSleep pattern disruption and deliriumSleep is a physiologic state that humans need to experience every day to re-
store physical and mental functions. Typically, humans adapt to a 24-hour
circadian pattern, where they sleep at night and are awake during the day.
This 24-hour internal clock (circadian pattern) is maintained by environmen-
tal factors, primarily light exposure, which aﬀects melatonin secretion at
night [111]. Conversely, sleep disruption may be another factor implicated
as a mediating factor in the development of delirium, at least preponderantly
in the ICU setting, if not in any hospitalized patient. Studies suggest that sleep
deprivation may lead to the development of memory deﬁcits [112–114].
Studies have shown that ‘‘chronic partial sleep deprivation’’ (ie, sleeping lim-
ited to 4 hours per night, for 5 consecutive nights) translates into cumulative
impairment in attention, critical thinking, reaction time, and recall [115,116].
Furthermore, studies have found that sleep deprivation (even just 36-consec-
utive hours) may lead to symptoms of emotional imbalance (ie, short temper,
mood swings, and excessive emotional response) likely due to a disconnect
between the amygdala and the prefrontal cortex [117].
The above ﬁndingsmay contribute tomany of the cognitive and behavioral
changes observed in delirious patients. In fact, studies have demonstrated that
sleep deprivation may lead to both psychosis [118] and delirium [51,119–121].
Mounting data suggest that cumulative sleep debt may not just be a cause of,
butmay aggravate or perpetuate delirium [122–127]. Using staﬀ observations,
there was a higher prevalence of delirium among sleep-deprived patients
[128,129]. Overall, delirious patients were reported to have irregular patterns
of melatonin release [130] and disrupted circadian rhythms, resulting in
fragmented sleep/wake cycles and nighttime awakenings [131].
The amount of sleep debt associated to the critical care environment is
not insigniﬁcant. Studies have found that the average ICU patient sleeps
about 1 hour and 51 minutes per 24-hour period [132]. Factors associated
with decreased length of sleep in the ICU include the high frequency of ther-
apeutic interventions (eg, blood pressure monitoring, blood draws and
ﬂushing of lines, dressing changes and wound care), the nature of diagnostic
procedures, pain, fear, and the noisy environment. As many as 61% of ICU
patients report sleep deprivation, placing it among the most common
stressors experienced during critical illness [133]. Previous studies used poly-
somnography (PSG) to demonstrate severe sleep fragmentation, a loss of
circadian rhythm, and a decrease or absence of both slow-wave sleep and
REM sleep in ICU patients [132,134,135]. In addition to causing emotional
distress, sleep deprivation in the critically ill has been hypothesized to con-
tribute to ICU delirium and neurocognitive dysfunction, prolongation of
mechanical ventilation, and decreased immune function [136].
Melatonin secretion is one reﬂection of this internal sleep/wake
mechanism. Melatonin levels are normally high during the night and
low during daytime, being suppressed by bright light. Urinary excretion
Box 2. Medications with anticholinergic effects
Alprazolam
Amantadine
Amitriptyline
Ampicillin
Atropine
Azathioprine
Captopril
Cefamandole
Cefoxitin
Chlorazepate
Chlordiazepoxide
Chlorthalidone
Cimetidine
Clindamycin
Codeine
Corticosterone
Cycloserine
Cyclosporin
Desipramine
Dexamethasone
Diazepam
Digoxin
Diltiazem
Diphenhydramine
Dipyridamole
Dyazide
Flunitrazepam
Flurazepam
Furosemide
Gentamycin
Hydralazine
Hydrochlorathiazide
Hydrocortisone
Hydroxyzine
Imipramine
Isosorbide
Keflin
Lanoxin
Methyldopa
Nifedipine
Oxazepam
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Oxybutynin chloride
Oxycodone
Pancuronium bromide
Phenelzine
Phenobarbitol
Piperacillin
Prednisolone
Ranitidine
Theophylline
Thioridazine
Ticrocillin
Tobramycin
Triamterene
Valproic acid
Vancomycin
Warfarin
Data from Tune LE, Egeli S. Acetylcholine and delirium. Dement Geriatr Cogn
Disord 1999;10:342–4.
801NEUROBIOLOGY MODEL OF DELIRIUMof 6-sulphatoxymelatonin (6-SMT)dthe chief metabolite of melatonind
closely parallels serum melatonin concentrations. Therefore, the urinary ex-
cretion of 6-SMT can serve as a reliable measurement of serum melatonin.
In a study of hospitalized, postoperative elderly patients, melatonin plasma
samples were obtained every 2 hours from 19 patients without delirium and
10 with delirium after major abdominal surgery. Results demonstrated that
patients without delirium showed nearly identical preoperative and postop-
erative melatonin secretion for 24 hours. On the other hand, patients with
delirium experienced melatonin levels that were lower than preoperative
values [137].
A study of medically hospitalized patients measured 6-SMT urinary
levels twice: ﬁrst in the acute phase of delirium (day when delirium rating
scale [DRS] R 14 points) and again after recovery (on the ﬁrst day when
DRS% 6 points). The results demonstrated that among the hyperactive de-
lirium patients, the levels of 6-SMT were lower during the acute delirium
state than after recovery (P! .001). In contrast, among the hypoactive de-
lirium patients, the levels of 6-SMT were higher during the acute delirium
state than after recovery (P ! .01). With the mixed patients, there was no
diﬀerence in the level of 6-SMT between the two phases of delirium
(P ! .45) [138].
A study of blood and urine melatonin levels revealed an abolition of the
circadian rhythm of physiologic melatonin release in deeply sedated ICU
patients [139]. These ﬁndings suggest that the dyssynchronization of the
melatonin secretion rhythm commonly found among critical care patients
Table 3
Anticholinergic drug used most frequently by the patients in the treatment and comparison groups
Drug
No.
patients
Percentage
of patients
Median (range)
no. prescriptionsa
per patient
Median (range)
day supply per
prescription
Treated with donepzil
Amitriptyline 18 4.3 2.0 (1–11) 30.0 (3–34)
Oxybutynin 15 3.6 5.0 (1–15) 30.0 (3–33)
Hyoscyamine 14 3.4 4.0 (1–11) 30.0 (10–30)
Diphenoxylate and atropine 12 2.9 1.0 (1–5) 5.0 (2–30)
Olanzapine 12 2.9 2.5 (1–13) 30.0 (4–30)
Hydroxyzine 11 2.6 4.0 (2–8) 30.0 (1–33)
Doxepin 11 2.6 6.0 (2–12) 30.0 (3–33)
Meclizine 9 2.2 2.0 (1–21) 8.0 (5–30)
Imipramine 7 1.7 6.0 (1–19) 30.0 (3–30)
Cyproheptadine 6 1.4 4.5 (1–11) 30.0 (2–30)
Not treated with donepzil
Meclizine 16 3.8 1.0 (1–8) 12.0 (4–33)
Amitriptyline 14 3.4 4.5 (1–12) 30.0 (1–33)
Hyoscyamine 9 2.2 2.0 (1–11) 30.0 (1–30)
Oxybutynin 8 1.9 1.5 (1–5) 30.0 (8–33)
Hydroxyzine 8 1.9 2.0 (1–12) 30.0 (3–30)
Dicyclomine 7 1.7 2.0 (1–9) 30.0 (5–31)
Belladonna alkaloids and Phenobarbital 7 1.7 3.0 (1–11) 30.0 (2–30)
Phenylephrine/codeine/promethazine 4 1.0 1.0 (1–2) 5.0 (2–10)
Diphenoxylate and atropine 4 1.0 1.0 (1–1) 4.5 (3–6)
Orphenarine 4 1.0 3.0 (1–8) 30.0 (10–33)
a Prescriptions for large supplies of medication were converted to 30-day equivalents (eg, a prescription for a 90-day supply of medication was counted as
three prescriptions, each with a 30-day supply).
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Fig. 2. Percentage of subjects with delirium by serum anticholinergic activity quintile. (From
Flacker JM, Cummings V, Mach JR, et al. The association of serum anticholinergic activity
with delirium in elderly medical patients. Am J Geriatr Psychiatry 1998;6(1):31–41; with
permission.)
803NEUROBIOLOGY MODEL OF DELIRIUM(possibly mediated or exacerbated by the use of sedative agents) may con-
tribute to the development of delirium (Fig. 5). It also suggests that sedative
agents may contribute to the development of delirium by more than one
mechanism (ie, disruption of sleep patterns, central acetylcholine inhibition,
disruption of melatonin circadian rhythm).
The immune system has long been regarded as a vulnerable target for
sleep deprivation. Cytokines synthesized by the immune system may play
a role in normal sleep regulation, by increasing non-REM sleep and decreas-
ing REM sleep, and during inﬂammatory events, an increase in cytokine
levels may intensify their eﬀects on sleep regulation [140]. Current evidence
suggests that acute and chronic sleep deprivation is associated with
decreased proportions of natural killer cells [141], lower antibody titers
following inﬂuenza virus immunization [142], reduced lymphokine-activated
killer activity, and reduced interleukin (IL)-2 production [143]. Moreover,
sleep deprivation may alter endocrine and metabolic functions, altering
the normal pattern of cortisol release and contributing to alterations of
‘‘glucocorticoid feedback regulation’’ [144], glucose tolerance, and insulin
resistance [145].Trauma, surgery, systemic inﬂammation, and deliriumDelirium may represent a central nervous system (CNS) manifestation of
a systemic disease state that has indeed crossed the blood brain barrier
(BBB). Many of the circumstances associated with a high incidence of delir-
ium (eg, infections, medication use, postoperative states) may be associated
with BBB integrity compromise. As a response to traumatic events (includ-
ing the trauma of surgery) the uniform cascade of interacting processes
Fig. 3. Anticholinergic drugs and physical function among frail elderly population. (From
Landi F, Russo A, Liperoti R, et al. Anticholinergic drugs and physical function among frail
elderly population. Clin Pharmacol Ther 2007;81(2):235–41; with permission.)
804 MALDONADOknown as the ‘‘systemic inﬂammatory response’’ is activated. Some surgical
procedures may increase the risk of developing delirium, presumably
because of the complexity of the surgical procedure, the extensive use and
type of intraoperative anesthetic agents, and potential postoperative compli-
cations [146]. The more intense the primary insult is, the more pronounced is
the inﬂammatory response. Illness processes and surgical procedures oﬀer
several triggering factors: use of anesthetic agents, extensive tissue trauma,
elevated hormone levels, blood loss and anemia, blood transfusions, use
of extracorporeal circulation, hypoxia, ischemia and reperfusion, formation
of heparin–protamin complexes, microemboli formation and migration, and
the inﬂammatory process. Similarly, studies have demonstrated that the
Fig. 4. Anticholinergic activity. Correlation analysis according to Pearson (r¼ 0,861; P! .001).
The results are reported in pmol/mL of atropine equivalents. (From Plaschke K, et al. Signiﬁcant
correlation between plasma and CSF anticholinergic activity in presurgical patients. Neurosci
Lett 2007;417(1):16–20; with permission.)
805NEUROBIOLOGY MODEL OF DELIRIUMseverity of the patient’s initial injury or underlying medical problem (as
measured by Acute Physiology and Chronic Health Evaluation [APACHE]
scores) is signiﬁcantly directly correlated with the development of delirium
[14,30,147].
During or after illness processes or surgery, leukocytes adhere to endo-
thelial cells (EC) and become activated. This leads to degranulation, which
releases free oxygen radicals and enzymes, which in turn leads to EC mem-
brane destruction, loosening of intercellular tights, extravascular ﬂuid shift,
and formation of perivascular edema, changes that are likely to occur within
the brain tissue as well. Thus, systemic inﬂammation as a response to surgi-
cal trauma may cause diﬀuse microcirculatory impairment. The most rele-
vant pathologies include leukocyte adhesion to vessel lining, endothelial
cell swelling, perivascular edema, narrowing of capillary diameters, and low-
ered functional capillary density. These morphologic changes lead to
a decrease of nutritive perfusion and to longer diﬀusion distance for oxygen.
Because ACh synthesis is especially sensitive to low oxygen tension,
decreased ACh availability and symptoms of its deﬁciency readily develop
[148].
The magnitude of the inﬂammatory response after surgery or induced by
medical illness has been implicated as a risk factor of neurocognitive decline,
including delirium. This has been well documented after various surgical
procedures [149–151]. Under normal conditions, the BBB inhibits cytokines
and many medications from passing across capillaries into the brain paren-
chyma so the brain is relatively protected from the harmful eﬀects of sys-
temic inﬂammation [152]. Chemokines are locally acting cytokines that
may enhance migration of inﬂammatory cells into the brain by
Fig. 5. Serum melatonin (ng/L) in eight critically ill subjects. The serum melatonin rhythm was
found to be disturbed in all but one patient (A, B). The exception was patient 8. Her melatonin
levels were low during her ﬁrst day in the ICU, rising to much higher peak values on days 3 to 4.
She began to recover a clear melatonin rhythm already on day 2, with a maximum at 4:00 AM.
(From Olofsson K, Alling C, Lundberg D, et al. Abolished circadian rhythm of melatonin secre-
tion in sedated and artiﬁcially ventilated intensive care patients. Acta Anaesthesiol Scand
2004;48(6):679–84; with permission.)
806 MALDONADOcompromising the BBB integrity [153–156]. Compromise of the BBB integ-
rity allows the brain to become more susceptible to the eﬀects of systemic
inﬂammation [153,157]. Transient increases in the levels of circulating in-
ﬂammatory markers (10 to 100 times more than baseline) has been
807NEUROBIOLOGY MODEL OF DELIRIUMhypothesized to result from tissue damage, adrenal stress response, cardio-
pulmonary bypass, and/or anesthesia [158,159].
A study was conducted examining the expression patterns of pro- and
anti-inﬂammatory cytokines in acutely medically ill, hospitalized elderly
patients (ages R65; n ¼ 185) with and without delirium [160]. Patients
underwent cognitive and functional examination by validated measures of
delirium, memory, and executive function, and measurements of C-reactive
protein (CRP) and cytokines (IL-1beta, IL-6, tumor necrosis factor [TNF]-
alpha, IL-8, and IL-10). A total of 34.6% of subjects developed delirium
within 48 hours after admission. Compared with patients without delirium,
delirious patients were older and had experienced more frequent preexistent
cognitive impairment. In patients with delirium, signiﬁcantly more IL-6
levels (53% versus 31%) and IL-8 levels (45% versus 22%) were above
the detection limit as compared with patients who did not have delirium,
even after adjusting for infection, age, and cognitive impairment. This
suggests that pro-inﬂammatory cytokines may contribute to the pathogene-
sis of delirium.
In a similar study, acutelymedically ill patients (n¼ 164), 70 years or older,
were studied within 3 days of hospital admission and reassessed twice weekly
until discharge, to identify and follow the clinical course of delirium [161].
Patients underwent measurements of apolipoprotein-E (APOE) genotype
and the level of circulating cytokines. Researchers found that delirium was
signiﬁcantly (P ! .05) associated with a previous history of dementia, age,
illness severity, disability, and low levels of circulating insulin-like growth
factor 1 (IGF-1). Recovery was signiﬁcantly (P ! .05) associated with lack
of APOE 4 allele and higher initial interferon (IFN)-gamma. It further
found a positive relationship between delirium with APOE genotype,
IFN-gamma, and IGF-I, but not with IL-6, IL-1, TNF-alpha, and leukemia
inhibitory factor.
In a cohort of elderly hip-fracture patients (n ¼ 41), serum was obtained
during the ﬁrst 10 hours after fracture and before surgery, 48 to 60 hours
postoperative, and 7 and 30 days postoperative, measuring CRP, IL-1beta,
IL-6, IL-8, TNF-alpha, IL-10, and IL-1 receptor antagonist (IL-1RA) [162].
A signiﬁcant increase was found postoperatively for CRP, IL-6, TNF-alpha,
IL-1RA, IL-10, and IL-8. CRP kinetics curves were higher in patients with
complications as a group, and in those suﬀering from infections, delirium,
and cardiovascular complications. Additional complications appeared in
patients with impaired mental status (IMS) versus cognitively intact
patients. Analyzing the interaction eﬀect of complications and IMS on
CRP and cytokine production demonstrated that the increase in CRP was
independently related to complications and IMS. IL-6, IL-8, and IL-10
were higher in IMS patients but not in patients with complications without
IMS. This suggests that only CRP signiﬁcantly and independently increases
in patients who are mentally altered and in patients with complications,
whereas cytokines signiﬁcantly increase only in mentally altered patients.
808 MALDONADOSimilarly, a study of cardiac surgery patients (n ¼ 42) measured the
serum concentrations of 28 inﬂammatory markers [163]. Inﬂammatory
markers were assigned to ﬁve classes of cytokines, which are capable of dis-
rupting BBB integrity in vitro. A class z score was calculated by averaging
the standardized, normalized levels of the markers in each class. Beginning
on postoperative day 2, patients underwent a daily delirium assessment. The
study found that patients who went on to develop delirium had higher
increases of chemokines compared with matched controls. Among the ﬁve
classes of cytokines, there were no other signiﬁcant diﬀerences between
patients with or without delirium at either the 6-hour or postoperative
day 4 assessments.
Several risk factors for delirium such as severe illness, surgery, and
trauma can induce immune activation and a physical stress response
comprising increased activity of the limbic-hypothalamic-pituitary-adreno-
cortical axis, the occurrence of a low T3 syndrome, and, possibly, changes
in the permeability of the BBB [164].
Furthermore, some data suggest that inﬂammation may enhance the det-
rimental eﬀects of hypoxia in cases of brain injury and long-term cognitive
dysfunction. Using a porcine model, Fries and colleagues [165] found that
acute lung injury/acute respiratory distress syndrome (ALI/ARDS) was
associated with signiﬁcantly greater hippocampal injury and higher serum
levels of protein S100b, a marker of glial injury, than seen in animals that
were exposed to hypoxemia alone without ALI/ARDS. These ﬁndings sug-
gest that systemic inﬂammation linked to ALI/ARDS may have contributed
to the brain injury seen in this model.Cortisol, the hypothalamic-pituitary-adrenal axis, and deliriumGlucocorticoid hormones are important for coping with stress and have
signiﬁcant eﬀects on the mobilization of energy substrates and inhibition of
nonvital processes [166,167]. Yet, glucocorticoid hormones may have delete-
rious eﬀects on mood and memory during prolonged excessive secretion.
Some have suggested that glucocorticoids may be important for the patho-
genesis of delirium, especially in later life [168,169]. In fact, delirium has
been reported in cases of hypercortisolism associated with surgery [169],
Cushing’s syndrome [51], and dementia [170]. In demented patients, signif-
icant diﬀerences were found in basal cortisol levels between groups of
patients with diﬀerent severities of delirium. Patients without delirium had
signiﬁcantly lower basal cortisol levels than patients with mild delirium
and these had signiﬁcantly higher basal cortisol levels than patients with
moderate/severe delirium. Signiﬁcant diﬀerences in post–dexamethasone
suppression test (DST) cortisol levels between patients with diﬀerent degrees
of delirium were also found, with the highest values in the moderate/severe
delirium group. An increase in the frequency of nonsuppressors with
increased severity of delirium was seen (Fig. 6) [170].
Fig. 6. Percentages of nonsupressors in delirium. A signiﬁcant diﬀerence in the occurrence of
nonsuppressors was found between patients with diﬀerent severity of delirium (P ¼ .004). An
increase in the frequency of nonsuppressors with increased severity of delirium was seen: no
delirium (n ¼ 105) 33%, mild delirium (n ¼ 47) 51%, and moderate/severe delirium (n ¼ 20)
70%, respectively. (From Robertsson B, Blennow K, Brane G, et al. Hyperactivity in the hypo-
thalamic-pituitary-adrenal axis in demented patients with delirium. Int Clin Psychopharmacol
2001;16(1):39–47; with permission.)
809NEUROBIOLOGY MODEL OF DELIRIUMStudies have found that, early after a stroke, delirium seems to be asso-
ciated with an increased adrenocortical sensitivity to adrenocorticotropic
hormone (ACTH) stimulation and a decrease in glucocorticoid-negative
feedback [171], even after controlling for possible confounding factors, in-
cluding the extent of functional impairment and age. Also, increased cortisol
excretion after stroke is associated with disorientation [172].
A key abnormality related to cortisol excess in delirium seems to be
abnormal ‘‘shut-oﬀ’’ of the hypothalamic-pituitary-adrenal (HPA) axis
tested by the DST. In experimental models, the hippocampal formation is
of prime importance for normal HPA axis shut-oﬀ. In this brain area, a close
interaction between neurotransmitters, notably acetylcholine, serotonin,
and noradrenaline, and glucocorticoid receptors, is relevant for the develop-
ment of delirium in elderly patients with stroke and neurodegenerative brain
diseases (Fig. 7) [173].
Steroid and thyroid hormones may act on nuclear gene transcription by
activating protein receptors, which in turn bind to hormone response
elements (HREs). Among these cell-speciﬁc processes regulated by steroid
receptors is energy metabolism through increased synthesis of respiratory
enzymes. As some of these enzymes are encoded by both nuclear and mito-
chondrial genes, coordination of their synthesis is probable, inter alia, at the
transcriptional level. Some have demonstrated a direct eﬀect of steroid hor-
mones on mitochondrial gene transcription, suggesting that glucocorticoid
Fig. 7. Glucocorticoid-neurotransmitter interactions. Alterations in neurotransmitter input
may inﬂuence glucocorticoid receptor expression in the brain, notably the hippocampus. A
decrease in receptor expression may decrease feedback sensitivity inducing high circulating
glucocorticoid levels, especially after stress. This may inﬂuence neurotransmitter synthesis
and receptor expression and also adversely aﬀect neuronal function, survival, and possibly
the development of delirium. (From Olsson T. Activity in the hypothalamic-pituitary-adrenal
axis and delirium. Dement Geriatr Cogn Disord 1999;10(5):345–9; with permission.)
810 MALDONADOreceptors (GR) rapidly translocate from the cytoplasm into mitochondria
after administration of glucocorticoids. Similar results were obtained for
thyroid hormone receptor (TR alpha) localization, import, and binding to
TR elements.
Excessive glucocorticoid levels seem to induce a vulnerable state in
neurons. The hippocampus is a major target for these eﬀects with its dense
concentration of GR. Glucocorticoid excess may thus exacerbate cell death
induced by hypoxia/ischemia, hypoglycemia, and seizures. This can be
related to numerous adverse eﬀects including inhibition of glutamate reup-
take in the synaptic cleft, inhibition of calcium eﬄux or sequestration, exac-
erbation of breakdown of cytoskeletal proteins including tau, increase in
reactive oxygen species, decrease in activity of antioxidant enzymes, a reduc-
tion in release of inhibitory neurotransmitters such as gamma-aminobutyric
acid (GABA), and decreased production of neurotrophins, notably brain
derived neutrophic factor [30]. Finally, glucocorticoid excess may contri-
bute to energy failure of neurons by inhibiting glucose transport into cells
[173–176].
811NEUROBIOLOGY MODEL OF DELIRIUMThe increased cortisol availability associated with illness and trauma (eg,
burns, surgery) or exogenous steroid administration may indeed be associ-
ated with disruption of hippocampal function [1]. This disruption of normal
hippocampal activity will further disinhibit the release of cortisol, thus sus-
taining high levels of circulating cortisol. High levels of circulating cortisol
may then be associated with mitochondrial dysfunction and apoptosis [177],
which may lead to confusion and disturbance of attention and memory
[178,179]. There is suspicion that an increase in circulating cortisol may
also exacerbate the catecholamine disturbances observed in delirium. If
this is true, it is possible that the stress response itself may contribute to
the pathogenesis of delirium [1].
Thus, the hippocampal-adrenal circuit may contribute to the ampliﬁca-
tion of deliriogenic factors [1]. There is evidence that relatively early during
the metabolic stress leading to delirium the hippocampus begins to malfunc-
tion [174,180]. This leads to some of the memory dysfunction and errors in
information processing, leading to confabulation, commonly seen in deliri-
ous patients. The loss of normal inhibition of adrenal steroidogenesis results
in continuous secretion of peak amounts of corticosteroids, leading to
further mitochondrial dysfunction and apoptosis and further exacerbation
of the catecholamine disturbances described above [181,182]. Glucocorti-
coids themselves can further potentiate ischemic neuronal injury in areas
of high concentration (eg, hypothalamus), as well as in areas where cortico-
steroid receptors are low (eg, cerebral cortex).Large neutral amino acids and deliriumAnother hypothesis in the etiology of delirium is that changes in large
neutral amino acids (LNAAs), which are precursors of several neurotrans-
mitters that are involved in arousal, attention, and cognition, may play
a role in delirium [183]. All LNAAs (isoleucine, leucine, methionine, phenyl-
alanine, tryptophan, tyrosine, and valine) enter the brain by using the same
saturable carrier, in competition with each other. As the concentration of
one LNAA increases, CNS entry of other LNAAs declines [184]. For exam-
ple, brain concentrations of serotonin may increase if the relative blood
concentration of tryptophan (TRP) increases. Alternatively, serotonin con-
centrations may decrease if other LNAA concentrations are increased rela-
tive to TRP. Phenylalanine (PHE) has the additional interesting property of
possible conversion to neurotoxic metabolites and competes with TRP for
entry into the brain and subsequent metabolism [185]. Several studies
have demonstrated a relationship between elevated PHE/LNAA ratios
and delirium.
A study of cardiac surgery patients (n ¼ 296) found that elevations of the
PHE/LNAA ratio were independently associated with postoperative delir-
ium [186]. Other studies of patients with septic encephalopathy have also
reported increased levels of PHE and PHE metabolites in the plasma and
812 MALDONADOCSF of those with encephalopathy [187,188]. Furthermore, elevated levels of
PHE have been associated with prolonged performance time and impaired
higher integrative function in older treated patients with phenylketonuria
[189,190]. Finally, studies of elderly medically ill patients suggest that an el-
evated plasma PHE/LNAA ratio during acute febrile illness is associated
with delirium (Fig. 8) [19,191].
Serotonin (5HT) is one of the neurotransmitters that may play an impor-
tant role in medical and surgical delirium. Normal 5HT synthesis and
release in the human brain is, among others, dependent on the availability
of its precursor tryptophan (TRP). Both increased and decreased serotoner-
gic activity have been associated with delirium. Hepatic encephalopathy has
been associated with both elevated TRP availability and increased cerebral
5HT. Excess serotonergic brain activity has been related to the development
of psychosis, as well as serotoninergic syndrome of which delirium is a main
symptom. On the other hand, alcohol withdrawal delirium, delirium in levo-
dopa-treated Parkinson patients, and postoperative delirium have been
related to reduced cerebral TRP availability from plasma suggesting dimin-
ished serotonergic function. Sudden discontinuation of serotonin (5HT)
reuptake inhibitors has been associated with a number of psychologic and
neuropsychiatric syndromes, including delirium [192–194].
Hepatic dysfunction may lead to decreased metabolism of precursor
amino acids (ie, phenylalanine, tyrosine, tryptophan), which leads to
increases in availability of tryptophan, which leads to increases in 5HT.
In fact, increased 5-hydroxyindoleacetic acid (5-HIAA) levels have been de-
scribed in the CSF of subjects with hepatic encephalopathy and in patients
suﬀering from hypoactive delirium [1,195–198]. On the contrary, some haveFig. 8. PHE/LNAA ratio during illness and recovery in subjects with and without delirium.
This ﬁgure demonstrates that delirious individuals had a signiﬁcantly higher PHE/LNAA ratio
during illness than nondelirious individuals (P ¼ .03). (From Flacker JM, Lipsitz LA. Large
neutral amino acid changes and delirium in febrile elderly medical patients. J Gerontol A
Biol Sci Med Sci 2000;55(5):B249–52; discussion B253–4; with permission.)
813NEUROBIOLOGY MODEL OF DELIRIUMsuggested that low 5HT levels, as it occurs in hypoxia, may be associated
with hyperactive delirium [199–201].Oxidative failure due to hypoxia, anemia, hypoperfusion,
or ischemia and neurotransmitter imbalancesSevere illness processes, combined with both decreased oxygen supply
and/or increased oxygen demand may lead to the same common end prob-
lem, namely decreased oxygen availability to cerebral tissue. Patients in the
critical care setting are particularly at risk to suﬀer the eﬀects of hypoperfu-
sion, hypoxemia, and hypoxia. There may be extrinsic factors leading to
decreased oxygen exchange, such as pump failure with mild global cerebral
oligemia (eg, cardiac disease, intraoperative hypotension), intrinsic lung
disease (eg, pulmonary edema, pneumonia, acute respiratory failure
[ARF], acquired respiratory distress syndrome [ARDS]), and anemia (eg,
failure to transport a suﬃcient amount of O2). There may also be sources
of increased O2 demand in medically ill individuals, including but not lim-
ited to hyperthermia (eg, an increase in O2 consumption as represented by
a rise in oxygen consumption (VO2) by 10% to 13% for every degree centi-
grade in body temperature [202]), seizures, burns, hyperthyroidism, myocar-
dial infarction, septic shock, multiorgan failure, and trauma, including the
trauma of surgery [203–206].
The work of Rossen and colleagues in 1943 [207] and later Corel and
colleagues in 1956 [208,209] laid the foundation of our understanding of
neuronal activity and its crucial dependence on the availability of sub-
strates for aerobic metabolism. Animal studies suggest that many factors
inﬂuence the hypoxic response: environmental conditions (eg, temperature,
PaO2 also aﬀected by atmospheric pressure), comorbidities (eg, age, gen-
eral health status), patterns of the hypoxic insult (ie, continuous versus in-
termittent), and ﬁnally duration (ie, chronic versus acute) of the hypoxic
event. In response to hypoxia, diverse reconﬁgurations of widespread neu-
ronal network seem to occur. A remodeling is accomplished at all levels of
the nervous system (ie, molecular, cellular, synaptic, neuronal, network):
synaptic transmission is depressed through presynaptic mechanisms and ex-
citatory/inhibitory alterations involving potassium (Kþ), sodium (Naþ),
and calcium (Ca2þ) channels [210]. More recently, Harukuni and Bhardwaj
[211] revisited the process by which cerebral ischemia leads to a rapid de-
pletion of energy stores triggering a complex cascade of cellular events, in-
cluding cellular depolarization and Ca2þ inﬂux, resulting in excitotoxic cell
death (Fig. 9).
Inadequate oxidative metabolism may be one of the causes of the prob-
lems observed in delirium, namely, inability to maintain ionic gradients
causing ‘‘spreading depression’’ [200,212–216]; abnormal neurotransmitter
synthesis, metabolism, and release [217–225]; and a failure to eﬀectively
eliminate neurotoxic by-products (also, see Fig. 1) [218,219,223].
Fig. 9. Mechanisms of brain injury after global cerebral ischemia. (From Harukuni I, Bhardwaj
A. Mechanisms of brain injury after global cerebral ischemia. Neurol Clin 2006;24:1–21; with
permission.)
814 MALDONADOIndeed, decreased oxygenation causes a failure in oxidative metabolism,
which leads to a failure of the ATP-ase pump system [226]. When the
pump fails, the ionic gradients cannot be maintained, leading to signiﬁcant
inﬂuxes of Naþ followed by Ca2þ, while Kþ moves out of the cell [226,227].
Some have theorized that it is the excess inward ﬂux of Ca2þ that precipi-
tates the most signiﬁcant neurobehavioral disturbances observed in delirious
patients [228,229]. The inﬂux of Ca2þ during hypoxic conditions is associ-
ated with the dramatic release of several neurotransmitters, particularly
GLU and dopamine (DA). GLU further potentiates its own release as
GLU stimulates the inﬂux of Ca2þ [228–230], and it accumulates in the
extracellular space as its reuptake and metabolism in glial cells is impeded
by the ATPase pump failure [226]. In addition, at least two factors facilitate
dramatic increases in DA: ﬁrst, the conversion of DA to norepinephrine
(NE), which is oxygen dependent, is signiﬁcantly decreased; second, the cat-
echol-o-methyl transferase (COMT) enzymes, required for degradation of
DA, get inhibited by toxic metabolites under hypoxic conditions, leading
to even more amassment of DA [231]. At the same time, serotonin (5HT)
levels fall moderately in the cortex, increase in the striatum, and remain sta-
ble in the brainstem (BS) [195].
815NEUROBIOLOGY MODEL OF DELIRIUMHypoxia also leads to a reduced synthesis and release of ACh, especially
in the basal forebrain cholinergic centers [17]. Indeed, cholinergic neuro-
transmission is particularly sensitive to metabolic insults, such as diminished
availability of glucose and oxygen [21]. The reason is simply that ACh syn-
thesis requires acetyl coenzyme A, which is a key intermediate linking the
glycolytic pathway and the citric acid cycle. Thus, reduction in cerebral
oxygen and glucose supply and deﬁciencies in enzyme cofactors such as
thiamine may induce delirium by impairing ACh production [232–234].
There are deﬁnite data correlating poor oxygenation and cerebral
dysfunction.
For instance, some have demonstrated that delirium can be induced in
healthy control subjects by dropping PaO2 to 35 mm Hg [33]. During car-
diac arrest, there is total loss of oxygen input. From the pioneer work of
Siesjo in 1978 [235], we know that once anoxia sets in, a neuron has about
12 seconds of remaining metabolic rate using its ATP, followed by 20 sec-
onds from the ATP-reserve phosphocreatine (PCr). In the delirious critically
ill patient, the problem is not total loss of oxygen input, but more a possible
imbalance in supply and demand, still leading to chronic hypoxic injury. A
recent prospective study of patients (n ¼ 101) admitted to the ICU examined
whether oxidative metabolic stress existed within the 48 hours before delir-
ium onset. As expected, older patients experienced a higher incidence of de-
lirium. The results further demonstrated that three measures of oxygenation
(ie, hemoglobin level, hematocrit, pulse oximetry) were worse in the patients
who later developed delirium. Similarly, clinical factors associated with
greater oxidative stress (eg, sepsis, pneumonia) occurred more frequently
among those diagnosed with delirium [236].
Studies have demonstrated a strong correlation between mental function
on postoperative days (POD) 3 and 7, and the O2 saturation on POD
0 [237]. Clinically signiﬁcant cognitive impairment has been observed in pa-
tients suﬀering from obstructive sleep apnea (OSA) and chronic obstructive
pulmonary disease (COPD) [238]. The severity of these deﬁcits is inversely
correlated with arterial oxygenation [239]. In thoracotomized patients, there
is a correlation between postoperative O2 saturations and delirium. Studies
have shown that decreased postoperative O2 saturations are associated with
the development of delirium, with delirium reversal after O2 supplementa-
tion [240]. Finally, septic patients suﬀer from both increased oxygen demand
and decreased oxygen delivery as they are proven to have lower hemoglobin
level, lower cerebral blood ﬂow, and lower cerebral O2 delivery compared
with controls [241].
Animal studies suggest that neuronal susceptibility to ischemic injury is
not uniform: particularly vulnerable are the CA1 and CA4 regions of the
hippocampus, the middle laminae of the neocortex, the reticular nucleus
of the thalamus, the amygdala, the cerebellar vermis, select neurons in the
caudate nucleus, and certain brain stem nuclei, such as the pars reticulata
of the substantia nigra [242]. This sensitivity appears to be caused by the
816 MALDONADOinherent properties of neurons in those brain regions, and not by uneven cir-
culation. Hypotheses for the diﬀerential susceptibilities of certain brain
regions to ischemia include the induction of certain enzyme systems such
as heat shock proteins, or c-fos or c-jun gene products, which confer a rela-
tive sensitivity to ischemia, and nonuniform cellular energy requirements
(eg, small surface neurons require less, or oxidative-enzymes-dependent cir-
cuitries) [243]. Indeed, the more membrane that a neuron has, the more ATP
must be dedicated to ion pumps. Conversely, the less cytoplasm a neuron
has, the fewer mitochondria will be available to supply ATP. Therefore,
the SAVR (surface area to volume ratio) of a neuron helps to deﬁne how
resistant a neuron may be to oxidative stress.
The basal ganglia, thalamus, Purkinje, layer 3 of the cortex, and the py-
ramidal neurons of the hippocampus are particularly vulnerable to hypoxia,
but the degree of damage may vary depending on the etiology [244–247].
Overall, the least susceptible neurons to oxidative stress are the small inhib-
itory interneurons (ie, GABAergic, glycinergic), while the most susceptible
neurons are those of the ACh, DA, histamine (HA), NE, and 5HT pathways
[68]. This constitutes another robust argument substantiating the neuro-
transmitter imbalances theories in delirium due to oxidative failure.
Besides hypoxia, a superimposed globalmild ischemic injury (ie, global oli-
gemic injury) is often present in critically ill patients galvanizing the oxidative
failure. Indeed, patients in the critical care setting are particularly at risk to
suﬀer the eﬀects of hypoperfusion resulting from a number of potentially
controllable extrinsic factors (eg, intraoperative hypotension, cardiac failure,
hypotensive anesthetic agents, diuretics, and blood pressure lowering agents).
Hypoxia, anemia, and hypoperfusion with global cerebral mild ischemia
(ie, oligemia) are all common factors leading to neurotransmitter imbalances
that have a well documented structural spreading to susceptible neurons in
a speciﬁc order. This ‘‘spreading depression’’ correlates clinically with the
symptoms and signs of progressing deliria [66,67,216], and makes another
robust argument substantiating this coherent etiologic theory on delirium
mechanisms.The role of dopamineElevations of DA have long been associated with the development of delir-
ium [19,26,248,249]. There are several additional metabolic pathways that
lead to signiﬁcant increases in DA under impaired oxidative conditions: ﬁrst,
signiﬁcant amounts of DA are released and there is a failure of adequate DA
reuptake. At the same time the inﬂux of Ca2þ stimulates the activity of tyro-
sine hydroxylase (TH) [250], which converts tyrosine to 3,4-dihydroxypheny-
lalanine (DOPA), thus leading to increased DA production and further
uncouples oxidative phosphorylation in brain mitochondria [227]. The out-
come is further disruption of adenosine triphospate (ATP) production.
Decreased ATP and the increased production of toxic metabolites of DA
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dent catechol-O-methyl transferase (COMT) [37,231], which is the major
extracellular deactivator ofDA, further leading to high levels of DA. Further-
more, an increase in the ﬁring rates of catecholamine neurons may further
induce TH synthesis, which leads to even more DA production [251].
The inﬂux of Ca2þ also stimulates DA release, anoxic depolarization [252],
and the activation of catabolic enzymes [229]. This is another mechanism by
which impairedoxidative conditions leads to the breakdown inATP-dependent
transporters, which in turn leads to a decrease in DA reuptake [253–255]. The
increases in DA can be considerable. In fact, levels as high as 500-fold increase
in extracellularDAconcentrations have been recorded in cases of striatal ische-
mia [195,198,220,221,256]. Of note, the excess in extracellular DA can in itself
promote more Ca2þ inﬂux, further perpetuating the problem [220]. The failure
to adequately limit the production of and eﬀectively eliminate toxicDAmetab-
olites is a source of ongoing cellular injury during hypoxia andmay contribute
to some of the features of a post-delirium syndrome [1]. Figiel and colleagues
[257] also found an excess of DA in association with delirium induced by elec-
troconvulsive therapy. Similarly, studies show that DA agonists can create
slower EEG in spite of motor hyperactivity [258], which represents a perfect
symptomatological match to hyperactive delirium.
The dramatic increases in DA availability may lead to some of the neuro-
behavioral alterations observed in delirious patientsdprimarily the signs of
hyperactive or mixed type delirium, namely increased psychomotor activity,
hyperalertness, agitation, irritability, restlessness, combativeness, distractibil-
ity, and psychosis (ie, delusions and hallucinations) (see Fig. 1) [256,259,260].
In addition to generation of H2O2 and quinone formation, L-Dopa- and
DA-induced cell death may result from induction of apoptosis, as evidenced
by increases in caspase-3 activity. Also, DA per se induces apoptosis by
a mechanism independent of oxidative stress [261].
Interestingly, depletion in DA by alphamethylparatyrosine actually pro-
tects neurons against hypoxic stress and injury [262,263]. Similarly, DA
blockade can be used to reduce hypoxic damage in the hippocampus [264].Hepatic dysfunction and the role of glutamate in deliriumDA may exert its deliriogenic activity by more than one mechanism. The
direct activity of DA can be observed in cases of toxicity with substances
known to increase DA release of availability, such as amphetamines, co-
caine, and dopamine. On the other hand, DA may have a secondary activity
by enhancing GLU-mediated injury.
Thus, increased GLU availability may be due to the inﬂux of Ca2þ
caused by a number of factors (eg, hypoxia, excess DA) best known of all
is liver failure. Hepatic failure leads to hyperammonemia, which in turn
leads to excessive N-methyl-D-aspartate (NMDA) receptor activation.
This leads to dysfunction of the glutamate-nitric oxide-cGMP (cyclic
818 MALDONADOguanosine monophosphate) pathway, which leads to reduced cGMP and
contributes to impaired cognitive function in hepatic encephalopathy.
As described above, the inﬂux of Ca2þ during hypoxic conditions is asso-
ciated with the release of several neurotransmitters, particularly high levels
of GLU [229,230,265,266]. Hypoxic conditions may further extend GLU
activity as the absence of extracellular mechanism of degradation require
the functioning of ATP-dependent reuptake, which is impaired under these
conditions [226]. GLU is an excitatory neurotransmitter that may lead to
neuronal injury via its activation of NMDA receptors [267–271]. Neverthe-
less, it appears that GLU requires the presence of DA to exert some of its
toxic eﬀects, namely its Ca2þ-induced neuronal injury [219,221,223,228].
At high levels, DA may cause enough depolarization of neurons as to
activate the voltage-dependent NMDA receptor, therefore facilitating the
excitatory eﬀect of GLU (see Fig. 1) [272].
At least in one study of high-risk adults (n ¼557) undergoing cardiac sur-
gery, serum concentrations ofNMDA receptor antibodies, asmeasured by se-
rum concentrations of (NMDA) receptor antibodies (NR2Ab) were
predictive of severe neurologic adverse events (eg, delirium, transient ischemic
attack, or stroke). Patients with a positive NR2Ab test (R2.0 ng/mL) preop-
eratively were nearly 18 times more likely to experience a postoperative neu-
rologic event than patients with a negative test (!2.0 ng/mL) (Fig. 10) [273].
Glutamate (the principal excitatory neurotransmitter) is metabolized by
glutamate decarboxylase (GAD) (using pyridoxal phosphate or vitamin
B6, as a cofactor) into GABA (the principal inhibitory neurotransmitter).Fig. 10. Preoperative serum NR2Ab and postoperative neurologic events. The 0 indicates no
neurologic event; 1, anxiety or agitation; 9, confusion/delirium, transient ischemic attack, or
stroke. Patients in group 9 had signiﬁcantly higher preoperative serum NR2Ab than groups
0 or 1 (P ¼ 0.0004). (From Bokesch PM, et al. NMDA receptor antibodies predict adverse neu-
rological outcome after cardiac surgery in high-risk patients. Stroke 2006;37(6):1432–36; with
permission.)
819NEUROBIOLOGY MODEL OF DELIRIUMGABA has also been implicated in the development of the delirium [274].
There is evidence to suggest that GABA activity is increased in delirium
related to hepatic encephalopathy, but decreased in delirium caused by
hypnotic or sedative withdrawal [275]. The precise role of GABA in hepatic
encephalopathy is unclear, but at least one source found that ﬂumazenil,
a benzodiazepine antagonist, reversed coma and improved hypoactive delir-
ium in cirrhotic patients [276]. Reduced GABA has also been implicated in
delirium that results from ethanol or CNS-depressant (eg, benzodiazepines,
propofol, barbiturates) withdrawal.
Excessive activation of NMDA receptors leads to neuronal degeneration
and cell death. Hyperammonemia and liver failure alter the function of
NMDA receptors and of some associated signal transduction pathways.
Acute intoxication with large doses of ammonia (and probably acute liver
failure) leads to excessive NMDA receptor activation, which is responsible
for ammonia-induced death. The function of the glutamate-nitric oxide-
cGMP pathway is impaired in brain in vivo in animal models of chronic
liver failure or hyperammonemia and in homogenates from brains of pa-
tients who died in hepatic encephalopathy. The impairment of this pathway
leads to reduced cGMP and contributes to impaired cognitive function in
hepatic encephalopathy. Learning ability is reduced in animal models of
chronic liver failure and hyperammonemia [277].
Hepatic dysfunction also is associated with an increase in unesteriﬁed
plasma fatty acids, which leads to increased tryptophan levels, which leads
to impairment in the active transport of homovanillic acid (HVA) through
the BBB and out of the CSF [198]. In fact, in cases of hepatic failure, the
above may lead to signiﬁcant increases in CSF-HVA levels, despite initial
normal DA levels. Eventually, this contributes to the excessive DA levels
described above.
Finally, there is evidence that hepatic failure may be associated with
a shift in the regional cerebral blood ﬂow (rCBF) patterns and cerebral met-
abolic rates from cortical to more subcortical areas of the brain [278–283].
In fact, studies of end-stage liver disease using single-photon emission com-
puted tomography (SPECT) brain scans demonstrated that their rCBF was
decreased in bilateral frontotemporal and right basal ganglia regions as
compared with control subjects and that impairment in cognitive tests was
correlated with ratios of rCBF values [284].Gamma-aminobutyric acid activity, central nervous system–depressant
abuse, withdrawal states, and deliriumGABA has also been implicated in the development of the delirious state
[274,285]. The role of GABA in hepatic encephalopathy and delirium is un-
clear, but at least one source found that ﬂumazenil, a benzodiazepine antag-
onist, reversed coma and improved hypoactive delirium in cirrhotic patients
[276,286]. GABA activity has been found to be increased in delirium related
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[275,287–290]. Reversely, reduced GABA serum levels are found in alcohol
withdrawal [291] and antibiotic-induced delirium [292]. GABA is formed by
the decarboxylation of glutamate by GAD. It is of note that GAD requires
B6 (pyridoxine as a cofactor), and B6 has already been implicated as a prom-
inent player in the development of delirium [20].
Oversedation has been found to be an independent predictor of
prolonged mechanical ventilation. In a prospective, controlled study
(n ¼ 128) of adults undergoing mechanical ventilation, subjects were ran-
domized to either continuous sedation or daily awakenings [293]. They
found that the median duration of mechanical ventilation was 4.9 days in
the intervention group (ie, daily awakening), as compared with 7.3 days in
the control group (P ¼ .004) (Fig. 11A), and the median length of stay in
the intensive care unit was 6.4 days as compared with 9.9 days, respectively
(P ¼ .02) (Fig. 11B).
Among the agents known to cause delirium and other cognitive impair-
ments in the medically ill patient, GABAergic medications have been shown
to be some of the most signiﬁcant and frequent culprits [6,89,103,294–297].
There are several mechanisms by which sedative agents (eg, benzodiaze-
pines, propofol) contribute to delirium: (1) interfering with physiologic sleep
patterns (ie, signiﬁcantly reduce slow-wave and REM sleep, increase spin-
dles, increase cortical activity at low doses, and decrease EEG amplitude)
[298–300]; (2) causing a centrally mediated acetylcholine deﬁcient state (ie,
interruption of central cholinergic muscarinic transmission at the level of
the basal forebrain and hippocampus) [103,296,297]; (3) enhancing
NMDA-induced neuronal damage [301]; (4) disrupting the circadian rhythm
of melatonin release [139]; (5) disruption of thalamic gating function (ie, the
ability of the thalamus to act as a ﬁlter, allowing only relevant information
to travel to the cortex) leading to sensory overload and hyper-arousal [248].
Studies have demonstrated a direct the relationship between benzodiazepine
use and the development of delirium [89]. In both Surgical-ICU and
Trauma-ICU the use of benzodiazepines has been identiﬁed as an indepen-
dent risk factor for the development of delirium [126]. In fact, studies have
demonstrated that lorazepam is an independent risk factor for daily transi-
tion to delirium (Fig. 12) [30].
Alcohol and CNS-depressant substances cause intoxication through
eﬀects on diverse ion channels and neurotransmitter receptors, including
GABAA receptorsdparticularly those containing d subunits that are local-
ized extrasynaptically and mediate tonic inhibitiondand NMDA receptors.
Alcohol dependence results from compensatory changes during prolonged
alcohol exposure, including internalization of GABAA receptors, which
allows adaptation to these eﬀects. The short-term eﬀects of alcohol result
from its actions on ligand-gated and voltage-gated ion channels [302,303].
Prolonged alcohol consumption leads to the development of tolerance and
physical dependence, which may result from compensatory functional
Fig. 11. (A) Analysis of the duration of mechanical ventilation, according to study group. After
adjustment for base-line variables (age, sex, weight, APACHE II score, and type of respiratory
failure), mechanical ventilation was discontinued earlier in the intervention group than in the
control group (relative risk of extubation, 1.9; 95% conﬁdence interval, 1.3 to 2.7; P ! .001).
(B) Analysis of the length of stay in the intensive care unit (ICU), according to study group. After
adjustment for baseline variables (age, sex, weight,APACHE II score, and type of respiratory fail-
ure), discharge from the ICU occurred earlier in the intervention group than in the control group
(relative risk of discharge, 1.6; 95% conﬁdence interval, 1.1 to 2.3;P¼ .02). (FromKress JP, et al.
Daily interruption of sedative infusions in critically ill patients undergoing mechanical ventila-
tion. N Engl J Med 2000;342(20):1471–77; with permission. Copyright  2000, Massachusetts
Medical Society.)
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Fig. 12. Lorazepam and the probability of transitioning to delirium. Lorazepam and the prob-
ability of transitioning to delirium. The probability of transitioning to delirium increased with
the dose of lorazepam administered during the previous 24 hours. This incremental risk was
large at low doses and plateaued at approximately 20 mg/d. (From Girard, et al. Delirium in
the intensive care unit. Critical Care 2008;12(Suppl 3):S3; with permission; and Adapted from
Pandharipande P, Shintani A, Peterson J, et al. Lorazepam is an independent risk factor for
transitioning to delirium in intensive care unit patients. Anesthesiology 2006;104:21–6; with
permission.)
822 MALDONADOchanges in the same ion channels. Similarly, acute administration of alcohol
is known to stimulate 5-HT turnover, while chronic alcohol intake is
reported to decrease 5-HT synthesis and release [304]. Not surprisingly,
plasma noradrenergic (NA) levels [305] and 5-HT function [306] have
been found to be elevated in alcoholic patients.
Ethanol modiﬁes the functional activity of many receptors and ion
channels, including NMDA [307,308], kainate [309], serotonin 5-HT3
[310], GABAA [311], and glycine [312] receptors as well as G protein–
coupled inwardly rectifying potassium channels [313] and calcium chan-
nels [314]. GABAA receptors containing the d subunit, in particular
a4b2d and a6b2d receptors, are exceptionally sensitive to ethanol. Brain
regions that express d subunits, including the cerebellum, cortical areas,
thalamic relay nuclei, and brainstem, are among those that are recognized
to mediate the intoxicating eﬀects of alcohol [315]. The mechanisms of
alcohol dependence are less well understood than are those responsible
for acute intoxication. However, it now appears that compensatory adap-
tation of GABAA receptors to prolonged ethanol exposure plays a critical
role in alcohol dependence. Among the possible adaptive mechanisms,
down-regulation of GABAA receptors, as a result of decreases in the sur-
face expression of a1 or g2 subunits, is emerging as an important candi-
date [316].
Compensatory up-regulation of NMDA and kainate receptors as well as
Ca2þ channels follow, leading to Ca2þ inﬂux and changes associated with
delirium [317]; these mechanisms may also have been implicated in alcohol
dependence and withdrawal seizures. For example, the inhibitory eﬀects of
ethanol on NMDA receptors leads to up-regulation in the number of
NMDA receptors in many brain regions, which may be an additional factor
in the susceptibility to alcohol withdrawal seizures [318–320]. The relevance
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nists are highly eﬀective anticonvulsants in animal models of alcohol with-
drawal seizures [321].
Alcohol withdrawal is associated with reduced density of synaptic
GABAA receptors as well as alterations in GABAA-receptor subunit compo-
sition that lead to reduced inhibitory eﬃcacy; both eﬀects would be expected
to predispose to seizures. Indeed, susceptibility to alcohol withdrawal
seizures has been associated with a loss of GABAA-mediated inhibition
[322]. Alcohol withdrawal has been linked to increased metabolism and
release of NA/NE (noradrenaline or norepinephrine) [323,324], reduced
a2 adrenoceptor function [325,326], reduced 5-HT function [327], and alter-
ations in neuroendocrine responsivity to challenge with NA and 5-HT
agents [328]. Withdrawal seizures are believed to reﬂect unmasking of these
changes and may also involve speciﬁc withdrawal-induced cellular events,
such as rapid increases in a4 subunit–containing GABAA receptors that
confer reduced inhibitory function [316].The role of histamine and deliriumHistamine receptors A1 (HA1) and A2 (HA2) are known to aﬀect the
polarity of cortical and hippocampal neurons [329,330] and pharmacologic
antagonism of either receptors is suﬃcient to cause delirium [331]. Others
have suggested that, during surgical stress and hypoxia, there may be an
excessive release of HA, which may lead to delirium [332]. In these cases,
blockade of either HA1 or HA2 receptors helped to limit neuronal death
within the hippocampus [333,334]. So, both excess and deﬁciency of HA
may be associated with delirium. Clinical experience has demonstrated that
drugs like diphenhydramine, both anti-HA and anti-ACh, can cause delirium.
Similarly, it has been reported that H2 blockers such as cimetidine and rani-
tidine may cause cognitive dysfunction and delirium in the elderly [1].The role of somatostatin and endorphines in deliriumThere is not a lot of data regarding somatostatin and delirium. Neverthe-
less, the available data on elderly delirious patients suggests that delirious
patients showed signiﬁcant reduction of somatostatin-like immunoreactivity
(SLI) in CSF, as compared with the controls. Koponen and colleagues
[335,336] also found a signiﬁcant correlation between SLI levels and Mini-
Mental State Examination scores. Koponen and colleagues [335,336]
suggest a role for somatostatinergic dysfunction in the genesis of some
symptoms of delirium, and postulate that somatostatinergic dysfunction
may be linked to the long-term prognosis of delirious patients [335,336].
Other studies have demonstrated signiﬁcant reductions in the b-endor-
phin-like immunoreactivity (BLI) values in the CSF of delirious patients
(n ¼ 69) compared with controls (n ¼ 8). The changes in BLI had no
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positive correlation with cognitive functioning as evaluated by the Mini-
Mental State exam [337,338].Electrolyte abnormalities, dehydration, and deliriumDehydration is a reliable predictor of impaired cognitive status and delir-
ium [15,339–341]. Objective data, using tests of cortical function, support
the deterioration of mental performance in mildly dehydrated younger
adults, and it would be expected the eﬀects would be more profound in
the elderly and medically ill [342]. Available evidence indicates the increased
susceptibility of older adults to dehydration and the resulting complications,
including delirium [343,344]. Dehydration in older adults has been shown to
be a reliable predictor of increasing frailty, progressive deterioration in cog-
nitive function, and an increased incidence in the development of delirium
[340,345–349]. Studies have demonstrated a signiﬁcant correlation between
cognitive dysfunction and severity of dehydration, induced by a combination
of ﬂuid restriction and heat stress [350]. Subjects exhibited progressive
impairment in mathematical ability, short-term memory, and visuomotor
function once 2% body ﬂuid deﬁcit was achieved. Similarly, other studies
have demonstrated impaired long-term memory following dehydration
resulting from heat stress [351]. Animal studies have identiﬁed neuronal mi-
tochondrial damage and glutamate hypertransmission in dehydrated rats.
Additional studies have identiﬁed an increase in cerebral nicotinamide
adenine dinucleotide phosphate-diaphorase activity (nitric oxide synthase,
NOS) with dehydration. Available evidence also implicates NOS as a neuro-
transmitter in long-term potentiation, rendering this a critical enzyme in fa-
cilitating learning and memory. With aging, a reduction of NOS activity has
been identiﬁed in the cortex and striatum of rats. The reduction of NOS
activity that occurs with aging may blunt the rise that occurs with dehydra-
tion, and possibly interfere with memory processing and cognitive function
[342]. Dehydration has been shown to be a reliable predictor of increasing
frailty, deteriorating mental performance, and poor quality of life. In other
words, dehydration may begin a cascade of events that lead to cognitive
dysfunction and delirium.
There are four main pathways by which dehydration may cause cognitive
dysfunction and delirium (Fig. 13) [342]: (1) dehydration may cause intracel-
lular changes leading to increased cytokine concentrations, increased anti-
cholinergic burden, and altered pharmacokinetics; (2) dehydration leads
to intravascular volume depletion, causing cerebral hypoperfusion, throm-
boembolic disorders, and cardiac ischemia; (3) dehydration causes extravas-
cular changes, leading to water and electrolyte imbalances, contraction
alkalosis, and uremia secondary to acute renal failure; and (4) studies
have identiﬁed neuronal mitochondrial damage and glutamate hypertrans-
mission in dehydrated animals. Other ways in which dehydration and ﬂuid
Fig. 13. Pathophysiology of cognitive dysfunction in moderate and severe dehydration. (From
WilsonMM,Morley JE. Impaired cognitive functionandmental performance inmilddehydration.
Eur J Clin Nutr 2003;57(Suppl 2):S24–9; with permission.)
825NEUROBIOLOGY MODEL OF DELIRIUMdeﬁcit may contribute to delirium include hypoperfusion (both cerebral and
renal), increased concentration of drugs and/or their metabolites, and de-
creased renal elimination of drugs/metabolites and toxic by-products [340].
Similarly, it has been well documented that Naþ abnormalities, as well as
other electrolytes, can lead to mental status changes and delirium. One
known mechanism is that Naþ leads to cell swelling, which then causes
anoxic depolarization [252]. Hypernatremic hyperosmolar delirium has
been documented in medically ill and postoperative patients [352–354].
Yet, hyponatremia has been equally associated with the development of de-
lirium, although the mechanism may not be so clearly understood [355–364].
Many have deﬁned alterations of serum electrolytes, glucose, and renal
function as both risk markers and causes of delirium [365]. Studies have sug-
gested that a blood urea nitrogen (BUN)/creatinine ratio greater than 18 is
an independent predisposing risk factor for delirium in general medical
patients [339]. Elevations in BUN/creatinine may be indicative of dehydra-
tion, congestive heart failure, poor oral intake, or other factors that may
contribute to the development of delirium. Others have similarly suggested
that in the postoperative population a number of ‘‘abnormal serum chemis-
tries’’ (ie, sodium!130 orO150 mEq/L; potassium!3.0 orO6.0 mEq/L;
glucose !60 or O300 mg/dL) are predictable independent risk factors for
postoperative delirium [366].The EEG and deliriumBack in 1959, Engel and Romano [2] declared ‘‘We thus arrive at the prop-
osition that a derangement in functional metabolism underlies all instances of
delirium and that this is reﬂected at the clinical level by the characteristic
826 MALDONADOdisturbance in cognitive functions and at the physiologic level by the character-
istic slowing of the EEG’’. Indeed, studies have demonstrated a very close
temporal relationship between local reduction of oxygen availability and
change in the EEG; the latter usually occurs 6 to 8 seconds after the local
oxygen tension begins to fall [367]. In fact, both hypoxia and hypoglycemia
produce slowing of the EEG [368]. These are two physiologic conditions
under which it is well established that the metabolism of the brain cannot
be successfully supported. EEG changes have also been described in associ-
ation with anticholinergic drug–induced delirium [369].
Some have suggested that changes in EEG frequency can be demon-
strated before any change in behavior or neuropsychiatric performance
becomes demonstrable and well before any change in total cerebral oxygen
uptake can be measured. The fundamental fact has been demonstrated that
the behavioral changes correlating most precisely with the slowing of EEG
frequency were those that had to do with awareness, attention, memory, and
comprehension, that is, the cognitive functions [2]. Data also suggest that
the signiﬁcant EEG ﬁnding is the degree of slowing rather than the absolute
frequency [370]. Thus, if the EEG initially is fast or in the upper range of
normal, a signiﬁcant reduction in the level of consciousness and EEG fre-
quency may be provoked by drugs, alcohol, hypoxia, and so forth, without
the EEG frequency necessarily falling below the accepted normal range.
Therefore, it is therefore possible to have a ‘‘normal EEG’’ in the presence
of an appreciable degree of cerebral insuﬃciency and reduction in the level
of awareness, as when a person whose premorbid alpha frequency is t1 to t2
per second shows a slowing to 8 to 9 per second during a moderate delirium
[371]. Findings conﬁrming there are instances when the EEG may be read as
‘‘normal’’ in delirium due to a fast baseline range has been documented by
others [372,373]. In these cases, a comparison with the same subject’s previ-
ous EEG demonstrates the abnormality.
Others have found an association between spectral EEG changes and se-
verity of cognitive deterioration in delirium. Spectral analysis of EEG found
that delirious patients showed signiﬁcant reductions of alpha percentage,
increased theta and delta activity, and slowing of the peak and mean fre-
quencies; these changes were also obvious in individual recordings. Further-
more, as previously described by Engel and Romano [2,54], the alpha
percentage and various ratio parameters correlated signiﬁcantly with Mini
Mental State score (MMSE), and delta percentage and mean frequency
with the lengths of delirium and hospitalization [55,56,374].
Similarly, serial quantitative electroencephalographic (QEEG) studies
performed in elderly delirious and control subjects demonstrated that
changes in scores for the relative power map and changes in relative power
in the alpha band had signiﬁcant associations with changes in the clinical
state as measured by the MMSE [375,376]. A study of ICU patients with
delirium measured the correlation between SAA (measured using a compet-
itive radioreceptor binding assay for muscarinergic receptors) and QEEG.
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show that that under comparable conditions patients in the delirium group
showed a higher relative EEG theta power and a reduced alpha power than
did the nondelirious patients. On the other hand, there was no signiﬁcant
diﬀerence in measured SAA levels [24].
In summary, studies suggest that in the right hands the EEG could be
a useful tool for the diagnosis and follow-up of delirium caused by various
conditions. Conventional EEG characteristics of delirium include slowing or
dropout of the posterior dominant rhythm, generalized theta or delta slow-
wave activity, poor organization of the background rhythm, and loss of
reactivity of the EEG to eye opening and closing. As delirium progresses,
generalized theta and delta slow waves appear. When the background fre-
quency slows to 5 or 6 Hz, loss of reactivity is seen. With further progression
of delirium, generalized delta slowing appears. When any of these character-
istic ﬁndings is seen, an electroencephalographer may report the presence of
an ‘‘encephalopathy,’’ which is the EEG term for global electrocerebral
derangement. Sometimes triphasic waves can be seen. These are character-
istic of a number of metabolic derangements (eg, hepatic failure, renal insuf-
ﬁciency, electrolyte abnormalities, and anoxia) [377]. These are paralleled by
the QEEG ﬁndings of increased absolute and relative slow-wave (theta and
delta) power, reduced ratio of fast-to-slow band power, reduced mean
frequency, and reduced occipital peak frequency [56,375,376].
Finally, some have demonstrated these changes in EEG activity could be
replicated by artiﬁcially increasing DA or decreasing or interfering with
ACh activity, speciﬁcally in the caudate nucleus [378,379], conﬁrming the
suspicion that both decreased central cholinergic activity (either caused by
hypoxia or by the use of substances with anticholinergic activity) or excess
dopamine activity (caused either by hypoxia or by the exogenous use of sub-
stances) may lead to the classic behavioral manifestations of delirium and
corresponding EEG changes.Common pathways
At the end, it may very well be that all the known etiologic ‘‘factors’’ for
the development of delirium may all act by similar mechanisms, namely
causing changes to neuronal membrane function, which in turn leads to
a number of neurotransmitter aberrations. Aﬀected neurons begin to expe-
rience abnormalities of membrane function and polarization. This may lead
to a domino-like eﬀect known as ‘‘spreading depression’’ by which, as one
neuron looses membrane integrity and stability, neighboring neurons have
a more diﬃcult time maintaining their own physiologic integrity and func-
tioning. Some have postulated that the patterns of cerebral structure vulner-
ability leads to a predictable pattern of spreading neuronal depression,
which causes the symptoms characteristic of delirium [1]. That progression
is postulated to go from the hippocampus, to the neocortex, the subcortical
828 MALDONADOnuclei, the brain stem, gray matter, moving to the cerebellar cortex, and ﬁ-
nally aﬀecting the spinal cord [66,67,216].
The cholinergic and the dopaminergic systems interact not only with each
other but with glutamatergic and GABA pathways. Studies suggest that ex-
cess dopamine may cause delirium and that dopaminergic antagonists are
often successfully used to treat cholinergic delirium [380,381]. Furthermore,
the interplay between DA and ACh in the production of delirium may be
further substantiated by the fact that D2 antagonists enhance ACh release,
which may be another mechanism by which they help alleviate the symp-
toms of delirium [382,383].
Besides the cerebral cortex, critical anatomic substrates of psychosis
pathophysiology would comprise the striatum, the substantia nigra/ventral
tegmental area, and the thalamus. The thalamus acts as a ﬁlter, allowing
only the relevant information to travel to the cortex. Illicit drugs (eg,
PCP, Ecstasy), as well as psychoactive medications frequently prescribed
to hospitalized patients (eg, benzodiazepines, opioids) could compromise
the thalamic gating function, leading to sensory overload and hyper-
arousal. Gaudreau and Gagnon [248] have proposed that drug-induced
delirium would result from such transient thalamic dysfunction caused
by exposure to medications that interfere with central glutamatergic, GA-
BAergic, dopaminergic, and cholinergic pathways at critical sites of
action.
Which neurotransmitter (or set of neurotransmitters) is involved, and the
degree to which it may be aﬀected, may well determine the motoric subtype
that the patient presents, the degree of disorientation, and the cognitive def-
icits that the patient may exhibit during the episode of delirium (Table 4).Theoretic implications for prevention and treatment options
This is meant to be a theoretic treatise on the prevention and manage-
ment of delirium. For a more clinical approach, please see Maldonado
JR, Delirium in the Acute Care Setting: Characteristics, Diagnosis and Treat-
ment, 2008 [384].Table 4
Neuronal circuitries and their incumbent neurotransmitters for alertness, attention, and judgment
Cognitive function Associated neuronal circuitries
Alertness Ascending reticular activating system
Diﬀerent circuitries of the brainstem
Attention Thalamocortical loops
Nondominant parietal lobe
Judgment/coherence Diﬀuse cortical interconnections,
somewhat more in the frontal lobes
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gic potential of the medications, and delirium, it would make sense to con-
sider two approaches that will potentially help prevent and treat delirium.
The ﬁrst approach is a systematic elimination of medications, either
known to cause delirium or with high anticholinergic potential, to prevent
delirium, if possible. Once delirium has presented, the elimination of any po-
tential oﬀending agent is imperative. Switch crucial medications to other
agents with the same beneﬁts but no known anticholinergic eﬀects. Always
pay special attention to hidden anticholinergic potentials and drug-drug
interactions (eg, impaired metabolism or additive eﬀect).
Second, the use of cholinesterase inhibitors as a way to prevent or treat
delirium should be considered. Indeed, acetylcholinesterase inhibitors
(ACI) have a well-established use in the antagonism of neuromuscular
blockade and the therapy of central anticholinergic syndrome (CAS).
They also have many favorable indications such as the prevention and ther-
apy of postanesthetic shivering and the treatment of various types of intox-
ication. Therefore, many have suggested that they potentially play a role in
delirium prevention [385]. In particular, physostigmine, a reversible acetyl-
cholinesterase inhibitor, has been widely used as ﬁrst-line treatment of the
CAS, as well as a great diagnostic and therapeutic agent for medication-
induced delirium [105].
The potential usefulness in prevention of delirium with the use of ACI
was demonstrated in a study using the agent rivastigmine, a dual inhibitor
of acetylcholinesterase (AChE) and butyrylcholinesterase (BuChE) [386].
The researchers followed men and women (n ¼ 246) aged 68 to 85 years
who were ambulatory outpatients who carried the diagnosis of vascular de-
mentia (VaD). Patients were divided into two homogeneous groups matched
for age and education levels. Group A received rivastigmine 3 to 6 mg/d,
while Group B received cardioaspirin 100 mg/d. Patients receiving rivastig-
mine began treatment on the lower dose of 3 mg/d and were titrated to the
higher dose of 6 mg/d after 16 weeks. All persons in the study group received
periodical neurologic and neuropsychological examinations over a 24-
month period. Both groups presented episodes of delirium, which occurred
during a concomitant medical illness (eg, complications after a fall, during
a sudden hospitalization, or after the patient received anesthesia). During
the follow-up period, 48% of the entire population presented episodes of de-
lirium. The mean duration of each episode was 7.45  5.31 days. When con-
sidering the two groups separately, 40% of patients in Group A
(rivastigmine group) presented episodes of delirium; whereas, 62% of pa-
tients in group B presented episodes of delirium (P ! .001). Moreover,
the mean duration of the delirium was shorter in Group A (mean duration
4.00  1.71 days) than in Group B (7.86  2.73 days; P ! .01). Another
study of dementia patients on chronic rivastigmine use found that the
830 MALDONADOrivastigmine group had a much lower incidence of delirium (45.5%), com-
pared with the control group (88.9%) (P ! .05) [387]. Nevertheless, there
have been two signiﬁcant failed prevention trials using the acetylcholinester-
ase agent, donepezil [388,389].
Finally, there have been at least 19 papers, mostly case reports, suggest-
ing that acetylcholinesterase inhibitor agents (eg, donepezil, galantamine,
physostigmine, rivastigmine) may be eﬀective in the treatment of delirium
[93,96,105,108,387,390–403].DopamineDopaminergic neurons are among the most susceptible to oxidative
stress, which, as explained earlier, may lead to massive releases of DA.
This in turn causes some of the classic behavioral symptoms of delirium,
but it also leads to further neuronal injury. Administered DA agonist agents
can produce slowing of the EEG in spite of motor hyperactivity [258] and
excess dopamine is known to cause delirium [380,381].
Antipsychotic agents have long been used in the management of delirium.
It is likely that initially its use was associated with the need for rapid tran-
quilization or neuroleptilization of agitated patients, but over time clinicians
have observed a rapid restoration of putative hippocampal functions (eg,
short-term memory) and reversal of other regional brain disturbances (eg,
agitation, psychosis, primitive reﬂexes) [1]. Data suggest that depletion in
DA by alphamethylparatyrosine actually protects neurons against hypoxic
stress and injury [262,263]. Similarly, dopaminergic blockade can be used
to reduce hypoxic damage in the hippocampus [264]. D2 antagonist agents
also enhance ACh release, which may be another mechanism by which they
help alleviate the symptoms of delirium [382,383]. Thus, antipsychotic
agents are not only eﬀective in the symptomatic management of the symp-
toms of delirium, but they also serve to address the underlying massive DA
surge inherent to the etiopathological entity of delirium. In fact, clinical and
experimental data suggest that neuroleptics may have a role even in the
treatment of hypoactive delirium [404]. In acutely ill populations, limited
data suggest that administration of antipsychotic agents with dopamine
receptor antagonist activity may reduce the rate or severity of delirium
[404,405].
The role of DA in facilitating GLU-mediated, Ca2þ-induced neuronal in-
jury and functional derangement has been discussed earlier in this article. If
that premise is correct, it is then possible that antipsychotics do much more
than acute management of agitation. The exact mechanisms are not clear
but, in the case of delirium, agents with DA-antagonist activity may block
or reverse the DA-mediated, GLU-precipitated hypoxic neuronal injury
[220]. Some data suggest that depletion of DA, as in cases of damage to
the substantia nigra, may in fact protect neurons against subsequent hyp-
oxic stress and injury [262,406].
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the treatment of delirium was conducted and included haloperidol and all
atypical antipsychotics for which data have been published [407]. The stud-
ies included (n ¼ 3) compared haloperidol with risperidone, olanzapine, and
placebo in the management of delirium and in the incidence of adverse drug
reactions. The authors concluded that the decreases in delirium scores were
not signiﬁcantly diﬀerent comparing the eﬀect of low-dose haloperidol
(!3.0 mg per day) with the atypical antipsychotics olanzapine and risperi-
done (odds ratio [OR] 0.63, 95% CI, 10.29–1.38; P ¼ .25); and that low-dose
haloperidol did not have a higher incidence of adverse eﬀects than the atyp-
ical antipsychotics. Finally, low-dose haloperidol may be eﬀective in de-
creasing the degree and duration of delirium in postoperative patients,
compared with placebo.
Ozbolt and colleagues [408] conducted a search of the published literature
using MEDLINE and PubMed for articles (in the format of review articles,
randomized controlled trials [RCTs], clinical trials, or meta-analyses) written
inEnglish. They found that risperidonewas themost thoroughly studied atyp-
ical antipsychotic for the management of delirium. In most studies, risperi-
done was found to be approximately 80% to 85% eﬀective in treating the
behavioral disturbances of delirium at doses of 0.5 to 4.0 mg per day. The
search indicated that olanzapine was approximately 70% to 76% eﬀective
in treating the behavioral manifestations of delirium at doses of 2.5 to 11.6
mg per day. Therewere very few studies conducted using quetiapine; although
available data suggest that it also appears to be a safe and eﬀective alternative
to high-potency antipsychotics. In the limited number of trials comparing
atypical antipsychotics to haloperidol, haloperidol consistently produced
a higher rate (an additional 10% to 13%) of extrapyramidal side eﬀects.
At least in theory, dopamine-antagonist agents should be able to prevent
delirium as well. One RCT addressed the issue of prophylactic haloperidol.
In at-risk patients older than 70 years, oral haloperidol 0.5 mg twice a day
was administered from up to 72 hours preoperatively and until the third
postoperative day. This study found that prophylactic haloperidol use did
not alter the incidence of postoperative delirium (15.1%) compared with
placebo (16.5%) with a relative risk (RR) ¼ 0.91 (95% CI, 0.59–1.44) [409].
Yet another study (n ¼ 430) demonstrated a modest reduction in the
overall incidence of postoperative delirium when haloperidol was adminis-
tered prophylactically (ie, 1.5 mg/d, started preoperatively and continued
for up to 3 days postoperatively), with patients in the haloperidol group
having a lower incidence of delirium versus placebo (15.1% versus 16.5%)
(RR 0.91 [0.6–1.3]); better DRS-R-98 scores (14.4  3.4 versus 18.4 
4.3) (mean diﬀerence 4.0 [2.0–5.8]; P ! .001); shorter delirium duration
was (5.4 days versus 11.8 days) (mean diﬀerence 6.4 days [4.0–8.0];
P ! .001); and shorter mean length of hospital stay (17.1  11.1 versus
22.6  16.7) (mean diﬀerence 5.5 days [1.4–2.3]; P! .001). The study found
no signiﬁcant haloperidol-related side eﬀects [404].
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(n ¼ 126) of patients undergoing cardiac surgery with cardiopulmonary by-
pass (CPB), randomly assigned patients to receive either 1 mg of risperidone
or placebo sublingually upon regaining consciousness immediately postop-
eratively. The incidence of postoperative delirium in the risperidone group
was lower than the placebo group (11.1% versus 31.7% respectively, P ¼
.009, RR 0.35 [0.16–0.77]) [410]. Finally, a recently presented abstract
[411] reported a signiﬁcant decrease in the incidence of postoperative delir-
ium following orthopedic joint replacement surgery (n ¼ 400). The study
compared olanzapine (5 mg Zydis formulation administered just preopera-
tively, and 5 mg administered immediately after surgery upon awakening) to
placebo. Researchers found the incidence of delirium in the intervention
group was 15%, compared with 41% in the placebo-controlled group (P
! .0001).NorepinephrineAs in the case of DA, acute NE (NA noradrenaline in Europe, NE nor-
epinephrine in the United States) released secondary to hypoxia or ischemia
leads to further neuronal injury and the development of worsening of delir-
ium [412]. At least one randomized trial demonstrated that the selective
alpha-2 agonist, dexmedetomidine (DEX), substantially decreased the inci-
dence of postoperative delirium compared with conventional, GABAergic
agents (3% versus 50%, respectively) [413]. It is theorized that the mecha-
nism for the ‘‘delirium-sparring eﬀect’’ is related to the receptor selectivity,
absence of anticholinergic side eﬀects, absence of respiratory depression,
and potential neuron-protective eﬀects. DEX has been shown to suppress
the increase of circulating catecholamine concentrations found during cere-
bral ischemia [414]. In fact, one study found that, compared with placebo,
DEX decreased plasma NE concentrations by 90% [415]. Another mecha-
nism for possible neuroprotection involves its ultra-early modulation of
the balance between pro- and anti-apoptotic proteins [416].SerotoninAs previously discussed, 5-HT is toxic in elevated concentrations. High
levels of 5-HT are found in cases of hepatic encephalopathy. Given its neu-
romodulatory eﬀect, elevated 5-HT should be associated with hypoactive
delirium.
At least one report suggests that the antiemetic agent ondansetron (ie,
a selective serotonin 5-HT[3]-type receptor antagonist) may be eﬀective in
the treatment of delirium [417]. Bayindir and colleagues [417] conducted
a prospective study of patients (n ¼ 35) who developed delirium in the
ICU after coronary artery bypass graft surgery. The investigators developed
a behavioral scoring scale, with normal scored as 0, and severe verbal and
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lirious, the patient received a single intravenous (IV) dose of ondansetron
(ie, 8 mg), and was reevaluated 10 minutes later. Before the treatment, 7
(20%) patients had a score of 2; 10 (28.6%) patients had a score of 3;
and 18 (51.4%) patients had a score of 4. After the treatment, 28 (80%) pa-
tients dropped their score to 0; 6 (17.1%) patients dropped to a score of 1;
and 1 (2.9%) patient remained at a score of 4. The mean score dropped from
3.20  1.01 to 0.29  0.75 after treatment. No adverse side eﬀects were
reported.Glutamate and NMDA receptorsAmmonia has been recognized as an important factor in the pathogenesis
of hepatic encephalopathy. Some have found that acute ammonia toxicity is
mediated by activation of NMDA receptors [418]. Ischemic injury is also
associated with a marked increase in extracellular GLU and activation of
GLU receptors, leading to additional Ca2þ inﬂux. Compounds that prevent
ammonia toxicity in mice (eg, carnitine) also prevent GLU toxicity in cul-
tured neurons. These compounds do not prevent activation of NMDA
receptors or the rise of Ca2þ. They interfered with subsequent steps in the
toxic process. The protective eﬀect of carnitine (also known as l-carnitine
or levovarnitine, is a quaternary ammonium compound biosynthesized
from the amino acids lysine and methionine) is mediated by activation of
metabotropic GLU receptors (mGluRs). Agonists of mGluRs, especially
of mGluR5, prevent GLU toxicity. Agonists of muscarinic receptors also
prevent GLU toxicity and there seems to be an interplay between muscarinic
and mGluRs in the protective eﬀect. The authors suggest that GLU toxicity
can be prevented at diﬀerent steps or by activating receptors coupled to the
transduction pathways interfering with the toxic process.
NMDA receptors modulate learning and memory, but excessive activa-
tion leads to neuronal degeneration and cell death. Hyperammonemia
and liver failure alter the function of NMDA receptors and of some asso-
ciated signal transduction pathways. The function of the glutamate–nitric
oxide–cGMP pathway is impaired in brain in vivo in animal models of
chronic liver failure. The impairment of this pathway leads to reduced
cGMP and contributes to impaired cognitive function in hepatic encepha-
lopathy, but there is some evidence to suggest this may be restored by phar-
macologic manipulation of brain cGMP, which may be achieved by
administering phosphodiesterase inhibitors (zaprinast or sildenaﬁl) or
cGMP itself [277].
The alpha-a adrenoreceptor agonists (eg, DEX) has demonstrated a ro-
bust eﬀect on neuroprotection modulated by GLU. The study compared
DEX and the GLU receptor antagonist cis-4(phosphonomethyl)-2-piperi-
dine carboxylic acid (CGS). The results demonstrated that DEX’s neuropro-
tective eﬃcacy was better than that produced by CGS [419].
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shown to provide signiﬁcant histologic neuroprotection in animal models of
global cerebral ischemia [92,400,401], its clinical use in ischemic stroke has
been shown to produce signiﬁcant undesirable side eﬀects (eg, delirium, psy-
chosis, hallucinations) [420]. The NMDA/dopamine agonist agents amanta-
dine and memantine have been used for the treatment of hypoactive-like
symptoms associated with coma, traumatic brain injury, and stroke
[421–423]. There are clinical data to suggest that their use may be indicated
in cases of extreme psychomotor retardation, apathy, or catatonia.Gamma-aminobutyric acidAs discussed above, GABAergic agents may lead to the development of
delirium by various mechanisms. In fact, among the pharmacologic agents
used in the general hospital and the critical care unit, benzodiazepine and
other GABAergic agents (ie, propofol) are among the best predictors of de-
lirium. Therefore, avoiding GABAergic agents is imperative. The only time
GABAergic agents have a role in the treatment of delirium is when the men-
tal status changes are presumed to be secondary to the withdrawal from
a CNS-depressant agent (eg, alcohol, benzodiazepines, barbiturates). Other-
wise, GABAergic agents should be avoided, if at all possible. This includes
most commonly used sleeping aids. Please see the following section for alter-
nate recommendations.
GABA levels are reported to be increased in patients suﬀering from
hepatic encephalopathy. Correspondingly, at least one study found that
ﬂumazenil, a benzodiazepine antagonist, reversed coma and improved hypo-
active delirium in cirrhotic patients [276].
Conversely, reduced GABA has been implicated in delirium that results
from ethanol and CNS-depressant withdrawal, thus the treatment of choice
for these conditions is the reintroduction of a benzodiazepine agent [424].Sleep deprivationThe mechanism of action of most commonly used sedative agents
includes either GABAergic activity or central anticholinergic eﬀects (eg,
benzodiazepine, barbiturates, propofol). Although the benzodiazepines
decrease sleep latency and awakenings and increase sleep duration and eﬃ-
ciency (sleep duration/time in bed), these drugs also signiﬁcantly reduce
slow-wave and REM sleep, increase spindles, increase cortical activity at
low doses, and decrease EEG amplitude at high doses [298–300]. Narcotics
also suppress deep and REM sleep and increase arousals and stage-1 sleep
[425].
Propofol (2,6-diisopropylphenol) is widely used in clinical anesthesia and
for sedation in the ICU because of its rapid onset and clear emergence [426].
Propofol potentiates and directly activates the GABAA receptor. GABA is
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of neuronal activity, including sleep [427,428].
Propofol, however, is often associated with adverse cardiovascular
eﬀects, including decreases in cardiac output and arterial blood pressure
[429]. Propofol seems to have a greater depressant eﬀect on the cardiovascu-
lar system than barbiturates. The GABAA receptor is a target of many gen-
eral anesthetics, including volatile general anesthetics [430], barbiturates
[431], and benzodiazepines [432], suggesting that propofol may aﬀect the
activity of the hypothalamic paraventricular nucleus.
Given the roles of melatonin in the regulation of the sleep-wake cycle,
resetting of circadian rhythm disturbances and its extensive antioxidant
activity have potential applications in critical care patients [433]. There
are some data to suggest that exogenous melatonin supplementation
may improve sleep quality and thus help prevent or alleviate delirium
[121,130,139,434]. More studies are required to substantiate these claims.
DEX is a potent alpha-2 agonist agent that achieves sedation without any
clinically signiﬁcant respiratory depression. Thus this agent is a valuable
alternative to the use of GABAergic agents (eg, benzodiazepines, propofol)
to achieve adequate sedation without risk of causing or exacerbating a delir-
ium. There are no case reports of DEX-induced delirium. On the other
hand, DEX may be used to transition patients who are diﬃcult to extubate
due to agitation upon lowering of conventional sedative agents. The recom-
mendation is to add DEX to the current sedation regimen. Once the patient
has been eﬀectively sedated for 12 to 24 hours on the combination, a slow
titration of the conventional sedatives is donedthe speed of this taper will
depend on the sedative agent and how long has the patient been on it.
This will be followed by a moderately slow titration oﬀ DEX.
Given the signiﬁcant disruptions in the sleep pattern of ICU patients and
the alterations in melatonin circadian rhythms, it would make sense to at-
tempt to correct for the changes by either providing patients with sources
of adequate lighting (either natural or via special lamps) or to provide
melatonin supplementation. There are some, but limited data suggesting
that exogenous melatonin supplementation may improve sleep quality and
thus may help prevent or alleviate delirium [121,130,139,433]. More studies
are needed to substantiate these claims. There are no available data on the
potential use of the melatonin agonist ramelteon. As in the case of melato-
nin, studies are required to assess ramelteon’s potential eﬀectiveness in cases
of sleep deprivation–induced delirium.KetamineAt least one randomized, double-blind study involving children undergo-
ing dental repair [435] demonstrated the eﬀectiveness of ketamine (versus
placebo) for the prevention of delirium in sevoﬂurane-induced anesthesia
using the Pediatric Anesthesia Emergence Delirium scale. The study group
836 MALDONADOexhibited a substantially lower incidence of emergence agitation (16.6%)
compared with the placebo group (34.2%).Future directions
Given the complexities already described and the multiple pathways and
mechanisms that likely ‘‘go wrong together’’ or ‘‘cause a domino-like’’
eﬀect, it would make sense to consider a treatment strategy that addresses
all these factors simultaneously. Unfortunately, there are very limited data
to support any of these approaches, let alone in combination. But only
well-designed treatment trials will be able to determine whether the theory
bears out in clinical success. The basic approach of treating delirium may
consider the neurochemical underpinnings described earlier. Thus, in treat-
ing an acutely delirious individual we should consider restoring adequate
function of all recognized dysfunctional pathways. How to eﬀectively do
that, to prevent neurochemical derangement or restore adequate function-
ing, should be the focus of future studies.Summary
Delirium is an acute or subacute organic mental syndrome characterized
by disturbance of consciousness, cognition, orientation, attention, psycho-
motor activity, sleep-wake cycle, and behavior. Delirium is likely to be the
most common and the most serious complication in the medically ill, partic-
ularly the elderly and the critically ill. Not only does it cause distress to
patients, families, and medical caregivers, but its presence is associated
with increased morbidity and mortality, prolonged hospital stays, poor
functional and cognitive recovery, increased placement in specialized inter-
mediate and long-term care facilities, and increased cost of care.
It is unlikely that we will ever be able to ﬁnd a single cause of delirium, or
a single pathway leading to delirium. Nevertheless, the better we are able to
understand how multiple clinical or environmental factors inﬂuence brain
chemistry and functioning, the better we will be able to understand the com-
plex sets of neurochemical cascades that are set in motion and that manifest
themselves in the symptoms of delirium. If we truly get to understand
the pathophysiological mechanisms that, working together, lead to the
disordered brain function that causes delirium, we may be able to ﬁnd
evidence-based medication treatments or environmental manipulations
that address each and every one of them to shorten the course of the syn-
drome. More importantly, given the recognized long-term cognitive and
functional eﬀects of delirium, we should eventually strive to ﬁnd ways to
prevent its development altogether. Given the complexities of the human
brain and the many intricacies in the interacting pathways that likely help
the brain function properly or go awry, we have a better chance of
837NEUROBIOLOGY MODEL OF DELIRIUMeﬀectively preventing and treating delirium by implementing multilevel
approaches that address the many pathways described in this article.Acknowledgment
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Suicidal ideation and attempts are common reasons for visits to the emer-
gency department and critical care hospitalizations and a common public
health problem.Most patients who make a suicide attempt have a psychiatric
disorder, most frequently a mood, psychotic, substance use, or personality
disorder. Demographic factors are not reliable predictors of a repeat attempt
in an individual patient, but regret at having survived, a viable plan that the
patient has rehearsed, severe depression with anxiety, command hallucina-
tions, and ongoing substance use increase the risk substantially, as do
a past and family history of depression. Patients who are at high risk of
another attempt and cannot be transferred promptly to a psychiatric service
should be managed jointly by the psychiatric and critical care teams with an
emphasis on protection of the patient, identiﬁcation of substance intoxica-
tion and withdrawal, making the environment safe, and instituting treatment
of the psychiatric disorder. Antidepressants reduce suicide risk but their slow
onset of action may make electroconvulsive therapy a desirable alternative
for severely depressed patients. Parenteral treatment is possible with benzo-
diazepines and antipsychotic drugs but not antidepressants.
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858 DUBOVSKY & DUBOVSKYto be suicide attempts, were treated in emergency departments in the United
States [1]. In the general population, the incidence of suicide attempts is es-
timated at 67 to 151 per 100,000 [2]. The actual number of suicides and sui-
cide attempts is undoubtedly underestimated, however, because many are
reported as accidents or undetermined deaths [3]. Suicidal ideation can be
identiﬁed in as many as 7% of primary care patients [4].
The lifetime prevalence of nonfatal suicide attempts has been estimated at
3% to 5% of the general United States population and as much as 16% of
community samples with a diagnosis of major depressive disorder [1]. Sui-
cide attempts tend to be repeated throughout the patient’s life, especially
in the presence of substance abuse and impulsivity [1]. In community sam-
ples, about 5% of people who develop depression commit suicide [5],
whereas the suicide rate is as high as 15% in depressed patients treated in
clinical settings. Another study found that only 3% of depressed patients
who committed suicide had received adequate pharmacotherapy and only
7% received weekly psychotherapy [6].
Most people who commit suicide have a psychiatric illness, the most com-
mon diagnoses being depression, schizophrenia, substance abuse, and per-
sonality disorders, often in combination [7,8]. Over a third of patients
who receive treatment in the emergency department for a suicide attempt
carry a diagnosis of major depressive disorder at the time of the attempt
[1]. More severe depression is associated with more suicide attempts [1].
Most suicide attempts occur early in the course of a depressive episode
and are associated with escalating hopelessness and isolation [1]. Comorbid
anxiety seems to increase the risk of suicide in depressed patients [9].
Suicide is frequently thought to be limited to more severely ill patients in
psychiatric settings. Nevertheless, the federally sponsored Sequenced Treat-
ment Alternatives to Relieve Depression (STAR*D) study found that
depressed patients in primary care practice had the same level of severity
as a sample of patients (N ¼ 2541) with nonpsychotic major depressive dis-
order [10]. In the same sample, a history of attempted suicide was reported
by 13% of depressed patients in primary care and 18% of those in specialty
care. Similarly, 43% of depressed primary care patients and 51% of spe-
cialty care patients reported feeling that ‘‘life was not worth living’’ the
week before the assessment. A family history of suicide was reported in
3% of depressed patients in each setting [10].
Among 4037 enrollees in the STAR*D study, 16.5% reported previous sui-
cide attempts [1]. Controlling for age, gender, and depressive symptom sever-
ity, previous attempters had more current general medical conditions
(P!.0001), more current alcohol and substance abuse (P!.0001), more
work hours missed in the past week (26.2% versus 18.2%, P!.0001), and
more current suicidal ideation (61.3% versus 45.5%, P!.0001) than nonat-
tempters. The results suggest that depression with suicidal behavior is a more
severe formof illness that requiresmore aggressive treatment, and they support
observations that suicidal behavior is often repeated until it is successful.
859MOOD DISORDERS AND THE OUTCOME OF SUICIDAL THOUGHTSAmong mood disorders, the risk of suicide is highest in bipolar illness
[11]. Patients with mixed states (coexisting manic and depressive symptoms)
are at particular risk because of the combination of suicidal thoughts and
high levels of energy and impulsivity. For this reason, manic patients are
also at high risk of suicide. A family history of suicide doubles the risk of
suicide attempts in this and probably in other populations [12].
It is estimated that 5% to 13% of schizophrenia patients commit suicide
[13]. A Spanish study of 83 patients with ﬁrst-episode psychosis found that
14.5% made a suicide attempt and 2.4% committed suicide over the 5 years
following the initial hospitalization [14]. Depressive symptoms accompany-
ing psychosis predicted later suicide, and abuse of cocaine and amphet-
amines increased the risk of suicide eightfold. Suicide attempts in
schizophrenia are more likely to be lethal and violent [13]. The introduction
of neuroleptics as treatments for schizophrenia did not seem to lower the
suicide risk from the era before medications were available [15].
Substance abuse, either as a primary disorder or a condition that is
comorbid with other psychiatric disorders, increases the risk of attempted
and completed suicide [7,8]. In a cohort of heroin abusers (N ¼ 387), nearly
12% attempted suicide over the 3-year follow-up period [16]. Those with
a history of a previous suicide attempt were at increased risk (ﬁve times)
of another attempt. One fourth of those with suicidal ideation at study en-
rollment (ie, baseline) made an actual attempt over the next 3 years. Alcohol
is involved in 25% to 35 % of all suicides [17,18]. Furthermore, the risk for
suicide associated with alcohol dependence increases with age [19]. Simi-
larly, Preuss and colleagues [20], in a cohort of patients (N ¼ 371) with a his-
tory of suicidal attempts, found a greater incidence of suicidal attempts
among patients with depression and alcohol abuse (61%) compared with
those suﬀering from depression alone (39%). Compared with nondrinking
teenagers, adolescents who use alcohol, especially if they began drinking
in their preteenage years, had almost a threefold increased risk of suicide at-
tempts [21]. Alcohol use is associated with more dangerous attempts. For
example, a review of 406 self-inﬂicted gunshot wounds to the head found al-
cohol in the blood of 40% of cases [22].
Because alcohol is the most frequently used and readily available sub-
stance, it is a common factor in suicide attempts. There are several reasons
why alcohol use increases the risk of suicide attempts and completed suicide
[23]. Alcohol not only reduces impulse control, but it provides a potentially
fatal substance on which to overdose. Alcohol directly causes depression,
and alcoholism is often comorbid with mood disorders. A family history
of alcoholism also increases the risk of suicidality, possibly because alco-
holic families are more likely to abuse their children (childhood abuse is
a risk factor for suicide), and possibly because of familial clustering of
alcoholism, depression, and suicide. It is important to evaluate patients
who have made a suicide attempt for the presence of alcohol and for
alcoholism.
860 DUBOVSKY & DUBOVSKYSuicidality in children and adolescents
Suicidal ideation in children is a serious symptom, with a strong associ-
ation with childhood depression and bipolar illness [24]. In a Dutch study,
childhood (%11 years) suicidal ideation (reported by parents) persisted into
adulthood (odds ratio, 10.7) and predicted a lifetime history of suicide at-
tempts (odds ratio, 5.8) [24]. Children with suicidal thoughts had an in-
creased risk of developing a mood or anxiety disorder in adulthood.
Suicidal ideation that starts in preadolescence predicts later negative out-
comes more strongly than adolescent onset suicidal thoughts. Adolescent
suicidality, however, still predicts adult suicide attempts, depression, anxi-
ety, and substance abuse. Suicidal ideation in childhood should not be dis-
missed as a passing phase.
Suicide is the third leading cause of death in adolescents [8], and 3% of
adolescents make medically serious suicide attempts [25]. Suicide rates per
100,000 for children aged 5 to 14 are 0.6 in the United States, 0.5 in the
Netherlands, and 0.1 in the United Kingdom; for individuals aged 15 to
24, rates increase to 9.9, 5, and 5.2, respectively [24]. In 2003, there were
3988 reported suicides among people 15 to 24 years old in the United States,
with 1487 occurring among those 15 to 19 years old [8]. From 1950 to 1990,
the suicide rate for adolescents 15 to 19 years old increased by 300% [26],
although it decreased by 35% between 1990 and 2003 [27]. The ratio of
attempted to completed suicide in adolescents is 50 to 100:1 [8,28–30]. A
2003 survey of students in grades 9 to 12 in the United States found that
16.5% of students had planned a suicide attempt, 8.5% had made a suicide
attempt, and 2.9% had made an attempt that required medical intervention
[31].
A mother’s report of depression in a child is usually accurate; however,
mothers are frequently unaware of suicidal thoughts in their adolescent chil-
dren, with such thoughts being reported much more frequently by the ado-
lescents themselves than the parents [32]. Risk factors for adolescent suicide
include family history of suicide, past history of an attempt, living outside
the home, homosexual or bisexual orientation, and history of abuse. Fire-
arms in the home, even if they are locked, are associated with an
increased risk of adolescent suicide.
In June 2003, the Food and Drug Administration (FDA) recommended
that paroxetine not be used in juvenile patients because of an increased risk
of suicide. In October 2004, a black box warning was added to all antide-
pressants package inserts [33,34]. The FDA black box warning was promp-
ted by analysis of aggregate data from 24 clinical trials that found
a doubling in suicidality (deﬁned as new-onset or increased suicidal thinking
or new suicide attempts) among pediatric patients on active drug (4%) com-
pared with placebo (2%). The data on which the FDA based their advisory
were extracted from 24 trials (23 trials conducted in nine drug company–
supported programs evaluating the eﬀectiveness of antidepressants in
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multicenter trial [the TADS trial]) lasting 4 to 16 weeks and involving 4582
children and adolescents. The antidepressants involved included ﬂuoxetine,
sertraline, paroxetine, ﬂuvoxamine, citalopram, bupropion, venlafaxine,
nefazodone, and mirtazepine. The trials were intended to assess the eﬀective-
ness of the medications in the treatment of major depression (16 trials); ob-
sessive-compulsive disorder (4 trials); generalized anxiety disorder (2 trials);
and social anxiety disorder (1 trial). Analysis of the data revealed there were
89 cases of suicidal behavior or ideation and 120 cases of possible suicidal
behavior or ideation. In addition, 11 cases were classiﬁed as self-injury
with nonsuicidal intent and an additional 47 events occurred in 21 patients
who had more than one event. Of note, no completed suicides occurred in
any of the trials [35].
It is important to bear in mind that none of the pediatric studies was
designed to evaluate suicide risk; the data were obtained only from events
that researchers happened to notice or report; the studies had diﬀerent
designs and durations and in general were too short adequately to evalu-
ate risks in actual clinical practice; and multiple statistical tests were per-
formed, increasing the likelihood of a spurious result [35]. It is also
possible that placebo patients dropped out of studies sooner than patients
in active treatment because of lack of beneﬁt, and before they exhibited
suicidality, artiﬁcially elevating the apparent risk in patients given antide-
pressants. Given that early onset depression is associated with an in-
creased likelihood of a bipolar disorder, it is possible that some cases of
bipolar mood disorders were missed in the initial evaluations and the con-
dition was exacerbated by antidepressants, leading to increased agitation
and impulsivity. Rates of suicidality were found to decrease in patients
on active antidepressant therapy [8]. Furthermore, a reanalysis of data in-
cluding seven more studies and a more conservative statistical model
found only a 0.7% greater incidence of suicidality with active drug versus
placebo [8]. Only the National Institutes of Mental Health–sponsored
TADS trial reported statistically signiﬁcantly increased suicidality in sub-
jects taking antidepressants versus placebo. For these patients, it may be
that increased energy or comfort with the clinician made it easier to reveal
thoughts that were concealed previously, something that was less likely to
occur with placebo [36]. The fact that no suicides occurred is not entirely
reassuring, however, in a relatively small sample. The FDA warning that
juvenile patients taking antidepressants be evaluated and followed care-
fully makes clinical sense. Similarly, there is no reason to deny the use
of antidepressants in adolescents in need when administered by competent
clinicians.
The warning by the FDA had a distinct impact on prescribing practices.
Before the FDA’s ﬁrst public health advisory, there had been a 36% per
year increase in antidepressant prescriptions for youth aged 6 to 17. Simi-
larly, from 1985 to 1999 there was a fourfold increase in per capita
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warning, antidepressant prescriptions for this population decreased by
0.8% per year, with paroxetine use in juvenile patients decreasing by
44%. After the FDA’s second warning prescriptions decreased by 10%
per year. Antidepressant prescriptions for adults also decreased, although
to a lesser degree during this period, whereas antidepressant prescriptions
for the elderly increased by 8%.
Did the decrease in antidepressant prescriptions for children and adoles-
cents improve treatment and reduce suicide rates in this population?
Between 1950 and 1990, before antidepressants were widely prescribed for
juvenile patients, the rate of adolescent suicide had increased by 300%.
Between 1990 and 2003, however, suicide rates decreased by 35% in associ-
ation with an increase in antidepressant prescriptions. Then, from 2003 to
2004, after the black box warning was introduced and antidepressant pre-
scriptions for children declined, the suicide rate increased by 18% [8]. Sim-
ilarly, a claims database study involving 65,349 newly diagnosed cases of
pediatric depression found that between 1999 and 2004, the rate of diagnosis
of depression in this population increased from 3 per 1000 to 5 per 1000.
Following the FDA advisory, the rate decreased back to pre-1999 levels, pri-
marily as a function of decreased diagnosis of pediatric depression by pedi-
atricians and family physicians [38]. Before the FDA 2004 advisory, 59% of
depressed children received a prescription for a selective serotonin reuptake
inhibitor. The trend toward increasing selective serotonin reuptake inhibitor
prescriptions was reversed after the advisory such that only 28% of depres-
sive episodes were treated with a selective serotonin reuptake inhibitor [38].
The reduction in antidepressant prescribing was not matched by an increase
in nonpharmacologic therapies. A study comparing adolescent suicide rates
in 588 zip code zones found a 0.23 per 100,000 decrease in adolescent suicide
for every 1% increase in antidepressant prescriptions [37]. Of note, if sui-
cidal thinking in adolescents does increase after starting an antidepressant,
it usually occurs within the ﬁrst month of treatment and most frequently
within the ﬁrst 7 to 10 days [36].
In addition to the decrease in the diagnosis and treatment of childhood
depression after the FDA advisory, there was a halo eﬀect on the diagnosis
and treatment of adult depression. An analysis of managed care claims from
1998 to 2005 involving 475,838 diﬀerent depressive episodes found that the
percentage of depressed adults who did not receive an antidepressant
increased from 20% to 30% after the FDA warning, without any parallel
increase in the use of other medications or psychotherapy [39]. In adults
and children, the FDA recommendation that depressed patients be seen
seven times in the ﬁrst 3 months of treatment was adhered to less than
5% of the time, and the frequency of monitoring did not increase after
the warning [40]. Only 60% of children and 40% of adults were seen three
times in the ﬁrst 3 months of treatment (a more liberal guideline) both be-
fore and after the FDA warning [40].
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The most robust neurobiologic ﬁnding in suicide has involved multiple
dimensions of serotonergic dysfunction, including reduced central serotonin
turnover and a polymorphism of the serotonin transporter [41,42]. The as-
sociation of serotonergic dysfunction is particularly strong for violent and
impulsive suicide, but it is not speciﬁc to any diagnosis. Similar ﬁndings
have been reported for other forms of violent and impulsive behavior,
such as ﬁresetting [43]. The association is understandable in that serotonin
modulates impulsivity and aggression, whether it is directed outward or to-
ward the self [44].
In the STAR*D study, patients in 18 primary care and 23 psychiatry cen-
ters (N ¼ 1879) began treatment with citalopram. Of these, 124 (9%) devel-
oped new-onset suicidal thoughts after starting the antidepressant. Among
the men in the study, two single nucleotide polymorphisms that ﬂanked
the transcription factor cyclic AMP response binding element protein gene
(CREB1) were signiﬁcantly associated with treatment-emergent suicidal
thoughts [45]. In a previous study conducted by these investigators the
same single nucleotide polymorphisms were associated with diﬃculty with
anger expression in depressed men [45]. No neurobiologic ﬁnding has yet
proved useful for predicting suicide risk.Outcome following a suicide attempt
Following a suicide attempt, the risk of another attempt is 12% to 30%
and the risk of completed suicide in the next year is 1% to 3% [46]. In
a study of 1573 attempted suicides evaluated in the psychiatric emergency
room of the Karolinska Hospital between 1981 and 1988, 11% died and
6% committed suicide over an average of 5 years of follow-up [47]. The
risk of successful suicide after an attempt was 8.3% for men and 4.3%
for women and was greatest during the ﬁrst year following an attempt. In
a study involving 925 patients admitted to psychiatric units following a sui-
cide attempt, expression of a wish to die was the best predictor of later suc-
cessful suicide [48].
A 12-month study conducted in the north of France [46] followed 605 adult
patientswhoweredischarged from the emergencydepartment after havingbeen
evaluated by a psychiatrist following a suicide attempt by overdose. Patients
were randomized tooneof three groups: (1) telephonecontact 1monthafter dis-
charge; (2) telephone contact at 3months after discharge; or (3) usual care (ie, no
contact, which constituted the control group). The principle of contacting par-
ticipants was to go back over the treatment recommended in the emergency de-
partment: if treatment was diﬃcult to follow a new one was suggested, or if
patients were considered at high risk of suicide an urgent appointment was
made at the emergency department in which they had originally been treated.
The psychotherapeutic approach used was psychologic support. The
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treatment and to provide brief crisis intervention when needed. Of the 107 par-
ticipants contacted at 1month, 72were ordinary calls (lasting 5–10minutes); 22
concerned crisis intervention (15–45 minutes); and 13 detected participants at
high risk of suicide. Seven of the 72 participants who seemed alright at the
time of contact attempted suicide during the following year. Of the 22 partici-
pants who required crisis intervention, 5 attempted suicide within a year. Thir-
teen participantswere sent to the emergency department; 10were considered by
the psychiatrist as being at risk and 8 of these were admitted to hospital. Only 1
of these 13 patients reattempted suicide, 6 months later. The authors conclude
that contacting patients a month after an overdose has the potential to reduce
further attempts and identify those at immediate risk.Predicting suicide and suicide attempts
A substantial number of individuals who die by suicide see their primary
care physician shortly before their death [7,8,49], most within 1 month of
dying [4]. Yet, physicians have not been very eﬀective at recognizing and
preventing its occurrence. Several studies have demonstrated that patients
who commit suicide by overdose often obtain the medication of the agent
used in the attempt from their primary care physician.
Feldman and associates [4] conducted a study to assess physician charac-
teristics associated with exploring suicidality in patients with depressive
symptoms and whether a patient’s request of antidepressant inﬂuenced phy-
sician’s behavior. The study used standardized patients portraying two con-
ditions (ie, major depression and adjustment disorder) who made
unannounced visits to 152 primary care physicians. The study revealed
that suicide was explored in only 36% of 298 encounters. Exploration of sui-
cidality was more common when the patient portrayed major depression
(versus adjustment disorder; P ¼ .03); when subjects requested an antide-
pressant (versus no request; P ¼ .02); in academic settings (P!.01); and
among physicians with personal experience with depression (P!.01).
The intervention consisted of a depression screening of randomly sam-
pled patients. It showed a decrease in rates of suicidal ideation from 29%
to 17% in the intervention group as expected; patients in the intervention
group had a more favorable course of depression in both degree and speed
of symptom reduction [49]. It is not true that patients who talk about suicide
do not go on to kill themselves. Patients who communicate suicidal
intention should always be taken seriously, especially in an acute care
setting.
Some demographic risk factors for suicide that have been reported in
population studies, including male gender, older age, unmarried, unem-
ployed, and recent loss, are not particularly helpful in an individual patient.
Careful application of general risk factors may not predict exactly who will
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the risk of suicide was higher in patients with a psychiatric history who were
employed and married [50]. Hopelessness, however, is a consistent predictor
of suicide risk [51]. One study showed that all-or-nothing thinking that cre-
ates the belief that if a problem cannot be solved perfectly it cannot be
solved at all, leading to hopelessness when one’s eﬀorts are not completely
successful, predicted later suicide attempts and suicide [52,53]. In adolescent
girls, a history of date rape increases the risk of a suicide attempt [52].
A history of violence against others predicts violence against the self. A
follow-up study of 550 patients who had been in a secure psychiatric setting
because of violent behavior found that 3.2% eventually committed suicide,
a rate more than 300 times higher than in the general population [54]. In the
United States, about 4% of people who kill someone else go on to commit
suicide. Occasionally, a depressed patient commits ‘‘suicide by police’’ by
engaging in a violent confrontation with strangers, but most violence by sui-
cidal people involves domestic partners, with most murderers being men.
The risk that a man who has made a suicide attempt may go on to kill a part-
ner is increased by a history of domestic violence in the relationship and the
presence of ﬁrearms in the home [55]. All patients who have made a suicide
attempt should be evaluated for a risk of violence to others, and vice versa.
Nonsuicidal self-injurious behavior, such as cutting, burning, hitting, or
less frequently biting or abrading parts of the body in ways that may be
obvious or covert, is usually associated with personality disorders. In these
cases, it serves as a mechanism for expiating guilt, creating a concrete phys-
ical sensation that distracts from mental disorganization, or manipulative
behavior. Nonsuicidal self-injurious behavior is not uncommon, however,
in depression and psychosis. Although patients usually do not intend non-
suicidal self-injurious behavior itself to have a fatal outcome, the occurrence
increases the risk of subsequent actual suicide attempts sixfold [56]. Patients
treated for nonsuicidal self-injurious behavior should be evaluated for sui-
cidal intention.
Given that suicide is a rare event (average rate in American adults 11 per
100,000), it is impossible to design a prospective study of absolute predictive
factors that involves fewer than 1 million subjects [57]. Although it remains
impossible to predict suicide precisely, it is possible to assess risk in a clini-
cally relevant manner [58,59]. Suicide risk assessment, which is not only pos-
sible but clinically necessary, is not the same as suicide prediction. In
addition to hopelessness, the presence of a plan, especially if the patient
has the means to carry it out, greatly increases suicide risk. The risk is
even higher if the patient has practiced the plan (eg, by taking a few extra
pills) and the patient cannot think of any reason not to die. Psychosis, espe-
cially if it includes hallucinated voices telling the patient to commit suicide
(command hallucinations), increases the risk even further. In hospitalized
patients with painful injuries or medical illnesses, the severity of pain at dis-
charge predicts the persistence of signiﬁcant suicidal ideation [60].
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contract’’ and promise not to kill themselves are at decreased risk. There
is no empiric support at all, however, for this approach [61]. Patients with
the features just outlined who cannot give a cogent reason why they would
not act on suicidal thoughts beyond a promise to the clinician should still be
considered to be suicidal.Treatment
Suicide prevention centers are relied on in some communities as a ﬁrst-
line treatment for suicidal individuals. Data over the past 30 years indicate,
however, that callers to these centers generally do not present a high risk [62]
and that the centers have not had a signiﬁcant impact on local suicide rates
[63,64]. Clinically meaningful detection and treatment of suicide risk occurs
most frequently in the primary care setting and in the emergency depart-
ment. The Centers for Disease Control and Prevention has published lists
of risk factors and protective factors for suicide (Boxes 1 and 2) [65], al-
though these are based on population studies and are not always predictive
in the individual patient. When the risk of suicide is high, or when theBox 1. Risk factors for suicide
 Family history of suicide
 Family history of child maltreatment
 Previous suicide attempts
 History of mental disorders, particularly depression
 History of alcohol and substance abuse
 Feelings of hopelessness
 Impulsive or aggressive tendencies
 Cultural and religious beliefs (eg, belief that suicide is noble
resolution of a personal dilemma)
 Local epidemics of suicide
 Isolation, a feeling of being cut off from other people
 Barriers to accessing mental health treatment
 Loss (relational, social, work, or financial)
 Physical illness
 Easy access to lethal methods
 Unwillingness to seek help because of the stigma attached to
mental health and substance abuse disorders or to suicidal
thoughts
Data from US Public Health Service 1999. Available at: http://www.cdc.gov/
ncipc/dvp/suicide/Suicide-risk-p-factors.htm. Accessed April 1, 2008.
Box 2. Protective factors for suicide
 Effective clinical care for mental, physical, and substance
abuse disorders
 Easy access to a variety of clinical interventions and support for
help seeking
 Family and community support
 Support from ongoing medical and mental health care
relationships
 Skills in problem solving, conflict resolution, and nonviolent
way of handling disputes
 Cultural and religious beliefs that discourage suicide and
support instincts for self-preservation
Data from US Public Health Service 1999. Available at: http://www.cdc.gov/
ncipc/dvp/suicide/Suicide-risk-p-factors.htm. Accessed April 1, 2008.
867MOOD DISORDERS AND THE OUTCOME OF SUICIDAL THOUGHTSpatient refuses to divulge enough information to assess risk, the most pru-
dent approach is to hospitalize the patient to a psychiatric ward. One
must keep in mind that 15% of suicides occur after a patient has refused vol-
untary hospitalization [66]. The most immediate concern is actively prevent-
ing the patient from acting on suicidal intention. Although patients may
ruminate about suicide for years, the acute risk lasts only hours to days.
Physically containing the patient until the acute impulse abates is the corner-
stone of suicide prevention in the short-term. Close observation may be nec-
essary, because attempts and even successful suicide have been known to
occur in the hospital. The period of highest risk after discharge from the
hospital is the ﬁrst 2 to 4 weeks postdischarge [66].
In the longer-term, almost any form of treatment that engages the patient
in a constructive relationship can reduce the risk of suicide [67]. Dialectical
behavior therapy (DBT), however, a specialized form of cognitive psycho-
therapy usually conducted in a group setting, has been shown to reduce sui-
cidal and self-injurious behavior and the tendency to drop out of treatment
in patients with personality disorders [68]. Although there is less research on
DBT for mood disorders, there is reason to believe that it may also be eﬀec-
tive for self-injurious behavior in major depression. A total of 101 clinically
referred women with recent suicidal and self-injurious behaviors were ran-
domized to 1 year of DBT or 1 year of community treatment by experts.
DBT was associated with better outcomes in the intent-to-treat analysis
than community treatment by experts in most target areas during the 2-
year treatment and follow-up period. Subjects receiving DBT were half as
likely to make a suicide attempt (hazard ratio, 2.66; P ¼ .005), required
less hospitalization for suicide ideation (F[1,92] ¼ 7.3; P ¼ .004), and had
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self-injurious acts combined. Subjects receiving DBT were less likely to
drop out of treatment (hazard ratio, 3.2; P!.001) and had fewer psychiatric
hospitalizations (F[1,92] ¼ 6; P ¼ .007) and psychiatric emergency depart-
ment visits (F[1,92] ¼ 2.9; P ¼ .04) [69].
A study of patients with borderline personality disorder (N ¼ 20) treated
with a 6-month course of DBT found signiﬁcant reductions in nonsuicidal
self-injury urges, nonsuicidal self-injury, suicide ideation, subjective distress,
depression, and hopelessness between baseline and 6 months. The authors
concluded that the use of DBT in a 6-month treatment format may be suf-
ﬁcient to target suicidal behavior and ideation [17–20,70–72].
Because suicidality is usually a symptom of a major psychiatric illness, ef-
fective treatment of the primary disorder usually eliminates the risk of sui-
cide. Relapse and recurrence are common in both mood and psychotic
disorders, however, so ongoing treatment and monitoring is necessary.
Somatic therapies (medications and electroconvulsive therapy) are selected
based on the features of the speciﬁc psychiatric disorder. When selecting
antidepressant agents, consider the fact that tricyclic antidepressants are
more dangerous in overdose than the selective serotonin reuptake inhibitors.
Only lithium [73] and clozapine have been shown to reduce suicide risk in-
dependent of their eﬀect on the primary disorder, the latter by more than
80% in one study [15].Management in the critical care setting
The goals of treatment for patients who are in a critical care setting because
they have made a suicide attempt are to keep the patient safe, treat the in-
juries, assess ongoing suicide risk, and begin or arrange deﬁnitive psychiatric
therapy. Many overdoses involve alcohol and other central nervous system
depressants, such as tranquilizers and sleeping pills, and these substances
are often ingested before violent suicide attempts. Early toxicology screening,
and a history obtained promptly from signiﬁcant others and the patient can
identify patients at risk of withdrawal syndromes and can clarify the cause
of continued confusion or agitation. Substance withdrawal should be sus-
pected whenever any acute unexplained change in behavior or mental status
occurs in a patient who is hospitalized after a suicide attempt after an initial
period of apparent stability. In this case, however, blood levels are likely to be
zero. Withdrawal from any combination of central nervous system depres-
sants can be diagnosed by challenge with phenobarbital or pentobarbital
[74]. Similarly, acute changes in mental status could also represent an over-
dose taking place in the hospital setting, as in the case of patients who ingest
medications brought into the hospital during admission.
Many patients feel temporarily better after a suicide attempt because the
escalating dysphoria that led to the attempt has decreased. This does not
mean, however, that the patient is safe. It is necessary to assess the ongoing
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Patients who openly express disappointment at having survived are at partic-
ularly increased risk, especially if they continue to express a wish to die or to
leave the hospital immediately. Patients whomade an obvious suicide attempt
but deny that they were trying to kill themselves, and patients who say that
they would never repeat the attempt but who cannot describe any coherent
reason why they would have changed their minds, are also at high risk.
Also at high risk are patients with ongoing confusion or psychosis, patients
who made a violent or very dangerous attempt with little chance of rescue,
and those with no available support system. Conversely, if a suicide attempt
has solved a problem temporarily (eg, by convincing a spouse not to leave or
by mobilizing family support), the risk during the acute hospital stay is lower.
Patients at high risk of suicide while in a nonpsychiatric setting need con-
tinued close observation. If a sitter is used, the sitter should have experience
working with psychiatric patients. Patients who actively resist treatment or
try to leave the hospital are best treated on inpatient units that can provide
both medical and psychiatric care, but if such a unit is not available, chem-
ical or physical restraint may be necessary. The use of emergency tranquili-
zation is a complicated issue, but controlled studies of antipsychotic drugs
with or without benzodiazepines or antihistamines have only been per-
formed in the emergency department and recommendations have to be ex-
trapolated to the inpatient setting. The American College of Emergency
Physicians, after an extensive literature review, found no class I studies of
the emergency treatment of nonpsychotic agitation [75]. The safest and
most rapidly eﬀective approach is probably with intramuscular benzodiaze-
pines, such as midazolam [75]. Atypical antipsychotic drugs are often used
for nonpsychotic agitation but the evidence of their eﬃcacy is not strong
[76,77]. Agitation in psychotic patients can be treated eﬀectively with anti-
psychotic drugs.
There are multiple potential means of suicide in the hospital that should
be addressed for patients with ongoing suicidal intention. Such patients
should not be in a bed near a window, even if the glass is unbreakable,
because they attempt to jump through it if they do not know this is not pos-
sible. Blocking electrical outlets that the patient can reach easily and mini-
mizing access to means of strangulation may be necessary. Most critical
care units are not as ‘‘suicide proof’’ as psychiatric units (eg, breakaway
shower heads and sloping doors to prevent hanging), necessitating close ob-
servation until transfer is possible. When the patient is to remain on a non-
psychiatric service, the psychiatric consultant should see the patient daily.
All states have provisions for involuntary hospitalization and treatment
of patients who present a danger to themselves or others or who are gravely
disabled or disorganized. These laws usually involve certiﬁcation by one or
more physicians of the need for hospitalization. Permission for involuntary
administration of medications in patients who are refusing treatment may
have to be obtained separately from permission to keep the patient in the
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which may require a physician to petition the court in person if a judge
does not come to the hospital for such proceedings.
When patients need prolonged care in a critical care setting, as may occur
with multiple severe injuries, treatment of the underlying psychiatric disorder
should be instituted by the psychiatric consultant. It is very important to con-
sider potential interactions between psychiatric medications and other medi-
cines the patient may be taking. Whereas psychosis can be reduced fairly
rapidly with antipsychotic drugs, antidepressants take a month or more to be
eﬀective. Patients who are severely depressed should be considered candidates
for electroconvulsive therapy, which is rapidly eﬀective and has fewer interac-
tions than antidepressants. The only contraindications to electroconvulsive
therapy are space-occupying lesion and recent myocardial infarction [66].
On rare occasions, such injuries as esophageal damage from ingestion of
lye or a gunshot or stab wound may interfere with the use of oral medica-
tions. Agitation can be treated with parenteral benzodiazepines, such as
midazolam or lorazepam, but there are no clinically practical parenteral
antidepressants. If it is not possible to administer medications by a feeding
tube, parenteral benzodiazepines may at least reduce distress and improve
sleep until an antidepressant can be administered.Summary
The risk of completed suicide is high in patients treated in a critical care
setting for a suicide attempt, especially if the attempt had high risk (eg,
shooting, hanging, large overdose) and a low chance of rescue. One should
keep in mind that some patients practice suicide with a mild attempt that
may seem to be just a gesture. Severe depression, psychosis, substance
abuse, hopelessness, expression of regret at being saved, a continued desire
to die, or a family history of suicide substantially increase the risk of suicide
in the near future. The lack of prospective data predicting exactly who will
eventually carry out a plan after expressing suicidal thoughts or making
a suicide attempt should in no way impede clinicians from asking patients
about a plan, the means to carry out the plan, and factors that might pre-
vent the patient from acting on the plan. Early transfer to a psychiatric
unit is desirable, but if continued treatment in the critical care setting is nec-
essary, collaboration with the consulting psychiatrist can reduce the ongoing
immediate suicide risk and manage agitation and nonadherence.References
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Posttraumatic Stress Disorder Following
Critical Illness
Erin K. Kross, MD, Cynthia J. Gries, MD, MSc,
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Posttraumatic stress disorder (PTSD) is a common psychiatric condition
that can occur after a traumatic event. PTSD is the fourth most common
psychiatric illness in the United States with estimates of lifetime prevalence
ranging from 5% to 6% in men to 10% to 14% in women [1]. Traumatic
events can provoke fear, helplessness, or horror in response to an event
that threatens life or safety [1]. Prevalence estimates for adults who are at
risk for PTSD range from 2% to 15% after combat in Vietnam to 14%
to 80% after rape [2]. In addition to PTSD, individuals exposed to traumatic
events also are at risk for other psychologic morbidity, such as depression,
panic disorder, generalized anxiety disorder, and substance abuse. The bur-
den of PTSD can be high and can result in an inability to work or return to
prior levels of functioning. Therefore, PTSD results in an increased cost to
society because of increased health care costs and decreased productivity.
The criteria for PTSD are deﬁned by the Diagnostic and Statistical
Manual of Mental Disorders, Fourth Edition (DSM-IV) [3]: a person must
have been exposed to a traumatic event, which involves a perceived or actual
threat to the person’s own life or physical integrity or that of another per-
son. The condition is characterized by a constellation of symptoms in three
domains: (1) symptoms of re-experiencing, (2) symptoms of avoidance and
emotional numbing, and (3) symptoms of increased arousal. These symp-
toms must meet two criteria to satisfy the diagnosis: (1) symptoms must
cause signiﬁcant impairment in social, occupational, or other important
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876 KROSS et alfunctional domains and (2) symptoms must be present for a least 1 month
after exposure to the traumatic event or events.
ICU treatment for critical illness exposes patients and their families to
enormous stress. This stress results from the experience of life-threatening
illness and the need for intensive, and often invasive, medical procedures.
Survivors of critical illness often report memories of pain and anxiety during
their ICU stay [4]. Therefore, the trauma of a critical illness and ICU treat-
ment meets the criteria of a traumatic event as stated by the DSM-IV crite-
ria of PTSD. A similar experience applies to family members of critically ill
patients, as the DSM-IV deﬁnition allows for a traumatic, life-threatening
event to be witnessed rather than personally experienced. Family members
of ICU patients may be at risk for PTSD as ICUs are a foreign and often
frightening environment for many family members. Family members may
be exposed to invasive monitoring for their loved ones and unfamiliar med-
ical procedures and devices. In addition, family members often are asked to
assume the role of surrogate decision maker, because the majority of
patients in ICUs are not able to participate in decisions about withholding
or withdrawing life support. The role of being a surrogate decision maker
seems to be associated with additional stress for some family members [5].
Therefore, three groups are considered that are at risk for PTSD after
ICU treatment. First, there are patients who survive a critical illness and
are discharged after ICU care. Second, there are family members of individ-
uals who survive critical illness. Finally, there are family members of
individuals who die during or shortly after their ICU stay. This article-
reviews the body of literature regarding adult ICU patients and their fami-
lies for prevalence of PTSD after critical illness in these three groups and
identiﬁes risk factors for the development of PTSD and suggestions for
clinical implications and further research in this ﬁeld.Survivors of critical illness
The bulk of the literature investigating PTSD after critical illness has
examined survivors of critical illness. Two systematic reviews of the topic
recently have been published; the ﬁrst looked at PTSD in 16 studies of med-
ical ICU patients [2] and the second looked at survivors of all intensive care
treatment [6]. For this review, only studies that evaluated the association
between medical ICU admission and PTSD (or posttraumatic stress symp-
toms) are included, similar to the review by Jackson and colleagues [2].
In that review, studies were required to use quantitative or objective mea-
sures of PTSD. Studies of patients in surgical or trauma ICUs were excluded
because of concern that the surgery or trauma itself may have elicited PTSD
symptoms rather than the ICU experience. Five of these studies were pro-
spective cohort studies [7–11] and one was a randomized controlled trial
[12]. The remainder of the studies included six retrospective cohort studies
[13–18] and four cross-sectional studies [19–22]. Since this review was
877POSTTRAUMATIC STRESS DISORDERpublished, there have been two other prospective cohort studies published
assessing prevalence of PTSD symptoms after critical illness [4,23]. Table 1
shows an overview of these studies.
The studies included in the review varied greatly in methodology. Criteria
for entry into each study diﬀered, including varied required lengths of stay
in an ICU. Some studies investigated all medical intensive care patients,
whereas others were restricted to those who had speciﬁc medical conditions,
such as acute lung injury or septic shock. Patients in the studies varied
regarding severity of illness and need for mechanical ventilation, both of
which may aﬀect the experience of ICU treatment. The numbers of subject
included in each study ranged from 20 to 143. A few of the studies evaluated
individuals at multiple time points [7,12,14,15,23]. In these, the initial eval-
uation occurred within 2 months of hospital discharge whereas follow-up
evaluations occurred at varying time points, up to as many as 8 years after
ICU discharge. The remaining studies surveyed patients at only one time
point, which ranged from 3 months to 13 years after discharge from an
ICU or hospital. Patient follow-up rates also varied in these studies, ranging
from 24% to 84% [2].
Several, although not all, of the studies, excluded subjects who had prior
psychiatric or neurologic illness [4,12,13,15,17,20]. The studies also varied in
the method in which PTSD was measured and assessed. Nine of the studies
used only standardized screening tools for assessment, including the Post-
Traumatic Stress Syndrome 10-Questions Inventory (PTSS-10), Impact of
Events Scale (IES), IES-Revised, Davidson Trauma Scale, Trauma Symp-
tom Checklist-33, and Experience of Treatment in Intensive Care 7-Item
Scale [4,7,8,11–13,16,18,20,21]. In most cases, these tools were administered
in person; however, in two studies they were administered by telephone
[18,20]. In this group of studies, the evaluation of PTSD was made solely
on information gathered from these screening tools. Five of the studies
used the Structured Clinical Interview for DSM-IV (SCID) after a screening
tool suggested PTSD [9,14,15,17,19]. In general, these ﬁve studies showed
lower prevalence of PTSD identiﬁed by the SCID. For example, one study
showed that only 57% of the subjects who screened positive via the PTSS-10
were subsequently identiﬁed as having PTSD when followed-up with the
SCID [19]. Most of these studies, however, did not assess using the SCID
in patients who did not screen positive on a screening tool.
Prevalence of PTSD ranged from 5% in a prospective cohort study that
used the IES [7] to 63% in the placebo group in a retrospective cohort study
that used the PTSS-10 and SCID to measure PTSD (see Table 1) [13].
Several of the studies that reported higher prevalence of PTSD (54%,
59%, and 63%) had particularly small sample sizes or were subgroup anal-
yses of larger populations [9,13,17]. There also was variation in the reported
prevalence based on time of assessment of symptoms. Speciﬁcally, preva-
lence was highest when assessment occurred close to the time of discharge
and decreased as time from discharge increased [2].
Table 1
Summary of studies assessing the prevalence of posttraumatic stress disorder in survivors of critical illness in the medical intensive care unit
Author and
reference no. Study design
Time between critical
illness and assessment
of posttraumatic
stress disorder Instrument used Sample size Response rate
Prevalence of
posttraumatic stress
disorder
Schelling, et al
1999 [17]
Retrospective
cohort
2 to 9 years PTSS-10, clinical
interview
54 Unknown 38% (18.5% in
treatment group,
59% in control
group)
Schelling, et al
1998 [16]
Retrospective
cohort
6 to 10 years PTSS-10 80 78% 27.5%
Stoll, et al
1999 [15]
Retrospective
cohort
2 time points at least
2 years apart (1 to
19 years after
discharge)
PTSS-10, clinical
interview
52 65% 25%
Eddleston, et al
2000 [10]
Prospective
cohort
3 months Selected PTSD
questions
143 63% 36% with ‘‘distressing
ﬂashback’’
Nelson, et al
2000 [22]
Cross-sectional 6 to 41 months
(mean 19 months)
Seven items pertaining
to PTSD
24 71% 39% with ‘‘bad
memories
or dreams’’
Schelling, et al
2001 [13]
Retrospective
cohort
21 to 49 months PTSS-10, SCID 20 84% 40% (63% in placebo
roup, 11% in
treatment group)
Scragg, et al
2001 [20]
Cross-sectional O5 years IES, TSC-99, ETIC-7 60 56% 15% with PTSD (30%
with posttraumatic s
tress symptoms)
Shaw, et al
2001 [21]
Cross-sectional Unknown IES 20 N/A 35%
Jones, et al
2003 [12]
Randomized
controlled trial
6 weeks and
6 months
IES 115 at 6 weeks,
102 at 6 months
80% 51% (at 6 months)
8
7
8
K
R
O
S
S
et
a
l
Kress, et al
2003 [9]
Prospective cohort Approximately
1 year
IES-R, clinical
interview
32 30% 18.5% (54% from
control group, 0%
from intervention
group)
Cuthbertson, et al
2004 [8]
Prospective cohort 3 months Davidson Trauma
Scale
78 70% 14%
Kapfhammer, et al
2004 [14]
Retrospective
cohort
Median of 8 years PTSS-10, SCID 46 58% 23.9%
Nickel, et al
2004 [19]
Cross-sectional Unknown PTSS-10, SCID 41 N/A 9.76% with PTSD
(17% with
posttraumatic stress
symptoms)
Capuzzo, et al
2005 [7]
Prospective cohort 1 week and
3 months
IES 63 at 3 months 73% 5%
Rattray, et al
2005 [11]
Prospective cohort Hospital discharge,
6 months and
12 months
IES 67 at 6 months,
60 t 12 months
73% 20% with high
avoidance scores,
18% with high
intrusion scores
Deja, et al
2006 [18]
Retrospective
cohort
57 þ/ 32 months PTSS-10 65 49.6% 29%
Girard, et al
2007 [4]
Prospective cohort 6 months PTSS-10 43 24% 14%
Sukantarat, et al
2007 [23]
Prospective cohort 3 and 9 months IES 51 88% 24%–38%
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880 KROSS et alSeveral risk factors for PTSD were identiﬁed in these studies, although
the methods used varied. Risk factors that were identiﬁed by more than
one study include more delusional memories as opposed to factual memories
[7,12,19], increased length of stay or duration of mechanical ventilation
[8,11,14], greater levels of sedation or neuromuscular blockade [4,9,22],
younger age [4,8,11,20], prior mental health history [8,19], and female gen-
der [4,10,20]. In one study, greater perceived social support was implicated
as protective against the development of PTSD [18].
In summary, it is diﬃcult to provide a precise estimate of the prevalence
of PTSD among survivors of critical illness, but these studies suggest it is
signiﬁcantly higher than seen in the general population and probably in
the range of 14% to 50%. Several risk factors for the development of
PTSD have been identiﬁed in those who are critically ill, including features
of the ICU stay that correlate with higher severity of illness and length of
stay and features of patients suggesting that some characteristics put indi-
viduals at increased risk.Family members of survivors of critical illness
Far fewer studies have investigated the prevalence of PTSD in family
members of individuals who survive their critical illness and these studies
are outlined in Table 2 [5,24]. The largest of these was conducted in France
by Azoulay and colleagues [5] and was a longitudinal study conducted in
21 medical-surgical ICUs in 2003. Family members were eligible for study
if they came to an ICU to visit a patient who had an ICU stay of greater
than 48 hours. The closest family member was identiﬁed and oﬀered partic-
ipation in the study. Telephone interviews were conducted 90 days after ICU
discharge or death. Family members completed the IES, the 36-Item Short
Form Health Survey (SF-36), and the Hospital Anxiety and Depression
Scale. The investigators considered IES scores greater than 30 as the cutoﬀ
for posttraumatic stress reaction (PTSR), indicating a signiﬁcant risk for
PTSD. A total of 459 patients were screened for inclusion. Two hundred
eighty-four family members consented and were able to be reached for fol-
low-up. Of these, 228 were family members of ICU survivors whereas 56
were family members of individuals who died in an ICU.
In this study, 94 (33.1%) family members screened positive for PTSR
with an IES score greater than 30 (see Table 2). When restricting analysis
to those whose family members who survived their ICU stay, 28.9% of fam-
ily members screened positive for PTSR. Factors independently associated
with an IES score greater than 30 in family members included female gen-
der, being a child of the ICU patient, history of cancer in the ICU patient,
higher illness severity scores, feeling that information was incomplete, shar-
ing in medical decision making in the ICU, and death of the patient in the
ICU.
Table 2
Summary of studies assessing the prevalence of posttraumatic stress disorder in family members o survivors of critical illness
Author and
reference no. Study design
Time between
critical illness
and assessment
of posttraumatic
stress disorder
Instrument
used Sample siz Response rate
Prevalence
of posttraumatic
stress disorder
Azoulay,
et al 2005 [5]
Prospective
cohort
90 days IES 284 total,
228 surv ors
62% 33.1% in entire
group; 28.9%
in survivors
Jones, et al
2004 [24]
Randomized
controlled trial
8 weeks, 6 months IES 90 at 8 wee s,
84 at 6 m nths
86% at 8 weeks,
81% at 6 months
49% at 6 months
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882 KROSS et alOther smaller studies have shown similar elevated prevalence of PTSD in
family members of ICU survivors. A study by Jones and colleagues [24] was
conducted as part of a randomized controlled trial of a rehabilitation pro-
gram after discharge from an ICU. The investigators identiﬁed the closest
family member of 104 recovering ICU patients. PTSD symptoms were
assessed using the IES at 8 weeks and 6 months after ICU discharge. The
investigators administered the interviews by telephone and used a cutoﬀ
of greater than 19 on the IES as indicative of symptoms of PTSD. There
was no diﬀerence in IES scores between the control and intervention groups.
IES scores in both groups were similar at the 8-week and 6-month inter-
views. The prevalence of an IES score greater than 19 was 49% at the
6-month interview.
One other smaller study looked at PTSD symptoms in family members
during an ICU stay [25]. This study included 32 family members of ICU
patients. The investigators used the IES to assess PTSD symptoms at two
time points: (1) within 1 week of admission to an ICU and (2) just before
anticipated ICU discharge. Using a cutoﬀ IES score of 30, they found a prev-
alence of PTSD of 81% in family members at the ﬁrst time point and 59% at
ICU discharge. These individuals, however, did not meet DSM-IV criteria
for PTSD as the measurements were made within 1 week of admission to
an ICU and, therefore, symptoms attributable to the ICU could not have
been present for the 1-month time period required for the diagnosis of
PTSD by DSM-IV criteria.
In summary, family members of patients who survive critical illness are at
increased risk for PTSD and estimates of the prevalence of PTSD in these
family members suggest prevalence in the 25% to 50% range, although
these studies are fewer in number. Risk factors are similar to those seen in
patients and include female gender, prior psychiatric illness, and severity
of illness of the patients. In addition, poor communication with health
care providers seems to be associated with increased symptoms of PTSD.Family members of those who die after critical illness
There are several studies that have looked at PTSD after bereavement not
speciﬁc to ICUs. In one such study, widows and widowers were interviewed
with the SCID 2 months after death of a spouse and the investigators found
that 10% of widows and widowers met criteria for PTSD at that time [26].
They found no signiﬁcant diﬀerence between types of death, when compar-
ing deaths from chronic illness versus sudden, unexpected death. They did
not discuss hospitalization or ICU admissions, however, before death in
their study.
There are three published studies examining PTSD symptoms in families
of patients who died (Table 3). The ﬁrst study to speciﬁcally examine the
prevalence of PTSD in family members of those who die in an ICU was
that by Azoulay and colleagues [5] (discussed previously). In that study,
Table 3
Summary of studies assessing the prevalence of posttraumatic stress disorder in family members of patients who die after critical illness
Author and
reference no. Study design
Time between
critical illness and
assess-ment of
posttraumatic
stress disorder Instrument used
Sample
size
Response
rate
Prevalence
of posttraumatic
stress disorder
Azoulay, et al
2005 [5]
Prospective
cohort
90 days IES 56
families
of those
who died
62% 50%
Laurtrette, et al
2007 [27]
Randomized
controlled trial
90 days IES 126 86% 45% in
intervention
group, 67% in
control group
Gries, et al
2008 [28]
Retrospective
cohort
6 to 36
months
PTSD
Checklist-
Civilian
Version
196 71% 15.3%
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days after death. Again, the overall prevalence of PTSD, deﬁned by IES
greater than 30, in the total study population (families of those who survived
and those who died) was 33.1%. When looking at the subgroup of family
members of those who had died, the prevalence of PTSD was 50%. Median
IES scores were higher, as was prevalence of those who had IES scores
greater than 30, in family members of patients who died in an ICU after
decisions to limit life-sustaining treatments (60%), and in family members
who were involved in decisions to limit life-sustaining treatments (80%).
Based on their results, the French group followed up that study with an
intervention with the goal of reducing the burden of psychologic symptoms
in family members whose loved ones died in an ICU [27]. This study
enrolled family members of 126 patients who died in an ICU in France. Par-
ticipants were randomly assigned to the intervention, which included a struc-
tured end-of-life care family conference and a bereavement brochure for the
family, or to usual care. Interviews were conducted using the IES to assess
PTSD 90 days after death. They found lower prevalence of PTSD, using IES
scores of greater than 30, in the intervention group (45% versus 67%). The
primary diﬀerences between the intervention and control group experiences
were attributed to clinician-family communication. In addition, family
members in the intervention group spent more time in family conferences
and more of the conference time talking than did the control group.
More recently a study from the United States examined the level of symp-
toms of PTSD in family members of 196 patients who died in an ICU using
the PTSD Checklist-Civilian Version between 6 and 36 months after death
[28]. This study found a prevalence of 15.3% and found that the prevalence
decreased with increasing time between death and survey administration.
Other factors associated with increased symptoms of PTSD included female
gender, history of medication use for emotions by the family member before
the critical illness, and a history of the family member seeing a psychiatrist,
neurologist, or pain specialist before the critical illness.
In summary, family members of patients who die in an ICU also seem at
increased risk for PTSD in the general population and prevalence estimates
include a broad range, from 15% to 65%. Risk factors include female gen-
der and prior use of medications for emotions or seeing a psychiatrist before
the critical illness [28].Limitations of current research
There are several challenges to studying PTSD in general and particularly
in this population after critical illness. The diagnosis of PTSD requires not
only symptoms of distress but also a precipitating traumatic event. There is
signiﬁcant comorbidity with PTSD and other psychiatric illnesses [1]. As
such, it often is diﬃcult to decipher the cause of PTSD symptoms and the
relative contribution of PTSD to an individual’s overall level of distress.
885POSTTRAUMATIC STRESS DISORDERIn studies in ICUs in particular, the assessment of PTSD that is related to
ICU care is challenging. It is diﬃcult to separate the experience of an
ICU from other aspects of health care and illness. It also is challenging in
this research setting to ensure that the traumatic event of interest is, in
fact, the ICU experience, and that other traumatic events that may have
been experienced in the past are not contributing to symptoms at the time
of assessment.
The studies that have looked at PTSD in the setting of critical care have
signiﬁcant methodologic limitations. Most of these studies likely overesti-
mate the prevalence of PTSD by using only screening tools for diagnostic
purposes. These screening instruments are not designed to deﬁnitively iden-
tify the presence, absence, or severity of PTSD. Although some of the stud-
ies (discussed previously) did follow-up with the SCID, most did not. In the
case of PTSD in family members, all relied on screening tools alone (al-
though one recent study used the SCID to assess anxiety, depression, and
complicated grief in family members of patients who died in an ICU) [29].
Most screening tools, including that used most commonly, IES, have not
been validated in patients who have had critical illness.
Additionally, most of the published studies on this topic have limited
sample sizes. Among studies of ICU survivors, the largest study had 150
patients in follow-up whereas most had fewer than 50 patients. There are
problems with low follow-up rates and the potential for nonresponse bias
in the samples. Although it is diﬃcult to assess the direction of the bias in-
troduced by nonresponse or loss to follow-up, the avoidant symptoms of
PTSD suggest that these studies with signiﬁcant nonresponse rates may un-
derestimate the burden of PTSD.
Finally, there are diﬃculties generalizing published results to all ICU
patients and their families. In the case of the French study of PTSD in fam-
ily members, it is diﬃcult to generalize these results to the United States
population. Prior studies in the United States have shown that family mem-
bers of critically ill patients are more satisﬁed with care when they are
involved in the decision-making process at the end of life [30], which seems
contrary to the ﬁnding by Azoulay and colleagues [5] where there was
increased prevalence of PTSD in family members involved in end-of-life
decision making.Relevance to critical care clinicians
It is important that critical care clinicians be aware that PTSD is a poten-
tial morbidity of critical illness for patients who survive their illness and for
family members of those who survive or die after their critical illness.
Although the diagnosis of PTSD can be made only after the incident of crit-
ical illness and, therefore, is beyond the scope of practice for most critical
care clinicians, it may be important to be aware of potential risk factors
for this morbidity during the course of critical illness and to counsel patients
886 KROSS et aland families that psychologic distress may occur after an ICU course. In this
way, patients and family members may be more aware of the risk for devel-
opment of these symptoms and may be able to seek appropriate counseling
and therapy as needed once the critical illness has ended.Summary
Despite the limitations (described previously), there is consistent evidence
in the literature that the prevalence of PTSD in survivors of critical care is
elevated above that seen in the general population. Similarly, prevalence for
family members of survivors and those who died during their ICU stay are
elevated. The experience of an ICU, for patients and their families, has the
potential to cause signiﬁcant psychologic distress. PTSD is an important
sequela of critical illness and should be considered by health care providers
when providing post-ICU care to survivors and their families and to families
of those who die in an ICU. Increased recognition, and perhaps screening,
may be important as there are eﬀective treatments available [1].
Future studies are needed to further assess the prevalence and burden of
PTSD in these three groups. It would be beneﬁcial not only to screen for
PTSD symptoms but also to follow-up positive screening with structured
clinical interviews. With increased awareness of PTSD as a common sequela
of critical illness, future interventions should be investigated to prevent and
to treat this adverse outcome in patients and family members. The French
study by Laurtrette and colleagues [28] is promising, showing decreased
symptom burden with communication-based intervention for families.
Additional interventions should be considered for patients and for family
members of ICU patients who are not expected to die.References
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Among the critically ill, infectious diseases can play a signiﬁcant role in
the etiology of neuropsychiatric disturbances. All critical care physicians
are familiar with delirium as a secondary complication of systemic infection.
This article focuses on key infectious diseases that commonly and directly
produce neuropsychiatric symptoms, including direct infection of the central
nervous system (CNS).
Crit Care Clin 24 (2008) 889–919HIV infection and AIDS
HIV-AIDS is often seen as the modern ‘‘great imitator,’’ a complex infec-
tious disease with multiple manifestations and interplay of myriad biopsy-
chosocial factors, including neuropsychiatric disorders related to direct
HIV-1 brain invasion, CNS opportunistic infections, manifestations of con-
current drug abuse, hepatitis C coinfection, and iatrogenic complications.
Diﬀerential diagnosis and management of HIV-AIDS–related neuropsychi-
atric disturbances can serve as a paradigm for other infectious diseases that
have neuropsychiatric manifestations.Medical hospitalization in HIV-AIDSWith the widespread availability of highly active antiretroviral therapy
(HAART) for HIV infection in developed countries, there have been
dramatic declines in HIV-related hospital admissions. Between 1995 and
1997, admissions dropped 33% to 75% [1–4]. Since that time, rates have* Corresponding author.
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0749-0704/08/$ - see front matter  2008 Elsevier Inc. All rights reserved.
doi:10.1016/j.ccc.2008.05.007 criticalcare.theclinics.com
890 FERRANDO & FREYBERGstabilized or rebounded slightly. The reasons for medical hospital admission
have also shifted. In two urban hospital studies [3,4], a drop in hospitaliza-
tion caused by opportunistic infections and cancers was observed, contrast-
ing with a rise in nonopportunistic complications, such as hepatitis C and
cardiovascular disease. Mean CD4 counts of HIV inpatients were seen to
increase by over 100 cells/mm3 from 1995 to 2001 [3].
Factors that seem to confer risk for medical hospitalization in the
HAART era include low CD4 count, female gender, lack of antiretroviral
treatment, and injection drug use [3,4]. The sociodemographic characteris-
tics of those at risk reﬂect the shifting demographics of the HIV epidemic,
limitations in access to care, and poor adherence to antiretroviral treatment.Epidemiology of psychiatric disorders in HIV-AIDS medical inpatientsThere are extensive epidemiologic data regarding psychiatric disorders in
ambulatory HIV-AIDS patients. Overall, studies reveal high rates of lifetime
and current substance abuse and depressive and anxiety disorders (see
Ferrando and Tiamson [5] for a review of this literature). As seen in Table 1,
among medially hospitalized HIV patients, studies indicate a similar proﬁle;
however, delirium, dementia, and manic-spectrum disorders seem to be
more common [6–10]. The most frequently diagnosed disorders are in the
depressive spectrum (range, 27%–83%), including depression secondary to
medical condition (or organic mood disorder), adjustment disorder with
depressed mood, major depressive disorder, or dysthymic disorder. Delirium
is diagnosed in 8% to 29% of patients, regardless of HIV stage, and is often
reported to be concurrent with HIV-associated dementia, diagnosed in 8%
to 22% of cases. Substance use disorders are diagnosed in 11% to 36% of
AIDS inpatients and up to 63% in HIV-positive, non-AIDS patients. One
study found that bipolar disorder and HIV-associated mania occurred in
11% of medical inpatients [10].HIV and the brainSince the beginning of the HIV epidemic, it has been recognized that HIV
can infect the CNS and produce a range of cognitive and behavioral symp-
toms that become more frequent and severe as the immune system declines
and symptomatic illness and AIDS ensue. In 1991, the American Academy
of Neurology published research diagnostic criteria for HIV-associated
cognitive, motor, and behavior disorders [11], which remained in widespread
use until the diagnostic criteria were recently updated by a work group con-
vened at the National Institutes of Mental Health [12]. Based on cumulative
research and clinical evidence, this group described three HIV-associated
neurocognitive disorders: (1) asymptomatic neurocognitive impairment,
(2) mild neurocognitive disorder, and (3) HIV-associated dementia. The
asymptomatic neurocognitive impairment category recognizes that a sub-
stantial percentage of HIV-infected patients have demonstrable impairment
Table 1
Frequency of psychiatric disorders reported in the inpatient medical setting
N % Male HIV risk
Medical
illnesses
Depressive
disorders
%
Dementia
%
Delirium
%
Substance
use
disorder
% Other
psychiatric
disorders
Perry SW and
Tross S, 1984
52 AIDS 98 Homosexual 79%
Homosexual þ
IVDU 12%
Other 9%
OI 71%
KS 17%
OIþKS 12%
Any 83% 11 29 11 Schizophrenia 2
Dilley JW
et al, 1985
13 AIDS 100 Homosexual
100%
OI 70%
OIþKS 15%
Other 15%
Adjustment
disorder 54%
MDD 15%
8 8 31 Panic 8
O’Dowd MA and
Mc Kegney P,
1990
67 AIDS 69 Not reported Not reported Adjustment
disorder 42%
MDD 3%
22 27 20 Axis II 6
Bialer P
et al, 1996
433 AIDS
116 HIVþ
79 Not Reported Not Reported Organic
mood 13%
Adjustment
disorder 13%
MDD 1%
22 29 36 Axis II 9
Ferrando SJ
et al, 1997
36 AIDS
4 HIVþ
60 Homosexual 34%
IVDU 31%
Heterosexual
31%
OI 89% MDD or 31%
dysthymic
disorder
19 19 19 Mania/
hypomania 11
Anxiety 8
Abbreviations: IVDU, intravenous drug user; KS, Kaposi’s sarcoma; MDD, major depressive disorder; OI, opportunistic illnesses.
8
9
1
N
E
U
R
O
P
S
Y
C
H
IA
T
R
IC
A
S
P
E
C
T
S
O
F
IN
F
E
C
T
IO
U
S
D
IS
E
A
S
E
S
892 FERRANDO & FREYBERGon neuropsychologic testing but little or no perceptible functional impair-
ment. The latter two disorders (mild neurocognitive disorder and HIV-asso-
ciated dementia) present with cognitive and behavioral symptoms associated
with functional impairment (mild in mild neurocognitive disorder, moderate
to severe in HIV-associated dementia). HIV-associated neurocognitive
disorders have been found to predict shorter survival [13,14], especially in
the setting of virologic failure on HAART [15]. The cognitive symptoms
of HIV-associated neurocognitive disorders are characteristic of subcorti-
cal-frontal pathology and include impairment in psychomotor processing
speed, executive function, and verbal memory. The potential behavioral
manifestations are broad and include apathy, depression, anxiety, mania,
and psychosis.
Neuropathologically, HIV traverses the blood-brain barrier primarily by
infected blood mononuclear cells, becoming activated macrophages once
they enter the brain. Neuropathologic changes seem to be a result of CNS
immune activation with release of neurotoxic cytokines and metabolites.
Substance abuse is an important cofactor for HIV neuropathology [16].
Subcortical brain structures, such as the basal ganglia and periventricular
white matter, are most aﬀected. If unchecked, this immune cascade leads
to neuronal cell apoptosis. Eﬀective suppression of CNS viral replication
and the resulting immune activation has the potential, however, to reverse
at least some of the neuropathologic changes.
HIV-associated neuropathology has received heightened attention in
recent years because of two associated developments. First, HIV-1 viral
load monitoring has demonstrated that the CNS is an independent sanctuary
site of viral replication [17]. The level and genetic proﬁle of HIV in the periph-
eral circulation may not correlate with that in the CNS. The second develop-
ment relates to the recognition that antiretroviral medications have diﬀering
levels of penetration into the CNS. It is hypothesized that poorly penetrating
antiretrovirals might inadequately treat CNS infection despite being eﬀective
peripherally. This has led to concerns that actively replicating virus in the
CNS could cause progressive cognitive decline in otherwise healthy HIV-
positive individuals and could also lead to a reseeding of the virus into the
peripheral circulation. Indeed, better CNS antiretroviral penetrance has
been found to correlate with better suppression of HIV in the cerebrospinal
ﬂuid (CSF) [18]. The past 10 years have seen a reduction in the incidence
of HIV-associated dementia from 7% per year in the pre-HAART era to
approximately 2% to 3% [19]. HAART regimens have been shown to reduce
CSF viral load to undetectable levels [17], to reverse white matter lesions on
MRI [20], to reverse brain metabolic abnormalities detected by proton MR
spectroscopy [21], and also to improve neuropsychologic test performance
[22,23]. Despite these hopeful ﬁndings, however, functionally signiﬁcant
cognitive and behavioral disturbances, without frank dementia, may persist
in approximately one fourth of HAART-treated patients [24,25], impeding
adherence to treatment [26] and ability to work [27].
893NEUROPSYCHIATRIC ASPECTS OF INFECTIOUS DISEASESDiﬀerential diagnosisDiﬀerential diagnosis is paramount when investigating for medical and
neuropsychiatric etiologic factors related to HIV illness and its treatment
(Box 1).
First, in assessing the hospitalized HIV-AIDS patient, it is important to
query for personal and family psychiatric history because neuropsychiatric
complications may be a manifestation of pre-existing psychopathology
[28,29]. Even in the presence of a prior psychiatric history, however, it is
imperative to rule out potentially exacerbating, if not etiologic, medical
factors. HIV-associated neurocognitive disorders are associated with a range
of cognitive or behavioral symptoms, including apathy, depression, sleep
disturbances, mania, and psychosis. CNS opportunistic illnesses and cancers
can also present with a wide range of neuropsychiatric symptoms as a result
of both focal and generalized neuropathologic processes (see Table 2).
Substance intoxication and withdrawal are also common in the medical
inpatient setting. HIV-infected substance users have high rates of pre-existing
comorbid psychopathology that may be exacerbated by ongoing substance
use. Further, abuse of multiple substances concurrently (eg, opioids, cocaine,
benzodiazepines, alcohol) can result in complex intoxication and withdrawal
states that may be very diﬃcult to treat.
Hepatitis C coinfection is associated with multiple neuropsychiatric com-
plaints, most frequently fatigue, depression, and cognitive dysfunction. The
pattern of cognitive impairment is similar to that of HIV, with impairment
in attention, concentration, psychomotor processing speed, verbal memory,
and executive dysfunction. Patients with end-stage liver disease and cirrhosis
experience superimposed delirium (hepatic encephalopathy). Combination
pegylated interferon alpha-2a treatment for hepatitis C has been extensively
documented to cause neuropsychiatric side eﬀects including depression,Box 1. Differential diagnosis of psychiatric disorders
and symptoms in HIV-AIDS medical inpatients
 Primary psychiatric disorder
 CNS HIV infection (minor neurocognitive disorder and
HIV-associated dementia)
 CNS opportunistic illnesses and cancers (Table 2)
 Substance intoxication and withdrawal
 Neuropsychiatric complications of hepatitis C and its treatments
 Neuropsychiatric side effects of HIV medications
 Drug-drug interactions
 Endocrine abnormalities (eg, hypogonadism, adrenal
insufficiency, thyroid disease)
Table 2
Opportunistic illnesses of the central nervous system in AIDS
OI CD4 Signs Focal CT/MRI Lumbar puncture
Toxoplasmosis !100 Fever
Delirium
Headache
Seizures
Y Ring-enhancing lesions
Basal ganglia
Gray-white junction
T gondii antibody or
PCRHigh speciﬁcity/
low sensitivity Other
routine CSF studies not
generally diagnostic
Cytomegalovirus !50 Delirium
Infections found at
diagnosis
Retina
Blood
Adrenal gland
Gastrointestinal tract
Y/N Ventricular enlargement
Increased periventricular
signal (T2 image)
CMV PCR
Variable speciﬁcity/
variable sensitivity
Elevated protein level,
pleocytosis,
hypoglycorrhachia
Cryptococcal
meningitis
!100 Fever
Delirium
Not universally seen
Increased intracranial
pressure (50%)
Seizures
N Nonspeciﬁc Cneoformans, India ink,
latex agglutination
or PCR
High speciﬁcity/high
sensitivity
Other routine CSF studies
not generally diagnostic
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Progressive
multifocal
leukoencephalopathy
(JCV)
!100 Mono/hemiparesis
Dysarthria
Gait disturbance
Sensory deﬁcit
Progressive dementia
Occasional
Visual loss
Seizures
Y Attenuated signal/
(T2 images)
Periventricular
White matter
Other areas:
Gray matter
Brainstem
Cerebellum
Spinal cord
JCV PCR
High speciﬁcity/high
sensitivity
Other routine CSF studies
not generally diagnostic
Central nervous
system
neoplasm/
lymphoma
!100 Afebrile
Delirium
Seizures (10%)
Increased intracranial
pressure
Y Lesions
Hypodense/ patchy
Nodular Enhancing
SPECT thallium
diﬀerentiates from
toxoplasmosis
EBV PCR
High speciﬁcity/high
sensitivity
Other routine CSF studies
not generally diagnostic
Abbreviations: CSF, cerebrospinal ﬂuid; EBV, Epstein-Barr virus; JCV, JC virus; OI, opportunistic illnesses; PCR, polymerasquf;e chain reaction; SPECT,
single-photon emission CT.
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896 FERRANDO & FREYBERGsuicidal ideation, anxiety, sleep disturbance, fatigue, mania, psychosis, delir-
ium, and cognitive dysfunction [30].
Multiple antiretroviral and other medications used in the context of HIV
have been reported to have neuropsychiatric side eﬀects. These include zido-
vudine [31], didanosine [32], abacavir [33], nevirapine [34], efavirenz, and
interferon alpha-2a. Most of these are uncommon or rare and causal rela-
tionships are often diﬃcult to determine. The most widespread clinical
concern has been generated by reports of sudden-onset depression and
suicidal ideation associated with interferon alpha-2a and efavirenz. Early
reports suggested that efavirenz may be associated with at least transient
neuropsychiatric side eﬀects in excess of 50% of patients [35]. Reported ef-
fects are protean and include depression, suicidal ideation, vivid nightmares,
anxiety, insomnia, psychosis, cognitive dysfunction, and antisocial behavior.
Drug interactions between antiretroviral and psychotropic medications
are important aspects of diﬀerential diagnosis in the hospital setting. In one
study, HIV-AIDS medical inpatients were prescribed an average of seven
medications during their admission [10]. Factors inﬂuencing drug-drug inter-
actions include medical illness severity, prior substance abuse, the likelihood
of multiple medications being initiated simultaneously, changes in volume of
distribution and protein binding, and hepatic and renal impairment.
HIV-AIDS inpatients often experience endocrinologic derangements that
may produce behavioral symptoms. These include clinical and subclinical
hypothyroidism [36], hypogonadism [37], and adrenal insuﬃciency [38],
and Graves’ disease (autoimmune thyroiditis) [36]. Thyroid deﬁciency,
including its subclinical forms, is present in approximately 16% of HIV-
infected patients [36]. Testosterone deﬁciency, with clinical symptoms of
hypogonadism, is present in up to 50% of men with symptomatic HIV or
AIDS and is likely to be present with concurrent acute medical illness
[37]. Deﬁciency of adrenal glucocorticoid production is present in up to
50% of severely ill HIV patients [38]. These endocrine deﬁciency states
have been associated with fatigue, low mood, low libido, and loss of lean
body mass and may be ameliorated by correction of the deﬁciency. Graves’
disease presents in the acute stages with activation symptoms including
anxiety, irritability, insomnia, weight loss, mania, and agitation.Diagnostic evaluationThe psychiatric evaluation of the HIV-AIDS inpatient is consistent with
the broad diﬀerential diagnosis and is focused on identifying potentially re-
versible underlying etiologies. A thorough psychiatric evaluation, including
presenting symptoms, personal and family history of psychiatric illness and
substance abuse, and a cognitive functioning examination are essential.
Box 2 contains a listing of such diagnostic tests.
In general, the diagnostic work-up should include complete blood count
with diﬀerential; serum chemistries (including liver and renal function tests,
Box 2. Diagnostic evaluation of the medical inpatient
with HIV-AIDS and neuropsychiatric disturbances
 Medical evaluation with screening laboratories: complete
blood count, chemistry screen (including liver and renal
function tests), urinalysis, chest radiograph,
electrocardiogram, blood and urine cultures (when applicable)
 Psychiatric diagnostic interview including personal and family
history
 Cognitive screen (HIV Dementia Scale)
 Additional laboratories when applicable: illicit drug toxicology
screen, serum psychotropic drug levels, thyroid function tests,
antithyroid antibodies, vitamin B12 and B6 levels, total or
bioavailable testosterone, dehydroepiandrosterone sulfate,
adrenocorticotropic stimulation test, 24-hour urine cortisol
 Evaluation for hepatitis C (including viral load)
 Review of antiretroviral regimen for neuropsychiatric side
effects
 Review of psychotropic mediations for efficacy,
neuropsychiatric side effects, drug interactions
 Neuroimaging (MRI, MR spectroscopy)
 Lumbar puncture
897NEUROPSYCHIATRIC ASPECTS OF INFECTIOUS DISEASESfasting glucose, and creatine phosphokinase); chest radiograph; electrocar-
diogram; blood and urine cultures (if indicated); toxicology screen; and
psychotropic medication serum levels (when available). Depending on the
clinical presentation, assays of thyroid function, vitamins B6 and B12, Vene-
real Disease Research Laboratory, serum total, free or bioavailable testos-
terone, adrenocorticotropic hormone stimulation, and 24-hour urinary
cortisol may be obtained. If brain imaging is required, MRI of the brain
with gadolinium contrast is preferred over CT because it produces better
visualization of brain tissue and of subcortical and posterior fossa structures
and focal lesions. A lumbar puncture may also be obtained if necessary
under sedation with ﬂuoroscopic guidance. Results are often nonspeciﬁc,
but important studies include opening pressure; culture (viral, fungal, myco-
bacterial); cell count; protein; neopterin; b2-microglobulin; and polymerase
chain reaction testing for cytomegalovirus, Epstein-Barr virus, JC virus, her-
pes simplex virus (HSV), and HIV-1.Psychiatric disorders in HIV-AIDS and their treatment
Depression
Depression is the most common psychiatric symptom and diagnosis
among medical inpatients with HIV-AIDS. Symptoms are often attributed
898 FERRANDO & FREYBERGto adjustment disorder or to medically related (organic) factors that may be
transient, related to improvement in physical symptoms. In one prospective
study assessing depressive symptoms at admission and discharge, however,
28% of HIV-AIDS medical inpatients had severe depression that persisted
at discharge [39]. In another study, 76% of patients who had a depressive
disorder during their admission continued to have signiﬁcant depressive
symptoms 3 to 6 weeks after discharge, with signiﬁcant predictors of depres-
sion during and after medical hospitalization being female gender, AIDS
diagnosis, and poor social support [10].
In the medical inpatient setting in particular, the diagnosis of depressive
disorder in HIV-infected patients may be confounded by somatic symptoms
common to depression, HIV illness, and its complications. These include
fatigue, appetite loss, sleep disturbance, and cognitive disturbances. Gener-
ally, in the presence of persistent depressed mood or loss of interest, an
inclusive approach toward somatic symptoms is preferred. This is based
on the fact that aﬀective and somatic subscales of depression screening
instruments (eg, the Beck Depression Inventory) are highly intercorrelated,
that these symptoms are more closely linked to measures of depression than
to measures of HIV-disease severity, and that both aﬀective and somatic
symptoms improve with antidepressant treatment [40,41].
In the medical inpatient setting, when antidepressant medication treat-
ment is considered, particular attention must be paid to side eﬀect proﬁle, he-
patic and renal function, and the potential for drug interactions. In addition
to standard antidepressants, such as serotonin and serotonin-norepinephrine
reuptake inhibitors, the initiation of psychostimulants and anabolic steroids,
particularly testosterone, is frequently used in the inpatient setting and is
given particular attention here.
Psychostimulants have been studied for the treatment of depressed
mood, fatigue, and cognitive impairment in the context of HIV infection,
particularly in advanced illness and where rapid onset of action is desirable.
Agents studied include methylphenidate (5–90 mg/day); dextroamphetamine
(5–20 mg/day); pemoline (35–150 mg/day); and the wakefulness agent
modaﬁnil (50–200 mg/day) [42–45]. These agents are eﬃcacious in treating
depressive symptoms in patients with advanced HIV. The primary side eﬀect
is overstimulation.
Testosterone deﬁciency, with clinical symptoms of hypogonadism
(depressed mood, fatigue, diminished libido, decreased appetite, and loss
of lean body mass) is present in up to 50% of men and women with symp-
tomatic HIV or AIDS [37]. The most common screening test for testoster-
one deﬁciency is total serum testosterone (deﬁciency is deﬁned as less than
300–400 ng/dL in men); however, serum-free (deﬁciency: !5–7 pg/mL in
men; !3 pg/mL in women) and bioavailable testosterone may be more
accurate measures. For testosterone replacement in men, commonly used
testosterone preparations include esteriﬁed depot testosterone (propionate,
enanthate, cypionate, initiated at 100–200 mg intramuscularly every 2 weeks,
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two patches, 5–10 mg, to clean dry skin daily), and transdermal testosterone
gel (one to four packets, 25–100 mg, to clean dry skin daily), with the depot
preparations being the least expensive and most studied. Patch and gel
formulations may produce less variability in serum testosterone levels and
in target symptoms. In women, transdermal testosterone, 150 mg per day
or equivalent, may be used to improve energy, well-being, muscle mass,
and restore normal menstrual functioning [37]. Reported side eﬀects for
men include irritability, tension, reduced energy, hair loss, testicular atro-
phy, reduced ejaculate volume, and acne. For women, there is particular
concern for virilizing side eﬀects; however, clinically these have been mini-
mal in the setting of physiologic replacement dosing in the range described.Delirium
Delirium is diagnosed in 11% to 29% of hospitalized HIV-AIDS patients
[10]. There are no data regarding speciﬁc or distinguishing symptom charac-
teristics for the delirium seen in HIV patients. Both the hypoactive and
hyperactive variants of delirium are seen, and in addition to cognitive distur-
bance, symptom manifestations include apathy, dysphoria, agitation, fear-
fulness, delusions, and hallucinations [46].
Delirium in the HIV-AIDS patient is often superimposed on HIV-associ-
ated neurocognitive disorders, particularly dementia, and patients with
these disorders are at increased risk for the development of delirium when
medically hospitalized. The etiology of delirium in HIV-AIDS patients is
generally multifactorial. Breitbart and colleagues [46] reported a mean of
12.6 medical complications in 30 delirious AIDS patients, with the most
common being hematologic (anemia, leukopenia, thrombocytopenia, hypo-
albuminemia) and infectious diseases (eg, septicemia, systemic fungal infec-
tions, Pneumocystis carinii pneumonia, tuberculosis, and disseminated viral
infections). Other potential etiologies are discussed previously in the diﬀer-
ential diagnosis section.
Central to the treatment of delirium is treatment of its underlying medical
causes. Symptomatic treatment includes educational, environmental, and
psychopharmacologic interventions. Education regarding the risk and
nature of delirium delivered to patients, their family, and the treatment
team can be preventative and can result in earlier treatment and improved
outcomes. Environmental interventions include titrating the level of stimu-
lation, sitting the patient up, placing patients next to a window, frequent
orientation, stabilizing sleep-wake cycles, and placing familiar people and
orienting objects in the room.
In terms of pharmacologic treatment, most practitioners treat delirium
with atypical antipsychotics, including olanzapine (available with dissolving
oral preparation and intramuscularly); risperidone (available in dissolving
oral preparation); quetiapine; aripiprazole (available intramuscularly); and
ziprasidone (available intramuscularly). The only double-blind clinical trial
900 FERRANDO & FREYBERGof delirium treatment in AIDS, however, compared haloperidol, chlorprom-
azine, and lorazepam [46]. In that study, Breitbart and colleagues [46]
screened HIV medical inpatients for delirium. Treatment was initiated early,
and when symptoms were mild to moderate in degree. Patients were severely
medically ill, because 9 (30%) of the 30 patients died within 1 week after
completing the protocol. There were three important ﬁndings. First, halo-
peridol (mean dose, 2.8 mg/day acutely and 1.4 mg/day maintenance) and
chlorpromazine (mean dose, 50 mg/day acutely and 36 mg/day mainte-
nance) were equally eﬃcacious. Second, the lorazepam arm (mean dose,
3 mg acutely) was stopped early because of worsening of delirium symp-
toms, including oversedation, disinhibition, ataxia, and increased confusion.
Third, adverse eﬀects in the antipsychotic arms were limited and included
mild extrapyramidal symptoms (EPS), such as decreased expressiveness,
rigidity, tremor, and mild akathisia.
Delirium is common in hospitalized HIV-AIDS patients, who should be
assessed frequently for early detection and treatment. A combination of psy-
choeducational, environmental, and pharmacologic interventions, primarily
with neuroleptic medications, is recommended. Benzodiazepines should be
avoided, except in cases of severe agitation that fails to respond to antipsy-
chotic agents or patients experiencing delirium secondary to alcohol or
other CNS-depressant agent withdrawal, and patients should be monitored
closely for the emergence of EPS.Mania
Manic symptomatology has been reported in 11% of all medically hospi-
talized HIV-AIDS patients [10] and may be seen in conjunction with
primary bipolar illness or with CNS HIV infection (HIV-associated mania).
Descriptively, HIV-associated mania is found to be a late-onset, secondary
aﬀective illness associated with HIV infection of the brain, being less asso-
ciated with a personal or family history of mood disorder. In addition,
the symptomatology of HIV-associated mania may include more irritability,
less hypertalkativeness, and more psychomotor slowing and cognitive im-
pairment compared with primary bipolar mania. Given that HIV-associated
mania is directly related to HIV brain infection, antiretroviral agents that
penetrate the blood-brain barrier may oﬀer some protection from incident
mania [47].
Practice guidelines recommend lithium, valproic acid, or oxcarbazepine
and carbamazepine as standard therapy for a manic episode of bipolar
aﬀective illness. In the context of HIV infection, however, there are partic-
ular considerations regarding their use. These include concern over the low
therapeutic index of lithium, the potential for valproic acid to stimulate
HIV-1 replication in cell culture models, and the enzyme-inducing and
hematologic side eﬀects of oxcarbazepine and carbamazepine.
There is relatively little research on the psychopharmacologic treatment
of HIV-associated mania. A case report on the use of lithium for
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a dosage of 1200 mg daily; however, signiﬁcant neurotoxicity (cognitive
slowing, ﬁne tremor) occurred, leading to discontinuation [48]. The most
commonly used mood stabilizer in the treatment of HIV-associated mania
is valproic acid. Valproic acid, up to 1750 mg daily, led to signiﬁcant im-
provement in acute manic symptoms, at serum levels more than 50 mg/L,
with few adverse eﬀects [49]. There have been reports of valproic acid
increasing HIV replication in vitro in a dose-dependent manner, and one
report of increased cytomegalovirus replication, perhaps mediated by alter-
ations in intracellular glutathione, which is an important mediator of HIV
replication. The clinical relevance of these ﬁndings remains controversial,
and there are no reports of valproic acid causing elevations in viral load
in vivo. Most recently, the anticonvulsant lamotrigine has received Food
and Drug Administration approval for maintenance therapy in bipolar
illness. It has been tested for HIV-associated peripheral neuropathy and
may be useful for treating mixed mania or bipolar depression in HIV;
however, patients with overt manic symptomatology generally require
a traditional mood stabilizer. This anticonvulsant requires careful upward
dose titration because of risk of severe hypersensitivity (Stevens-Johnson
syndrome).
Given the limitations of mood stabilizers in HIV, there is widespread
clinical use of atypical antipsychotics for acute and maintenance treatment
of HIV-associated mania; however, there are no clinical trial data. Clinicians
generally choose olanzapine, risperidone, or quetiapine as alternatives to
traditional mood stabilizers; however, these agents may exacerbate meta-
bolic syndrome or cause extrapyramidal symptoms in patients with exten-
sive basal ganglia HIV involvement. Benzodiazepines may be useful for
adjunctive treatment, but acute and maintenance therapy may be compli-
cated by tolerance, dependence, and cognitive impairment, including the
possibility of causing delirium and disinhibition.Psychosis
HIV infection may be directly linked to the onset of psychosis, which is
deﬁned by the presence of thought disorder, hallucinations, or delusions.
Psychosis in HIV is most often a manifestation of substance intoxication
or withdrawal, delirium, HIV-associated neurocognitive disorders, mood
disorders with psychotic features, or schizophrenia. Estimates of the preva-
lence of new-onset psychosis in patients with HIV range from 0.5% to 15%
[50]. One study compared 20 HIV-infected patients with new-onset psy-
chosis (and no prior psychotic episodes or current substance abuse) with
20 demographic and HIV illness-matched nonpsychotic patients. The
former group tended to have worse global neuropsychologic impairment,
was more likely to have a prior history of substance abuse, and had signif-
icantly higher mortality at follow-up, suggesting that psychotic HIV-AIDS
patients had an increased CNS vulnerability [51].
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phrenia and schizoaﬀective disorder, may have poor access to HIV care,
may present to the emergency and medical inpatient setting with untreated
advanced HIV illness, and may be at risk for poor adherence to care, unless
provided with comprehensive supportive services including psychiatric treat-
ment, housing, and community case management.
In general, treatment with antipsychotic medication requires awareness
of HIV-infected patients’ susceptibility to neuroleptic-induced EPS as
a result of HIV-induced neuronal damage to the basal ganglia. Movement
disorders (acute dystonia, parkinsonism, ataxia) can be seen in advanced
HIV disease in the absence of antipsychotic exposure. General recommenda-
tions include avoidance of high-potencyD2 blocking agents (eg, haloperidol);
avoidance of depot neuroleptics; and the consideration that maintenance
antipsychotic medication may not be necessary for the complete remission
of new-onset or transient psychotic symptoms. Most clinicians prefer the
use of atypical antipsychotics in this population.
A literature search on the use of antipsychotic medication in HIV-AIDS
revealed six studies published since 1993; these studies described treatment
of psychosis occurring in delirious, schizophrenic, andmanic patients. Agents
reported in the literature include haloperidol (mean dose, 3 mg) [52]; thiorid-
azine (mean dose, 145 mg/day) [36]; molindone (20–180 mg/day) [53]; cloza-
pine (mean dose, 27 mg/day) [54]; risperidone (mean dose, 3.3 mg/day) [55];
and olanzapine (10–15 mg/day) [56]. Haloperidol was reported to have
a high incidence of EPS [36] and caution is encouraged with clozapine because
of the risk for agranulocytosis and interaction with ritonavir.Herpes simplex encephalitis
A number of viruses can cause viral encephalitis including HSV [57]. HSV
is the etiologic agent for herpes simplex encephalitis (HSE), the most com-
mon source of acute viral encephalitis in the United States with an annual
incidence of 2000 cases yearly [57,58]. Two principle forms of HSV exist:
HSV-1, which typically leads to orolabial lesions; and HSV-2, which is re-
sponsible for genital herpes lesions. HSV-2 infections more typically result
in aseptic meningitis, whereas HSV-1 causes HSE. HSE is a potentially
lethal infection with a mortality rate of up to 70% if left untreated and
25% to 30% with treatment [57,59]. Half of HSE cases occur in people
over the age of 50, whereas a third of cases are in people under 20 years
of age [60].
Clinically, HSE often presents with acute onset of symptoms, such as fe-
ver, altered mental status, seizures, and focal neurologic signs, such as apha-
sia and hemiparesis. Without treatment, patients may progress to coma [58].
Before the acute presentation, there may be a prodrome characterized by
headache, fatigue, mild fever, and irritability. Although the mechanisms
for pathogenesis in humans are unknown, HSV-1 infection most commonly
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ral regions. Involvement is often bilateral, although asymmetric.
HSE leaves up to 80% of people who survive infection with a number of
residual cognitive and neuropsychiatric sequelae [57]. Cognitively, patients
may experience signiﬁcant limitations in anterograde memory formation
with additional impairment in retrograde memory. The cognitive eﬀects of
HSE are dependent on the sites of the brain involved. Although HSV-1
infection is often bilateral, impairments seen clinically may be dependent
on lateralization of HSV-1–related brain injuries. In particular, right hemi-
spheric involvement often leads to subtle deﬁcits with less functional impair-
ment. Left hemispheric neuronal damage, however, creates diﬃculties in
language function and verbal memory [57]. Additional impairments, such
as semantic aphasia or mutism, are found in up to 46% of patients with
HSE and, more rarely, auditory agnosia has also been documented
[57,58]. Long-term consequences of HSE include memory impairment and
behavioral and personality changes [57]. Neuropsychiatrically, patients
may exhibit symptoms of aggression and disinhibition consistent with
a Klu¨ver-Bucy syndrome. Early treatment may ameliorate some of these
symptoms; however, particularly in the young and old, cognitive impair-
ments secondary to HSE may lead to postencephalitic dementia [57].
HSE is diagnosed using a combination of clinical features and laboratory
and imaging ﬁndings (Table 3). Noncontrast CT imaging demonstrates
abnormalities in up to 50% of scans including a midline shift. MRI, how-
ever, remains the most sensitive imaging tool in diagnosing HSE and is
recommended as the ﬁrst diagnostic step after the clinical examination
[58]. MRI ﬁndings include focal hyperintensities on T2-weighted imaging.
Electroencephalography (EEG) may also be used and initially may show
some generalized or focal slowing over the temporal lobes (sites that are
commonly a focus for HSV-1 infection), but may change to lateralized,
epileptiform activity [57]. Lumbar puncture may demonstrate an elevated
opening pressure, CSF leukocytosis, and xanthochromia in addition to
a normal CSF glucose level. Polymerase chain reaction demonstrates the
presence of HSV-1 infection in the CSF.
HSE is treated with intravenous acyclovir. Recovery is determined in part
by how quickly treatment is begun, with increased morbidity and mortality
associated with delays in treatment [60]. Although acyclovir treatment of
HSV infection in HSE is widely accepted, there is no well-deﬁned treatment
speciﬁc for the cognitive and neuropsychiatric symptoms associated with
HSE. It has been proposed that using dopamine antagonists in a carefully
monitored manner may be useful in treating the behavioral disturbances
associated with HSE in the acute period. This is based on evidence from
an animal study suggesting activation of the mesostriatal dopamine system
in HSE. Other treatments used in clinical practice for the neurobehavioral
sequelae of HSE include anticonvulsants, benzodiazepines, antipsychotics,
stimulants, and cholinesterase inhibitors [57].
Table 3
Clinical features and diagnosis of non-HIV infectious diseases with neuropsychiatric manifestations
Disease Signs Focal CT/MRI Laboratory tests
Neuropsychiatric
sequelae Treatment
Herpes encephalitis Fever
Altered mental
status
Focal neurologic
signs
Seizures
Aggression/
disinhibition
Language
impairments
Yes Midline shift
T2 focal
hyperintensities
EEG
Lumbar puncture
PCR
Diﬃculties in
language function
and verbal memory
Semantic aphasia
or autism
Behavioral and
personality changes
Klu¨ver-Bucy
syndrome
Intravenous acyclovir
Pediatric autoimmune
neuropsychiatric
disorders associated
with streptococcal
infections
Age of onset between
ages 3 and 11 years
OCD or tic disorder
symptoms
Temporal association
between symptoms
and group
A-hemolytic
streptococcal
infection
No Basal ganglia
enlargement
Antistreptococcal
antibody titers
D8/17 B-lymphocyte
marker
[ antibasal
ganglia Ab’s
OCD or tic disorder
symptoms
Other movement
disorders
Plasma exchange
Intravenous Ig
PCN or azithromycin
Neurocysticercosis Seizures
Agitation
Psychosis
Focal neurologic
signs
Depression
Dementia
Yes Ring-enhancing
lesions
Visualization
of scolex in
cystic structure
ELISA
EITB
Seizures
Psychosis-like states
Dementia
Antihelmenthic agents:
praziquantel,
albendazole
Steroids
Anticonvulsants
9
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O
&
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R
E
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B
E
R
G
Neurosyphilis General paresis
Psychosis
Emotional lability
Anhedonia
Social withdrawal
Dementia
No Lesions correlate to
speciﬁc deﬁcits
VDRL
Rapid plasma regain
Fluorescent
treponemal
antibody-absorption
assay
Lumbar puncture
Mood disorders
Psychosis-like states
Behavioral changes:
disinhibition
Dementia
PCN
Ceftriaxone
Creutzfeldt-Jakob
disease
Rapidly progressive
cognitive decline
Extrapyramidal signs,
ataxia, myoclonus,
dysphagia
Akinetic mutism
Agitation
Psychosis
Depression
No Cortical ribboning
Basal ganglia
and cortical
abnormalities
Variant CJD:
hyperintensity in
pulvinar thalami
EEG: periodic sharp
wave complexes
Tonsil biopsy
for variant
Creutzfeldt-Jakob
disease
14-3-3 assay
Rapidly progressive
dementia
Cerebellar signs
Visual signs
Myoclonus
Pyramidal symptoms
Extrapyramidal
symptoms
Akinetic mutism
Mood disorders
Psychosis-like states
No eﬀective treatment
has been identiﬁed
Abbreviations: EEG, electroencephalogram; EITB, enzyme-linked immunoelectrotransfer; OCD, obsessive-compulsive disorder; PCN, penicillin; PCR,
polymerase chain reaction; VDRL, Venereal Disease Research Laboratory.
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with streptococcal infections
Over the last 20 years, there has been mounting evidence for connections
between group A b-hemolytic streptococcal infections and the development
of neuropsychiatric symptoms. Sir William Osler made the original
observation that patients with Sydenham’s chorea, a complication of group
A b-hemolytic streptococcal infection, also exhibited behaviors consistent
with tics and obsessive-compulsive disorder (OCD). Later work demon-
strated that as many as 70% to 80% of patients with Sydenham’s chorea
also have clinical features meeting diagnostic criteria for OCD, particularly
in children [61,62]. Based on work with children who exhibited abrupt onset
of OCD symptoms or tics following group A b-hemolytic streptococcal
infection, the development of these symptoms was linked to an immune sys-
tem–mediated response to the original infection, termed ‘‘pediatric autoim-
mune neuropsychiatric disorders associated with streptococcal infections’’
(PANDAS) [61,63]. Age of symptom onset is approximately 3 years younger
in PANDAS than childhood-onset OCD. Additionally, the abrupt onset
and relapsing-remitting pattern of symptoms in PANDAS diﬀers from the
more gradual onset and chronic pattern in childhood OCD [62,64]. There
may be a heritable component to PANDAS, because children with
PANDAS have parents and grandparents with signiﬁcantly higher rates
of streptococcal infection complications, such as rheumatic fever, compared
with controls [63].
Diagnostic criteria for PANDAS include (1) age of onset between the
ages of 3 and 11 years; (2) meeting criteria for OCD or a tic disorder; (3)
episodic severity of symptoms; (4) association with group A b-hemolytic
streptococcal infection; and (5) association with neurologic abnormalities,
including hyperactivity, tic, or choreoform movements [61,62]. Although
resembling childhood-onset OCD, PANDAS is distinguished clinically by
a distinct temporal relationship between a group A b-hemolytic streptococ-
cal infection and onset of OCD or tics. To make a more deﬁnitive diagnosis
(see Table 3), obtaining antistreptococcal antibody titers (including anti-
streptolysin O and antideoxyribonuclease B antibodies) that rise during
a symptomatic exacerbation and fall with symptomatic improvement is
often needed. Use of these antistreptococcal antibody titers, however, is
complicated by the fact that titers may remain high for months following
infection [62]. There is also evidence that antibodies directed against the
basal ganglia are found more commonly in patients with PANDAS relative
to people with uncomplicated streptococcal infections [65]. This ﬁnding may
shed further light on PANDAS’ pathophysiology given that preliminary
MRI suggests basal ganglia enlargement in PANDAS patients [66]. In deter-
mining susceptibility to PANDAS, studies have indicated that patients with
PANDAS are more likely to also have lymphocytes that are positive for the
D8/17 marker. This B-lymphocyte alloantigen marker is also associated
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Sydenham’s chorea, further suggesting an immune basis [61,62].
Ultimately, based on the clinical and diagnostic features of PANDAS, it
has been suggested that the pathophysiology of PANDAS is based on the
development of an autoimmune reaction in patients who are susceptible
(ie, based on family history, immunologic markers). This reaction occurs
in response to infection with group A b-hemolytic streptococcus where
the immune system inappropriately generates antibodies against epitopes
on the basal ganglia that resemble streptococcal antigens through the pro-
cess of molecular mimicry [62]. The resulting immune-mediated inﬂamma-
tory process in the basal ganglia then may lead to the clinical features of
PANDAS [63].
Treatment of PANDAS has been largely based on immunomodulatory
therapies. Notably, signiﬁcant symptomatic improvements have been demon-
strated in patients following use of plasma exchange and intravenous
immunoglobulin. In one study, severity of OCD symptoms diminished by
45% to 58% following treatment with either plasma exchange or intravenous
immunoglobulin [63,67]. Despite this, immunomodulatory therapies have
not been recommended as the routine treatment of PANDAS [62]. Use of
antibiotic prophylaxis to prevent neuropsychiatric exacerbations following
recurrent streptococcal infections has yielded mixed results. Although one
double-blind, placebo-controlled trial found no beneﬁt over placebo in
preventing PANDAS exacerbations, another trial found that either penicillin
or azithromycin were able not only to lower rates of streptococcal infections
but also to decrease symptom exacerbations in PANDAS patients [68,69].Neurocysticercosis
Neurocysticercosis (NCC) is the most common parasitic disease of the
nervous system, particularly in developing countries in Asia, Latin America,
and Africa. Because of rising rates of immigration from areas where it is
more prevalent, however, NCC is appearing more frequently in North
America and Europe. Annually, more than 50,000 deaths worldwide are
attributable to NCC. Even more patients are left alive with chronic, irrevers-
ible brain damage. Moreover, NCC is the major etiology for acquired
epilepsy in endemic areas [70]. NCC is caused by infection with the tape-
worm Taenia solium. Humans are the deﬁnitive host for T solium, whereas
pigs serve as the intermediate host. NCC results generally from fecal-oral
transmission where people ingest the eggs of the tapeworm from contami-
nated food or water. Commonly, this route of transmission occurs through
handling of food by others already infected or from improperly cleaned
food. Autoinfection also occurs, albeit less frequently [62]. Once in the intes-
tine, the eggs hatch and migrate throughout the body by way of the
bloodstream, ultimately depositing into various tissues where they develop
into the larval cysticercus form. When the site of larval deposition is in
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extent of nervous system involvement. The four main types of NCC are (1)
parenchymal, (2) subarachnoid, (3) ventricular, and (4) spinal [62].
Neurologically, seizures are the most common manifestation of NCC,
occurring in 70% of infected patients, especially in the parenchymal form
of the disease. The seizures are typically simple partial or generalized tonic-
clonic, although patients may also present with focal neurologic deﬁcits based
on the sites of infection. Stroke, intracranial hypertension, hydrocephalus,
meningeal inﬂammation, ﬁbrosis, or cyst formation may also occur [70,71].
As a result, NCC is on the diﬀerential diagnosis of most neurologic disorders
in endemic regions [71].
Given the varied neurologic presentations of NCC, it is not surprising
that NCC also has many diﬀerent psychiatric manifestations. Up to 15%
of people infected with NCC exhibit only psychiatric sequelae [71]. In a study
examining rates of T solium infection among chronic psychiatric inpatients
in a community in Venezuela, 18.5% of the inpatients were infected versus
1.6% of controls [72]. Commonly, patients present with acute psychiatric
decompensation [62], mimicking psychotic states, such as schizophrenia.
In one case report, NCC was marked by acute psychosis characterized by
agitation, thought disorganization, paranoia, and auditory-visual hallucina-
tions [70,73]. Other psychiatric manifestations of NCC include depression or
dementia; suspicion for NCC-related dementia ought to be high if it occurs
in patients who are younger, also have a history of seizures, have acute onset
of symptoms, and are from an area where NCC is endemic [62].
The diagnosis of NCC is often diﬃcult because the symptoms of NCC
often resemble those from a broad diﬀerential of other disorders (see
Table 3). NCC most commonly is diagnosed, however, from clinical history,
imaging, and laboratory techniques. Besides biopsies that often prove diﬃ-
cult to do, brain imaging using CT and MRI scans allows for visualization
of lesions from Taenia infection. In active disease, ring-enhancing lesions are
most typically seen; visualization of the parasite’s scolex within a cystic
structure is pathognomonic for NCC [70]. Infection outside the brain paren-
chyma makes visualization more diﬃcult [62]. Laboratory studies are often
used to conﬁrm the diagnosis by investigating patient serology for anti-
bodies related to Taenia infection. ELISA and enzyme-linked immunoelec-
trotransfer are often used for antibody detection [62].
NCC treatment has been controversial with few rigorous, large-scale
studies conducted examining the various treatment options. The location
of cysts, degree, size and severity of local inﬂammation around lesions,
and symptom severity all aﬀect the treatment choice. This is complicated
by ﬁndings that the treatments themselves may exacerbate the already pres-
ent inﬂammatory response leading to symptomatic worsening [74]. Never-
theless, NCC has been treated for over 20 years using antihelminthic
agents, such as praziquantel and albendazole [62,70,74]. Other agents may
be given in concert with these drugs including steroids (to treat pericystic
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of NCC-related seizures). In some instances, surgery may also be needed
for placement of ventricular shunts to treat hydrocephalus secondary to
arachnoiditis [70,74].Neurosyphilis
Cases of syphilis have been documented since the late 1400s and, with the
HIV epidemic in recent years, have had global resurgence. By the 1920s,
more than 20% of patients in American mental hospitals had tertiary neuro-
syphilis (NS) [75]. With the advent of antibiotics, such as penicillin, the
incidence and prevalence of syphilis and resultant NS dropped signiﬁcantly;
however, in parallel with the HIV epidemic, rates of infection (largely by
sexual intercourse) began to rise again. There has been an 81% increase
in cases of syphilis infection among men since 2000, with an annual
incidence of 0.2 to 2.1 cases per 100,000 immunocompetent individuals
[75–77]. This has been an important health problem because syphilis facili-
tates coinfection with HIV [77].
Known as the original ‘‘great imitator,’’ syphilis has a number of presen-
tations in virtually all organ systems including the CNS. Consequently, NS
has been linked with a diverse array of cognitive and psychiatric syndromes.
Untreated, symptomatic NS develops in 4% to 9% of patients infected with
syphilis [78].
NS is caused by Treponema pallidum, the spirochete responsible for syph-
ilis. Infection may be either symptomatic or asymptomatic. Although NS
classically presented with tabes dorsalis or general paresis, these are less
common today. Instead, patients with NS are asymptomatic or may present
with seizures, ocular symptoms, or with psychiatric and behavioral changes
[75]. Early NS may occur within 5 years of infection, whereas late NS
(involving the brain parenchyma) typically occurs within 5 to 25 years of
infection. HIV infection, however, may accelerate the clinical progression
to symptomatic NS [78]. The general paresis form of NS is the type most
commonly associated with psychiatric symptoms [75]. The psychiatric pre-
sentation of NS typically begins insidiously with mood changes including
symptoms of mania or depression. Up to 27% of patients with the general
paresis form of NS develop depression characterized by melancholia, sui-
cidal ideation, and psychomotor retardation. Patients may also present
with psychosis of acute or insidious onset that may mimic schizophrenia
[79]. Personality changes in patients with NS can include emotional lability,
antisocial behaviors, anhedonia, social withdrawal, explosive temper, giddi-
ness, hypersexuality, or less attention to personal details. As NS progresses,
however, intellectual functioning worsens. Ultimately, symptoms of demen-
tia predominate leading to disability and ﬁnally death [75,79]. NS often
leads to cortical atrophy and brain lesions. Lesions imaged by MRI in the
temporoparietal region have been associated with cognitive impairments
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frontal lobes are associated with overall psychiatric morbidity [80]. Impor-
tantly, although prompt treatment of NS is necessary to halt the progression
of the illness, it is not expected that patients’ mental status will improve
completely, because of neuronal loss [75].
Diagnosis of NS is diﬃcult because unlike other infectious organisms,
T pallidum cannot be grown in culture (see Table 3). Because so many cases
of NS are asymptomatic, many infected patients are missed. If the index of
suspicion is suﬃciently high, however, NS is diagnosed serologically by the
rapid plasma regain and Venereal Disease Research Laboratory tests; CSF
may be used in the Venereal Disease Research Laboratory assay. If positive,
results are conﬁrmed with a microhemagglutination assay for T pallidum or
with the ﬂuorescent treponemal antibody-absorption assay [75].
NS is treated with a 10- to 14-day course of aqueous penicillin G (18–
24 million units/day with 3–4 million units given intravenously every
4 hours). An alternative is to treat the patient with procaine penicillin
(2.4 million units daily intramuscularly) combined with probenecid,
500 mg orally, four times daily, particularly if compliant with treatment; cef-
triaxone may be used if the patient is allergic to penicillin [75,77]. Sexual
partners of the patient may also need evaluation and treatment [75]. There
has been little documentation speciﬁcally addressing treatment of psychiat-
ric symptoms associated with NS. A recent study by Sanchez and Zisselman
[77] recommended use of a typical antipsychotic, haloperidol, or the atypical
agents, quetiapine or risperidone, to treat psychosis in NS patients. An an-
ticonvulsant, such as divalproex sodium, was also recommended to address
agitation and for mood stabilization [77]. Smaller case reports supported
atypical antipsychotics, such as olanzapine and quetiapine, in treatment of
NS-associated psychosis [81,82].Creutzfeldt-Jakob disease
Prion disorders have received much attention in the media given recent
epidemics of bovine spongiform encephalopathy (also known as ‘‘mad
cow disease’’) and the resulting health risks associated with possible trans-
mission to humans. There are a number of diseases caused by the prion pro-
tein, a novel infectious agent composed of a protein ordinarily found in all
humans. These diseases are known as ‘‘transmissible spongiform encepha-
lopathies’’ and are found in many mammals including cattle in the form
of bovine spongiform encephalopathy; in sheep (known as ‘‘scrapie’’); and
in humans. Prion diseases are believed to occur when the naturally occurring
form of the prion protein acquires an abnormal conformational state that
facilitates conversion of surrounding prion protein into the pathogenic
form, ultimately leading to cell death [83]. In the CNS, this process leads
to marked neurodegeneration causing spongiform changes, and conse-
quently, a reactive astrocytosis [84].
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feldt and A.M. Jacob, respectively [85]. This disease, Creutzfeldt-Jakob
disease (CJD), is the most well-known of the human prion diseases,
although it is relatively rare with an overall annual incidence of one case
per million [83]. Four forms of CJD exist: (1) sporadic CJD, (2) familial
CJD, (3) variant CJD, and (4) iatrogenic CJD.
Most CJD cases are sporadic in nature, constituting up to 85% of all
reported CJD [83]. Sporadic CJD, similar to the average incidence, has an
incidence between 0.5 and 1 per million, although the rate rises to three cases
per million among people 65 to 74 years old [85]. In sporadic CJD, the mis-
folding of the prion protein occurs likely because of a spontaneous mutation
in the gene encoding the prion protein. Although the precise signiﬁcance
relating to pathogenesis is unknown, up to 85% of patients with sporadic
CJD are homozygote for two copies of the methionine amino acid at codon
129 of the prion protein (Met/Met) [85].
Up to 10% to 15% of CJD cases are familial in origin. Familial CJD is
inherited in an autosomal-dominant fashion. Changes in the prion protein
involve mutations found in the prion protein (up to 24 individual amino
acid substitutions thus far documented) or through insertion of octapeptide
repeats [85]. Among the groups with the highest prevalence of familial CJD
are Libyan Jews and clusters of families in Chile, Slovakia, Japan, and the
United States.
Variant CJD (also known as ‘‘new variant CJD’’) was ﬁrst described in
1996 after a number of CJD cases in the United Kingdom were identiﬁed
having features that varied from the classic presentation of sporadic CJD.
Namely, patients with variant CJD tend to be younger (mean age of 26 years
in variant CJD versus 61 years in sporadic CJD); progression of disease is
slower (13 months in variant CJD versus 4 months in sporadic CJD);
EEG patterns consistent with sporadic CJD may be absent; and psychiatric
symptoms are more prominent earlier in the disease progression [85–87].
Signiﬁcantly, evidence points to the possibility that variant CJD may be
caused by eating tissues of cattle infected with bovine spongiform encepha-
lopathy, leaving open the possibility that in the coming years many more
people may become ill following exposure to cattle that were unscreened
for bovine spongiform encephalopathy before the 1990s. Variant CJD
may be also transmissible by blood including transfusions [84,85].
Lastly, iatrogenic CJD has been documented following exposure to tis-
sues from patients infected with CJD or from surgical instruments that
have come into contact with those infected. Cases have been reported of
patients developing CJD following corneal transplantation or dura mater
grafts from infected donors and by cadaveric pituitary growth hormone [85].
Clinically, sporadic CJD presents as a rapidly progressive dementia with
average disease duration of only 4 months until death. Moreover, the
neurologic and neuropsychiatric symptoms associated with CJD often
mimic those found in other dementias, such as Alzheimer’s disease or
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ramidal signs, cerebellar ataxia, sensory complaints, myoclonus, and
dysphagia. In advanced stages of illness, patients can exhibit akinetic
mutism and may ultimately die from aspiration pneumonia [83]. Although
sporadic CJD was classically believed to present with primarily neurologic
manifestations with some psychiatric symptoms appearing late in the
course of illness, more recently it has been demonstrated that psychiatric
symptoms commonly occur at diagnosis and throughout progression of
the disease. Up to a third of cases of sporadic CJD may demonstrate emo-
tional abnormalities and 10% of patients with CJD are hospitalized psychi-
atrically [88]. In contrast to sporadic CJD, psychiatric and neuropsychiatric
symptoms are often the most prominent aspects in the clinical presentation
of variant CJD [87].
Psychiatric sequelae of CJD include depressed mood and apathy [89]. A
prodromal phase has been described characterized by fatigue, weight loss,
impaired sleep, poor judgment, and unusual behavior. Patients may also
display unusually intense emotional responses; anxiety; agitation; and psy-
chotic symptoms, such as delusions and hallucinations [87,88]. At times, pre-
sentations of primarily depression or psychosis in CJD have made it diﬃcult
to distinguish from primary psychiatric disorders and led to misdiagnosis or
delays in diagnosis of CJD [90]. Neuropsychologic testing revealed focal
cortical deﬁcits in sporadic CJD in contrast to more generalized deﬁcits in
variant CJD [91].
Based on criteria suggested by the World Health Organization, deﬁnite
diagnosis of sporadic CJD involves either neuropathologic examination or
detection of the pathogenic scrapie form of the prion protein in brain sam-
ples by Western blot (see Table 3) [92]. To receive a probable diagnosis of
sporadic CJD patients must have two of the following clinical signs: (1)
cerebellar or visual signs; (2) myoclonus, pyramidal, or extrapyramidal
signs; or (3) akinetic mutism. Additionally, patients must have detection
of the 14-3-3 protein in the CSF or an EEG consistent with CJD coupled
with disease duration leading to death in less than 2 years, or investigation
not suggestive of an alternative diagnosis [83].
Besides use of clinical symptoms, diagnosis is also based on EEG, imag-
ing, and laboratory ﬁndings. Typical EEG ﬁndings in sporadic CJD include
periodic sharp wave complexes that have either biphasic or triphasic waves
or complexes with mixed spikes. In contrast, EEGs of patients with variant
CJD do not show periodic sharp wave complexes, but rather have nonspe-
ciﬁc slow wave activity [92]. MRI has been used extensively in diagnosis of
CJD. There are abnormalities in the basal ganglia and cortex and a unique
pattern of ‘‘cortical ribboning.’’ Variant CJD patients prominently display
a pattern of hyperintensity in the pulvinar thalami [83]. In applying labora-
tory testing for diagnosis, the detection of the 14-3-3 protein in the CSF of
patients with CJD is both quite sensitive and speciﬁc for the sporadic form
of the disease, although less so in the variant form [93]. A clear diagnosis of
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scrapie form of the prion protein [94].
Presently, there is no eﬀective treatment for CJD. A focus of potential
treatment strategies has been to block accumulation of the pathogenic scra-
pie form of the prion protein. The antimalarial agent quinacrine and the
phenothiazines have been tried with little success in animal and human
trials. Another recent approach has been development of vaccines to
develop antibodies against the prion protein, although the results of these
eﬀorts have been unclear thus far [84].Lyme disease encephalopathy (neuroborreliosis)
Lyme disease, caused by infection with the tic-borne spirochete Borrelia
burgdorferi, has been associated with a variety of manifestations, including
neuropsychiatric symptoms, or neuroborreliosis. Over the past 20 years,
there has been signiﬁcant controversy regarding the neuropsychiatric man-
ifestations of neuroborreliosis, which is related to the fact that symptoms
are often nonspeciﬁc (fatigue, sleep disturbance, generalized cognitive com-
plaints, low mood, all symptoms of depression); serologic testing may show
evidence of prior systemic exposure but cannot determine whether or not
there is acute disease; and symptoms may persist after acute antibiotic
treatment [95,96]. Further, the mechanisms of the neuropsychiatric manifes-
tations are not precisely known, being possibly related to direct CNS infec-
tion with the organism, to acute or long-term inﬂammatory processes
associated with systemic or CNS infection, or some combination of these.
Over the past 10 years, there is accumulating evidence that B burgdorferi
may adhere to endothelial cells at the blood-brain barrier, causing vasculitis
and increased blood-brain barrier permeability, leading to CNS invasion
and adherence to astrocytes, resulting in a deleterious inﬂammatory cascade
[97]. The resulting changes in CNS, including abnormalities in subcortical
frontotemporal white matter and basal ganglia functioning [98], may explain
the more chronic neuropsychiatric symptoms and why antibiotic treatment
of these chronic symptoms is generally not associated with improvement in
symptoms or CNS pathology [95–97].
In the early stages of acute Lyme disease, patients may present with men-
ingitis, cranial neuritis, and radiculoneuritis [96]. In many such cases, there
are positive CSF ﬁndings for B burgdorferi antibody (IgG) and elevated
protein. Cognitive deﬁcits associated with acute and chronic Lyme disease
include poor attention and concentration, impaired verbal memory, word-
ﬁnding diﬃculties, psychomotor slowing, and executive dysfunction, all
consistent with subcortical-frontal pathology. Interestingly, study of Lyme
disease patients with chronic cognitive complaints indicates that those
with abnormal CSF are more likely than those with normal CSF to have
actual neuropsychologic deﬁcits. In those with normal CSF, cognitive com-
plaints are more likely to be associated with concurrent depression [96].
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borelliosis may present with depression, mood lability, irritability, anxiety,
panic attacks, and more rarely, mania, psychosis, and obsessive-compulsive
symptoms. There are no large-scale well-controlled studies, however, to sug-
gest that patients with Lyme disease have a greater burden of such symp-
toms than the general population.
In terms of diagnosis, neurologic examination is usually nonfocal. Bedside
cognitive evaluation may be normal to mildly abnormal and more extensive
neuropsychologic testing may be necessary to detect the characteristic deﬁcits
mentioned previously. Lumbar puncture and CSF evaluation may reveal
B burgdorferi DNA detected by polymerase chain reaction and antibody to
B burgdorferi, nonspeciﬁc protein elevation, and CSF pleocytosis. The CSF
may be normal, however, in a substantial number of cases. Standard struc-
tural neuroimaging including brain CT orMRI with contrast is often normal
in both the acute and chronic stages of the disease. Quantitative single-
photon emission CT of the brain has proved more useful in detecting abnor-
mality, including hypoperfusion in frontal subcortical and cortical regions
[98]. This method has been used to follow response to antibiotic treatment.
In terms of treatment, intravenous infusion of ceftriaxone, 2 g daily for
30 days, followed by oral doxycycline, 200 mg daily for 60 days, has been
tested [95]. Other regimens in the literature include intravenous penicillin
or a derivative, amoxicillin. Although such regimens have been helpful for
neuroborreliosis with clear evidence of abnormal CSF in acute and chronic
disease, results have been less favorable in patients with chronic symptoms
and minimal objective evidence of CNS infection.
In terms of psychotropic medication treatment for psychiatric comorbid-
ities, the literature is quite sparse. Treatment is generally symptomatic,
addressing symptoms of depression (ie, with selective serotonin reuptake
inhibitors); fatigue and cognitive complaints (ie, with psychostimulants or
modaﬁnil); and mood lability and psychosis (ie, with atypical neuroleptics).
Given the subcortical involvement of the spirochete, however, it is impor-
tant to assess for extrapyramidal side eﬀects with the use of atypical neuro-
leptic medications.Summary
This article reviews the clinical characteristics and treatment of a number
of infectious diseases that have prominent neuropsychiatric manifestations.
Although each entity has unique characteristics, there are several common
themes that are important for clinicians to remember. First, maintain an in-
dex of suspicion, especially when patients present with new-onset psychiatric
symptoms without a history of prior psychiatric illness. It is commonplace
to overlook medical or neurologic illness in assuming a primary psychiatric
diagnosis. Second, clinicians should take a thorough risk assessment history,
915NEUROPSYCHIATRIC ASPECTS OF INFECTIOUS DISEASESincluding sexual risk behavior, blood-borne exposures, and travel history.
Third, although a thorough diagnostic work-up is necessary to identify
and treat the infection, equally important is a full characterization of the
psychiatric and cognitive symptoms associated with the infection so as to
track the eﬀects of treatment. This becomes particularly important when
patients have residual deﬁcits that aﬀect everyday function and ability to
work. Finally, it is important to remember that concurrent treatment with
antibiotics and psychotropic medications is often necessary. For most of
these infectious diseases, formal study of psychotropic medications is
relatively infrequent, so clinicians should be vigilant regarding potential
drug-drug and drug-disease interactions. Fortunately, when these principles
are followed, neuropsychiatric manifestations of infectious diseases can be
successfully identiﬁed and treated.References
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Heart and lung diseases are associated with a high prevalence of psychi-
atric disorders. These psychiatric disorders may occur as premorbid risk
factors, as comorbidities, and as complications of the heart and lung condi-
tions. In intensive and critical care settings, appropriate diagnosis and man-
agement of psychiatric problems can alter the medical outcome. The most
common issues are anxiety, depression, and agitation and delirium. This
article addresses diﬀerential diagnosis and management, with an emphasis
on the intensive care and critical care settings.
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922 SHAPIRO et alIn general, psychiatric disorders are diﬀerentiated from normal mental
functioning by the presence of signiﬁcant subjective distress or impairment
in adaptive functioning caused by the mental state itself [1]. This criterion
helps to deﬁne the set of ‘‘adjustment disorders,’’ in which clinically signif-
icant emotional distress occurs following a stressful circumstance, and
persists for more than a few days, but does not meet criteria for another psy-
chiatric disorder. Adjustment disorders with depressed mood or anxious
mood are common in medically ill patients. They often remit spontaneously
or in response to brief supportive interventions, such as clariﬁcation of the
patient’s concerns, education about his or her condition, or provision of
social support.
More severe depression problems occur in major depressive disorder and
bipolar aﬀective disorder. The cardinal feature of major depressive disorder
(Box 1) is the presence of a major depressive episode. A major depressive
episode is deﬁned by the presence of at least ﬁve of the following: persistent
depressed mood most of the day; persistent loss of interest in usually enjoy-
able activities; sleep disturbance; appetite disturbance; diﬃculty thinking,
concentrating, or making decisions; fatigue or loss of energy; inability to
experience pleasure; psychomotor retardation or agitation; and thoughts
of death or suicidal ideation. Either depressed mood or persistent loss of
interest must be included among the features of the episode. The symptoms
must persist for at least 2 weeks. Major depressive disorder is deﬁned by the
occurrence of a major depressive episode that cannot be better ascribed to
another mental disorder or to another medical condition, and is not sub-
stance-induced, and in which the symptoms cause signiﬁcant subjective dis-
tress or impairment in functioning. In bipolar aﬀective disorder, signiﬁcant
depressive symptoms may occur, including major depressive episodes, but
the patient also has episodes of abnormal, clinically signiﬁcant mood eleva-
tion or irritability (mania or hypomania). In dysthymic disorder, mood
symptoms that are below the threshold of a major depressive episode are
persistent chronically over at least 2 years. Mood disorders are designated
‘‘secondary’’ when they are attributed to a medical condition, substance,
or substance withdrawal. Other mood disorders may occur that do not
meet criteria for any of these speciﬁc diagnoses because they are below
the severity or duration thresholds or have atypical features.
Panic disorder and generalized anxiety disorder are the most common
anxiety disorders associated with cardiac and pulmonary diseases. The
sine qua non of panic disorder (Box 2) is the occurrence of recurring panic
attacks, which are episodes of acute fear or anxiety with abrupt onset and
numerous associated physical symptoms, such as shortness of breath, chok-
ing sensations, chest discomfort, palpitations, dizziness, lightheadedness,
nausea, paresthesias, chills, hot ﬂushes, and sweating, and fears of death,
loss of control, or of going crazy; these symptoms are not caused by another
medical condition or induced by a substance. They may also be accompa-
nied by a sense of detachment from oneself (ie, depersonalization) or
Box 1. Diagnostic criteria for major depressive disorder
A. Five (ormore) of the following symptoms have been present during the
same 2-week period and represent a change from previous functioning;
at least one of the symptoms is either (1) depressedmood or (2) loss of
interest or pleasure. Note: Do not include symptoms that are clearly
caused by a generalmedical condition, or mood-incongruent delusions
or hallucinations.
(1) Depressed mood most of the day, nearly every day, as indicated
by either subjective report (eg, feels sad or empty) or observation
made by others (eg, appears tearful). Note: in children and
adolescents, can be irritable mood.
(2) Markedly diminished interest or pleasure in all, or almost all,
activities most of the day, nearly every day (as indicated by either
subjective account or observation made by others).
(3) Significant weight loss when not dieting or weight gain (eg,
a change of more than 5% of body weight in a month), or decrease
or increase in appetite nearly every day. Note: In children, consider
failure to make expected weight gains.
(4) Insomnia or hypersomnia nearly every day.
(5) Psychomotor agitation or retardation nearly every day (observable
by others, not merely subjective feelings of restlessness or being
slowed down)
(6) Fatigue or loss of energy nearly every day
(7) Feelings of worthlessness or excessive or inappropriate guilt
(which may be delusional) nearly every day
(not merely self-reproach or guilt about being sick)
(8) Diminished ability to think or concentrate, or indecisiveness, nearly
every day (either by subjective account or as observed by others)
(9) Recurrent thoughts of death (not just fear of dying), recurrent
suicidal ideation without a specific plan, or a suicide attempt or
a specific plan for committing suicide
B. The symptoms do not meet criteria for a mixed episode.
C. The symptoms cause clinically significant distress or impairment in
social, occupational, or other important areas of functioning.
D. The symptoms are not caused by the direct physiologic effects of
a substance (eg, a drug of abuse, a medication) or a general
medical condition (eg, hypothyroidism).
E. The symptoms are not better accounted for by bereavement (ie, after
the loss of a loved one), the symptoms persist for longer than 2
months or are characterized by marked functional impairment,
morbid preoccupation with worthlessness, suicidal ideation,
psychotic symptoms, or psychomotor retardation.
Data from American Psychiatric Association. Diagnostic and statistical manual of mental
disorders, 4th edition, revised. Washington: American Psychiatric Association; 2000.
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Box 2. Diagnostic criteria for panic disorder
A. Both (1) and (2):
(1) Recurrent unexpected panic attacks
(2) At least one of the attacks has been followed by 1 month
(or more) of one (or more) of the following:
(a) Persistent concern about having additional attacks
(b) Worry about the implications of the attack or its
consequences (eg, losing control, having a heart attack,
‘‘going crazy’’)
(c) A significant change in behavior related to the attacks
B. Presence or absence of agoraphobia.
C. The panic attacks are not caused by the direct physiologic
effects of a substance (eg, a drug of abuse, a medication) or
a general medical condition (eg, hyperthyroidism).
D. The panic attacks are not better accounted for by another
mental disorder, such as social phobia (eg, occurring on
exposure to feared social situations); specific phobia (eg, on
exposure to a specific phobic situation); obsessive-
compulsive disorder (eg, on exposure to dirt in someone with
an obsession about contamination); posttraumatic stress
disorder (eg, in response to stimuli associated with a severe
stressor); or separation anxiety disorder (eg, in response to
being away from home or close relatives).
Data from American Psychiatric Association. Diagnostic and statistical manual
of mental disorders, 4th edition, revised. Washington: American Psychiatric Asso-
ciation; 2000.
924 SHAPIRO et alfrom reality (ie, derealization). In generalized anxiety disorder, the primary
feature is persistent nervousness, worry, or fearfulness, associated with
fatigue, irritability, restlessness, diﬃculty concentrating, muscle tension, or
sleep disturbance, which continues over a period of months, cannot be
controlled, causes distress or impairs function, and is neither caused by
a medical condition nor substance-related (Box 3). Secondary forms of these
disorders may be caused by medical conditions, as side eﬀects of substances
including medications, or as eﬀects of withdrawal from substances.Psychiatric disorders associated with chronic lung disease
Anxiety symptoms commonly accompany many pulmonary disorders [2].
These have been best studied in chronic conditions, such as asthma and
chronic obstructive pulmonary disease [3,4]. The anxiety experienced by
Box 3. Diagnostic criteria for generalized anxiety disorder
A. Excessive anxiety and worry (apprehensive expectation),
occurring more days than not for at least 6 months, about
a number of events or activities (eg, work or school
performance).
B. The person finds it difficult to control the worry.
C. The anxiety and worry are associated with three (or more) of
the following six symptoms (with at least some symptoms
present for more days than not for the past 6 months). Note:
Only one item is required in children.
(1) Restlessness or feeling keyed up or on edge
(2) Being easily fatigued
(3) Difficulty concentrating or mind going blank
(4) Irritability
(5) Muscle tension
(6) Sleep disturbance (difficulty falling or staying asleep,
or restless unsatisfying sleep)
D. The focus of the anxiety and worry is not confined to features
of an axis I disorder (eg, the anxiety or worry is not about
having a panic attack [as in panic disorder], being
embarrassed in public [as in social phobia], being
contaminated [as in obsessive-compulsive disorder], being
away from home or close relatives [as in separation anxiety
disorder], gaining weight [as in anorexia nervosa], having
multiple physical complaints [as in somatization disorder], or
having a serious illness [as in hypochondriasis], and the
anxiety and worry do not occur exclusively during
posttraumatic stress disorder.
E. The anxiety, worry, or physical symptoms cause clinically
significant distress or impairment in social, occupational, or
other important areas of functioning.
F. The disturbance is not caused by the direct physiologic effects
of a substance (eg, a drug of abuse, a medication) or a general
medical condition (eg, hyperthyroidism) and does not occur
exclusively during a mood disorder, a psychotic disorder, or
a pervasive developmental disorder.
Data from American Psychiatric Association. Diagnostic and statistical manual
of mental disorders, 4th edition, revised. Washington: American Psychiatric Asso-
ciation; 2000.
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926 SHAPIRO et alaﬀected patients may be described as either generalized anxiety or panic.
Some patients with respiratory disease have a combination of both types
of anxiety. Patients with acute respiratory failure seem even more anxious
that those with stable chronic disease. Most of this increase seems to be
panic rather than generalized anxiety [5]. Given the description of a panic
attack, there may be some overlap between these symptoms and those of
acute respiratory failure. Many patients with acute respiratory failure expe-
rience shortness of breath, choking, and chest discomfort. There are others,
however, who are overwhelmed by these and the other classic symptoms of
panic including fear of dying, losing control, going crazy, depersonalization,
or derealization.
Various models have been oﬀered to explain this apparent connection
between pulmonary symptoms and the experience of panic (Box 4) [6].
One model involves the psychological theory that some patients are prone
to misinterpreting physical sensations within their bodies or ‘‘interoceptive
cues’’ that may be associated with dyspnea. These include hyperventilation,
chest tightness, tachycardia, and other physical symptoms. They may ‘‘cat-
astrophize’’ the signiﬁcance of these physical symptoms, leading them to
believe that the symptoms are much more dangerous than is actually the
case. This misinterpretation escalates their sense of anxiety. This anxiety
heightens their focus on and sensitivity to somatic sensations, likely leading
them to become even more preoccupied with their physical symptoms. These
are again misinterpreted, leading to even more anxiety. This positive feed-
back cycle continues, leading to a heightened sense of anxiety and even
more physical symptoms of panic [7]. Some patients with acute respiratory
failure are likely prone to this cycle. For them, the primary issue is fear and
the catastrophic misinterpretation of unexpected physical symptoms.
Other models for the connection between acute respiratory failure and
panic focus more directly on pulmonary pathophysiology. Various
researchers have demonstrated a connection between sodium lactate infu-
sion and the experience of panic symptoms [8,9]. They theorize that theBox 4. Contributing factors in anxiety associated
with lung disease
Catastrophizing cognitions
CO2 sensitivity
Medication side effects
a. Corticosteroids
b. Methylxanthines
c. b2-adrenergic agonists
d. Substance abuse (eg, cocaine)
e. Substance withdrawal (eg, alcohol)
927HEART AND LUNG DISEASEmetabolism of lactate to carbon dioxide is likely the key in producing panic
symptoms. Others have demonstrated a connection between inhalation of
exogenous carbon dioxide and the experience of panic symptoms [10,11].
The exact connection between the elevation of carbon dioxide and the devel-
opment of panic symptoms remains unclear, although some patients are
likely more vulnerable to experience anxiety in this setting than others
[12]. One theory is that in vulnerable individuals the medullary chemorecep-
tors are abnormally sensitive to even small increases in carbon dioxide level
in the bloodstream. This leads to activation of the locus coeruleus, which
leads in turn to autonomic activation [13]. This leads to increased plasma
norepinephrine, increased diastolic blood pressure, and an exaggerated ven-
tilatory response, which leads to the symptomatic experience of a panic
attack [14]. Patients with acute respiratory failure with resultant changes
in blood carbon dioxide levels are vulnerable to experiencing panic symp-
toms according to this model.
There are likely other factors to consider in patients with acute respira-
tory failure who are experiencing panic symptoms. Many medications that
are used to treat pulmonary disease produce anxiety as a side eﬀect.
Corticosteroids are used to treat numerous acute and chronic pulmonary
conditions. Their use may contribute to a variety of psychiatric symptoms
including anxiety. These side eﬀects are dose-dependent. Some patients
experience a spectrum of psychiatric symptoms, with irritability and insom-
nia at low doses. This may progress to anxiety at moderate doses and psy-
chosis at large doses [15]. Other pulmonary medications are also associated
with anxiety. These include b2-adrenergic agonists and methylxanthines.
b2-Adrenergic agonists frequently cause restlessness, apprehension, anxiety,
and tremor [16]. Again, there is a dose and time relationship. Inhaled med-
ications tend to have less of an eﬀect than systemic ones. Methylxanthines
are associated with anxiety, fear, and panic [16]. Blood levels may be useful
in diagnosing theophylline toxicity. Recreational drug use may also contrib-
ute to anxiety experienced by patients with acute respiratory failure during
medical hospitalizations. Patients who are acutely intoxicated on stimulants,
such as cocaine or amphetamines, often seem very anxious [17]. Others who
are withdrawing from sedatives including alcohol, benzodiazepines, barbitu-
rates, or opioids may also seem very anxious [18,19].
Treatment of anxiety in this setting should focus on identiﬁcation of these
possible secondary causes of anxiety. Therapeutic medications, such as ste-
roids, b2-adrenergic agonists, and methylxanthines, that are contributing to
anxiety may be tapered or switched to alternative therapies. Treatment of
withdrawal from sedative drugs is also essential, whether these are drugs
of abuse or those prescribed for the management of a pre-existing anxiety
disorder. There may be some concern about the use of benzodiazepines in
the setting of acute respiratory failure. Some benzodiazepines have been
shown to decrease patient performance in some pulmonary function tests
including forced expiratory volume in 1 second. They also have been shown
928 SHAPIRO et alto increase PCO2 and decrease responsiveness to carbon dioxide challenge
[20]. These may be of signiﬁcant concern in patients with acute respiratory
failure. Some patients with acute respiratory failure seem to beneﬁt from
benzodiazepines; however, the literature is mixed regarding eﬃcacy
[21,22]. Small doses of short-acting benzodiazepines, such as alprazolam
and lorazepam, may be suited to a safe trial in patients with respiratory dis-
ease. If the patient is in a closely monitored setting or already requires
mechanical ventilation, there may be less need for concern. Antidepressant
medications including tricyclics and serotonin reuptake inhibitors seem safe
and eﬀective in treating anxiety in patients with respiratory failure [6]. It is
generally accepted, however, that these take weeks to achieve a full antianx-
iety eﬀect; their use in acute respiratory failure is often limited. Buspirone
seems safe and may also be eﬀective in relieving anxiety and obsessive symp-
toms in patients with respiratory failure, but also may take weeks to reach
its full eﬀect [23]. Other medications may be used in the acute setting, but
these are generally poorly studied regarding safety and eﬃcacy in this
patient population. There may be a role for antipsychotics, antihistamines,
gabapentin, or pregabalin in select patients.
Nonpharmacologic interventions may also be eﬀective in relieving anxi-
ety. These include controlled breathing exercises, progressive relaxation,
guided imagery, hypnosis, biofeedback, and participation in pulmonary
rehabilitation [6]. Cognitive behavioral therapy techniques may also be
eﬀective. This approach targets anxiety that is caused by the misinterpreta-
tion of ‘‘interoceptive cues,’’ which leads to the escalating cycle of anxiety
and panic. Patients learn to assign new meanings to unexpected and disturb-
ing bodily perceptions. This leads them to feel more conﬁdent and in control
of their breathing and, consequently, less anxious [24].
Psychiatric factors may play a role in patients who seem diﬃcult to wean
from mechanical ventilation. These include delirium, anxiety, and depres-
sion. Delirium is characterized by global cerebral dysfunction caused by
a patient’s medical condition. This manifests as a temporary disturbance
in consciousness and cognitive ability (Box 5) [1]. This may make the patient
unaware of his or her medical condition or unable to understand or coordi-
nate full participation in the weaning process from mechanical ventilation.
Delirium may be related to metabolic disarray as a direct physiologic con-
sequence of pulmonary dysfunction (hypoxia, hypercapnia) or a number
of other comorbid medical conditions common in critically ill patients. Iso-
lated hypoxia has been shown to have a signiﬁcant impact on cognitive func-
tion, including loss of judgment, inattention, and motor incoordination with
even a slight decrease in oxygenation, and progressing to memory impair-
ment with moderate decrease, and loss of consciousness with signiﬁcant
decrease in oxygenation. Hypercapnia rarely presents in isolation, but is
usually accompanied by hypoxia and acidosis. Slight increases in PCO2 cause
inattention, forgetfulness, drowsiness, and psychomotor slowing. This may
progress to loss of consciousness at signiﬁcantly increased levels [25]. Other
Box 5. Diagnostic criteria for delirium
A. Disturbance of consciousness (ie, reduced clarity of
awareness of the environment) with reduced ability to focus,
sustain, or shift attention.
B. A change in cognition (eg, memory deficit, disorientation,
language disturbance) or the development of a perceptual
disturbance that is not better accounted for by a pre-existing,
established, or evolving dementia.
C. The disturbance develops over a short period of time (usually
hours to days) and tends to fluctuate during the course of the
day.
D. There is evidence from the history, physical examination,
or laboratory findings that the disturbance is caused by the
direct physiologic consequences of a general medical
condition; or, symptoms developed during substance
intoxication or were etiologically related to medication use;
or, developed during or shortly after a withdrawal syndrome.
(More than one etiology may be present, and in some
instances no specific etiology, or a cause other than those
listed above, may be identified.)
Data from American Psychiatric Association. Diagnostic and statistical manual
of mental disorders, 4th edition, revised. Washington: American Psychiatric Asso-
ciation; 2000.
929HEART AND LUNG DISEASEcontributors to delirium must also be considered, and may include other
metabolic abnormalities, infections, toxic eﬀects of medications or recrea-
tional drugs, and withdrawal from medications or recreational drugs.
Anxiety sometimes interferes with the ability to wean from mechanical
ventilation. This anxiety may be directly related to pulmonary pathophysi-
ology. It may be related to side eﬀects of prescribed medications or the rapid
tapering of intravenous sedatives. Patients may become physiologically de-
pendent on intravenous sedatives that are used to treat agitation or discom-
fort associated with mechanical ventilation. If these medications are stopped
or tapered too rapidly for a planned weaning trial, signiﬁcant withdrawal
symptoms may occur, including signiﬁcant anxiety [26].
There are a range of psychologic reactions to mechanical ventilation that
may also contribute to a patient’s emotional state. One should consider the
practical limitations on one’s life and experience during mechanical ventila-
tion. Patients may not be able to communicate fully because of tracheal
intubation, sedatives, or neuromuscular blockade. It has been reported
that the inability to talk is the single greatest contributor to anxiety in me-
chanically ventilated patients [27]. Associated sleep disruption can intensify
930 SHAPIRO et alfeelings of anxiety. Patients may also experience frightening nightmares.
Some report never being able truly to rest. This complaint is supported by
studies that have found that the average amount of sleep in ICU patients
is as low as 1.8 hours per 24-hour period and that, while sleeping, awaken-
ings from sleep typically occur more than six times per hour, resulting in ab-
sence of deep, restorative sleep [28,29]. Pain may be another factor that can
have substantial psychologic impact, leading to feelings of anxiety or depres-
sion. Loss of independence is a common worry because many patients must
depend on others for suctioning, moving, or toileting [30]. Sensory alter-
ation may also be a concern, and this may involve deprivation or overstim-
ulation. Staﬀ or visitors may withdraw from the patient, perhaps because
the patient cannot communicate or does not seem alert. Others withdraw
because of fear of critical illness or end-of-life issues. Many patients experi-
ence sensory overload because of the activity, noise, and light present in the
ICU throughout day and night [31].
These factors sometimes limit the patient’s fully understanding what
mechanical ventilation means to them. For some, it means the conscious
and continuous fear of death or disability. For others, it means the loss of
independence. They may have the sense that they are entirely dependent
on a machine or other people for the most basic bodily functions, and
they sense that they have no control. They may not know or trust all of
the people involved in their care. Nursing staﬀ may change several times
each day. The struggle with independence is a common theme for patients
both during mechanical ventilation and at the time of attempted wean.
Patients who only become anxious when weaning is attempted may fear
change or have a lack of conﬁdence in the weaning process or themselves.
Some fear that they will not be capable of spontaneous breathing after
a prolonged period of reliance on the mechanical ventilator. Other emo-
tions commonly experienced are anger, frustration, discouragement, and
loneliness [32]. Intervening with these psychologic reactions before attemp-
ted weaning may prove eﬀective. Taking time to talk can mitigate patients’
anxiety about their limited communication. Allowing the patient to write
or use an alphabet or picture board may be helpful. Allowing patients
to make choices when possible and keeping them informed of planned pro-
cedures and test results may give them more of a sense of control or inde-
pendence. Continuity of nursing and other care with frequent visits may
reduce their sense of isolation or fear of strangers. Frequent orientation
and visits with friends and family may address sensory alteration [31].
Many patients have feelings of sadness, but one should also consider the
diagnosis of depression in the patient who is diﬃcult to wean. Prospective
studies of patient’s mood states before attempted weaning have demon-
strated increased symptoms of depression compared with controls, cardiac
surgery patients, and cancer patients [33]. The connection between mood
symptoms and diﬃculty weaning from mechanical ventilation, however,
remains unclear.
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tilation, one should evaluate for the presence of delirium, anxiety, and
depression. The distinction between these diagnoses can sometimes be chal-
lenging and more than one may coexist in the same patient. Delirium may
resemble anxiety, especially when the patient is agitated, or depression,
especially when the patient is hypoactive. Cognitive testing should be part
of the evaluation process. New-onset or ﬂuctuating cognitive deﬁcits or
a ﬂuctuating level of arousal or responsiveness are indicative of delirium.
Interview should be attempted when sedation has been minimized or discon-
tinued. Feelings of sadness, worthlessness, hopelessness, anhedonia, and
wish for death may all support a diagnosis of depression. Reversal of any
identiﬁed causes of delirium is critical so that the presence of anxiety or
depression can be clariﬁed. Once delirium is resolved, patients are much
better able actively to participate in the weaning process.
Antipsychotic medication may be eﬀective in managing delirium, espe-
cially when the patient is agitated or has psychotic symptoms [34]. Anxiety
may be treated with benzodiazepines, such as lorazepam, with due attention
to the impact on respiratory status, as previously discussed. If some aspect
of anxiety is caused by the rapid taper of intravenous sedatives, these may be
replaced with longer-acting oral agents of the same class that can subse-
quently be tapered at a more gradual pace. Antipsychotic medication may
also be eﬀective in the management of anxiety and may present less concern
for impact on respiratory status. These too can be added as intravenous sed-
atives are tapered. The antipsychotic medication can then be tapered over
subsequent days as tolerated. Antidepressant medication may play a role
in the treatment of patients with severe depression [35], but their beneﬁts
may be limited because of the prolonged length of time necessary for
them to reach full eﬀect. Because of this, stimulants may be preferred for
the treatment of depression in the acute setting. There have been case
reports of patients who seemed depressed, had diﬃculty weaning from
mechanical ventilation, and were successfully treated with methylphenidate
in doses of 5 to 30 mg/day [36,37]. Nonpharmacologic treatments may also
be eﬀective in relieving anxiety and depression in patients on mechanical
ventilation, thereby assisting with weaning. These include hypnosis, guided
imagery, biofeedback, and music therapy [38].Psychiatric disorders associated with heart disease
Certain psychologic factors and psychiatric disorders are associated with
increased risk for the development of heart disease. A high level of anxiety
symptoms, especially phobic anxiety, has been linked particularly to ele-
vated risk of sudden cardiac death, but not nonfatal coronary disease, in
large-scale prospective epidemiologic studies [39,40]. High levels of anger
and hostility have been linked to increased atherosclerosis, earlier age of
onset of clinical coronary disease symptoms, and higher risk of major
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but the strength of the association has been questioned in the face of
some negative studies [41–46]. A robust association of previous depressive
symptoms and major depressive disorder with incident coronary artery
disease (nonfatal myocardial infarction [MI], acute coronary syndromes,
cardiac death) has been demonstrated in numerous epidemiologic studies
in nonclinical samples; the increase in risk associated with depression has
been estimated as approximately 70% [47–49]. ‘‘Negative aﬀect states’’
related to depression, including ‘‘vital exhaustion’’ and ‘‘type D personality’’
(negative aﬀectivity combined with social inhibition) also demonstrate
increased risk for coronary artery disease [50–52]. An in-depth review of
psychologic factors as risk factors for heart disease is beyond the scope of
this article but is available elsewhere [53,54].
The most common psychiatric problems in patients hospitalized for an
acute coronary event are anxiety and depression. Patients may not bring
these symptoms to the attention of their physicians on their own initiative,
and several studies have shown that emotional disturbances are underrecog-
nized in usual cardiac care [55,56]. Early recognition oﬀers opportunity to
reduce psychiatric morbidity and may have beneﬁts for cardiac outcomes.
Although such symptoms as fatigue, low energy, and sleep and appetite dis-
turbance may discriminate poorly between acute coronary patients with and
without clinically meaningful psychiatric problems, other symptoms, such as
feeling persistently sad, loss of self-esteem, and feeling unable to experience
interest or pleasure about ordinarily pleasurable matters (ie, anhedonia), are
eﬀective discriminators of depression [57]. It is probably worthwhile for cli-
nicians caring for patients in acute cardiac care settings to inquire speciﬁ-
cally about such symptoms, because they suggest that intervention might
be indicated.
Two studies have demonstrated that anxiety in the period immediately af-
ter an acute coronary event is associated with adverse cardiac outcomes.
Moser and Dracup [58] measured anxiety symptoms with a self-report ques-
tionnaire in the ﬁrst 48 hours of hospitalization in 86 post-MI patients. The
rate of in-hospital complications including reinfarction, new-onset ischemia,
ventricular ﬁbrillation, sustained ventricular tachycardia, and in-hospital
death was 19.6% in patients with anxiety symptoms above the median, com-
pared with 6% for patients with lower levels of anxiety (P!.01). Adjusting
for other prognostic risk factors, these investigators estimated that anxiety
was associated with a 4.9-fold increased relative risk of cardiac complica-
tions in the post-MI period. Likewise, Frasure-Smith and colleagues [59]
found that a high self-reported anxiety symptom level in 222 post-MI
patients was associated with a greater than twofold increased risk of recur-
rent acute coronary syndromes, even after adjusting for other prognostic
factors. Recently, Frasure-Smith and Lesperance [60] extended this observa-
tion in a 2-year follow-up study of patients with stable coronary artery dis-
ease 2 months after MI. Of 804 subjects, over 5% met criteria for a diagnosis
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symptoms in the clinically signiﬁcant range. Major adverse cardiac events
in the follow-up period were signiﬁcantly associated with both generalized
anxiety disorder (odds ratio, 2.09; 95% conﬁdence interval [CI], 1.08–
4.05) and elevated anxiety symptoms (odds ratio, 1.67; 95% CI, 1.18–2.37).
There have been no large-scale trials directed primarily at treatment of
anxiety disorders or high levels of anxiety symptoms speciﬁcally in cardiac
patients, although some smaller-scale studies suggest that counseling or
relaxation training interventions may be beneﬁcial in reducing anxiety out-
comes [61–63]. Benzodiazepines (eg, lorazepam), serotonin reuptake inhibi-
tors, and buspirone are generally well-tolerated for pharmacotherapy of
anxiety disorders and have little to no cardiovascular eﬀect, other than a ten-
dency to lower heart rate by one to two beats per minute. Drug-drug inter-
actions between serotonin reuptake inhibitors that inhibit the cytochrome
P-450 2D6 system and b-adrenergic blockers may exacerbate the negative
chronotropic eﬀects of b-blockers [64].
Depression seen in patients after acute coronary events may be a transient
adjustment response, but may also be a manifestation of previous history of
depressive disorder, continuation of a ﬁrst episode of depression with onset
before the coronary event, or onset of major depression after the coronary
event. Major depressive episodes are common, with point-prevalence of
about 15%, compared with a lifetime prevalence of 6% to 10% in the gen-
eral population in the United States [49,65,66]. Moreover, only a minority of
major depressive episodes seen in the early aftermath of an acute coronary
syndrome quickly remit without intervention [55–57].
Depression after an acute coronary syndrome is associated with a mark-
edly increased risk of recurrent cardiac events and cardiac death, even after
adjusting for other prognostic factors [49,65,67]. Frasure-Smith and col-
leagues [56] demonstrated a greater than threefold increased risk of death
over 6-month follow-up associated with major depression immediately after
MI. An elevated level of depression symptoms after acute coronary syn-
dromes predicts major adverse events and cardiac mortality up to 5 years
after the acute event, in a dose-dependent manner [68–70]. Depression has
a similarly negative prognostic impact for patients admitted to hospital
for congestive heart failure, whether or not of ischemic etiology [71,72].
Mechanisms mediating these eﬀects of depression and impairing survival in-
clude abnormalities in platelet function; autonomic derangements; increased
inﬂammatory activation; and impaired adherence to lifestyle modiﬁcation
(smoking cessation, adherence to medication, exercise, diet modiﬁcation)
(Box 6) [73–76]. Eﬀective treatment of depression after acute coronary syn-
dromes is an important goal.
In this regard, four large trials in recent years have examined treatment of
depression in coronary patients. Of these, the SADHART trial, a random-
ized, placebo-controlled, double-blind trial of sertraline treatment for major
depression following admission for acute coronary syndromes, enrolled
Box 6. Possible mechanisms linking depression and coronary
diseasea
A. Physiologic
1. Platelet activation
2. Sympathetic nervous system activation
3. Increased circulating inflammatory factors
B. Behavioral
1. Smoking
2. Reduced adherence to medication regimen
3. Reduced adherence to recommendations for exercise
and diet
a See text for references.
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began within 30 days of the index event [77,78]. In the remaining studies,
active treatment began several weeks to several months after a previous
coronary event. The SADHART trial showed that sertraline treatment for
depression immediately after an acute coronary event (dose range, 50–
200 mg/day) had no adverse eﬀect on heart rate, blood pressure, cardiac
conduction measures, and left ventricular function, and was not associated
with an increase in adverse events, compared with placebo treatment.
Sertraline was modestly eﬀective in treatment of depression, particularly
for patients with recurrent or more severe depression, or onset of depression
before the index cardiac event. These ﬁndings suggest that antidepressant
treatment with sertraline need not be withheld from patients even early in
the post–acute coronary syndrome period. There was no diﬀerence in eﬃ-
cacy or safety proﬁle for patients with left ventricular ejection fraction above
versus below 30%, suggesting safety in congestive heart failure and in acute
coronary syndromes.
The ENRICHD trial, a large randomized trial of a cognitive behavioral
psychotherapy intervention in acute post-MI patients with either major de-
pression or a history of major depression and current minor depression,
demonstrated that, compared with usual care, a relatively low-intensity
intervention (generally, 6–10 psychotherapy sessions over 6 months) was
associated with a statistically signiﬁcant although clinically modest eﬀect
on depression symptoms. The intervention had no eﬀect, however, on the
study’s principal outcome measure, survival free of recurrent MI or cardiac
death over 3.5-year (mean) follow-up [79]. Complicating the analysis of the
ENRICHD study, some patients with severe depression received sertraline
or other antidepressants. Patients who received sertraline had a 42% lower
rate of death than patients who did not receive antidepressant therapy, but
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of this ﬁnding is uncertain.
In the CREATE trial, 284 patients with stable coronary artery disease
and major depression were doubly randomized to receive either interper-
sonal psychotherapy or clinical management visits without psychotherapy,
and to receive the serotonin reuptake inhibitor citalopram or placebo. Cit-
alopram treatment was superior to placebo treatment, whereas interpersonal
psychotherapy showed no greater eﬃcacy than clinical management visits in
reducing depression symptoms [80]. Citalopram was not associated with
a higher rate of adverse events than placebo.
Finally, a European study of post-MI depression intervention (MIND-
IT) found signiﬁcant diﬀerences in most depression outcome measures for
therapy with the antidepressant mirtazepine compared with placebo [81].
Mirtazepine’s safety proﬁle was favorable. Another interesting aspect of
this study was the ﬁnding that persistence of depression, in comparison
with good treatment response, was associated with worse cardiac outcomes
at 18-month follow-up: treatment nonresponders had a recurrent event rate
(cardiac-related hospitalization or cardiac death) of 25.6%, versus 7.4% for
responders. By intention-to-treat analysis, however, a cardiac beneﬁt was
not signiﬁcantly associated with antidepressant treatment [82]. A similar
result was noted in the ENRICHD trial [83].
These results leave the ﬁeld in an unsettled state: treatment of depression
after an acute coronary event seems to be at least modestly eﬀective with
respect to depression outcome, and recovery from depression seems to be
associated with favorable cardiac outcome, yet it remains to be demon-
strated that treatment of depression has a favorable eﬀect on cardiac out-
come. Still, for the patient in an acute treatment setting, the available
data suggest that treatment of depression with either cognitive behavior
therapy, citalopram, or sertraline can be undertaken with a reasonable
expectation of safety and with the goal of improvement in mood.Post–coronary artery bypass graft depression
Depressive disorders and elevated depression symptoms are common after
coronary artery bypass graft (CABG) surgery, with prevalence of about 15%
for depressive disorder at 1 to 2 weeks after surgery, and a substantially
higher rate of elevated depressive symptoms [84,85]. These depressive syn-
dromes are associated with increased morbidity and mortality. Major depres-
sion at 1 week after CABG surgery was associated with doubled risk of
recurrent cardiac events in a 12-month follow-up study of 302 consecutive
patients. Depression was as strong a predictor of adverse outcome as low
ejection fraction, diabetes, and priorMI [84]. Development of new depression
symptoms after surgery, failure to achieve remission of depression symptoms
over 6 months after surgery, and severe symptoms were all associated with
more mortality in a 5-year follow-up study of over 800 patients [85].
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speciﬁcally in post-CABG patients. An observational study [86] found
that patients undergoing CABG while on SSRI antidepressant therapy actu-
ally had worse prognosis than patients not taking antidepressants, but
because treatment assignment was not randomized it cannot be determined
whether this eﬀect was caused by more severe depression or medical condi-
tions in the treated patients, an adverse eﬀect of the treatment, or another
confounding factor.Post–cardiac surgery delirium and neuropsychologic impairment
Delirium is an acute condition characterized by a waxing and waning dis-
turbance in level of consciousness, reduced awareness of the environment,
inability to sustain and focus attention, and impaired cognition, sometimes
associated with disorientation, hallucinations, or delusions. Patients may be
agitated or hypoactive. By deﬁnition, delirium is a direct physiologic con-
sequence of an underlying medical problem, intoxication, or withdrawal
(see Box 5) [1]. Delirium occurs in 10% to 50% of cardiac surgery patients,
and may be unrecognized, especially in those patients who are not overtly
agitated (so-called ‘‘hypoactive’’ delirium) [87,88]. Delirium after cardiac
surgery is associated with risk of self-harm (eg, because of self-extubation,
inappropriate removal of lines, and falls) and with substantially longer
length of stay in the ICU and heightened mortality [88–93]. Its prevention
and treatment is important for improved outcomes.
Kornfeld and coworkers [94], pioneers in the description of delirium after
cardiac surgery, recognized two syndromes, one characterized by confusion
immediately on regaining consciousness, and one developing after a so-
called ‘‘lucid interval.’’ Kornfeld identiﬁed the combination of long cardio-
pulmonary bypass time along with postoperative sleep loss, the combination
of sensory overload and sensory monotony, and the absence of clear-cut day
and night periods as contributing factors for delirium arising in the ICU
after a lucid interval, and recognized that human contact, reassurance,
quiet, an opportunity to sleep, and transfer out of the ICU were helpful
in many cases. In both forms of delirium, however, Kornfeld recognized
the ‘‘organic’’ etiology of the disturbance of consciousness. The unfortunate
term ‘‘ICU psychosis’’ is a misnomer that may have the unintended eﬀect of
misleading care providers to attribute delirium solely to the ICU environ-
ment, while neglecting the role of toxic, metabolic, infectious, and cerebro-
vascular etiologic factors.
In contemporary practice, risk factors for delirium in cardiac surgery pa-
tients include older age; prior cerebrovascular disease or cognitive impair-
ment; alcohol abuse or dependence; azotemia; hyponatremia; infection;
and prolonged sedation with narcotics, benzodiazepines, or propofol.
Depression, peripheral vascular disease, and atrial ﬁbrillation are also iden-
tiﬁed as risk factors in some studies [88,95–98]. In a study of 1267 CABG
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period had a signiﬁcantly greater risk for postoperative delirium [92]. An-
other large (N ¼ 8139) Scandinavian study of CABG and valve surgery pa-
tients, focusing speciﬁcally on the development of psychotic symptoms
(hallucinations, delusions), identiﬁed a similar list of independent risk fac-
tors including older age; preoperative renal failure, dyspnea, heart failure,
and left ventricular hypertrophy; perioperative hypothermia; and postoper-
ative hypoxemia, low hematocrit, renal failure, hypernatremia, infection,
and stroke. ‘‘Oﬀ-pump’’ surgery was not associated with a lower incidence
of delirium [93].
In addition to correction of underlying causes of delirium, treatment of
postcardiac surgery delirium often requires use of antipsychotic medication
to reduce psychotic symptoms and agitation [64]. Although rigorous clin-
ical trials are lacking, widespread clinical practice embraces the oﬀ-label
use of a variety of antipsychotic agents including haloperidol, olanzapine
(which can be given as an orally disintegrating tablet), and quetiapine,
despite the acknowledged metabolic, infectious, and cardiovascular risks
of this class of medications. All of these agents have potential to provoke
torsade de pointes, although the incidence of this complication is quite
low. Parameters to be monitored before and during antipsychotic
treatment of delirium should include blood pressure, QTc interval, and
potassium and magnesium levels. The prophylactic eﬀect of another anti-
psychotic medication, risperidone, was tested in a randomized, double-
blinded, placebo-controlled study. A total of 126 patients undergoing
cardiac surgery with cardiopulmonary bypass were randomized to receive
either risperidone, 1 mg, or placebo on regaining consciousness after sur-
gery. The incidence of delirium was 11.1% in risperidone-treated patients
versus 31.7% in placebo-treated patients (P ¼ .009; relative risk ¼ 0.35;
95% CI, 0.16–0.77) [99]. Aripiprazole, a drug with less propensity for
QT prolongation and metabolic side eﬀects, may be a reasonable alterna-
tive agent for antipsychotic treatment of delirium [100], but controlled
studies have not been reported.
Recent studies indicate that substitution of dexmedetomidine, a centrally
acting, selective a2-adrenergic agonist, for other sedative agents also may
substantially reduce the incidence or duration of delirium after cardiac sur-
gery [101–104]. In the early report of Maldonado and coworkers [101], the
incidence of delirium after cardiac valve surgery was reduced from 50% to
under 5%, and the recent MENDS trial demonstrated a reduction in the
incidence of delirium from over 30% to about 10% [104]. In an open trial
in 20 cases, introduction of dexmedetomidine facilitated weaning and extu-
bation in 65% of patients who had failed previous weaning trials because of
agitation [103]. Problems noted with dexmedetomidine include inadequate
sedation, excessive pain, bradycardia, hypotension, and a case of cardiac
arrest [105,106]. There are conﬂicting reports about its use to reduce opioid
requirements for pain [107,108].
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prevalence reports vary. In what may be the largest follow-up study, impair-
ment in multiple domains of neuropsychological function was noted in
almost half of patients at discharge following surgery, but the prevalence
of impairment fell sharply over the next 6 months. The prevalence of impair-
ment was somewhat higher when the same patients were re-examined 5 years
after surgery; cognitive impairment at the point of discharge after surgery
was a predictor of impairment at 5-year follow-up [109]. The list of risk fac-
tors for chronic neuropsychologic impairment after cardiac surgery includes
many of the same factors as that for delirium: advanced age, prior neuropsy-
chologic impairment, prior head injury, prior cerebrovascular events includ-
ing transient ischemic attacks, and history of alcohol abuse or dependence
[110,111]. The hoped-for cognitive beneﬁt of ‘‘oﬀ-pump’’ surgery has not
been established [112–114].Psychiatric complications after left ventricular assist device
In addition to the problems common to cardiac surgery patients in gen-
eral, patients who undergo implantation of ventricular assist devices experi-
ence discomfort and anxiety related to the device. Depending on the speciﬁc
type of device, noise, the pressure of the device on the stomach, tethering to
a machine, and the visible extracorporeal circulation of blood are disturbing
features. Once out of the ICU setting, the need to change batteries, master
the control panel, and respond to alarms can be cognitively diﬃcult chal-
lenges for ventricular assist device patients, many of whom have pre-existing
or new neuropsychologic deﬁcits secondary to prior cerebrovascular disease
or hypoperfusion, hypoxic episodes, embolic events, or metabolic disarray
[111,115]. The ongoing risks of infection, bleeding, and thromboembolic
complications (especially stroke) contribute to anxiety associated with ven-
tricular assist device treatment.Substance withdrawal
Alcohol and benzodiazepine withdrawal is a common problem in the
ICU, and often unrecognized, although life-threatening if untreated
[19,116]. Alcohol-related medical conditions aﬀect the hospital course of
up to 12% to 30% patients in all medical settings [117]. Consequences of al-
cohol use account for nearly 25% of hospitalizations for traumatic injury,
and many of these patients require intensive care [118]. In one study, alcohol
use was directly responsible for approximately 20% of all ICU admissions
[119].
Withdrawal syndromes can arise from a number of clinical circum-
stances. Physicians may already be aware of the patient’s alcohol use and
anticipate withdrawal. Occult alcohol abuse is not uncommon, and it may
be diagnosed only when the patient starts to manifest classic symptoms.
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ative-hypnotic dependence, as from lorazepam or alprazolam. Patients may
also withdraw from sedative or anesthetic agents speciﬁc to the critical care
setting, such as propofol [120]. Last, barbiturate withdrawal may also occur
with similar manifestations.
Alcohol, benzodiazepines, and barbiturates all interact with the g-amino-
butyric acid (GABA)A receptor, a neurotransmitter receptor with a chloride
ion channel and several binding sites [121,122]. Benzodiazepines bind to the
benzodiazepine site on the GABAA receptor, which increases the frequency
of the chloride channel opening in the presence of GABA [121]. Barbiturates
increase the duration of time this channel is open; at high doses, sustained
channel opening can occur even in the absence of GABA, which contributes
to the substantial lethality risk of barbiturate overdose [121,123,124]. Etha-
nol also acts as an agonist at the GABA receptor. This common pathway
can result in similar behavioral eﬀects, cross-tolerance, and additive proper-
ties when used concurrently [125].
Management of alcohol-benzodiazepine withdrawal includes a rapid
replenishing of medications that target the GABA receptor. Typically, this
involves the administration of benzodiazepine medications at a dose high
enough to control the agitation and autonomic response of withdrawal, lim-
ited by the need to prevent oversedation and respiratory depression. Many
institutions have developed protocols and guidelines for the management of
withdrawal syndromes in the ICU, which typically include a stratiﬁed sys-
tem of management with oral or intravenous benzodiazepines [126]. Pheno-
barbital is also occasionally used in this setting, especially in complicated
cases where benzodiazepines have proved ineﬀective [127]. Adjustments
may need to be made for patients with signiﬁcant liver dysfunction.
Several speciﬁc aspects of withdrawal may aﬀect the course of patients
with pre-existing cardiopulmonary disease. The autonomic eﬀects of with-
drawal, including prolonged hypertension or tachycardia, can precipitate
cardiac ischemia, pump failure, and abnormalities in heart rhythm caused
by increased myocardial oxygen demand [128]. This is balanced by the ten-
dency of benzodiazepines to cause hypotension, which can also increase car-
diac demand by reﬂex tachycardia. Management of withdrawal can be
especially diﬃcult if the patient also requires the use of antihypertensive
or cardioprotective agents (eg, b-blockers), because the autonomic manifes-
tations of withdrawal may be masked. Also, there is some evidence to
suggest that medications used to treat hypertension, such as nitrates,
b-blockers, and calcium channel blockers, have diﬀerent eﬀects in patients
undergoing alcohol withdrawal [129]. During early stages of withdrawal,
negative inotropic eﬀects of b-blockers may be reduced, but negative chro-
notropic eﬀects increased, whereas vasodilator eﬀects of nitrates may be re-
duced. Antipsychotic medications are necessary at times to address severe
agitation associated with withdrawal, despite the risk of adverse cardiac
rhythm eﬀects, such as QT prolongation and torsade de pointes [128].
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compromise (because of underlying restrictive or obstructive processes)
and may be more diﬃcult to extubate. For these patients, one of the main
complications of alcohol withdrawal lies with the benzodiazepine-mediated
reduction in ventilatory drive associated with hypoxia, especially at higher
doses [128,130].Children with severe heart and lung disease
Children with heart and lung diseases including bronchopulmonary dys-
plasia, asthma, cystic ﬁbrosis, a1-antitrypsin deﬁciency, congenital heart dis-
eases, familial cardiomyopathy, and acute myocarditis may require critical
and intensive care. Intensive and critical care of the pediatric patient
requires understanding not only of disease pathophysiology and medical
and surgical intervention, but also of the developmental level of the patient.
Child psychiatrists are trained to assess the children with regard to their
physical, motor, language, cognitive, sexual, and emotional development.
In medically ill children, this assessment takes on a greater level of complex-
ity, because there can be a disruption in the normal developmental progres-
sion and a regression to more developmentally primitive and at times less
adaptive cognitive functioning and coping mechanisms [131,132]. In addi-
tion, work with the medically ill child necessitates work with the parents
and other signiﬁcant ﬁgures in the child’s life. Young children fear separa-
tion from their parents, whereas older children and teenagers balance the
need for their parents with desires for acceptance into their peer group, a sense
of autonomy, and a feeling of mastery of age-appropriate tasks and social
roles. At times these desires can overwhelm the ability of the growing child
to accept and constructively participate in his or her medical care. Respect
for the importance of these normal feelings in the psychological lives of young
patients is essential, even in intensive and critical care settings.
Although a comprehensive review is not possible here, the importance of
exaggerated anxiety over body image and issues of identity in pediatric heart
and lung transplant patients are highlighted. In evaluation of seriously ill
children with heart and lung disease for possible transplantation, one is con-
cerned with the patient’s degree of understanding of the procedure, based on
age, developmental level, and cognitive status; parents, too, must be
assessed to ascertain their comprehension of the procedure, and the risks,
beneﬁts, and alternatives available, to enable them to make an informed
decision. Those providing care must also be mindful of the psychological,
social, and emotional resources that the parents are able to contribute in
helping the child cope with the transplant process.
Given a particular child’s developmental level, his or her conceptualiza-
tion of illness, body image, and medical procedures can vary tremendously.
For example, discussing heart transplantation with a 7 year old is consider-
ably diﬀerent than with a 15 year old. Each requires a tailored approach,
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developmentally appropriate concerns that may arise. In cases of cardiac
transplantation, it is not only young children who can experience magical
thinking. Pediatric patients may develop all varieties of fantasy regarding
the new heart and what impact it may have on their own thoughts and
feelings. Children may fear, in a conscious, literal, and concrete sense, the
replacement of their pretransplant identity with the identifying characteris-
tics of the organ donor (eg, language spoken, religious beliefs, emotional at-
tachment to signiﬁcant others, sex). In older children, anxiety over body
image, threats to self-esteem because of the facts of being ill, taking medica-
tion, scars and changes in appearance and habitus, and limited ability to
participate in school and physical activity, combined with a nearly over-
whelming need to ﬁt in with peers, is developmentally typical [133]. Aware-
ness of this constellation of feelings should be helpful in working with young
patients and their reactions toward their illness, and may also serve to guide
the clinician in anticipating and resolving issues with noncompliance that
inevitably arise. One survey estimated that 25% to 40% of pediatric trans-
plant survivors have been found to have some psychiatric issues [134].
Additionally, there are diﬀerent outcomes based on whether the patient
had received the transplant as a result of congenital cardiac disease rather
than an acquired cardiac condition [135].End-of-life care
Physicians who care for chronically and critically ill patients with cardio-
pulmonary disease routinely confront the challenge of providing both eﬀec-
tive and compassionate end-of-life care. This can be further complicated by
the presence of psychiatric comorbidities, such as major depression and anx-
iety. Psychiatrists can assist in the eﬀective management of these patients.
This topic is addressed elsewhere in this issue.References
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ICU teams are a critical part of the solid organ transplant process.
Although kidney transplant recipients usually do not require recovery
time in the ICU, virtually all other solid organ recipients receive care
from these teams at some point either pretransplantation or posttransplan-
tation. The ICU team is essential in the preparation, stabilization, and
recovery of patients undergoing these extraordinary surgical procedures.
In addition, transplant recipients may experience medical decompensation
requiring ICU treatment years following the initial transplant hospitaliza-
tion. The psychosocial issues involved during these critical periods of trans-
plantation are important for intensive care physicians and clinicians to
understand to provide comprehensive care to transplant patients.
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950 DIMARTINI et alThis article provides a brief overview of transplant epidemiology, fol-
lowed by a review of the psychosocial issues relevant to the phases of the
transplant process. Considered are the pretransplant evaluation phase, psy-
chiatric disorders in transplant patients, and cognitive impairments and
delirium with additional issues speciﬁc to particular organs. Also covered
is the side eﬀects of immunosuppressive medications and special issues aris-
ing with living donors. The relevance of these issues to ICU care is
emphasized.Epidemiology of organ transplantation in the United States
For most organ types the numbers of candidates added to the wait list
each year exceeds the numbers receiving transplants (Fig. 1) [1]. In some
areas (eg, kidney, liver, lung transplantation) living organ donation has
become one option to address the organ shortage (see later section on spe-
cial issues in living donors). Without an identiﬁed living donor, transplant
candidates routinely wait for years for an organ, and living donation is
not a possibility for all types of transplantation (eg, heart). For all major
organ types over 40% of United States wait-listed candidates waited 2 years
or more for an organ [2]. Although only 0.5% become medically unsuitable
and are removed from the wait-list, 2% refuse transplant after being wait-
listed, and 10% to 18% die on the wait-list [2].
Although most transplant candidates are not in the ICU before transplan-
tation, the ICU staﬀ occasionally cares for critically ill transplant candidates
on the wait list (see later pretransplant section). For example, the highest
transplant status listing for liver and heart transplant candidates is deﬁned
as requiring critical care and these patients have the highest priority to receive
donated organs. For liver candidates, less than 0.01% is in the highest status
(status 1AorB).Less than10%ofheart candidates have the status (status 1A).
Of the status 1 liver candidates (fulminant failure not expected to survive
7 days), over 50% receive an organ within a week and 10% die. Of the status0
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Fig. 1. Waiting list statistics in United States: 1996–2006.
951PSYCHIATRIC ASPECTS OF ORGAN TRANSPLANTATION1A heart candidates, 37% are transplanted within 30 days, whereas 11% die
within that time [2]. For lung transplant candidates, respiratory failure requir-
ing continuous mechanical ventilation is only a relative contraindication to
lung transplantation and the allocation of lungs depends on a complex algo-
rithm of which mechanical ventilation is only one factor.
Following transplantation, recipients of living liver and kidney grafts
show the highest long-term survival rates (76% alive 10 years posttransplan-
tation); deceased liver and heart recipients have somewhat lower 10-year
survival (59% and 53%, respectively); and lung and intestine recipients
have the poorest 10-year survival (41% and 26%, respectively) [2]. These
survival statistics are from transplants performed over 10 years ago, how-
ever, and advances in technology, immunosuppression, and medical care
have improved the survival rates. Graft survival rates can be signiﬁcantly
lower than patient survival rates (eg, 43% for kidney graft survival and
52% for liver graft survival after 10 years), demonstrating that many trans-
plant recipients could face retransplantation 5 to 10 years after their ﬁrst
organ [2] or eventually may require kidney transplantation because of the
chronic use of nephrotoxic immunosuppressive medications.Pretransplant period
Transplant evaluation
The primary goal of a pretransplant psychosocial evaluation is to deter-
mine whether a patient has physiologic or psychosocial characteristics that
may negatively aﬀect posttransplant outcomes (Box 1). Psychosocial factors
include cognitive, behavioral, psychologic, and social issues that may inter-
fere with adjustment to transplantation or ability to adhere to posttrans-
plant medical directives. Many candidates present with at least a few
psychosocial issues that require additional attention. Early identiﬁcationBox 1. Purpose and goals of a transplant
psychosocial evaluation
1. Foster development of individualized treatment plans
2. Establish and strengthen patient-caregiver relationships
3. Encourage patient education and informed consent
4. Evaluate patient coping skills, strengths and weaknesses
5. Assess treatment adherence, barriers to adherence
6. Diagnose psychiatric disorders and give treatment options
7. Identify presence and availability of support system
8. Provide patient with informational and support resources
9. Assist patients and families in developing care plans
10. Participate in team selection of transplant candidates
952 DIMARTINI et alof these issues during the pretransplant evaluation allows transplant teams
the opportunity to develop treatment plans that minimize any negative im-
pact of these factors, while also optimizing patient and caregiver prepared-
ness for transplantation.
In an optimal situation, the psychosocial evaluation consists of a thor-
ough patient interview exploring a variety of issues relevant to transplanta-
tion (Box 2). Family members or other caregiving individuals, who help to
provide care to the patient following transplantation, may also be inter-
viewed. ICU staﬀ can assist in the pretransplant information gathering pro-
cess. During their own interviews with patients and families about ICU care
they may learn important aspects of how the patient and family are dealing
with the immediate stresses and preparing for the future. They may also
identify the patient’s and family’s level of sophistication with medical infor-
mation. In addition, the ICU staﬀ can provide valuable information about
a patient’s symptoms and behaviors while in the ICU along with observa-
tions about the availability and appropriateness of family and caregiver sup-
port. In some cases, the patient is not able to be interviewed and the
psychosocial evaluator has to rely solely on other sources (family,Box 2. Content of a comprehensive psychosocial evaluation
1. History of end-stage organ disease (eg, onset, course,
symptomatology)
2. Circumstances leading to transplant referral (expected,
emergent)
3. Attitude toward transplantation, level of interest
4. Expectations and concerns regarding transplantation
5. Understanding of transplant process (eg, risks, benefits,
long-term)
6. History of treatment adherence (eg, medications,
appointments, diet)
7. Past history of other medical problems, experience with
illness or hospitalization
8. Current or past psychiatric history, including cognitive
functioning and personality disorders
9. Current or past history of substance use or abuse
10. Coping skills, defense mechanisms
11. Family history of medical illnesses and psychiatric illnesses
12. Social history (eg, educational level, employment, living
situation)
13. Support system (eg, family, friends, church members, others)
14. Mental status examination
953PSYCHIATRIC ASPECTS OF ORGAN TRANSPLANTATIONcaregivers, medical care providers, and records) to gather relevant informa-
tion (see cognitive functioning and acute-fulminate organ failure sections).Acute or fulminant organ failureUnder such conditions as fulminant liver failure or acute cardiomyopa-
thy, patients may require emergent evaluation for transplantation. In these
situations, patients often play a minimal role in their evaluation because of
the presence of stupor, coma, or mechanical ventilation. Both patients and
family members may be overwhelmed with the seriousness of the situation,
and the task of having to learn and decide about transplantation.
For patients with fulminant hepatic failure from acetaminophen (repre-
senting 96% of transplants because of acute drug-induced hepatotoxicity)
[3] or other toxic ingestion or overdose, a thorough psychiatric evaluation
is necessary to determine whether the overdose was accidental or inten-
tional. Details regarding the ingestion, prior history of suicide attempts or
other self-destructive behaviors, substance abuse, psychiatric disorders, cur-
rent stressors, and other risk factors for future suicide attempts must be ob-
tained. Many of these patients recover to the point of avoiding transplant,
but a small group proceeds on to transplant and require careful consider-
ation about their candidacy.Decisions to list patients and potential dilemmasFollowing completion of the pretransplant evaluation, all information
and test results are reviewed, often in a transplant team meeting, to decide
whether a patient can be listed for transplantation. For patients with signif-
icant psychosocial risk factors, transplant teams may request that additional
requirements (eg, addiction counseling, psychiatric treatment, behavioral
changes, establishing an adequate support system) be met as a condition
to being listed for transplantation. In some cases, patients are not able to
complete these requirements because of becoming too ill or they die while
attempting to meet candidacy requirements. This is especially likely for pa-
tients being evaluated for transplantation while in the ICU. At times, diﬀer-
ences in opinion among transplant team members and other health care
providers arise regarding a particular patient’s candidacy for transplanta-
tion. Resolution of these diﬀerences requires open discussion among team
members and others involved in the patient’s care. These discussions not
only oﬀer an opportunity to resolve diﬀerences, but help to ease the anxiety
and discomfort that accompanies declining a patient for transplantation.
Additional consultations with medical ethics teams, risk management, and
the hospital’s legal department may be necessary and instructive with diﬃ-
cult cases (eg, when a candidate or his or her family is challenging candidacy
requirements or the candidacy decision of the transplant team). Thorough
documentation is essential to delineate the speciﬁc issues involved,
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with the patient or family.Speciﬁc coping challenges during the pretransplant period
Waiting period
After patients are listed for transplantation, they may experience a period
of elation and relief. Following this, new concerns arise as the realities of the
waiting period become evident. Many patients and their families perceive
the wait period to be the most psychologically stressful part of the trans-
plant experience. This stress is especially heightened if the candidates are
waiting in the ICU. Patients and their families must endure the uncertainty
of whether a donor organ will arrive in time and the degree of medical
deterioration or loss of functioning the patient will experience before trans-
plantation. For some, health continues a slow decline, whereas others suﬀer
through repeated exacerbations or rapid progression of their disease. Some
experience recurrent hospitalizations or prolonged stays in an ICU until
a donor organ becomes available. Helping patients to weather the uncer-
tainty of the waiting period requires health care providers to be aware of
the stresses unique to this stage of the transplant process.Preparing for death or maintaining hope
The realization that patients listed for transplantation are also facing ter-
minal illness is often overshadowed by the focus on continued medical care
and the pursuit of a donor organ. Patients, families, transplant teams, and
other health care providers may overlook or delay discussions on issues
relating to end-of-life care, such as living wills, powers-of-attorney, pallia-
tive care, and do-not-resuscitate orders [4,5]. Instead, staﬀ energy is often
directed at the stabilization and preparation of patients for transplant sur-
gery and postoperative care. Patients and families may resist attempts to ad-
dress end-of-life issues, partly because of denial. They may also believe that
acknowledgment of these issues reﬂects a sense of hopelessness about trans-
plantation or that the transplant team has become less committed to the
pursuit of an organ for them. These concerns can be addressed in collabo-
ration with the transplant team with respect to balancing a hopeful outlook
with appropriate acknowledgment of the potential for an undesired out-
come [6,7]. Additionally, wait-listed candidates may develop medical contra-
indications to transplantation (eg, infection, serious stroke or brain damage,
hemodynamic instability) and both patient and family should be made
aware that their eligibility might change over time for many reasons. By
encouraging timely discussion about end-of-life care, patients can also be
allowed the opportunity to take an active role in directing their care at
a time they are still well enough to do so. Psychologic or spiritual-pastoral
counseling may help patients and families negotiate these transitions and
prepare them for either transplantation or death.
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During the course of the waiting period, it is not unusual for listed
patients to become acquainted with one another during clinic visits and hos-
pital stays. This familiarity can be beneﬁcial to both patients and family
members, serving as an additional source of information and support.
This can be especially true when the patient is waiting in the ICU and their
family members interact with other families in the ICU waiting areas. None-
theless, this familiarity can become problematic as patients become sicker
and the wait for a donor organ more desperate. Inevitably, one patient
undergoes transplantation before another, which may raise feelings of jeal-
ousy among patients and families still waiting. These feelings may be unex-
pected, but are understandable in the context of the life-or-death nature of
transplantation. In some situations, jealousy may manifest as questions
about ranking on the organ wait list, how donor organs are assigned, or
body size or blood type requirements. It may emerge in the form of renewed
frustrations and fears about the ongoing waiting period [8]. Acknowledging
these feelings and answering questions can be beneﬁcial for patients and
families, although care must be taken not to share conﬁdential information
about other patients.Psychiatric disorders aﬀecting organ transplant patients
Similar to other medically ill populations, organ transplant candidates
and recipients are at elevated risk for signiﬁcant psychiatric symptoms
and diagnosable psychiatric disorders. The development of psychiatric
symptoms in transplant patients can reﬂect the exacerbation of a pre-
existing disorder or the development of a new-onset disorder. Mood- and
anxiety-related disorders are the most common psychiatric illnesses
observed both pretransplant and posttransplant, although delirium and cog-
nitive impairment are also often experienced by many transplant patients in
the perioperative period. In subpopulations of transplant recipients with his-
tories of substance abuse or dependence (eg, patients with alcoholic liver dis-
ease or hepatitis C) the risk for relapse remains a concern both pretransplant
and posttransplant. There has been increased recognition that posttraumatic
stress disorder (PTSD) may result from traumatic experiences related to the
transplant or the ICU stay. There is mounting evidence that each of these
classes of psychiatric disorders can aﬀect patient health and psychologic
outcomes after organ transplantation.
The ICU staﬀ plays an essential role in the identiﬁcation of psychiatric
symptomatology and psychiatric consultants typically rely on the ICU
staﬀ’s input about these issues. The ICU staﬀ’s round-the-clock observa-
tions of the patient’s behaviors and aﬀective and cognitive states provide
the data from which diagnoses can be made and treatment decided. In
addition, their observations of the patient’s sleep-wake cycles, physical
and motoric activity, appetite, and eating provide evidence of important
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interactions with family and staﬀ are also important to note. Patients and
families may voice concerns to the ICU staﬀ that they may feel reluctant
to discuss with the transplant team. These concerns may reveal important
aspects of their psychologic and aﬀective states, sense of hopefulness, and
their readiness either to pursue transplantation or engage in the posttrans-
plant recovery and rehabilitation process. The following sections review
the prevalence, presentation, and issues relevant to psychiatric disorders
in transplant populations. Treatment of these disorders is discussed later.Mood disorders: depression and anxietyComorbid psychiatric disorders are common among medically ill trans-
plant candidates: as many as 25% of patients with advanced pulmonary dis-
ease, 40% of patients with advanced hepatic disease, and 50% of patients
with advanced cardiac disease experience anxiety or depressive disorders
[9–11]. Following transplant up to 20% of kidney recipients, 30% of liver
recipients, and 63% of heart recipients have been found to develop these dis-
orders especially during the ﬁrst posttransplant year [12–15]. Some anxiety
disorders (eg, panic disorder) seem to be more common both before and
after transplantation in patients with end-stage lung disease compared
with patients with other types of end-stage organ diseases [14,16,17].
In addition to the multiple psychosocial stressors facing these patients
(eg, reduced quality of life, disability, ﬁnancial pressures), medications
and physiologic impairment (eg, electrolyte imbalance, thyroid disorders,
and nutritional deﬁciencies) can produce secondary psychiatric symptom-
atology. Among patients evaluated for transplantation, many are psycho-
logically worn down by the eﬀects of worsening chronic disease. Others
with acute failure may be overwhelmed with the suddenness of their disease
and its life-or-death implications. Apathy, fatigue, and memory impairment
caused by depression can interfere with a patient’s ability or motivation to
adhere to a posttransplant regimen of medications, self-monitoring, exer-
cise, and clinic appointments. Excessive or irrational fears caused by an anx-
iety disorder can cause patients to avoid tests, treatments, hospitals, and
other circumstances that raise their level of distress. Anxiety and depression
may negatively impact their adjustment to transplantation and early inter-
vention is recommended [17–21].
Patients with depression may manifest symptoms of depressed mood,
irritability, loss of interest in activities, changes in appetite, insomnia or
hypersomnia, psychomotor agitation or retardation, poor memory and con-
centration, thoughts of death or suicidal ideation, and feelings of worthless-
ness or guilt. In a critically ill patient in the ICU, the diagnosis of depression
can be challenging because many of these symptoms may also be manifesta-
tions of physical illness (Box 3). The presence of anhedonia, guilt, hopeless-
ness, helplessness, and suicidal ideation may be clues that depression is
Box 3. Symptoms and behaviors of anxiety and depression
in the medically Ill
Somatic symptoms and behaviorsa
Fatigue or generalized weakness
Appetite disturbances (anorexia or hyperphagia)
Sleep disturbances (insomnia or hypersomnia)
Increased or excessive physical complaints (out of proportion
to the degree of physiologic disturbance)
Psychomotor agitation or retardation
Heightened pain perception
Jitteriness, tremor, sweating
Nausea, gastrointestinal complaints
Chest tightness or palpitations
Shortness of breath or feeling of choking
Dizziness or lightheadedness
Affective and cognitive symptoms and behaviorsb
Sadness, tearfulness, irritability
Feeling edgy, anxious, overwhelmed
Impaired attention, concentration, memory
Loss of interest, pleasure in enjoyable activities
(eg, ability to enjoy visit from family, friends)
Social withdrawal or apathy
Guilt, feeling like a burden to others
Feelings of hopelessness or helplessness
Nightmares, flashbacks, avoidance
Problems with treatment adherence
Heightened vigilance over care needs
Thoughts of death, fears of dying, heightened worries about
health
Passive wish for death, suicidal ideation
a Somatic symptoms may be attributable to the medical illness or depression
or anxiety.
b Affective or cognitive symptoms may be clues to presence of depression
or anxiety in the setting of severe medical illness.
957PSYCHIATRIC ASPECTS OF ORGAN TRANSPLANTATIONcontributing to the clinical presentation [8]. The presence of persistent
irritability, rather than sadness or tearfulness, may also suggest depression.
Patients may be reticent to complain of depression during this period of
time, feeling ‘‘I should not be depressed’’ having just received a life-saving
procedure. Medical contributions to depression may include medications,
rapid taper of steroids, metabolic derangements, and central nervous system
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dynamics, and the stress of the illness and hospitalization may all contrib-
ute. It is important carefully to evaluate the patient with complaints of
depression; residuals of delirium, psychotic symptoms, PTSD, anxiety,
and cognitive problems may complicate the diagnosis. Families and care-
givers may experience symptoms and distress, and the dynamics in their re-
lationship with the patient undergo changes during the transplant process
and the focus shifts from one of caregiving to rehabilitation [14,22–25].
Anxiety disorders are also common in transplant patients. Patients with
pre-existing anxiety disorders frequently have an exacerbation of symptoms
in the transplant setting. Preoperatively patients worry about their health,
the outcome of the transplant evaluation, and whether the transplant will
actually occur. In the perioperative period, patients and families are anxious
as to whether the graft will function, whether complications and graft rejec-
tion will occur, and whether the patient will survive and have an improved
quality of life. Pretransplant, patients are frequently in denial with regard to
the rigors and stressors they face posttransplant. These issues become reality
in the perioperative period and patients are particularly vulnerable to anx-
iety at this time. Anxiety symptoms may increase with the stress of the
ICU stay, metabolic derangements, sleep deprivation, postoperative compli-
cations, episodes of graft rejection, and medication side eﬀects. Excessive or
irrational fears may cause patients to avoid or refuse tests or treatment and
be uncooperative with care. Conﬂicts over daily care, such as the timing of
medications, meals, rehabilitation, and tests, can be related to a patient’s
attempt to control rising fears related to worsening health and an uncertain
wait for a donor organ [8]. In evaluating the patient it is important to rule
out cardiac arrhythmias, angina, electrolyte imbalances, respiratory distress,
seizures, CNS infections, and other CNS pathology as contributing to or
causing anxiety symptoms [14,22–26].Posttraumatic stress disorderWith the onset of medical illness and the need for transplantation
patients with pre-existing PTSD from combat experiences or other trauma
may experience a recurrence or acute increase in PTSD symptoms. In addi-
tion, the life-threatening nature of transplant-related events, transplant sur-
gery, and the ICU stay can cause new-onset PTSD [27,28]. There is
increasing evidence that the ICU experience can cause PTSD in a signiﬁcant
percentage of general medical patients, with up to 44% experiencing PTSD
symptoms [28,29]. Patients have described vivid ﬂashbacks, severe disturb-
ing nightmares, exaggerated startle responses, and severe anxiety among
other symptoms. In a few cases, transplant patients, while delirious, experi-
enced delusions and hallucinations of life-threatening events that led to the
development of PTSD [28]. In one study, PTSD experienced during the ﬁrst
year after heart transplantation (but not non-PTSD anxiety symptoms)
959PSYCHIATRIC ASPECTS OF ORGAN TRANSPLANTATIONpredicted mortality during the subsequent 2-year follow-up period [27]. Pro-
active evaluation, diagnosis, and treatment of anxiety or delirium could
lessen symptoms and distress but whether these measures would prevent
the onset of PTSD or improve outcomes is not known.Psychotic disordersAlthough it is rare for transplant candidates to have histories of psychotic
disorders (ie, schizophrenia, schizoaﬀective disorder, bipolar disorder), such
patients can do well posttransplant if their disorders are well-controlled [30].
These patients should undergo an extensive pretransplant psychiatric evalu-
ation. Information on how they have tolerated prior hospitalizations and
speciﬁcally ICU stays can help to guide future treatment planning and
help the ICU and transplant teams prepare for their ICU stay. Patients
with psychotic disorders may experience disturbances in judgment or reality
testing when faced with new experiences, multiple stresses, or situations
where they lack a sense of control. This is especially true in the ICU where
stressors related to the severity of their illness, perceived loss of control, and
excessive environmental stimulation may precipitate psychotic symptoms.
In this context these patients may become agitated, irritable, delusional,
or paranoid. They may experience auditory or visual hallucinations or
become uncooperative with their medical care. Although the etiology of
their symptoms is linked to their underlying psychiatric disorders, the treat-
ment of these symptoms and behaviors is similar to treatments oﬀered for
behavioral symptoms caused by medical decompensation related to end-
stage organ failure (eg, hepatic encephalopathy [HE]; see later).Substance abuseWhether to oﬀer new organs to patients with substance abuse or depen-
dence disorders has been a source of debate within the transplant commu-
nity and society at large. Although concerns have been raised over
posttransplant relapse and its potential to contribute to nonadherence, even-
tual graft failure, and patient death, there is little evidence that carefully
selected individuals experience high rates of relapse. A recent meta-analysis
demonstrated relapse rates as low as 3% to 6% of patients per year among
individuals transplanted after histories of alcohol or illicit drug use [31].
Even those on methadone maintenance do not seem to relapse often while
remaining on treatment [32].
Transplant teams often expect patients to achieve a certain duration of
pretransplant abstinence (often at least 6 months) before they are listed
for transplant. Although this may allow for some demonstration of patients’
commitment to abstinence, stable abstinence is measured in years and
patients in end-stage organ failure may not be able to survive the added
wait time. More importantly, patients must gain understanding of and
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requires participation in formal rehabilitation programs, addiction treat-
ment or 12-step groups, and family education. For patients in the ICU,
requirements for addiction rehabilitation and speciﬁc periods of abstinence
may not be achievable in the time before transplantation. These patients
may generate a great deal of emotion and even conﬂict among team mem-
bers because personal opinions on these candidates may be very diﬀerent.
Because there is no national policy for these cases, the decision is left to
the treating physicians and clinicians and each transplant team must deter-
mine the relative importance of these issues with respect to their own policy
and selection criteria. Teams should apply their criteria consistently, how-
ever, to prevent disagreements over individual cases.
For ICU staﬀ, the care of patients with addictive disorders who need
transplantation requires adoption of a well-informed, nonjudgmental
stance. Patients with histories of alcohol or benzodiazepine dependence
should be monitored for the development of withdrawal symptoms. Many
withdrawal syndromes, especially for alcohol, opioids, and sedative hyp-
notics, present with symptoms of sympathetic hyperactivity (tachycardia,
hypertension, hyperthermia). This may complicate transplant management,
confuse the diagnostic picture when evaluating medical complications, and
result in increased morbidity. Medications may be required to avoid serious
complications of withdrawal, such as autonomic instability and seizures. If
the patient is alcohol dependent, administration of thiamine may be
required to prevent the Wernicke-Korsakoﬀ syndrome. Opioid-dependent
patients on methadone maintenance continue to require their outpatient
dose of methadone, along with additional opioid medications for treatment
of pain [33]. Patients dependent on opioids may have substantial tolerance
to these medications and may require higher than expected doses to achieve
adequate pain control. Although patients with substance abuse may have
comorbid anxiety disorders, treatment of their symptoms requires cautious
use of benzodiazepines and optimized use of other psychotropic agents. In
addition to medication management, it is equally important to obtain con-
sultation with specialists in addiction and arrange for the patient to receive
treatment for the substance use disorder as soon as practical.Pretransplant organ-speciﬁc cognitive disorders and encephalopathy
Cognitive disorders and delirium
Through the pretransplant to posttransplant phases patients frequently
experience reductions in cognitive functioning ranging from subclinical or
mild symptoms to frank delirium (Table 1). Impairment in cognitive func-
tion often results from end-stage organ disease and its physiologic sequelae
but may also occur because of other comorbid disease processes (eg, CNS
vascular disease from diabetes or hypertension); damage from prior
Table 1
Delirium and other cognitive disorders
Symptoms Acute delirious state
Mild cognitive disorder
or early signs of delirium
Onset Often rapid Slow, insidious
Clouding of
consciousness
Yes No
Waxing and waning
of alertness
Yes No or mild
Disorientation Yes No or mild
Fluctuation of
symptoms over brief
periods of time
Yes, often severe No
Sleep-wake cycle
disturbance
Yes, often severe Possibly present
Increased or decreased
psychomotor activity
Yes No or mild
Sensory misperceptions
(illusions, hallucinations)
Sometimes No
Tangential, rambling,
incoherent thought
or speech
Sometimes No
Impaired reality testing
or delusions
Sometimes No
Impaired attention
or concentration
Yes, often severe No or mild
Memory impairment Yes, both short- and
long-term memory
aﬀected
Yes, mainly short-term
memory aﬀected
Disturbances in
executive function-
planning,
organization,
abstraction
Yes, often severe Yes
Mood or personality
changes
Yes Sometimes
Data from Trzepacz PT. Delirium. In: Levenson J, editor. Textbook of psychosomatic med-
icine. Washington: American Psychiatric Publishing; 2005. p. 91–130.
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(eg, stroke), medication side eﬀect, or head trauma. Before transplantation
it is critical to diﬀerentiate between the ﬂuctuating course of a delirium,
which is potentially reversible, and more persistent cognitive deﬁcits that
may represent a pre-existing dementia or a static cognitive impairment.
The reversibility or even progression of deﬁcits may in part rely on age;
the homeostatic reserve of the brain; prior CNS insults; and the ability to
withstand future transplant-related stresses (eg, prolonged anesthesia, use
of cardiac bypass, hemodynamic ﬂuctuations, and posttransplant immuno-
suppressives). Although the restoration of normal organ functioning and
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tive impairments, deﬁcits may take months to years to resolve [34].
In heart failure, low cardiac output and CNS hypoperfusion from
reduced cerebral blood ﬂow can contribute to cognitive impairments.
Impaired cerebrovascular reactivity and ischemia may result, even in the
absence of acute cerebrovascular events. Cardiac medications, including
inotropic agents, can also contribute to cognitive impairments. CNS micro-
emboli are common in pre–heart transplant patients, especially for those
on ventricular assist devices (see section on VADs). In end-stage lung dis-
ease, hypoxia and hypercapnia may cause mild to severe cognitive deﬁcits
in these patients, particularly in the areas of executive functioning, atten-
tion, and memory [35]. Oxygen therapy may improve cognitive functioning
in certain candidates and these patients can beneﬁt from lung transplanta-
tion but the extent to which these deﬁcits are reversible is unclear [35]. He-
patic and uremic encephalopathies are two speciﬁc areas considered in
detail later.
Evaluation of delirium during this period of time must include careful
medical examination of the patient and review of the medications and lab-
oratory studies (Box 4). Brain imaging, electroencephalogram recording,
and lumbar puncture may also provide important information. The diﬀeren-
tial diagnosis is broad and includes metabolic derangements, infections, and
side eﬀects of medications (Boxes 5 and 6) [22]. Environmental attributes
can also contribute to the development of delirium. These factors include
disruption of the normal day-night cycle with constant stimulation in the
ICU, sleep disruption, and lack of orienting cue. To the extent possible, nor-
malization of the sleep-wake cycle should be attempted in the ICU, and
waking the patient during the night should be avoided unless necessary.
Room lights should be oﬀ or dimmed during the night unless they are nec-
essary to provide care to the patient. Frequent reorientation to time andBox 4. Diagnostic tools to identify cognitive disorders
 Patient and family interview and observations
 Review of medications
 Screening cognitive examinations (MMSE, CAM-ICU,
NEECHAM, ICDSC)
 Formal neuropsychologic testing
 Laboratory studies
 Electroencephalogram
 CNS imaging
Data from Trzepacz PT. Delirium. In: Levenson J, editor. Textbook of psychoso-
matic medicine. Washington: American Psychiatric Publishing; 2005. p. 91–130.
Box 5. Potential causes of delirium in transplant patients
Metabolic
Dehydration
Volume overload
Hypoxia
Electrolyte imbalances
Hyponatremia, hypernatremia
Hyperkalemia
Hypercalcemia
Hypomagnesemia
Acidosis
Alkalosis
Infectious
Sepsis
Pneumonia
Spontaneous bacterial peritonitis
Abscesses
Cellulitis
Meningitis, encephalitis
Endocarditis
Organ failure
Hepatic encephalopathy
Uremic encephalopathy
CNS hypoperfusion
Medications (see Box 6)
Endocrine
Hypothyroidism
Hyperthyroidism
Cerebrovascular
Seizures
Cerebral edema
Cerebrovascular accident, embolic or hemorrhagic
Subdural hemorrhage
Hypertensive encephalopathy
Miscellaneous
Alcohol or drug intoxication and withdrawal states
Autoimmune disorders, vasculitis
Disseminated intravascular coagulation
Fever
Sensory deprivation
Sleep deprivation
Neuroleptic malignant syndrome
Malignant hyperthermia
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Box 6. Medications commonly used in transplant patients
that may cause delirium
Immunosuppressants
Corticosteroids
Calcinurein inhibitors (tacrolimus, cyclosporine)
Analgesic pain medications
Opioid analgesics
Nonsteroidal anti-inflammatory medications
Antimicrobials
Acyclovir, ganciclovir
Amphotericins
Cephalosporins
Interferon-a
Vancomycin
Aminoglycosides
Anticholinergics
Antihistamines
Diphenhydramine
Hydroxyzine
Benztropine
Atropine
Scopolamine
Tricyclic antidepressants
Amitriptyline
Doxepin
Phenothiazines
Chlorpromazine
Antiemetics and related medications
Proclorperazine
Promethazine
Metoclopramide
Cardiac medications
b-blockers
Clonidine
Digoxin
Sedative-hypnotics
Benzodiazepines (eg, diazepam, lorazepam)
Barbiturates
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Miscellaneous
Cimetidine
Ranitidine
Baclofen
Lithium
Stimulants
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patient and why the patient is hospitalized may also be helpful. Breitbart
and coworkers [36] noted that delirious patients with perceptual distur-
bances and severe delusions were more likely to experience later delirium-
related distress than those without these symptoms. Whether treatment of
delirium can prevent future distress or the development of delirium-related
PTSD symptoms is unknown.Liver disease and hepatic encephalopathyHE is a speciﬁc type of delirium commonly experienced by patients with
hepatic dysfunction. Symptoms of HE may be considered on a continuum
from subclinical or minimal to overt and severe. In addition to the signs
and symptoms that characterize delirium (see Table 1) patients can also
have aﬀective-emotional dysregulation; psychosis; behavioral disturbances;
bioregulatory disturbances; and disturbances of the motor system including
asterixis, tremor, increased deep tendon reﬂexes, increased muscle tone,
ataxic gait, bradykinesia, slurred speech, or incoordination. Patients with
HE associated with acute fulminant hepatic failure are at risk for cerebral
edema, increased intracranial pressure, seizures, and death pretransplant
[37,38]. The prognosis for these patients is poor with or without liver trans-
plant particularly if the intracranial pressure is greater than 40 mm Hg or
cerebral perfusion pressure is less than 40 mm Hg [39]. For patients with
acute liver failure who experience an acute change in mental status or prog-
ress to advanced-stage HE, head CT is recommended to evaluate for cere-
bral edema or intracranial bleed [40]. Persistent HE is rare but can be
observed in patients with extensive portocaval collateral circulation or after
surgical or transjugular portosystemic stent shunting procedures [41]. An
electroencephalogram may show common abnormalities, such as general-
ized slowing of dominant rhythm or less commonly nonconvulsive seizures;
neuropsychologic testing assessing psychomotor speed, praxis, concentra-
tion, and attention is more eﬃcient and perhaps more sensitive in determin-
ing minimal HE [38,40,42].
HE most likely has a multifactor pathogenesis. Changes in brain metab-
olism and disorders of neurotransmission seem to be contributing factors.
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absorption of ammonia in the gastrointestinal tract, it is not the only sub-
stance implicated in the pathogenesis of HE. HE can be precipitated by sig-
niﬁcant protein intake; gastrointestinal hemorrhage (causing increased
protein load in the intestine); uremia; use of some psychoactive medications
or diuretics; dehydration; or electrolyte imbalance [42,43]. Treatments
should be aimed at correcting precipitating factors and should include
administration of a nonabsorbable disaccharide (eg, lactulose), which acts
as an osmotic laxative to ﬂush out ammonia. Additional treatments include
the use of nonabsorbable antibiotics to reduce intestinal bacteria that con-
vert protein to ammonia. A protein-restricted diet may not be feasible for
patients with advanced liver disease with the loss of muscle mass and
cachexia. Medications that can contribute to symptoms of HE or slow intes-
tinal motility, such as those with anticholinergic activity and opioid analge-
sics, should be avoided.Renal disease and uremic encephalopathyChronic renal failure results in multiple catabolic, metabolic, and endo-
crinologic processes that contribute to the development of uremic encepha-
lopathy. The accumulation of neurotoxic substances, such as urea, uric acid,
guanidine compounds, hippuric acid, and indoleacetic acid, is believed to
contribute to the encephalopathy; no single metabolite has been identiﬁed
as the sole cause. Other pathophysiologic changes implicated in uremic
encephalopathy include hormonal elevations, and electrolyte imbalances
including acidosis, hyponatremia, hyperkalemia, hypocalcemia and hyper-
magnesemia, anemia, malnutrition, and CNS factors, such as increased cal-
cium and decreased g-aminobutyric acid and glycine activity.
The symptoms of uremic encephalopathy typically ﬂuctuate and can
begin insidiously with patients experiencing mild cognitive impairment, irri-
tability, or insomnia. Physical symptoms (eg, slurred speech, muscle
twitches, or restless legs) can also occur. Symptoms can progress slowly
or rapidly to confusion, lethargy, overt delirium, seizures, psychosis, catato-
nia, and stupor or coma. An electroencephalogram can aid in the diﬀerential
diagnosis of encephalopathy, typically showing generalized slowing of the
dominant rhythm, versus seizures and nonconvulsive status epilepticus,
which can occur in uremia and be mistaken for uremic encephalopathy.
Removal of uremic toxins by hemodialysis, correction of electrolyte imbal-
ances and anemia, and the treatment of malnutrition can diminish the symp-
toms of encephalopathy and improve cognition. Seizures may require
treatment with anticonvulsants.
Uremic encephalopathy is also associated with a cliniconeuroradiologic
syndrome termed ‘‘posterior reversible (leuko)encephalopathy syndrome’’
(PRES). Characteristic radiographic ﬁndings on CT or MRI are seen in
the posterior cortical and subcortical white matter. Risk factors for
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mune disorders; thrombotic thrombocytopenic purpura; infections (specif-
ically viral) and sepsis; and nonspeciﬁc renal inﬂammatory conditions (eg,
glomerulonephritis, hepatorenal syndrome) [44]. Early recognition allows
corrective action to be taken. Action is especially important with respect
to severe or unstable blood pressure, which frequently accompanies the
syndrome [44]. Prompt treatment may avoid potentially permanent brain
damage.Heart failure and ventricular assist devicesThe extreme shortage of donated hearts and the growing list of heart
transplant candidates indicates that VAD therapy will play an increasingly
signiﬁcant role in the treatment of end-stage heart disease. Progress in the
development of VADs from external or paracorporeal devices to implant-
able devices has dramatically improved both the physical and psychologic
health of patients with end-stage heart failure. Although these devices are
primarily used as bridges to transplantation, they can also bridge a patient
to recovery (eg, after an acute illness, such as fulminant myocarditis) and are
now also oﬀered as ‘‘destination’’ therapy for some patients ineligible for
transplant. The newest VADs now include implantable left ventricular or
biventricular versions that have been miniaturized and have improved pa-
tient mobility, easy of wearability, and routinely allow discharge from the
hospital. Portable pneumatic drivers and battery packs are compact and
lightweight and can be worn on a shoulder strap or towed on a luggage-
type carrier. Most patients can achieve New York Heart Association func-
tional status I or II while supported on a VAD. Patients can also achieve
signiﬁcant gains in physical and physiologic rehabilitation and rebuild mus-
cle mass, potentially stabilizing their cardiac condition [45]. Many patients
can engage in light to moderate physical activity (including walking, driving,
dancing, and even work).
Despite improvements in quality of life, mobility, and functioning for
VAD patients, however, psychologic and cognitive problems are not uncom-
mon. In the ﬁrst 1 to 2 weeks postimplant while patients are often in the
ICU they report coping well with the VAD and having low symptoms of dis-
tress but feel as if they were not doing as well as they had anticipated before
VAD implantation [46]. Adjusting to the VAD can be psychologically diﬃ-
cult. Incorporating the machinery into their body can evoke feelings of
a damaged body image and sense of self and these feelings can be especially
traumatic if the VAD implantation is in response to an emergency [47].
Patients can feel vulnerable, apprehensive with the machinery sounds and
alarms, and can fear a VAD malfunction [47]. Although patients may be
too ill before implantation, psychotherapy afterward to address these issues
may ease the transition onto a VAD and help them prepare for eventual
transplant.
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posttransplant physical recovery and emotional well-being as patients who
never required VAD support, they may have poorer residual cognitive func-
tioning posttransplant [16,48]. Cognitive impairments may in part be caused
by the higher risk of thromboembolism while supported on a VAD. Al-
though there is a low incidence of thromboembolic complications (0.24
per 100 LVAD days), a high incidence of circulating microemboli on trans-
cranial Doppler ultrasonography has been demonstrated in VAD patients
[49]. Using cognitive P300 evoked potentials as a general indicator of neuro-
cognitive functioning, one study showed in the short term that VAD implan-
tation could improve neurocognitive impairment by the time patients left
the ICU [50]. Nevertheless, although many of the microembolic events are
clinically silent [49] the chronic eﬀect of microembolic events (ie, silent in-
farctions) on cognitive functioning is speculated to be signiﬁcant over
time. Although it is not feasible repeatedly to perform CT of the brain,
transcranial Doppler may be beneﬁcial for predicting the risk and periodic
neuropsychologic or cognitive testing may identify silent cerebral infarctions
[48].Treatment issues: medications for psychiatric disorders
Although psychiatric symptoms may seem to be normal reactions to sig-
niﬁcant stresses of the transplant experience, lack of timely diagnosis and
treatment can lead to unneeded suﬀering, reduced adherence to medical
care, heightened physical pain, and greater functional impairment. Never-
theless, it is a complex challenge to identify and correct underlying patho-
physiologic processes ﬁrst that could be causing or contributing to
psychiatric symptoms. There may be signiﬁcant overlap in the physical
and psychologic symptoms of the patient’s medical condition and their psy-
chiatric illness (see Box 3). If medications are needed to treat psychiatric
symptoms, careful consideration must be given to the choice of medication,
symptoms to be treated, side eﬀects of the medications, adverse drug inter-
actions, and the type and severity of organ failure with respect to alteration
in pharmacokinetics. A full discussion of this topic is beyond the scope of
this article (Table 2 provides some guidelines and suggestions). In these
cases psychiatric consultation can assist in the diagnosis and selection and
monitoring of psychotropics. Brief psychotherapy, even in the ICU setting,
may also be beneﬁcial.
In cases of delirium and other psychotic symptoms it is important to
avoid medications that may worsen symptoms. Low doses of typical and
atypical antipsychotics may be most appropriate in these circumstances.
Haloperidol, risperidone, and quetiapine are common choices, depending
on the route of administration available [51]. Haloperidol may be given par-
enterally or orally. The lowest possible doses of this medication are sug-
gested because it may cause extrapyramidal (parkinsonian) symptoms;
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and quetiapine are currently only available in oral forms. Risperidone and
olanzepine are available in a quick-dissolving tablet that dissolves in seconds
when placed on the tongue and may be useful if swallowing pills is a prob-
lem. These medications still need to be swallowed after dissolution and
require an intact gastrointestinal tract for absorption. Atypical
antipsychotics can cause or worsen hyperglycemia and hyperlipidemia
(which can also be side eﬀects of immunosuppressive medications) and
they also carry a small risk of QT prolongation [51]. When treating delirium
regular scheduled doses of medication are preferable to as-needed doses to
stabilize symptoms. Delaying treatment until symptoms become problem-
atic and then using as-needed dosing may create a situation in which higher
doses are needed to control behaviors.
Lithium and divalproex (sodium valproate, valproic acid) are commonly
used to treat mania, but are complicated to use in the peritransplant period.
Large ﬂuid volume shifts, the combined nephrotoxicity of other medica-
tions, and frequent use of diuretics make use of lithium potentially danger-
ous and impractical. Divalproex has many drug interactions and also
a small risk of hepatotoxicity. Its use in patients with liver disease is not rec-
ommended. Side eﬀects of divalproex include thrombocytopenia, nausea,
vomiting, and ataxia. Atypical antipsychotics can eﬀectively treat symptoms
of mania, psychosis, and mood dysregulation in these patients.
Anxiety symptoms may be safely treated short-term with benzodiaze-
pines; however, use of these medications may cause or worsen symptoms
of delirium and cognitive impairment. If a benzodiazepine is used,
a short-acting medication with no active metabolites is suggested, such as
lorazepam. The lowest possible dose for the shortest period of time is sug-
gested. As with delirium, treating anxiety with a regularly scheduled medi-
cation, rather than as-needed, may allow more consistent alleviation of
symptoms and avoid an escalation of symptoms or a requirement for
a higher dose. For those patients with pre-existing alcohol or benzodiaze-
pine addiction, care must be taken with longer-term use of benzodiazepines
to avoid precipitating a relapse of the addiction. In general, although
benzodiazepines are quick acting and eﬀective for immediate treatment of
anxiety, for patients with more persisting anxiety consideration of a nonad-
dicting agent for longer-term use is suggested.
Both anxiety and depression may be treated with selective serotonin re-
uptake inhibitors (eg, ﬂuoxetine, paroxetine, sertraline, and citalopram).
These medications are relatively safe in the medically ill patient; however,
it is important to be aware that ﬂuoxetine has a relatively long half-life
and that ﬂuoxetine, paroxetine, and sertraline may have cytochrome
P-450 drug-drug interactions with medications typically administered to
these patients. Venlafaxine has relatively few drug-drug interactions but
in high doses may worsen hypertension. Fluvoxamine and nefazodone
have very signiﬁcant interactions with calcinurein inhibitors and should
Table 2
Psychotropic medications in transplant patients
Medication Most common uses in transplant Issues
Antidepressants
SSRIs Depression/anxiety disordersa,b
Fluoxetine Long half-life, takes many days to clear after
discontinuation; potential drug interactions
Paroxetine Mild anticholinergic eﬀects; discontinuation syndrome more problematic
than other SSRIs; potential drug interactions
Sertraline Potential drug interactions
Fluvoxamine Raises levels of cyclosporine and tacrolimus by inhibition CYP450 3A4
Citalopram Few drug interactions
Escitalopram Few drug interactions
Tricyclics Depression/anxiety disordersb All have cardiac eﬀects: cardiac conduction changes, tachycardia and arrhythmias
have been described; QT prolongation
Amitriptyline Signiﬁcant anticholinergic side eﬀects
Imipramine Signiﬁcant anticholinergic side eﬀects
Nortriptyline Fewer anticholinergic side eﬀects; therapeutic level established (50–150 ng/mL)
Doxepin Moderate anticholinergic side eﬀects
Desipramine Fewer anticholinergic side eﬀects; may cause anxiety and agitation
Others
Trazodone Sleep Risk of priapism; poor antidepressant eﬃcacy, may help with medication-induced
sleep disturbances and nightmares caused by PTSD
Mirtazapine Depression/anxiety disorders Increased appetite or weight gain, can reduce nausea, may cause neutropenia
Nefazodone Depression Potential severe hepatotoxicity; avoid in liver disease; raises levels of cyclosporine
and tacrolimus by inhibition of CYP450 3A4
Bupropion Depression/smoking cessation Risk of seizure in high doses; dose reduction in hepatic failure
Venlafaxine Depression/anxiety disorders/pain Dose reductions in hepatic and renal failure; dose-dependent elevations in blood
pressure
Duloxetine Depression/pain Potential hepatoxicity; avoid in end-stage renal disease and patients with hepatic
dysfunction
Benzodiazepines All have abuse potential; risk of withdrawal syndrome with abrupt discontinuation
after continued use
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Lorazepam Anxiety disorders/alcohol and drug withdrawalc No active metabolites; may be given orally, intramuscularly, intravenously
Diazepam Anxiety disorders/alcohol and drug withdrawal Long half-life; active metabolites
Clonazepam Anxiety disorders
Temazepam Sleep No active metabolites
Alprazolam Anxiety disorders Short half-life; risk of withdrawal between doses
Antipsychotics Delirium/hallucinations/delusionsb
Typical
Haloperidol Use lowest possible dose; risk of extrapyramidal symptoms and neuroleptic
malignant syndrome is less with intravenous administration
Atypical
Risperidone Delirium/hallucinations/delusionsb Risk of metabolic syndrome in all
Olanzapine Similar to haloperidol in dose O6 mg
Risk of metabolic syndrome, hyperlipidemia, hyperglycemia, weight gain
Aripiprazole Less risk of metabolic syndrome
Ziprasidone Less risk of metabolic syndrome; risk of QT prolongation
Quetiapine Moderate risk of metabolic syndrome; some weight gain
Stimulants Depression/fatigue/ADHDb All have abuse potential; should see response within several days; may decrease
appetite
Methylphenidate Avoid in agitated depression
Dextroamphetamine Small risk of cardiac side eﬀects
Other medications
Lithium Bipolar disorder Potential nephrotoxicity; serious side eﬀects with toxic levels; drug interactions with
diuretics, ACE inhibitors and others
Clonidine Posttraumatic stress disorder Risk of hypotension, sedation
Prazosin Posttraumatic stress disorder May help nightmares and sleep disturbance related to PTSD
Buspirone Anxiety disorders May have respiratory stimulating properties
Abbreviations: ACE, angiotensin-converting enzyme; ADHD, attention deﬁcit–hyperactivity disorder; PTSD, posttraumatic stress disorder; SSRI, selective seroto-
nin reuptake inhibitors.
a Anxiety disorders include the following: anxiety disorder secondary to medications and medical conditions, generalized anxiety disorder, posttraumatic stress dis-
order, phobias including social phobia, panic disorder, obsessive-compulsive disorder, and other anxiety disorders.
b These uses pertain to all drugs in the class.
c May be used to treat alcohol withdrawal, sedative-hypnotic withdrawal, and as adjunctive medication in other withdrawal states. 9
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972 DIMARTINI et albe avoided [52]. Bupropion may increase the risk for seizures at higher
doses and can cause symptoms of restlessness or tremulousness. It should
be used cautiously during the immediate peritransplant period until the
patient is stable.Neuropsychiatric side eﬀects of immunosuppressive medications
Calcineurin-inhibiting immunosuppressive medications
(tacrolimus and cyclosporine)
Calcineurin-inhibiting immunosuppressive medications (CIIs) are the
mainstay of immunosuppressive medication regimens for most solid organ
transplant recipients. Tacrolimus and cyclosporine seem to have similar neu-
rotoxic side eﬀect proﬁles with up to 40% to 60% of transplant recipients
experiencing mild symptoms including tremulousness, headache, restless-
ness, insomnia, vivid dreams, photophobia, hyperesthesias and dysasthesias,
anxiety, and agitation [53]. Moderate to severe neuropsychiatric side eﬀects
(ie, cognitive impairment, coma, seizures, focal neurologic deﬁcits, dysar-
thria, cortical blindness, and delirium) occur less often but can reach 21%
to 32% in the early postoperative period [53]. Although there can be
many possible etiologies for neuropsychiatric symptoms or mental status
in the early posttransplant period (see Boxes 5 and 6), the possibility that
they reﬂect CII side eﬀects should always be entertained.
The etiology of CII neurotoxicity is unclear, most likely multifactorial,
and may involve biochemical or physiologic derangements or direct or indi-
rect neurotoxic processes (eg, immune system dysregulation). CII neurotox-
icity has been associated with biochemical and electrolyte derangements
including higher plasma levels, intravenous administration, hypocholestero-
lemia, and hypomagnesemia [53]. Disruption of the blood-brain barrier,
whether structural (eg, previous strokes, hypertension, ischemia-reperfusion
injury) or physiologic (eg, HE), has also been associated with neurotoxicity
and is hypothesized to cause neurotoxicity by allowing higher CII drug
levels in the CNS [53].
Correcting the metabolic disturbance or decreasing the drug blood level
can result in a resolution of symptoms, although for severe symptoms the
type of CII may need to be switched (eg, from tacrolimus to cyclosporine)
or discontinued altogether. Anticonvulsants can successfully treat CII-
induced seizures and are not required long-term. Seizures may cease if
reduction or discontinuation of the drug is possible [53]. Treatment of
mild symptoms can include sleep medications for sleep disruption or benzo-
diazepines or b-blockers (if the cardiovascular system can tolerate b block-
ade) for symptoms of anxiety, tremor, or restlessness. These treatments
should be short-termed with the expectation that most symptoms caused
by CII side eﬀects spontaneously resolve as the CII blood levels are reduced
973PSYCHIATRIC ASPECTS OF ORGAN TRANSPLANTATIONin the early posttransplant phase. The longer-term use of benzodiazepines is
not recommend for symptoms of tremor, anxiety, or restlessness because the
ability satisfactorily to taper patients oﬀ of these medications at a later
point, especially after they develop physiologic and psychologic dependence,
becomes problematic. The temporary use of these agents, however, may
provide symptom relief as other antidepressants and anxiolytics are being
instituted and adjusted to therapeutic doses. Serotonin reuptake inhibiting
antidepressants can be more safely used long-term for symptoms of depres-
sion and anxiety, although these medications can take 3 to 4 weeks to
become eﬀective. Symptoms of cognitive impairment, agitation, and delir-
ium can be treated with haloperidol or atypical antipsychotics. Psychiatric
consultation is recommended to assist in the correct diagnosis and choice
of appropriate medication therapy (see Table 2).
CIIs have also been associated with PRES. Clinical symptoms can be var-
ied ranging from mental status changes to focal neurologic symptoms. Mod-
erate to serious symptoms of neurotoxicity warrant a CT or MRI of the
brain to evaluate for PRES (also seen in uremic encephalopathy). Charac-
teristic neuroradiologic abnormalities (low attenuation of white matter on
CT scan or corresponding hyperintense lesions on T2-weighted MRI
images) are most commonly seen in the cortical and subcortical white matter
typically involving the posterior lobes (parietal or occipital), although cases
have been reported involving in the anterior brain, cerebellum, and brain-
stem [44]. Speciﬁc ﬁndings on MRI ﬂuid attenuation inversion recovery
sequences and apparent diﬀusion coeﬃcient mapping (sensitive to water dif-
fusion) provide further evidence toward the theory of neurotoxicity involv-
ing a vasogenic edema and may help compared with diﬀusion-weighted
MRI images in distinguishing vasogenic from cytotoxic edema [54].
Although PRES usually occurs in the early postoperative period it can
also occur years later. Both symptoms and radiologic ﬁndings can resolve
with discontinuation of the CII.
Finally, a rare, severe multifocal demyelinating sensorimotor polyneur-
opathy has been seen in patients treated with CIIs and can occur within
weeks posttransplant. Polyneuropathies in general can be severely limiting,
may impair physical recovery, and could play a role in the liberation from
mechanical ventilation. Early recognition of the symptoms is critical to
recovery and sensitive electrophysiologic testing may be required. Many
of these CII polyneuropathies can improve or be reversed following drug
discontinuation, plasmapheresis, or intravenous immunoglobulin, suggest-
ing an immune-mediated cause (eg, dysimmune neuropathy) [55,56].CorticosteroidsAlthough chronic corticosteroid use is becoming less essential in transplant
immunosuppression, high dosages are still used in the early postoperative
974 DIMARTINI et alphase and also as ‘‘pulsed’’ dosages to treat acute rejection. Behavioral
and psychiatric side eﬀects of corticosteroids are well described but conclu-
sions regarding the incidence, characteristic eﬀects, or the speciﬁc dosages
required to cause such eﬀects are not well established. The reported inci-
dence of serious psychiatric side eﬀects is low (5%–6%) and includes
a wide range of cognitive (diminished memory, concentration, attention,
mental speed, distractibility), aﬀective (depression, anxiety, irritability, emo-
tional lability, hypomania, mania), psychotic (visual and auditory hallucina-
tions, delusions, thought confusion, racing thoughts), and behavioral
(restlessness, agitation, hypervigilance, aggression) symptoms [57–60].
Although dosage is not clearly related to timing, nature, intensity, or duration
of symptoms [58], the risk of steroid psychosis mainly occurs with dosages
of 40 mg/day or more of prednisone or its equivalent [59]. The average length
of time from the institution of steroid therapy to the onset of steroid psychosis
is 6 days [59]. Pre-existing personality disturbances, psychiatric disorders, or
prior history of steroid psychosis does not clearly increase risk [57,59]. Brain
wave slowing, including electroencephalographic increases in central theta
activity [61] and decreases in amplitude and frequency of a-rhythm [59],
can be seen and normalize following corticosteroid withdrawal.
Similar to the treatment of CII side eﬀects, the treatment of steroid-
induced symptoms should target speciﬁc symptoms with the expectation
that therapy will only be required during steroid therapy. For most trans-
plant patients steroids can be dramatically reduced or eliminated, which
should alleviate the symptoms. The use of sleep medications or benzodiaze-
pines may be eﬀective short-term. Serotonin reuptake inhibiting antidepres-
sants can be more safely used long-term for symptoms of depression, anxiety,
or mood dysregulation but may require 3 to 4 weeks to become eﬀective. The
use of haloperidol or atypical antipsychotics can also be eﬀective for mood
dysregulation, psychosis, mania, irritability, agitation and aggression, or
delirium. Psychiatric consultation is recommended to assist in the correct di-
agnosis and choice of appropriate medication therapy (see Table 2).Special issues
Living donation
Living donors constitute 44% of all organ transplant donors in the United
States [62]. Most living donors donate a kidney (95%) or a portion of the liver
(4%). The remaining 1% consists of pancreas, intestine, and lung donors.
Living donors may be related to the recipient biologically (eg, siblings) or
emotionally (eg, spouses, close friends); or may have more distant relation-
ships (eg, acquaintances through an organization, such as a faith-based
group); or may have no relationship (ie, anonymous or altruistic donors).
Living donors constitute a unique patient population in that they are
healthy individuals who receive a major surgical intervention solely for
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chologic and the physical risks for these individuals, they receive not only
careful medical evaluations but careful psychosocial assessments to deter-
mine their suitability and willingness to donate. Even the healthiest donors,
however, can have medical or psychiatric complications perioperatively or
later in their recovery.
Before considering psychiatric sequelae in particular, it is noteworthy
that the general medical outcomes of living donor surgery show an increas-
ingly favorable proﬁle, especially in kidney and liver donors [63–66]. The
literature in other types of donors (eg, lung, intestine) is extremely sparse
and the focus here is on kidney and liver donors. The perioperative mor-
tality rate among kidney donors is 0.03% [64,65]. Several large patient
series (numbers of 3000–5500) report that perioperative major complica-
tions (eg, re-exploration for bleeding) occur in less than 1% of donors
[65]. Minor perioperative complications (eg, urinary tract infection, wound
infection, need for blood transfusion) are more common, occurring in 4%
to 8% of donors [65]. Although there are greater risks when donating a por-
tion of the liver [63,67], the perioperative mortality rate for living liver
donors is low (0.2%–0.3%) [63,66]. Recent patient series have shown over-
all rates of complications to be 14% to 32%, with the minor complication
of biliary leakage being particularly prevalent [66]. Although the very long-
term medical outcomes of liver donation are not yet known, the liver
regenerates and the risk of long-term hepatic damage is believed to be
low [66]. In kidney donation, the data available to date suggest low risk
of renal disease or other organ system impairment even 20 to 30þ years
postdonation [68]. Long-term follow-up data remain sparse, however,
even for kidney donors.
Reported rates of perioperative psychiatric disturbances in living
donors are quite variable, ranging from 0% to 14% [69–73]. These distur-
bances include delirium, anxiety, depression, and rarely psychosis. It
should be noted that these rates are generally based on referrals for psy-
chiatric evaluation and likely underestimate the actual numbers of donors
experiencing psychiatric distress early in their recovery from surgery.
Donors frequently comment that their perioperative pain was much
greater than they had expected [74,75]. In addition, because of the perio-
perative steroids used to reduce inﬂammation, donors may experience
restlessness, agitation, insomnia, and emotional lability. Because donors
are healthy before donation, they may be more alert and less impaired
postoperatively and can be more observant of the sights and sounds of
the ICU environment, which can be emotionally disturbing. ICU staﬀ
should be attentive to donor psychic and physical discomfort. Donors
should be asked about their emotional state and level of pain, and every
eﬀort should be made to alleviate pain and psychiatric symptoms or dis-
tress. Psychiatric or pain management consultation may be sought to
ensure their comfort.
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well-being following the initial recovery period after donation [76–78], and
extremely few donors report that they regret having donated. They fre-
quently report psychologic beneﬁts from donation, including the gratiﬁca-
tion they experience in being able to help another person, and feelings of
increased self-esteem [79–81].Advanced directives: chronic rejection in lung transplantation
as an exampleThe emphasis on aggressive if not sometimes heroic treatment of complica-
tions following transplantation is understandable given the general goal of
medical care to protect and sustain life. This is especially relevant for trans-
plant recipients because early identiﬁcation and treatment may prevent worse
complications or even loss of life. This goal of sustaining and extending life
coupled with the tremendous commitment and eﬀort put forth by the team,
patient, and caregivers to get to and through transplant creates an environ-
ment in which dialogs about advanced directives are not often initiated [82].
Although this issue is important for all transplant patients, the develop-
ment of chronic rejection in lung transplant recipients is a particular oppor-
tunity for such discussion. Chronic rejection of the lung transplant occurs in
60% to 75% of recipients by 5 years posttransplant and is the leading cause
of death among recipients [82]. The clinical manifestation of chronic rejec-
tion is the bronchiolitis obliterans syndrome, and patients with this lesion
have frequent hospitalizations often requiring mechanical ventilation in
the ICU [83]. For lung transplant recipients, an ICU admission is associated
with signiﬁcant morbidity and mortality; only 43% are alive 1 year later and
most die in the ICU [82,83].
Once chronic rejection is identiﬁed in lung recipients, the overall progno-
sis is poor but the course of illness can be highly variable. With these
patients, as with other transplant recipients, the expected prognosis, their
speciﬁc clinical course, and the risks of ongoing procedures, treatments,
and interventions should be discussed with exploration of the patient’s pref-
erences. Optimally, these discussions should be undertaken when the situa-
tion is not dire, potentially when the patient is not ill or hospitalized.
Unfortunately, these opportunities are often missed [82] and the ICU and
transplant teams may need to consider discussions of palliative care and
end-of-life decisions while the patient is critically ill.Health care provider stress from repeated lossesHealth care providers who care for patients awaiting transplantation in-
evitably experience the loss of some of these patients before a donor organ
becomes available. Even posttransplant over the course of repeated hospi-
talizations or a prolonged stay, health care providers may become close to
certain patients and emotionally invested in their outcome. The deaths of
977PSYCHIATRIC ASPECTS OF ORGAN TRANSPLANTATIONthese patients may be especially diﬃcult to accept. With repeated experi-
ences of caregiving and loss, health care providers may develop burnout car-
ing for transplant patients. In turn, burnout leads to emotional exhaustion,
feeling a lack of personal accomplishment, and negative attitudes toward
patients, ultimately compromising caregiver eﬀectiveness [84,85]. Avoiding
burnout requires sensitivity to the impact of end-of-life issues and patient
deaths on critical care staﬀ. In addition, temporary reductions in clinical
workload, greater attention to patient assignments, individual or group dis-
cussions after the loss of a patient, and added support from colleagues help
to reduce burnout [4,86,87]. Novel approaches to burnout have incorpo-
rated additional techniques, such as the use of mindfulness meditation [88].Summary
Transplantation is a challenging process for patients, caregivers, and
medical professionals alike. Patients undergo acute and chronic pathophys-
iologic changes and can experience substantial emotional distress with the
tremendous lifestyle changes and psychologic stresses they must endure.
These stresses are accentuated in the ICU setting where the life-threatening
nature of their medical state brings these issues to sharp focus. Although the
ICU may be only one period of the patient’s transplant hospital experience
it is a critical time and the care provided by the ICU team is essential to their
immediate and overall long-term outcomes. In addition to their medical
needs the ICU staﬀ must address the psychologic and psychiatric needs of
the patients. Psychiatric disorders are common in these patients and their
identiﬁcation and prompt treatment are important aspects of the ICU teams
care. This article reviews the essential aspects of the transplant process with
speciﬁc relevance to the ICU stay. Psychiatric disorders common to trans-
plantation are also described and discussed. This overview should provide
ICU staﬀ the information necessary to deal with the psychiatric needs of
this unique and complex patient population.References
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